

# THE ALGER

# SEMI-ANNUAL REPORT APRIL 30, 2023 (UNAUDITED)

Alger is a signatory to the PRI and carbon neutral.



# **Table of Contents**

# The Alger Funds

Shareholders' Letter	1
Fund Highlights	18
Portfolio Summary	38
Schedules of Investments	40
Statements of Assets and Liabilities	74
Statements of Operations	84
Statements of Changes in Net Assets	89
Financial Highlights	99
Notes to Financial Statements	138
Additional Information	180

#### Dear Shareholders,

#### The Pendulum of Market Sentiment

"In the short run, the market is a voting machine but in the long run, it is a weighing machine." – Benjamin Graham.

Stock prices may have fluctuated over the six month period ended April 30, 2023, mostly based on interest rate movements, but we agree with Graham that over the longer term, company earnings and cash flows ultimately determine stock prices. We believe the rise in interest rates and the corresponding decline in equity valuations are subsiding, leaving Graham's proverbial scale to determine where stocks are headed. In the final two months of 2022, optimism surrounding the potential peak of the Federal Reserve Bank's (Fed) tightening cycle was reinforced by lower-than-expected core Consumer Price Index (CPI) readings for both November and December. Persistent inflation, particularly in wages, remained a focal point for the Fed, and the inverted yield curve amplified fears of a policy misstep or a looming economic downturn. Fed Chairman Jerome Powell indicated in December 2022, that the institution would maintain its "higher-for-longer" approach for interest rates and projected a long-run terminal rate exceeding 5.0%, which sparked concerns about the sustainability of a stock market rebound.

The first quarter of 2023 saw a reversal in the bearish investor sentiment that had marked much of the previous year. In February, the Fed reduced the pace of rate hikes to 25 basis points (bps), after a 50 bps hike in December. Powell, acknowledging the disinflation trend, did not resist the easing of financial conditions, and U.S. Treasury yields fell during the first quarter. In March, concerns around bank funding and liquidity emerged following the collapse of two regional banks, leading to significant deposit outflows at the regional level. However, the Fed, U.S. Treasury, and Federal Deposit Insurance Corporation (FDIC) took steps to contain market concerns. These steps included announcing an emergency liquidity program, guaranteeing uninsured deposits at the impacted regional banks, and allowing some bank mergers and acquisitions to take place. At the end of March, the Fed raised rates by another 25 bps, bringing the Federal Funds rate to 5.0%. In April, U.S. Gross Domestic Product (GDP) grew 1.1%, missing the 2.0% forecast and falling from the prior quarter's 2.6%, despite robust consumer spending.

Among non-U.S. equities, developed markets saw strong performance during the fiscal sixmonth period ended April 30, 2023. Notable strength was driven by Europe avoiding an energy crisis due to a mild winter, and global supply chain bottlenecks seeing continued relief. As such, the MSCI EAFE Index was up 24.6%, driven by strong performance in the Financials and Industrials sectors, while the Real Estate and Energy sectors experienced relative weakness. From a broader perspective, the MSCI ACWI Index rose 13.0% during the fiscal six-month period, where the Communication Services and Information Technology sectors showed strong results, while the Healthcare and Energy sectors saw weaker performance. Within Emerging Markets, notable strength was driven by China reopening its borders, and the MSCI Emerging Markets Index was up 16.5% during the fiscal sixmonth period. Strong performance within the Communication Services and Information Technology sectors was slightly offset by relative weakness in the Real Estate and Energy sectors.

During the fiscal six-month period, growth outperformed value, with the Russell 3000 Growth Index returning 10.8%, outperforming the Russell 3000 Value Index, which posted a return of 3.4% for the period. There was also a notable bifurcation between small- and large-cap stocks, where the -3.5% return of the Russell 2000 Index considerably underperformed the 7.2% return of the Russell 1000 Index during the fiscal six-month period.

# Slow Dance into Recession

The Conference Board's Index of Leading Economic Indicators (LEI) – a composite of economic information that includes housing, consumer confidence and durable goods orders – has historically proven to be a strong predictor of recessions, particularly when the index moves into negative territory. The LEI fell into negative territory in August 2022, and as of March 2023, it shows a year-over-year decline of 7.8%.

Further, over the past thirteen tightening cycles, the United States has only achieved a soft landing (i.e., an economic slowdown without a recession) on three occasions (1984, 1994-1995 and 2020). In each of these instances, interest rates were increased by only 300 bps. As of April 30, 2023, the Fed has increased rates by approximately 500 bps since it began its hiking cycle in March 2022. If history is any guide, we find it unlikely that the Fed can successfully orchestrate a soft landing, given the Fed has now hiked well above the approximate "soft landing" rate increase of 300 bps.

Further challenging the ability for a soft landing is the lagged impact of the Fed's aggressive tightening cycle. It is important to note the strong historical relationship between small bank lending standards and U.S. corporate business spending, known as capital expenditures. As bank lending standards tighten, fewer loans are made and companies' cost of capital rises. As a result, companies reduce their capital projects, either due to a lack of funds or because the higher cost makes these projects less financially attractive. In our view, bank lending standards will likely continue to tighten and slow business capital expenditures, pressuring earnings for more economically sensitive companies that rely on capital expansion projects.

As of the writing of this letter, the Fed has continued to tighten financial conditions via its interest rate increases and the roll-off of debt from its balance sheet. Further, the broader money supply growth is decelerating and is now in outright contraction for the first time since 1938, which is likely to slow economic activity. For these reasons, we believe the United States may have already entered a recession.

# Going Forward

We continue to believe that unprecedented levels of innovation are creating compelling investment opportunities - corporations are digitizing their operations, cloud computing growth continues to support future innovation, and artificial intelligence, which is at an inflection point in our view, potentially enabling significant increases in productivity. In the Healthcare sector, we believe that advances in surgical technologies and innovations within biotechnology offer attractive opportunities ahead. As such, we intend to continue to focus on conducting in-depth fundamental research as we seek leaders of innovation rather than taking short-term bets on market sentiment. We believe doing so is the best strategy for helping our valued shareholders reach their investment goals.

# Portfolio Matters Alger Capital Appreciation Fund

The Alger Capital Appreciation Fund returned 9.42% for the fiscal six-month period ended April 30, 2023, compared to the 11.51% return of the Russell 1000 Growth Index. During the reporting period, the largest sector weightings were Information Technology and Healthcare. The largest sector overweight was Healthcare and the largest sector underweight was Information Technology.

# **Contributors to Performance**

The Consumer Discretionary and Industrials sectors provided the largest contributions to relative performance. Regarding individual positions, Microsoft Corporation; NVIDIA Corporation; TransDigm Group Incorporated; MercadoLibre, Inc.; and Apple Inc. were among the top contributors to absolute performance.

Microsoft is a beneficiary of corporate America's transformative digitization. Microsoft's CEO expects technology spending as a percent of GDP to jump from about 5% now to 10% in 10 years and that Microsoft will continue to capture market share within the technology sector. The company operates through three segments: Productivity and Business Processes (Office, LinkedIn, and Dynamics), Intelligent Cloud (Server Products and Cloud Services, Azure, and Enterprise Services), and More Personal Computing (Windows, Devices, Gaming, and Search). While the company reported operating results that met consensus estimates, their investment in OpenAI's ChatGPT captured the attention of investors, contributing to positive performance. Throughout the period, Microsoft surprised investors with continual rollouts of new AI capabilities across the company's portfolio (e.g., Bing, GitHub, Teams, Office 365). Furthermore, the company announced Microsoft Graph of data to provide AI virtual assistance. We believe Microsoft's investment in OpenAI provides a first-mover advantage in the AI transformer model space.

# Detractors from Performance

The Healthcare and Communication Services sectors were the largest detractors from relative performance. Regarding individual positions, Tesla, Inc.; UnitedHealth Group Incorporated; Signature Bank; Albemarle Corporation; and Humana Inc. were among the top detractors from absolute performance.

UnitedHealth Group is an integrated healthcare benefits company uniquely positioned to address rising healthcare costs for its customers, due to its vertical integration, size, and scale. The Optum health benefits services unit, which accounts for approximately 45% of the company's operating earnings, in our view, has the potential to grow even further as customers look for ways to manage rising healthcare costs. During the period, shares detracted from performance due to several factors: (1) many 2022 healthcare winners with shorter duration profiles and persistent earnings profiles, such as UnitedHealth Group, underperformed in the first quarter of 2023, (2) uncertainty surrounding Medicare Advantage reimbursement levels from the Federal government in 2023, which will be determined later in the year, and (3) increased regulatory scrutiny in the form of potential Medicare Advantage audits across the industry. While these concerns have impacted UnitedHealth in the near-term, we believe company fundamentals remain intact given its large-scale business model, competitive advantages, and medium- to long-term growth prospects.

# Alger 35 Fund

The Alger 35 Fund generated a 1.91% return for the fiscal six-month period ended April 30, 2023, compared to the 8.63% return of the S&P 500 Index. During the reporting period, the largest sector weightings were Information Technology and Consumer Discretionary. The largest sector overweight was Consumer Discretionary and the largest sector underweight was Financials.

# **Contributors to Performance**

The Consumer Discretionary and Real Estate sectors provided the largest contributions to relative performance. Regarding individual positions, MercadoLibre, Inc.; Advanced Micro Devices, Inc.; TransMedics Group, Inc.; Cabaletta Bio, Inc.; and Netflix, Inc. were among the top contributors to absolute performance.

MercadoLibre is the largest e-commerce company in Latin America, with its largest markets being Brazil, Argentina, and Mexico. The company offers a comprehensive suite of services, including an online marketplace for buyers and sellers, payment solutions through Mercado Pago, merchant and buyer financing through Mercado Credito, shipping services through Mercado Envios, and asset management through Mercado Fondo, among other services. We believe the e-commerce market within Central and South America remains underpenetrated, creating a favorable backdrop for MercadoLibre, as they have been growing and investing heavily to expand its first mover advantage. Moreover, we believe that the company's growing fintech payments business, Mercado Pago, is well-positioned to potentially emerge as a leader in Central and South America, as well as an emerging online advertising presence that offers attractive margin expansion potential, in our view. During the period, shares contributed to performance after the company reported resilient fiscal fourth quarter earnings that exceeded analyst estimates. Notable drivers that contributed to the earnings beat included strong gross-merchandise-value and an increase in the average take-rate within both e-commerce and Mercado Pago.

# **Detractors from Performance**

The Information Technology and Communication Services sectors were the largest detractors from relative performance. Regarding individual positions, 908 Devices Inc.; JD.com, Inc.; RAPT Therapeutics, Inc.; Rivian Automotive, Inc.; and Alphabet Inc. were among the top detractors from absolute performance.

Alphabet is a global technology company specializing in cloud operating systems and digital advertising. Company revenues are primarily driven by online advertising on its Google search platform, along with selling hardware devices and apps on Google Play. Shares detracted from results during the period as the company reported mixed results. The company's net revenues were slightly below analysts' estimates as advertisers reduced their spending during the period. However, growth in Alphabet's cloud computing segment—Google Cloud—saw an acceleration during the period.

# Alger Growth & Income Fund

The Alger Growth & Income Fund returned 9.20% for the fiscal six-month period ended April 30, 2023, compared to the 8.63% return of the S&P 500 Index. During the reporting period, the largest sector weightings were Information Technology and Healthcare. The largest sector overweight was Energy and the largest sector underweight was Consumer Discretionary.

# Contributors to Performance

The Financials and Materials sectors provided the largest contributions to relative performance. Regarding individual positions, Microsoft Corporation; Broadcom Inc.; Apple Inc.; Meta Platforms Inc.; and KLA Corporation were among the top contributors to absolute performance. Shares of Microsoft Corporation contributed to performance in response to developments identified in the Alger Capital Appreciation Fund discussion.

# **Detractors from Performance**

The Healthcare and Industrials sectors were the largest detractors from relative performance. Regarding individual positions, UnitedHealth Group Incorporated; Bank of America Corp; CVS Health Corporation; Cheniere Energy Partners, L.P.; and Pfizer Inc. were among the top detractors from absolute performance. Shares of UnitedHealth Group Incorporated detracted from performance in response to developments identified in the Alger Capital Appreciation Fund discussion.

# Alger Mid Cap Growth Fund

The Alger Mid Cap Growth Fund returned 5.45% for the fiscal six-month period ended April 30, 2023, compared to the 6.60% return of the Russell Midcap Growth Index. During the reporting period, the largest sector weightings were Information Technology and Industrials. The largest sector overweight was Information Technology and the largest sector underweight was Consumer Discretionary.

#### **Contributors to Performance**

The Information Technology and Energy sectors provided the largest contributions to relative performance. Regarding individual positions, Prometheus Biosciences, Inc.; Constellation Software Inc.; Chipotle Mexican Grill, Inc.; Cadence Design Systems, Inc.; and TransDigm Group Incorporated were among the top contributors to absolute performance.

TransDigm Group specializes in the production of engineered aerospace components, systems and subsystems. Its core Power and Control segment includes operations that primarily develop, produce and market systems and components that provide power to or control power of aircrafts utilizing electronic, fluid, power and mechanical motion control technologies. During the period, the company reported solid fiscal first quarter results, where both revenues and earnings beat analyst estimates. Better-than-expected results were driven by strength in all three of their major market channels – commercial original equipment manufacturing (OEM), commercial aftermarket and defense – as well as strong order bookings. Moreover, management raised their fiscal full year guidance, noting favorable trends in the commercial aerospace market recovery.

# Detractors from Performance

The Consumer Discretionary and Consumer Staples sectors were the largest detractors from relative performance. Regarding individual positions, CrowdStrike Holdings, Inc.; First Republic Bank; Aritzia, Inc.; BILL Holdings, Inc.; and Enphase Energy, Inc. were among the top detractors from absolute performance.

BILL Holdings is the leading provider of business-to-business (B2B) commerce solutions for small- and medium-sized businesses (SMBs), including streamlining financial operations such as accounts payables (AP) and accounts receivables (AR). Their target market is primarily U.S. SMBs with revenues up to \$100 million. The company earns revenue from: (1) subscription fees charged for access to its cloud-based services; (2) usage-based transaction

fees, including payments-related fees; and (3) interest earned on funds held on behalf of customers. The company is positioned as a back-office financial operations and an AP automation software-as-a-service (SaaS) platform for the SMB segment of B2B payments. According to our analysis, roughly 42% of B2B payments are still made via physical check, and 93% of businesses with less than \$1 billion of annual revenue reported receiving physical checks as payment. During the period, shares detracted from performance, as the company reported weaker than expected results. Specifically, growth in total payment volume and transaction growth weakened due to the challenging macroeconomic backdrop, along with fewer net-customer additions. Despite these events, we believe company fundamentals remain intact and are well positioned to continue to penetrate the underserved SMB market with its differentiated product offerings over the long-term.

# Alger Mid Cap Focus Fund

The Alger Mid Cap Focus Fund generated a -1.89% return for the fiscal six-month period ended April 30, 2023, compared to the 6.60% return of the Russell Midcap Growth Index. During the reporting period, the largest sector weightings were Information Technology and Healthcare. The largest sector overweight was Healthcare and the largest sector underweight was Financials.

#### **Contributors to Performance**

The Energy and Communication Services sectors provided the largest contributions to relative performance. Regarding individual positions, Prometheus Biosciences, Inc.; Insulet Corporation; Coupa Software, Inc.; Bentley Systems, Incorporated; and Viridian Therapeutics, Inc. were among the top contributors to absolute performance.

Coupa Software is a cloud-based spend management platform that digitizes many areas of core transactional spending functions, including travel and expense management, invoicing and procurement. On December 12, 2022, Coupa announced that it entered into a definitive agreement to be acquired by Thoma Bravo for \$8 billion, or \$81 per share, in an all-cash transaction. Shares contributed to performance in response to the Thoma Bravo announcement, as the acquisition price was at a sizable premium.

#### **Detractors from Performance**

The Information Technology and Healthcare sectors were the largest detractors from relative performance. Regarding individual positions, RAPT Therapeutics, Inc.; BILL Holdings, Inc.; Constellation Energy Corporation; CrowdStrike Holdings, Inc.; and CyberArk Software Ltd. were among the top detractors from absolute performance. Shares of BILL Holdings detracted from performance in response to developments identified in the Alger Mid Cap Growth Fund discussion.

#### Alger Weatherbie Specialized Growth Fund

The Alger Weatherbie Specialized Growth Fund generated a -3.20% return for the fiscal six-month period ended April 30, 2023, compared to the 1.88% return of the Russell 2500 Growth Index. During the reporting period, the largest sector weightings were Industrials and Healthcare. The largest sector overweight was Real Estate and the largest sector underweight was Materials.

#### **Contributors to Performance**

The Energy and Real Estate sectors provided the largest contributions to relative performance. Regarding individual positions, FirstService Corp; SiteOne Landscape Supply,

Inc.; SPS Commerce, Inc.; Planet Fitness, Inc.; and Hamilton Lane Incorporated were among the top contributors to absolute performance.

SPS Commerce is a global provider of cloud-based supply chain management solutions for fulfillment, analytics, drop shipping and other use cases. The SPS Commerce platform improves the way retailers, suppliers, grocers, distributors, and logistics companies manage orders, monitor sell-through performance, and discover new products by leveraging cloud technology. During the period, shares contributed to performance as the company reported strong operating results, where revenues came in above consensus estimates. Additionally, recurring revenue increased 20% year-over-year, driven by double digit growth in both fulfillment and analytics. Despite a difficult macroeconomic environment with high inflation and recession concerns, management expressed confidence in its subscription-based business model, which is largely reliant on the number of client connections with only a small portion tied to volumes. Moreover, we believe the company is a key beneficiary of supply chain digitalization over the long-term, given the growing influence of e-commerce.

#### **Detractors from Performance**

The Healthcare and Industrials sectors were the largest detractors from relative performance. Regarding individual positions, Montrose Environmental Group Inc.; Xometry, Inc.; StepStone Group, Inc.; Globant SA; and Progyny, Inc. were among the top detractors from absolute performance.

Xometry is a leading two-sided marketplace for on-demand manufacturing services. The company provides real-time access to global manufacturing demand and capacity, with sourcing and pricing available across a network of buyers and sellers. This marketplace enables buyers (e.g., engineers and product designers) to efficiently source manufacturing processes and sellers of manufacturing services to grow their businesses. Xometry's AI-enabled technology platform is powered by proprietary machine learning algorithms, resulting in a sophisticated marketplace for manufacturing. During the period, the company reported weaker-than-expected revenues and revised their forward guidance below consensus. Management noted that suppliers accepted orders more quickly than usual on the Xometry platform due to a challenging macroeconomic environment, causing the proprietary algorithm to reduce market pricing, resulting in weaker revenue growth and gross margin compression. The company adjusted their proprietary algorithm in January and the company stated that it expects gross margins to improve throughout the year.

# Alger Small Cap Growth Fund

The Alger Small Cap Growth Fund returned -2.15% for the fiscal six-month period ended April 30, 2023, compared to the -0.29% return of the Russell 2000 Growth Index. During the reporting period, the largest sector weightings were Healthcare and Information Technology. The largest sector overweight was Healthcare and the largest sector underweight was Industrials.

# **Contributors to Performance**

The Information Technology and Real Estate sectors provided the largest contributions to relative performance. Regarding individual positions, NeoGenomics, Inc.; Manhattan Associates, Inc.; HubSpot, Inc.; Neogen Corp; and Wingstop, Inc. were among the top contributors to absolute performance.

Hubspot is a cloud-based marketing and sales platform for SMBs, focusing on inbound marketing strategies to attract, engage, and convert website visitors into customers. Its platform provides a comprehensive suite of applications including search engine optimization (SEO), blogging, marketing automation, customer relationship management (CRM), and analytics, utilizing a centralized database for personalized interactions. In our view, this approach fosters warmer prospect engagement compared to traditional methods like cold calling and email blasts. Over the years, the company has evolved from a small business CRM vendor to a comprehensive provider of marketing, sales and content management solutions for global SMBs. With an approximate 3% combined market share, a large customer base, robust partner network and extensive HubSpot suite, we believe the company is well positioned to capture additional market share in the large SMB front office applications industry, as well as to expand in the upmarket segment (i.e., companies with 200 to 2,000 employees). Shares contributed to performance during the period, as the company reported better-than-expected operating results, noting strong quarterly execution against a difficult macroeconomic environment.

# Detractors from Performance

The Healthcare and Industrials sectors were the largest detractors from relative performance. Regarding individual positions, Magnolia Oil & Gas Corp.; Xometry, Inc.; BILL Holdings, Inc.; HealthEquity Inc; and CareDx, Inc. were among the top detractors from absolute performance. Shares of BILL Holdings, Inc. detracted from performance in response to developments identified in the Alger Mid Cap Growth Fund discussion.

# Alger Small Cap Focus Fund

The Alger Small Cap Focus Fund returned -3.55% for the fiscal six-month period ended April 30, 2023, compared to the -0.29% return of the Russell 2000 Growth Index. During the reporting period, the largest sector weightings were Healthcare and Information Technology. The largest sector overweight was Healthcare and the largest sector underweight was Consumer Discretionary.

# Contributors to Performance

The Healthcare and Energy sectors provided the largest contributions to relative performance. Regarding individual positions, Prometheus Biosciences, Inc.; Heska Corporation; Guidewire Software, Inc.; Inspire Medical Systems, Inc.; and Wingstop, Inc. were among the top contributors to absolute performance.

Guidewire Software offers on-premises and cloud-based solutions for property and casualty insurance companies, automating processes such as premium billings, claims management, and policy fulfillment. Under the InsuranceSuite brand, the company provides three core systems: BillingsCenter, ClaimsCenter, and PolicyCenter. During the period, shares contributed to performance after the company reported strong operating results, where revenues and operating profits exceeded analyst estimates. Moreover, strong performance was attributable to ongoing cloud traction as the company continued to see large cloud momentum across tier-1 and tier-2 carriers. Management also raised gross margin guidance by 200 bps for the full year, approximately 500 bps ahead of what management projected in October 2022.

# Detractors from Performance

The Industrials and Information Technology sectors were the largest detractors from relative performance. Regarding individual positions, Xometry, Inc.; HealthEquity Inc.;

RBC Bearings Incorporated; 908 Devices Inc.; and Paycom Software, Inc. were among the top detractors from absolute performance. Shares of Xometry, Inc. detracted from performance in response to developments identified in the Alger Mid Cap Growth Fund discussion.

# Alger International Focus Fund

The Alger International Focus Fund recorded a 10.83% return for the fiscal six-month period ended April 30, 2023, compared to the 20.96% return of the MSCI ACWI ex USA Index. During the reporting period, the largest sector weightings were Consumer Discretionary and Financials. The largest sector overweight was Consumer Discretionary and the largest sector underweight was Communication Services.

# Contributors to Performance

The Healthcare and Consumer Discretionary sectors provided the largest contributions to relative performance. Regarding individual positions, Moncler SpA; Ferrari NV; LVMH Moet Hennessy Louis Vuitton SE; ASML Holding NV; and HENSOLDT AG were among the top contributors to absolute performance.

ASML is the market leader in providing photolithography systems for the semiconductor industry. ASML's cutting-edge technology is essential to the semiconductor manufacturing process of increasingly smaller and more powerful microchips, which are widely used in consumer electronics, telecommunications, automotive, and various other industries. Despite macroeconomic weakness, the company reported strong results during the period, where earnings came in better-than-expected. Further, management noted a robust order backlog, reflecting strong demand for Extreme Ultraviolet Lithography and raised fiscal 2023 revenue guidance well above analyst estimates.

# Detractors from Performance

The Financials and Energy sectors were the largest detractors from relative performance. Regarding individual positions, VERBIO Vereinigte BioEnergie AG; Angel One Limited; Teleperformance SA; Arezzo Industria e Comercio S.A.; and Alfen NV were among the top detractors from absolute performance.

VERBIO is a leading producer of the complete range of biofuels (biodiesel, bioethanol and biomethane) and byproducts at industrial scale. The company benefits from environmental protection tailwinds and an increasing effort to curb greenhouse gas emissions globally. Moreover, with biomethane serving as a direct substitute for natural gas, there is heightened investor focus on VERBIO's ability to scale and serve as a solution to a potential energy crisis in Europe. During the period, shares detracted from performance as natural gas prices plummeted due to warmer-than-expected temperatures in Europe and the region's ability to maintain high levels of gas storage throughout the winter. As a result, demand for biomethane slowed during the period, which negatively impacted company results.

# Alger Health Sciences Fund

The Alger Health Sciences Fund returned 0.14% for the fiscal six-month period ended April 30, 2023, compared to the 8.63% return of the S&P 500 Index and the 2.29% return of the Russell 3000 Healthcare Index.

# Contributors to Performance

Regarding individual positions, Prometheus Biosciences, Inc.; Reata Pharmaceuticals, Inc.; TransMedics Group, Inc.; Tenet Healthcare Corporation; and GE Healthcare Technologies Inc. were among the top contributors to absolute performance.

Prometheus Biosciences is a biotechnology company focused on developing precision-based medicines to treat autoimmune conditions, primarily those afflicting the intestines such as inflammatory bowel disease (IBD) indications, like ulcerative colitis and Crohn's disease, by leveraging a proprietary bioinformatics database. Shares contributed to performance during the period as the company reported positive Phase 2 clinical trial results from its IBD study, as the drug PRA023 demonstrated significant patient improvement that was well above expectations. On April 15, 2023, the company entered into an agreement to be acquired by Merck & Co. Inc. for \$9.6 billion in cash, which was approximately a 75% premium from the prior trading day's value. The deal is expected to close in the third quarter of 2023.

#### **Detractors from Performance**

Regarding individual positions, Charles River Laboratories International, Inc.; Medpace Holdings, Inc.; UnitedHealth Group Incorporated; Tandem Diabetes Care, Inc.; and Shockwave Medical, Inc. were among the top detractors from absolute performance. Shares of UnitedHealth Group Incorporated, Inc. detracted from performance in response to developments identified in the Alger Capital Appreciation Fund discussion.

I thank you for putting your trust in Alger.

Sincerely,

Dudgylly

Daniel C. Chung, CFA Chief Executive Officer, Chief Investment Officer Fred Alger Management, LLC

Investors cannot invest directly in an index. Index performance does not reflect the deduction for fees, expenses, or taxes.

This report and the financial statements contained herein are submitted for the general information of shareholders of the funds. This report is not authorized for distribution to prospective investors in a fund unless preceded or accompanied by an effective prospectus for the fund. Performance of funds discussed above, other than the Alger 35 Fund and the Alger Mid Cap Focus Fund, represents the six-month period return of Class A shares prior to the deduction of any sales charges and includes the reinvestment of any dividends or distributions. Performance for the Alger 35 Fund represents Class Z shares. Performance for the Alger Mid Cap Focus Fund represents Class I shares.

The performance data quoted in this material represents past performance, which is not an indication or a guarantee of future results.

Standard performance results can be found on the following pages. The investment return and principal value of an investment in a Fund will fluctuate so that an -10 -

investor's shares, when redeemed, may be worth more or less than their original cost. Current performance may be lower or higher than the performance quoted. For performance data current to the most recent month-end, visit us at www.alger.com, or call us at (800) 992-3863.

The views and opinions of the funds' management in this report are as of the date of the Shareholders' Letter and are subject to change at any time subsequent to this date. There is no guarantee that any of the assumptions that formed the basis for the opinions stated herein are accurate or that they will materialize. Moreover, the information forming the basis for such assumptions is from sources believed to be reliable; however, there is no guarantee that such information is accurate. Any securities mentioned, whether owned in a fund or otherwise, are considered in the context of the construction of an overall portfolio of securities and therefore reference to them should not be construed as a recommendation or offer to purchase or sell any such security. Inclusion of such securities in a fund and transactions in such securities, if any, may be for a variety of reasons, including, without limitation, in response to cash flows, inclusion in a benchmark, and risk control. The reference to a specific security should also be understood in such context and not viewed as a statement that the security is a significant holding in a fund. Please refer to the Schedule of Investments for each fund which is included in this report for a complete list of fund holdings as of April 30, 2023. Securities mentioned in the Shareholders' Letter, if not found in the Schedules of Investments, may have been held by the funds during the fiscal sixmonth period ended April 30, 2023.

# **Risk Disclosures**

#### Alger Capital Appreciation Fund

Investing in the stock market involves risks, including the potential loss of principal. Growth stocks may be more volatile than other stocks as their prices tend to be higher in relation to their companies' earnings and may be more sensitive to market, political, and economic developments. Local, regional or global events such as environmental or natural disasters, war, terrorism, pandemics, outbreaks of infectious diseases and similar public health threats, recessions, or other events could have a significant impact on investments. A significant portion of assets may be invested in securities of companies in related sectors, and may be similarly affected by economic, political, or market events and conditions and may be more vulnerable to unfavorable sector developments. Foreign securities involve special risks including currency fluctuations, inefficient trading, political and economic instability, and increased volatility. Active trading may increase transaction costs, brokerage commissions, and taxes, which can lower the return on investment. At times, cash may be a larger position in the portfolio and may underperform relative to equity securities.

# Alger 35 Fund

Investing in the stock market involves risks, including the potential loss of principal. Growth stocks may be more volatile than other stocks as their prices tend to be higher in relation to their companies' earnings and may be more sensitive to market, political, and economic developments. Local, regional or global events such as environmental or natural disasters, war, terrorism, pandemics, outbreaks of infectious diseases and similar public health threats, recessions, or other events could have a significant impact on investments. A significant portion of assets may be invested in securities of companies in related sectors, and may be similarly affected by economic, political, or market events and conditions and may be

more vulnerable to unfavorable sector developments. Investing in companies of small and medium capitalizations involves the risk that such issuers may have limited product lines or financial resources, lack management depth, or have limited liquidity. Foreign securities involve special risks including currency fluctuations, inefficient trading, political and economic instability, and increased volatility. The Fund is classified as a "non-diversified fund" under federal securities laws because it can invest in fewer individual companies than a diversified fund. Assets may be focused in a small number of holdings, making them susceptible to risks associated with a single economic, political or regulatory event than a more diversified portfolio. Active trading may increase transaction costs, brokerage commissions, and taxes, which can lower the return on investment. At times, cash may be a larger position in the portfolio and may underperform relative to equity securities.

#### Alger Growth & Income Fund

Investing in the stock market involves risks, including the potential loss of principal. Growth stocks may be more volatile than other stocks as their prices tend to be higher in relation to their companies' earnings and may be more sensitive to market, political, and economic developments. Local, regional or global events such as environmental or natural disasters, war, terrorism, pandemics, outbreaks of infectious diseases and similar public health threats, recessions, or other events could have a significant impact on investments. A significant portion of assets may be invested in securities of companies in related sectors, and may be similarly affected by economic, political, or market events and conditions and may be more vulnerable to unfavorable sector developments. Income-producing securities may cut or fail to declare dividends due to market downturns or for other reasons. At times, cash may be a larger position in the portfolio and may underperform relative to equity securities.

#### Alger Mid Cap Growth Fund

Investing in the stock market involves risks, including the potential loss of principal. Growth stocks may be more volatile than other stocks as their prices tend to be higher in relation to their companies' earnings and may be more sensitive to market, political, and economic developments. Local, regional or global events such as environmental or natural disasters, war, terrorism, pandemics, outbreaks of infectious diseases and similar public health threats, recessions, or other events could have a significant impact on investments. A significant portion of assets may be invested in securities of companies in related sectors, and may be similarly affected by economic, political, or market events and conditions and may be more vulnerable to unfavorable sector developments. Investing in companies of medium capitalizations involves the risk that such issuers may have limited product lines or financial resources, lack management depth, or have limited liquidity. Foreign securities involve special risks including currency fluctuations, inefficient trading, political and economic instability, and increased volatility. Active trading may increase transaction costs, brokerage commissions, and taxes, which can lower the return on investment. At times, cash may be a larger position in the portfolio and may underperform relative to equity securities.

#### Alger Mid Cap Focus Fund

Investing in the stock market involves risks, including the potential loss of principal. Growth stocks may be more volatile than other stocks as their prices tend to be higher in relation to their companies' earnings and may be more sensitive to market, political, and economic developments. Local, regional or global events such as environmental or natural disasters, war, terrorism, pandemics, outbreaks of infectious diseases and similar public health threats, recessions, or other events could have a significant impact on investments. Investing in -12-

companies of medium capitalizations involves the risk that such issuers may have limited product lines or financial resources, lack management depth, or have limited liquidity. Assets may be focused in a small number of holdings, making them susceptible to risks associated with a single economic, political or regulatory event than a more diversified portfolio. A significant portion of assets may be invested in securities of companies in related sectors or industries, and may be similarly affected by economic, political, or market events and conditions and may be more vulnerable to unfavorable sector or industry developments. Foreign securities involve special risks including currency fluctuations, inefficient trading, political and economic instability, and increased volatility. Active trading may increase transaction costs, brokerage commissions, and taxes, which can lower the return on investment. At times, cash may be a larger position in the portfolio and may underperform relative to equity securities.

#### Alger Weatherbie Specialized Growth Fund

Investing in the stock market involves risks, including the potential loss of principal. Growth stocks may be more volatile than other stocks as their prices tend to be higher in relation to their companies' earnings and may be more sensitive to market, political, and economic developments. Local, regional or global events such as environmental or natural disasters, war, terrorism, pandemics, outbreaks of infectious diseases and similar public health threats, recessions, or other events could have a significant impact on investments. A significant portion of assets may be invested in securities of companies in related sectors, and may be similarly affected by economic, political, or market events and conditions and may be more vulnerable to unfavorable sector developments. Investing in companies of small and medium capitalizations involves the risk that such issuers may have limited product lines or financial resources, lack management depth, or have limited liquidity. Assets may be focused in a small number of holdings, making them susceptible to risks associated with a single economic, political or regulatory event than a more diversified portfolio. Foreign securities and Emerging Markets involve special risks including currency fluctuations, inefficient trading, political and economic instability, and increased volatility. At times, cash may be a larger position in the portfolio and may underperform relative to equity securities.

#### Alger Small Cap Growth Fund

Investing in the stock market involves risks, including the potential loss of principal. Growth stocks may be more volatile than other stocks as their prices tend to be higher in relation to their companies' earnings and may be more sensitive to market, political, and economic developments. Local, regional or global events such as environmental or natural disasters, war, terrorism, pandemics, outbreaks of infectious diseases and similar public health threats, recessions, or other events could have a significant impact on investments. A significant portion of assets may be invested in securities of companies in related sectors, and may be similarly affected by economic, political, or market events and conditions and may be more vulnerable to unfavorable sector or industry developments. Investing in companies of small capitalizations involves the risk that such issuers may have limited product lines or financial resources, lack management depth, or have limited liquidity. At times, cash may be a larger position in the portfolio and may underperform relative to equity securities.

#### Alger Small Cap Focus Fund

Investing in the stock market involves risks, including the potential loss of principal. Growth stocks may be more volatile than other stocks as their prices tend to be higher in relation to their companies' earnings and may be more sensitive to market, political, and economic

developments. Local, regional or global events such as environmental or natural disasters, war, terrorism, pandemics, outbreaks of infectious diseases and similar public health threats, recessions, or other events could have a significant impact on investments. A significant portion of assets may be invested in securities of companies in related sectors or industries, and may be similarly affected by economic, political, or market events and conditions and may be more vulnerable to unfavorable sector or industry developments. Investing in companies of small capitalizations involves the risk that such issuers may have limited product lines or financial resources, lack management depth, or have limited liquidity. Assets may be focused in a small number of holdings, making them susceptible to risks associated with a single economic, political or regulatory event than a more diversified portfolio. At times, cash may be a larger position in the portfolio and may underperform relative to equity securities.

#### Alger International Focus Fund

Investing in the stock market involves risks, including the potential loss of principal. Growth stocks may be more volatile than other stocks as their prices tend to be higher in relation to their companies' earnings and may be more sensitive to market, political, and economic developments. Local, regional or global events such as environmental or natural disasters, war, terrorism, pandemics, outbreaks of infectious diseases and similar public health threats, recessions, or other events could have a significant impact on investments. A significant portion of assets may be invested in securities of companies in related sectors, and may be similarly affected by economic, political, or market events and conditions and may be more vulnerable to unfavorable sector developments. Assets may be focused in a small number of holdings, making them susceptible to risks associated with a single economic, political or regulatory event than a more diversified portfolio. Foreign securities and Emerging Markets involve special risks including currency fluctuations, inefficient trading, political and economic instability, and increased volatility. Investing in companies of small capitalizations involves the risk that such issuers may have limited product lines or financial resources, lack management depth, or have limited liquidity. At times, cash may be a larger position in the portfolio and may underperform relative to equity securities.

#### Alger Health Sciences Fund

Investing in the stock market involves risks, including the potential loss of principal. Growth stocks may be more volatile than other stocks as their prices tend to be higher in relation to their companies' earnings and may be more sensitive to market, political, and economic developments. Local, regional or global events such as environmental or natural disasters, war, terrorism, pandemics, outbreaks of infectious diseases and similar public health threats, recessions, or other events could have a significant impact on investments. A significant portion of assets will be invested in healthcare companies, which may be significantly affected by competition, innovation, regulation, and product obsolescence, and may be more volatile than the securities of other companies. A significant portion of assets may be invested in securities of companies in related industries, and may be similarly affected by economic, political, or market events and conditions and may be more vulnerable to unfavorable sector developments. Assets may be focused in a small number of holdings, making them susceptible to risks associated with a single economic, political or regulatory event than a more diversified portfolio. Investing in companies of small capitalizations involves the risk that such issuers may have limited product lines or financial resources, lack management depth, or have limited liquidity. Private placements are offerings of a

company's securities not registered with the SEC and not offered to the public, for which limited information may be available. Such investments are generally considered to be illiquid. Foreign securities involve special risks including currency fluctuations, inefficient trading, political and economic instability, and increased volatility. Active trading may increase transaction costs, brokerage commissions, and taxes, which can lower the return on investment. At times, cash may be a larger position in the portfolio and may underperform relative to equity securities.

For a more detailed discussion of the risks associated with a fund, please see the prospectus.

Before investing, carefully consider a fund's investment objective, risks, charges, and expenses. For a prospectus and summary prospectus containing this and other information or for The Alger Funds' most recent month-end performance data, visit www.alger.com, call (800) 992-3863 or consult your financial advisor. Read the prospectus and summary prospectus carefully before investing.

# Distributor: Fred Alger & Company, LLC

# NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE.


Definitions:

- Earnings per share (EPS) is calculated as a company's profit divided by the outstanding shares of its common stock.
- The Consumer Price Index (CPI) measures the monthly change in prices paid by U.S. consumers. The Bureau of Labor Statistics (BLS) calculates the CPI as a weighted average of prices for a basket of goods and services representative of aggregate U.S. consumer spending.
- The MSCI ACWI captures large- and mid-cap representation across developed markets and emerging markets countries. The index covers approximately 85% of the global equity opportunity set.
- The MSCI ACWI ex USA Index captures large- and mid-cap representation across developed markets countries (excluding the US) and emerging markets countries. The index covers approximately 85% of the global equity opportunity set outside the US.
- The MSCI EAFE Index captures large- and mid-cap representation across Emerging Markets countries. The index covers approximately 85% of the free float-adjusted market capitalization in each country. The MSCI Emerging Markets Index is a free float-adjusted market capitalization index that is designed to measure equity market performance in the global emerging markets.
- The MSCI Emerging Markets Index captures large- and mid-cap representation across Emerging Markets countries. The index covers approximately 85% of the free float-adjusted market capitalization in each country.
- The Russell 1000 Growth Index measures the performance of the large-

cap growth segment of the U.S. equity universe. It includes those Russell 1000 companies with higher growth earning potential as defined by Russell's leading style methodology. The Russell 1000 Growth Index is constructed to provide a comprehensive and unbiased barometer for the large-cap growth segment.

- The Russell 1000 Index measures the performance of the large-cap segment of the US equity universe. It is a subset of the Russell 3000 Index and includes approximately 1,000 of the largest securities based on a combination of their market cap and current index membership.
- The Russell 2000 Growth Index measures the performance of the smallcap growth segment of the U.S. equity universe. It includes those Russell 2000 companies with higher growth earning potential as defined by Russell's leading style methodology. The Russell 2000 Growth Index is constructed to provide a comprehensive and unbiased barometer for the small-cap growth segment.
- The Russell 2000 Index measures the performance of the small-cap segment of the US equity universe. The Russell 2000 Index is constructed to provide a comprehensive and unbiased barometer of the small-cap segment.
- The Russell 2500 Growth Index measures the performance of the small to mid-cap growth segment of the U.S. equity universe. It includes those Russell 2500 companies with higher growth earning potential as defined by Russell's leading style methodology. The Russell 2500 Growth Index is constructed to provide a comprehensive and unbiased barometer of the small to mid-cap growth market.
- The Russell 2500 Index measures the performance of the small to midcap segment of the US equity universe, commonly referred to as "smid" cap. The Russell 2500 Index is constructed to provide a comprehensive and unbiased barometer for the small to mid-cap segment.
- The Russell 3000 Growth Index combines the large-cap Russell 1000 Growth, the small-cap Russell 2000 Growth and the Russell Microcap Growth Index. It includes companies that are considered more growth oriented relative to the overall market as defined by Russell's leading style methodology. The Russell 3000 Growth Index is constructed to provide a comprehensive, unbiased, and stable barometer of the growth opportunities within the broad market.
- The Russell 3000 Healthcare Index is an unmanaged index that measures the performance of those companies in the Russell 3000 Index involved in the medical services or healthcare field. Also included are companies involved in research, development and production of pharmaceuticals and biotechnology
- The Russell 3000 Index measures the performance of the largest 3,000 US companies of the investable US equity market. The Russell 3000 Index is constructed to provide a comprehensive, unbiased and stable barometer of the broad market.

- The Russell 3000 Value Index measures the performance of the broad value segment of the US equity value universe. It includes those Russell 3000 companies with lower price-to-book ratios and lower forecasted growth values. The Russell 3000 Value Index is constructed to provide a comprehensive, unbiased and stable barometer of the broad value market.
- The Russell Microcap Growth Index measures the performance of the microcap growth segment of the US equity market. It includes Russell Microcap companies with relatively higher price-to-book ratios, higher I/B/E/S forecast medium term (2 year) growth and higher sales per share historical growth (5 years).
- The Russell Microcap Index measures the performance of the microcap segment of the US equity market. The Russell Microcap Index is constructed to provide a comprehensive and unbiased barometer for the microcap segment trading on national exchanges.
- The Russell Midcap Growth Index measures the performance of the midcap growth segment of the U.S. equity universe. It includes those Russell Midcap Index companies with higher growth earning potential as defined by Russell's leading style methodology. The Russell Midcap Growth Index is constructed to provide a comprehensive and unbiased barometer of the mid-cap growth market.
- The Russell Midcap Index measures the performance of the mid-cap segment of the US equity universe. The Russell Midcap Index is constructed to provide a comprehensive and unbiased barometer for the mid-cap segment.
- The S&P 500 Index is an unmanaged index considered representative of large-cap growth stocks.




#### HYPOTHETICAL \$10,000 INVESTMENT IN CLASS A SHARES

The chart above illustrates the change in value of a hypothetical \$10,000 investment made in the Alger Capital Appreciation Fund Class A shares, with a maximum sales charge of 5.25%, and the Russell 1000 Growth Index (an unmanaged index of common stocks) for the ten years ended April 30, 2023. Figures for the Alger Capital Appreciation Fund Class A shares and the Russell 1000 Growth Index include reinvestment of dividends. Figures for the Alger Capital Appreciation Fund Class A shares also include reinvestment of capital gains. Performance for Alger Capital Appreciation Fund Class C and Class Z shares will vary from the results shown above due to differences in expenses and sales charges those classes bear. Investors cannot invest directly in any index. Index performance does not reflect deduction for fees, expenses, or taxes.

AVERAGE ANNUAL TOTAL RETURNS			
	1 YEAR	5 YEARS	10 YEARS
Class A	(7.95)%	7.71%	11.37%
Class C	(4.51)%	8.06%	11.14%
Class Z	(2.50)%	9.25%	12.35%
Russell 1000 Growth Index	2.34%	13.80%	14.46%

The performance data quoted represents past performance, which is not an indication or a guarantee of future results. The Fund's average annual total returns include changes in share price and reinvestment of dividends and capital gains. Class A returns reflect the maximum initial sales charge and Class C returns reflect the applicable contingent deferred sales charge. The chart and table above do not reflect the deduction of taxes that a shareholder would have paid on Fund distributions or on the redemption of Fund shares. Investment return and principal will fluctuate and the Fund's shares, when redeemed, may be worth more or less than their original cost. Current performance may be higher or lower than the performance quoted. For updated performance, visit us at www.alger.com or call us at (800) 992-3863.




The chart above illustrates the change in value of a hypothetical \$10,000 investment made in the Alger 35 Fund Class Z shares and the S&P 500 Index (an unmanaged index of common stocks) from March 29, 2018, the inception date of the Alger 35 Fund Class Z shares, through April 30, 2023. Effective May 7, 2021, Class P shares of the Alger 35 Fund were reclassified as Class Z shares. The reclassified Class Z shares have the same annual returns as the Class P shares because the shares are invested in the same portfolio of securities and the reclassified Class Z shares have the same expenses as the Fund's Class P shares. Historical performance prior to May 7, 2021 is that of the Fund's Class P shares. Figures for the Alger 35 Fund Class Z shares and the S&P 500 Index include reinvestment of dividends. Figures for the Alger 35 Fund Class Z shares also include reinvestment of capital gains. Investors cannot invest directly in any index. Index performance does not reflect deduction for fees, expenses, or taxes.

# PERFORMANCE COMPARISON AS OF 4/30/23

AVERAGE ANNUAL TOTAL RETURNS				
			Since	
	1 YEAR	5 YEARS	Inception	
Class Z (Inception 3/29/18)	(8.70)%	9.35%	9.41%	
S&P 500 Index	2.66%	11.45%	11.32%	

The performance data quoted represents past performance, which is not an indication or a guarantee of future results. The Fund's average annual total returns include changes in share price and reinvestment of dividends and capital gains. Effective May 7, 2021, Class P shares of the Alger 35 Fund were reclassified as Class Z shares. The reclassified Class Z shares have the same annual returns as the Class P shares because the shares are invested in the same portfolio of securities and the reclassified Class Z shares have the same expenses as the Fund's Class P shares. Historical performance prior to May 7, 2021 is that of the Fund's Class P shares. The chart and table above do not reflect the deduction of taxes that a shareholder would have paid on Fund distributions or on the redemption of Fund shares. Investment return and principal will fluctuate and the Fund's shares, when redeemed, may be worth more or less than their original cost. Current performance may be higher or lower than the performance quoted. For updated performance, visit us at www.alger. com or call us at (800) 992-3863.






The chart above illustrates the change in value of a hypothetical \$10,000 investment made in the Alger Growth & Income Fund Class A shares, with a maximum sales charge of 5.25%, and the S&P 500 Index (an unmanaged index of common stocks) for the ten years ended April 30, 2023. Figures for the Alger Growth & Income Fund Class A shares and the S&P 500 Index include reinvestment of dividends. Figures for the Alger Growth & Income Fund Class A shares also include reinvestment of capital gains. Performance for the Alger Growth & Income Fund Class C and Class Z shares will vary from the results shown above due to differences in expenses and sales charges those classes bear. Investors cannot invest directly in any index. Index performance does not reflect deduction for fees, expenses, or taxes.

PERFORMANCE COMPARISON AS OF	F 4/30/23
------------------------------	-----------

AVERAGE ANNUAL TOTAL RETURNS			
	1 YEAR	5 YEARS	10 YEARS
Class A	(2.11)%	10.72%	10.81%
Class C	1.54%	11.08%	10.57%
Class Z	3.62%	12.31%	11.75%
S&P 500 Index	2.66%	11.45%	12.20%

The performance data quoted represents past performance, which is not an indication or a guarantee of future results. The Fund's average annual total returns include changes in share price and reinvestment of dividends and capital gains. Class A returns reflect the maximum initial sales charge and Class C returns reflect the applicable contingent deferred sales charge. The chart and table above do not reflect the deduction of taxes that a sharebolder would bave paid on Fund distributions or on the redemption of Fund shares. Investment return and principal will fluctuate and the Fund's shares, when redeemed, may be worth more or less than their original cost. Current performance may be higher or lower than the performance quoted. For updated performance, visit us at www.alger.com or call us at (800) 992-3863.



#### HYPOTHETICAL \$10,000 INVESTMENT IN CLASS A SHARES

The chart above illustrates the change in value of a hypothetical \$10,000 investment made in the Alger Mid Cap Growth Fund Class A shares, with a maximum sales charge of 5.25%, and the Russell Midcap Growth Index (an unmanaged index of common stocks) for the ten years ended April 30, 2023. Figures for the Alger Mid Cap Growth Fund Class A shares and Russell Midcap Growth Index include reinvestment of dividends. Figures for the Alger Mid Cap Growth Fund Class A shares also include reinvestment of capital gains. Performance for the Alger Mid Cap Growth Fund Class B, Class C and Class Z shares will vary from the results shown above due to differences in expenses and sales charges those classes bear. Investors cannot invest directly in any index. Index performance does not reflect deduction for fees, expenses, or taxes.


#### PERFORMANCE COMPARISON AS OF 4/30/23

AVERAGE ANNUAL TOTAL RETURNS						
1 YEAR 5 YEARS 10 YEARS						
Class A	(7.61)%	7.00%	9.06%			
Class B	(7.33)%	7.86%	9.21%			
Class C	(4.17)%	7.30%	8.77%			
Russell Midcap Growth Index	1.60%	8.96%	10.84%			
			Since			
	1 YEAR	5 YEARS	Inception			
Class Z (Inception 5/28/15)	(2.08)%	8.49%	7.76%			
Russell Midcap Growth Index	1.60%	8.96%	8.85%			

The performance data quoted represents past performance, which is not an indication or a guarantee of future results. The Fund's average annual total returns include changes in share price and reinvestment of dividends and capital gains. Class A returns reflect the maximum initial sales charge and Class B and C returns reflect the applicable contingent deferred sales charge. The chart and table above do not reflect the deduction of taxes that a shareholder would have paid on Fund distributions or on the redemption of Fund shares. Investment return and principal will fluctuate and the Fund's shares, when redeemed, may be worth more or less than their original cost. Current performance may be higher or lower than the performance quoted. For updated performance, visit us at www.alger.com or call us at (800) 992-3863.

\* Pursuant to the U.S. Securities and Exchange Commission's rules on Fair Fund and Disgorgement Plans, the Alger Mid Cap Growth Fund received a Fair Fund distribution of \$9,346,397 on September 10, 2021, which contributed approximately 0.61% and 0.31% to its five and ten year annual returns, respectively.






The chart above illustrates the change in value of a hypothetical \$10,000 investment made in the Alger Mid Cap Focus Fund Class I shares and the Russell Midcap Growth Index (an unmanaged index of common stocks) from June 14, 2019, the inception date of the Alger Mid Cap Focus Fund Class I shares, through April 30, 2023. Figures for the Alger Mid Cap Focus Fund Class I shares and the Russell Midcap Growth Index include reinvestment of dividends. Figures for the Alger Mid Cap Focus Fund Class I shares also include reinvestment of capital gains. Performance for the Alger Mid Cap Focus Fund Class A, C, Y and Z shares will vary from the results shown above due to differences in the expenses and sales charges that those classes bear. Investors cannot invest directly in any index. Index performance does not reflect deduction for fees, expenses, or taxes.

AVERAGE ANNUAL TOTAL RETURNS			
			Since
	1 YEAR	5 YEARS	Inception
Class I (Inception 6/14/19)	(14.99)%	n/a	7.96%
Class Z (Inception 6/14/19)	(14.72)%	n/a	8.27%
Russell Midcap Growth Index	1.60%	n/a	7.40%
			0.
			Since
	1 YEAR	5 YEARS	Inception
Class Y (Inception 2/26/21)	(14.66)%	n/a	(18.05)%
Russell Midcap Growth Index	1.60%	n/a	(5.90)%
			Since
	1 YEAR	5 YEARS	Inception
Class A (Inception 7/29/21)	(19.54)%	n/a	(24.73)%
Class C (Inception 7/29/21)	(16.56)%	n/a	(22.96)%
Russell Midcap Growth Index	1.60%	n/a	(12.40)%
			(.=

The performance data quoted represents past performance, which is not an indication or a guarantee of future results. The Fund's average annual total returns include changes in share price and reinvestment of dividends and capital gains. Class A returns reflect the maximum initial sales charge and Class C returns reflect the applicable contingent deferred sales charge. The chart and table above do not reflect the deduction of taxes that a sharebolder would bave paid on Fund distributions or on the redemption of Fund shares. Investment return and principal will fluctuate and the Fund's shares, when redeemed, may be worth more or less than their original cost. Current performance may be higher or lower than the performance quoted. For updated performance, visit us at www.alger.com or call us at (800) 992-3863.





— 10 years ended 4/30/23


The chart above illustrates the change in value of a hypothetical \$10,000 investment made in the Alger Weatherbie Specialized Growth Fund Class A shares, with a maximum sales charge of 5.25%, and the Russell 2500 Growth Index (an unmanaged index of common stocks) for the ten years ended April 30, 2023. From August 30, 2017 to September 30, 2019, the Fund was named Alger SMid Cap Focus Fund. Prior to August 30, 2017, the Fund followed different investment strategies under the name Alger SMid Cap Growth Fund and prior to March 1, 2017 was managed by different portfolio managers. Accordingly, performance prior to those dates does not reflect the Fund's current investment strategies and investment personnel. Figures for the Alger Weatherbie Specialized Growth Fund Class A shares also include reinvestment of dividends. Figures for the Alger Weatherbie Specialized Growth Fund Class C, Class I, Class Y and Class Z shares will vary from the results shown above due to differences in expenses and sales charges those classes bear. Investors cannot invest directly in any index. Index performance does not reflect deduction for fees, expenses, or taxes.

#### PERFORMANCE COMPARISON AS OF 4/30/23

AVERAGE ANNUAL TOTAL RETURNS			
	1 YEAR	5 YEARS	10 YEARS
Class A	(15.47)%	5.20%	8.68%
Class C	(12.29)%	5.54%	8.42%
Class I	(10.69)%	6.38%	9.27%
Class Z	(10.45)%	6.71%	9.62%
Russell 2500 Growth Index	(0.07)%	6.69%	9.87%
			Since
	1 YEAR	5 YEARS	Inception
Class Y (Inception 8/30/17)	(10.30)%	6.78%	8.81%
Russell 2500 Growth Index	(0.07)%	6.69%	8.36%

The performance data quoted represents past performance, which is not an indication or a guarantee of future results. The Fund's average annual total returns include changes in share price and reinvestment of dividends and capital gains. Class A returns reflect the maximum initial sales charge and Class C returns reflect the applicable contingent deferred sales charge. The chart and table above do not reflect the deduction of taxes that a shareholder would have paid on Fund distributions or on the redemption of Fund shares. From August 30, 2017 to September 30, 2019, the Fund was named "Alger SMid Cap Focus Fund." Prior to August 30, 2017, the Fund followed different investment strategies under the name "Alger SMid Cap Growth Fund" and prior to March 1, 2017 was managed by different portfolio managers. Accordingly, performance prior to those dates does not reflect the Fund's current investment strategies and investment personnel. Investment return and principal will fluctuate and the Fund's shares, when redeemed, may be worth more or less than their original cost. Current performance may be higher or lower than the performance quoted. For updated performance, visit us at www.alger. com or call us at (800) 992-3863.

#### HYPOTHETICAL \$10,000 INVESTMENT IN CLASS A SHARES



The chart above illustrates the change in value of a hypothetical \$10,000 investment made in the Alger Small Cap Growth Fund Class A shares, with a maximum sales charge of 5.25%, and the Russell 2000 Growth Index (an unmanaged index of common stocks) for the ten years ended April 30, 2023. Figures for the Alger Small Cap Growth Fund Class A shares and the Russell 2000 Growth Index include reinvestment of dividends. Figures for the Alger Small Cap Growth Fund Class A shares also include reinvestment of capital gains. Performance for the Alger Small Cap Growth Fund Class B, Class C, Class Y and Class Z shares will vary from the results shown above due to differences in expenses and sales charges those classes bear. Investors cannot invest directly in any index. Index performance does not reflect deduction for fees, expenses, or taxes.

# PERFORMANCE COMPARISON AS OF 4/30/23


AVERAGE ANNUAL TOTAL RETURNS			
	1 YEAR	5 YEARS	10 YEARS
Class A	(14.88)%	3.96%	7.33%
Class B	(14.84)%	4.56%	7.40%
Class C	(11.85)%	4.22%	7.04%
Class Z	(9.90)%	5.45%	8.28%
Russell 2000 Growth Index	0.72%	4.00%	8.44%

	1 YEAR	5 YEARS	Since Inception
Class Y (Inception 12/31/21)	(9.79)%	n/a	(27.04)%
Russell 2000 Growth Index	0.72%	n/a	(17.76)%

The performance data quoted represents past performance, which is not an indication or a guarantee of future results. The Fund's average annual total returns include changes in share price and reinvestment of dividends and capital gains. Class A returns reflect the maximum initial sales charge and Class B and C returns reflect the applicable contingent deferred sales charge. The chart and table above do not reflect the deduction of taxes that a shareholder would bave paid on Fund distributions or on the redemption of Fund shares. Investment return and principal will fluctuate and the Fund's shares, when redeemed, may be worth more or less than their original cost. Current performance may be higher or lower than the performance quoted. For updated performance, visit us at www.alger.com or call us at (800) 992-3863.

\* Pursuant to the U.S. Securities and Exchange Commission's Rules on Fair Fund and Disgorgement Plans, the Alger Small Cap Growth Fund received a Fair Fund distribution of \$3,738,004 on September 10, 2021, which contributed approximately 0.12% and 0.06% to its five and ten year annual returns, respectively.

#### HYPOTHETICAL \$10,000 INVESTMENT IN CLASS A SHARES




The chart above illustrates the change in value of a hypothetical \$10,000 investment made in the Alger Small Cap Focus Fund Class A shares, with an initial 5.25% maximum sales charge, and the Russell 2000 Growth (an unmanaged index of common stocks) for the ten years ended April 30, 2023. Prior to August 7, 2015, the Fund followed different investment strategies under the name "Alger Growth Opportunities Fund" and prior to February 12, 2015 was managed by a different portfolio manager. Accordingly, performance prior to those dates does not reflect the Fund's current investment strategies and investment personnel. Figures for the Alger Small Cap Focus Fund Class A shares and the Russell 2000 Growth Index include reinvestment of dividends. Figures for the Alger Small Cap Focus Fund Class C, Class I, Class Y and Class Z shares will vary from the results shown above due to differences in expenses and sales charges those classes bear. Investors cannot invest directly in any index. Index performance does not reflect deduction for fees, expenses, or taxes.

# PERFORMANCE COMPARISON AS OF 4/30/23

AVERAGE ANNUAL TOTAL RETURNS				
	1 YEAR	5 YEARS	10 YEARS	
Class A	(11.60)%	0.66%	7.36%	
Class C	(8.12)%	1.07%	7.20%	
Class I	(6.44)%	1.85%	8.05%	
Class Z	(6.18)%	2.17%	8.37%	
Russell 2000 Growth Index	0.72%	4.00%	8.44%	

	1 YEAR	5 YEARS	Since Inception
Class Y (Inception 2/28/17)	(6.18)%	2.17%	6.72%
Russell 2000 Growth Index	0.72%	4.00%	6.35%

The performance data quoted represents past performance, which is not an indication or a guarantee of future results. The Fund's average annual total returns include changes in share price and reinvestment of dividends and capital gains. Class A returns reflect the maximum initial sales charge and Class C returns reflect the applicable contingent deferred sales charge. The chart and table above do not reflect the deduction of taxes that a shareholder would have paid on Fund distributions or on the redemption of Fund shares. Prior to August 7, 2015, the Fund followed different investment strategies under the name "Alger Growth Opportunities Fund" and prior to February 12, 2015 was managed by a different portfolio manager. Accordingly, performance prior to those dates does not reflect the fund's current investment strategies and investment. Investment return and principal will fluctuate and the Fund's shares, when redeemed, may be worth more or less than their original cost. Current performance may be higher or lower than the performance quoted. For updated performance, visit us at www.alger.com or call us at (800) 992-3863.



#### HYPOTHETICAL \$10,000 INVESTMENT IN CLASS A SHARES

The chart above illustrates the change in value of a hypothetical \$10,000 investment made in the Alger International Focus Fund Class A shares, with a maximum sales charge of 5.25%, and MSCI AC World Index ex USA (an unmanaged index of common stocks) for the ten years ended April 30, 2023. Before March 28, 2018, the Fund followed different investment strategies and was managed by different portfolio managers. Prior to May 31, 2013, the Fund was named "Alger International Growth Fund," and from May 31, 2013 to August 15, 2018 the Fund was named "Alger International Growth Fund." Performance prior to March 28, 2018 reflects these prior management styles and does not reflect the Fund's current investment strategies and investment personnel. Figures for the Alger International Focus Fund Class A shares and the index include reinvestment of dividends. Figures for the Alger International Focus Fund Class A, class I and Class Z shares will vary from the results shown above due to differences in expenses and sales charges those classes bear. Investors cannot invest directly in any index. Index performance does not reflect deduction for fees, expenses, or taxes.

#### PERFORMANCE COMPARISON AS OF 4/30/23


AVERAGE ANNUAL TOTAL RETURNS				
	1 YEAR	5 YEARS	10 YEARS	
Class A	(7.56)%	2.03%	3.91%	
Class B	(7.31)%	2.72%	4.07%	
Class C	(4.16)%	2.31%	3.66%	
Class Z	(1.99)%	3.58%	4.93%	
MSCI AC World Index ex USA	3.61%	2.99%	4.45%	

	1 YEAR	5 YEARS	Since Inception
Class I (Inception 5/31/13)	(2.36)%	3.27%	4.59%
MSCI AC World Index ex USA	3.61%	2.99%	4.73%

The performance data quoted represents past performance, which is not an indication or a guarantee of future results. The Fund's average annual total returns include changes in share price and reinvestment of dividends and capital gains. Class A returns reflect the maximum initial sales charge and Class B and C returns reflect the applicable contingent deferred sales charge. The chart and table above do not reflect the deduction of taxes that a sharebolder would have paid on Fund distributions or on the redemption of Fund shares. Investment return and principal will fluctuate and the Fund's shares, when redeemed, may be worth more or less than their original cost. Before March 28, 2018, the Fund followed different investment strategies and was managed by different portfolio managers. Prior to May 31, 2013, the Fund was named "Alger Large Cap Growth Fund," and from May 31, 2013 to August 15, 2018 the Fund was not reflect the Fund's entrement or the strategies and investment performance may be bigher or lower than the performance quoted. For updated performance, visit us at wmw.alger.com or call us at (800) 992-3863.

\* Pursuant to the U.S. Securities and Exchange Commission's Rules on Fair Fund and Disgorgement Plans, the Alger International Focus Fund received a Fair Fund distribution of \$159,091 on September 10, 2021, which contributed approximately 0.02% and 0.01% to its five and ten year annual returns, respectively.





The chart above illustrates the change in value of a hypothetical \$10,000 investment made in the Alger Health Sciences Fund Class A shares, with a maximum sales charge of 5.25%, the Russell 3000 Healthcare Index and the S&P 500 Index (each an unmanaged index of common stocks) for the ten years ended April 30, 2023. Figures for the Alger Health Sciences Fund Class A shares, the Russell 3000 Healthcare Index and the S&P 500 Index include reinvestment of dividends. Figures for the Alger Health Sciences Fund Class A shares, the Russell 3000 Healthcare Index and the S&P 500 Index include reinvestment of dividends. Figures for the Alger Health Sciences Fund Class A shares also include reinvestment of capital gains. Performance for the Alger Health Sciences Fund Class C and Class Z shares will vary from the results shown above due to differences in expenses and sales charges those classes bear. Investors cannot invest directly in any index. Index performance does not reflect deduction for fees, expenses, or taxes.

#### PERFORMANCE COMPARISON AS OF 4/30/23

AVERAGE ANNUAL TOTAL RETURNS					
	1 YEAR	5 YEARS	10 YEARS		
Class A	(3.56)%	5.00%	10.18%		
Class C	0.01%	5.32%	9.92%		
Russell 3000 Healthcare Index	4.61%	11.18%	12.60%		
S&P 500 Index	2.66%	11.45%	12.20%		
			Since		
	1 YEAR	5 YEARS	Inception		
Class Z (Inception 5/28/15)	2.16%	6.50%	6.93%		
Russell 3000 Healthcare Index	4.61%	11.18%	8.85%		
S&P 500 Index	2.66%	11.45%	10.96%		

The performance data quoted represents past performance, which is not an indication or a guarantee of future results. The Fund's average annual total returns include changes in share price and reinvestment of dividends and capital gains. Class A returns reflect the maximum initial sales charge and Class C returns reflect the applicable contingent deferred sales charge. The chart and table above do not reflect the deduction of taxes that a shareholder would have paid on Fund distributions or on the redemption of Fund shares. Investment return and principal will fluctuate and the Fund's shares, when redeemed, may be worth more or less than their original cost. Current performance may be higher or lower than the performance quoted. For updated performance, visit us at www.alger.com or call us at (800) 992-3863.

\* Pursuant to the U.S. Securities and Exchange Commission's Rules on Fair Fund and Disgorgement Plans, the Alger Health Sciences Fund received a Fair Fund distribution of \$179,832 on September 10, 2021, which contributed approximately 0.01% to its five and ten year annual returns.

## PORTFOLIO SUMMARY† April 30, 2023 (Unaudited)

SECTORS	Alger Capital Appreciation Fund	Alger 35 Fund	Alger Growth & Income Fund	Alger Mid Cap Growth Fund
Communication Services	9.9%	17.4%	8.6%	4.3%
Consumer Discretionary	17.0	28.7	6.9	14.4
Consumer Staples	0.0	0.0	7.3	1.0
Energy	3.7	6.6	6.0	3.8
Financials	7.7	0.0	12.4	4.7
Healthcare	15.9	10.0	13.8	18.7
Industrials	6.9	4.5	5.9	17.7
Information Technology	36.0	27.9	27.0	27.3
Materials	2.0	2.7	2.5	3.4
Real Estate	0.0	1.6	3.4	3.6
Utilities	0.0	0.0	1.4	0.0
Short-Term Investments and				
Net Other Assets	0.9	0.6	4.8	1.1
	100.0%	100.0%	100.0%	100.0%

SECTORS	Alger Mid Cap Focus Fund	Alger Weatherbie Specialized Growth Fund	Alger Small Cap Growth Fund	Alger Small Cap Focus Fund
Communication Services	5.3%	0.3%	3.9%	0.0%
Consumer Discretionary	12.2	11.2	11.2	3.6
Consumer Staples	0.0	0.0	6.1	0.9
Energy	3.6	5.8	5.9	6.9
Financials	0.9	10.8	2.3	0.0
Healthcare	26.4	24.2	30.3	49.4
Industrials	10.9	19.1	8.3	9.2
Information Technology	37.5	18.1	26.9	27.8
Materials	1.2	0.0	2.7	0.0
Real Estate	0.0	6.0	1.5	0.0
Short-Term Investments and				
Net Other Assets	2.0	4.5	0.9	2.2
	100.0%	100.0%	100.0%	100.0%

SECTORS	Alger Health Sciences Fund
Healthcare	98.3%
Short-Term Investments and	
Net Other Assets	1.7
	100.0%

#### PORTFOLIO SUMMARY† April 30, 2023 (Unaudited) (Continued)

	Alger International
COUNTRY	Focus Fund
Argentina	2.8%
Australia	3.7
Brazil	5.8
China	11.2
Denmark	2.5
France	14.0
Germany	6.2
Hong Kong	4.0
India	5.3
Ireland	3.0
Italy	6.8
Japan	3.3
Mexico	2.5
Netherlands	8.6
Norway	1.1
Spain	1.9
Sweden	1.7
Switzerland	3.6
United Kingdom	5.4
United States	2.7
Short-Term Investments,	
Cash and Net Other Assets	3.9
	100.0%

† Based on net assets for each Fund.

# THE ALGER FUNDS | ALGER CAPITAL APPRECIATION FUND Schedule of Investments April 30, 2023 (Unaudited)

COMMON STOCKS—98.8%	SHARES	VALUE
ADVERTISING-0.7%		
The Trade Desk, Inc., CI. A*	197,203	12,688,04
AEROSPACE & DEFENSE—3.4%		
HEICO Corp.	83,456	14,074,02
TransDigm Group, Inc.	58,538	44,781,57
		58,855,59
APPAREL ACCESSORIES & LUXURY GOODS-1.2%		
LVMH Moet Hennessy Louis Vuitton SE	21,766	20,936,30
APPAREL RETAIL—0.2%		
The TJX Cos., Inc.	49,374	3,891,65
APPLICATION SOFTWARE—4.3%		
Adobe, Inc.*	30,535	11,528,79
Cadence Design Systems, Inc.*	59,400	12,441,33
Datadog, Inc., Cl. A*	136,286	9,182,95
Intuit, Inc.	69,159	30,703,13
Salesforce, Inc.*	54,383	10,787,95
		74,644,16
AUTOMOBILE MANUFACTURERS—1.2%		
Tesla, Inc.*	120,890	19,863,43
AUTOMOTIVE PARTS & EQUIPMENT—0.1%		
Mobileye Global, Inc., Cl. A*	23,970	902,23
BIOTECHNOLOGY—7.0%		
AbbVie, Inc.	143,306	21,656,40
Biogen, Inc.*	41,866	12,736,89
Natera, Inc.*	627,777	31,840,84
Prometheus Biosciences, Inc.*	115,528	22,406,65
Regeneron Pharmaceuticals, Inc.*	10,783	8,645,70
Vaxcyte, Inc.*	345,362	14,791,85
Vertex Pharmaceuticals, Inc.*	26,141	8,907,02
		120,985,38
BROADLINE RETAIL—7.9%		
Amazon.com, Inc.*	854,089	90,063,68
MercadoLibre, Inc.*	36,642	46,809,78
		136,873,47
CARGO GROUND TRANSPORTATION-0.4%		
Old Dominion Freight Line, Inc.	19,853	6,360,70
CASINOS & GAMING—3.5%		
Flutter Entertainment PLC*	92,458	18,474,73
Las Vegas Sands Corp.*	425,304	27,155,66
MGM Resorts International	334,872	15,042,45
		60,672,84
COMMUNICATIONS EQUIPMENT—0.8%		
Arista Networks, Inc.*	81,985	13,130,71
CONSTRUCTION MACHINERY & HEAVY TRANSPORTATION E		
Wabtec Corp.	100,723	9,837,61

## THE ALGER FUNDS | ALGER CAPITAL APPRECIATION FUND Schedule of Investments April 30, 2023 (Unaudited) (Continued)

COMMON STOCKS—98.8% (CONT.)	SHARES	VALUE
CONSTRUCTION MATERIALS—1.2%		
Martin Marietta Materials, Inc.	58,096	\$ 21,100,46
COPPER-0.1%		
Freeport-McMoRan, Inc.	63,995	2,426,05
DIVERSIFIED BANKS—1.0%		
JPMorgan Chase & Co.	122,625	16,951,68
DIVERSIFIED SUPPORT SERVICES—0.4%		
Cintas Corp.	13,355	6,086,808
ELECTRICAL COMPONENTS & EQUIPMENT-0.4%		
Eaton Corp. PLC	41,193	6,884,17
ENVIRONMENTAL & FACILITIES SERVICES—1.2%		
GFL Environmental, Inc.	319,336	11,591,89
Waste Management, Inc.	55,323	9,186,38
		20,778,28
FINANCIAL EXCHANGES & DATA-2.1%		
CME Group, Inc., Cl. A	57,769	10,731,74
S&P Global, Inc.	68,654	24,892,56
		35,624,31
FOOTWEAR-0.8%		
NIKE, Inc., Cl. B	112,454	14,250,17
HEALTHCARE DISTRIBUTORS-0.5%		
McKesson Corp.	24,732	9,008,38
HEALTHCARE EQUIPMENT-2.9%		
Boston Scientific Corp.*	367,571	19,157,80
Dexcom, Inc.*	77,537	9,408,34
Intuitive Surgical, Inc.*	71,083	21,411,62
		49,977,76
HEALTHCARE FACILITIES—1.1%		
Acadia Healthcare Co., Inc.*	252,051	18,220,76
HOTELS RESORTS & CRUISE LINES—1.6%		
Booking Holdings, Inc.*	4,774	12,824,44
Trip.com Group Ltd. <sup>#,*</sup>	413,506	14,683,59
		27,508,04
INTERACTIVE HOME ENTERTAINMENT-0.0%		
Roblox Corp., Cl. A*	22,768	810,54
INTERACTIVE MEDIA & SERVICES—5.8%		
Alphabet, Inc., Cl. C*	542,109	58,667,03
Meta Platforms, Inc., Cl. A*	171,577	41,233,38
		99,900,42
INTERNET SERVICES & INFRASTRUCTURE-0.2%		
MongoDB, Inc., Cl. A*	14,057	3,373,11
INVESTMENT BANKING & BROKERAGE-0.1%	,	.,,.
LPL Financial Holdings, Inc.	12,291	2,566,85
,	, !	_,,

## THE ALGER FUNDS | ALGER CAPITAL APPRECIATION FUND Schedule of Investments April 30, 2023 (Unaudited) (Continued)

COMMON STOCKS—98.8% (CONT.)	SHARES	VALUE
LIFE SCIENCES TOOLS & SERVICES-1.3%		
Charles River Laboratories International, Inc.*	19,758	\$ 3,756,391
Danaher Corp.	80,344	19,034,297
		22,790,688
MANAGED HEALTHCARE—1.9%		
UnitedHealth Group, Inc.	68,321	33,620,081
MOVIES & ENTERTAINMENT—3.4%		
Liberty Media Corp. Series C Liberty Formula One*	141,656	10,226,14
Live Nation Entertainment, Inc.*	103,100	6,988,118
Netflix, Inc.*	77,280	25,496,990
The Walt Disney Co.*	157,213	16,114,33
		58,825,58
OIL & GAS EQUIPMENT & SERVICES—1.1%		
Schlumberger Ltd.	367,143	18,118,50
OIL & GAS EXPLORATION & PRODUCTION—2.1%		
Diamondback Energy, Inc.	121,047	17,212,88
Hess Corp.	43,459	6,304,16
Pioneer Natural Resources Co.	59,129	12,863,51
		36,380,56
OIL & GAS STORAGE & TRANSPORTATION-0.5%		
Cheniere Energy, Inc.	53,229	8,144,03
PASSENGER GROUND TRANSPORTATION—0.5%		
Uber Technologies, Inc.*	301,094	9,348,96
PHARMACEUTICALS—1.2%		
AstraZeneca PLC <sup>#</sup>	168,450	12,333,90
Catalent, Inc.*	44,882	2,249,48
Eli Lilly & Co.	12,861	5,091,15
Reata Pharmaceuticals, Inc., CI. A*	16,797	1,660,55
		21,335,10
PROPERTY & CASUALTY INSURANCE-0.5%		
The Progressive Corp.	64,354	8,777,88
RESTAURANTS-0.5%		
Yum China Holdings, Inc.	138,629	8,481,32
SEMICONDUCTORS—9.1%		
Advanced Micro Devices, Inc.*	154,347	13,793,99
First Solar, Inc.*	42,049	7,677,30
Marvell Technology, Inc.	657,058	25,940,65
NVIDIA Corp.	319,212	88,578,13
ON Semiconductor Corp.*	100,221	7,211,90
Taiwan Semiconductor Manufacturing Co., Ltd.#	166,790	14,060,39
		157,262,38
SPECIALTY CHEMICALS—0.7%		
Albemarle Corp.	62,253	11,545,44

#### THE ALGER FUNDS | ALGER CAPITAL APPRECIATION FUND Schedule of Investments April 30, 2023 (Unaudited) (Continued)

	0110750		
COMMON STOCKS—98.8% (CONT.)	SHARES		VALUE
SYSTEMS SOFTWARE—14.2%		•	o
Microsoft Corp.	714,180	\$	219,438,947
Oracle Corp.	89,050		8,434,816
Palo Alto Networks, Inc.*	48,981		8,937,073
ServiceNow, Inc.*	18,241		8,380,280
			245,191,116
TECHNOLOGY HARDWARE STORAGE & PERIPHERALS—7.1%			
Apple, Inc.	722,188		122,540,860
TRANSACTION & PAYMENT PROCESSING SERVICES—4.0%			
PayPal Holdings, Inc.*	101,687		7,728,212
Visa, Inc., Cl. A	261,012		60,745,323
			68,473,535
TOTAL COMMON STOCKS			
(Cost \$1,104,426,270)			1,705,946,076
PREFERRED STOCKS—0.1%	SHARES		VALUE
DATA PROCESSING & OUTSOURCED SERVICES—0.1%			
Chime Financial, Inc., Series G <sup>*,@,(a)</sup>	27,841		1,197,441
(Cost \$1,922,972)			1,197,441
SPECIAL PURPOSE VEHICLE—0.2%			VALUE
DATA PROCESSING & OUTSOURCED SERVICES—0.2%			
Crosslink Ventures Capital C, LLC, CI. A*.@.(a).(b)			2,896,878
(Cost \$2,775,000)			2,896,878
Total Investments			
(Cost \$1,109,124,242)	99.1%	\$	1,710,040,395
Affiliated Securities (Cost \$2,775,000)			2,896,878
Unaffiliated Securities (Cost \$1,106,349,242)			1,707,143,517
Other Assets in Excess of Liabilities	0.9%		15,620,089
NET ASSETS	100.0%	\$	1,725,660,484

# American Depositary Receipts.

(9) Security is valued in good faith at fair value determined using significant unobservable inputs pursuant to procedures established by the Valuation Designee (as defined in Note 2).

<sup>(b)</sup> Deemed an affiliate of the Fund in accordance with Section 2(a)(3) of the Investment Company Act of 1940. See Note 11 - Affiliated Securities.

\* Non-income producing security.

<sup>®</sup> Restricted security - Investment in security not registered under the Securities Act of 1933. Sales or transfers of the investment may be restricted only to qualified buyers.

			<u>% of net assets</u>		<u>% of net assets</u>
	<u>Acquisition</u>	<u>Acquisition</u>	(Acquisition	<u>Market</u>	<u>as of</u>
<u>Security</u>	<u>Date(s)</u>	<u>Cost</u>	<u>Date)</u>	<u>Value</u>	<u>4/30/2023</u>
Chime Financial, Inc., Series G	8/24/21	\$1,922,972	0.06%	\$1,197,441	0.07%
Crosslink Ventures Capital C, LLC, Cl. A	10/2/20	2,775,000	0.08%	2,896,878	0.17%
Total				\$4,094,319	0.24%

## THE ALGER FUNDS | ALGER 35 FUND Schedule of Investments April 30, 2023 (Unaudited)

COMMON STOCKS—99.4%	SHARES	VALUE
ADVERTISING—3.2%		
The Trade Desk, Inc., CI. A*	12,762	\$ 821,107
AEROSPACE & DEFENSE—4.5%		
HEICO Corp.	6,961	1,173,903
APPLICATION SOFTWARE—3.5%		
HubSpot, Inc.*	1,243	523,241
Paycom Software, Inc.*	1,310	380,384
•		903,625
BIOTECHNOLOGY—5.9%		
Natera, Inc.*	19,289	978,338
Vaxcyte, Inc.*	12,828	549,423
		1,527,761
BROADLINE RETAIL—10.4%		
Amazon.com, Inc.*	11,277	1,189,160
JD.com. Inc.#	11,238	401,421
MercadoLibre, Inc.*	864	1,103,751
		2,694,332
CASINOS & GAMING-7.0%		_,,.
Flutter Entertainment PLC*	4.240	847,227
Las Vegas Sands Corp.*	8,758	559,198
MGM Resorts International	9,102	408.862
	0,102	1,815,287
CONSTRUCTION MATERIALS-2.7%		.,•.•,=•
Martin Marietta Materials, Inc.	1,906	692,259
ELECTRONIC EQUIPMENT & INSTRUMENTS-2.4%	1,000	,
908 Devices. Inc.*	92,106	622,637
FOOTWEAR-4.0%	02,100	,
Deckers Outdoor Corp.*	1,161	556,514
On Holding AG, Cl. A*	14,427	468,156
	,	1,024,670
HEALTHCARE EQUIPMENT-2.1%		.,•,•. •
TransMedics Group, Inc.*	6,844	541,360
HEALTHCARE TECHNOLOGY-2.0%	0,011	041,000
Veeva Systems, Inc., Cl. A*	2,877	515,213
HOTELS RESORTS & CRUISE LINES-7.3%	2,011	010,210
Booking Holdings, Inc.*	248	666,205
Hilton Worldwide Holdings, Inc.	3,765	542,235
Trip.com Group Ltd.#*	19,338	686,693
	19,550	1,895,133
INTERACTIVE MEDIA & SERVICES—5.2%		1,095,155
Alphabet, Inc., Cl. A*	12,518	1,343,682
MOVIES & ENTERTAINMENT-9.0%	12,310	1,343,002
Live Nation Entertainment, Inc.*	9,375	635,438
Netflix. Inc.*	9,375 3.400	,
	-,	1,121,762
Spotify Technology SA*	4,337	579,423
		2,336,623
OIL & GAS EQUIPMENT & SERVICES—4.0%	20.000	1 000 570
Schlumberger Ltd.	20,802	1,026,579

COMMON STOCKS—99.4% (CONT.)	SHARES	VALUE
OIL & GAS EXPLORATION & PRODUCTION-2.6%		
Pioneer Natural Resources Co.	3,066	\$ 667,008
REAL ESTATE SERVICES—1.6%		
FirstService Corp.	2,794	421,168
SEMICONDUCTOR MATERIALS & EQUIPMENT-2.1%		
ASML Holding NV	864	550,247
SEMICONDUCTORS-5.8%		
Advanced Micro Devices, Inc.*	5,433	485,547
Analog Devices, Inc.	2,684	482,798
NVIDIA Corp.	1,938	537,776
		1,506,121
SYSTEMS SOFTWARE—9.0%		
Crowdstrike Holdings, Inc., CI. A*	5,719	686,566
Microsoft Corp.	5,364	1,648,143
		2,334,709
TECHNOLOGY HARDWARE STORAGE & PERIPHERALS—5.1%		
Apple, Inc.	7,852	1,332,327
TOTAL COMMON STOCKS		
(Cost \$24,138,498)		25,745,751
Total Investments		
(Cost \$24,138,498)	99.4%	\$ 25,745,751
Unaffiliated Securities (Cost \$24,138,498)		25,745,751
Other Assets in Excess of Liabilities	0.6%	161,687
NET ASSETS	100.0%	\$ 25,907,438

\* Non-income producing security.

# American Depositary Receipts.

# THE ALGER FUNDS | ALGER GROWTH & INCOME FUND Schedule of Investments April 30, 2023 (Unaudited)

COMMON STOCKS—90.9%	SHARES	VALUE
AEROSPACE & DEFENSE—1.6%		
General Dynamics Corp.	5,161	\$ 1,126,853
Raytheon Technologies Corp.	19,001	1,898,200
TransDigm Group, Inc.	2,476	1,894,140
		4,919,193
APPLICATION SOFTWARE—0.8%	c 000	0.040.000
Adobe, Inc.*	6,939	2,619,889
ASSET MANAGEMENT & CUSTODY BANKS-2.7%	0.750	4 500 000
BlackRock, Inc., Cl. A	6,750	4,530,600
Blackstone, Inc.	34,194	3,054,55
The Carlyle Group, Inc.	28,838	874,65
BIOTECHNOLOGY-3.2%		8,459,80
AbbVie. Inc.	46.601	7,042,343
Amgen, Inc.	6,523	1,563,82
Gilead Sciences, Inc.	16,572	1,362,38
	10,572	9,968,55
BROADLINE RETAIL—1.9%		3,300,33
Amazon.com, Inc.*	56,435	5,951,07
BUILDING PRODUCTS-0.5%	00,100	0,000,000
Johnson Controls International PLC	27,591	1,651,04
CABLE & SATELLITE—1.1%	21,001	.,
Comcast Corp., Cl. A	82,688	3,420,80
COMMODITY CHEMICALS-0.3%	. ,	-, -,
Dow, Inc.	16,874	917,94
COMMUNICATIONS EQUIPMENT—1.0%		
Cisco Systems, Inc.	64,544	3,049,70
CONSUMER ELECTRONICS-0.4%		
Garmin Ltd.	13,701	1,345,02
CONSUMER STAPLES MERCHANDISE RETAIL—0.8%		
Walmart, Inc.	16,865	2,546,10
COPPER—0.6%		
Southern Copper Corp.	24,207	1,859,82
DIVERSIFIED BANKS—4.0%		
Bank of America Corp.	119,052	3,485,84
JPMorgan Chase & Co.	65,009	8,986,84
		12,472,68
ELECTRIC UTILITIES—0.7%		
NextEra Energy, Inc.	27,588	2,114,06
ELECTRICAL COMPONENTS & EQUIPMENT—1.4%		
Eaton Corp., PLC	26,751	4,470,62
FINANCIAL EXCHANGES & DATA-0.9%		
CME Group, Inc., Cl. A	15,920	2,957,45
FOOD DISTRIBUTORS-0.6%		
Sysco Corp.	23,111	1,773,53
GOLD-0.4%		
Newmont Corp.	25,323	1,200,31
HEALTHCARE DISTRIBUTORS-0.6%	<u></u>	
Cardinal Health, Inc.	21,057	1,728,78

COMMON STOCKS—90.9% (CONT.)	SHARES	 VALUE
HEALTHCARE EQUIPMENT—0.6%		
Medtronic PLC	21,661	\$ 1,970,06
HOME IMPROVEMENT RETAIL—2.4%		
The Home Depot, Inc.	24,615	7,397,79
HOUSEHOLD PRODUCTS—1.7%		
The Procter & Gamble Co.	33,253	5,200,10
INDUSTRIAL CONGLOMERATES—1.8%		
Honeywell International, Inc.	28,196	5,634,68
INDUSTRIAL GASES—1.2%		
Air Products & Chemicals, Inc.	12,931	3,806,36
INTEGRATED OIL & GAS-4.5%		
Chevron Corp.	35,654	6,010,55
Exxon Mobil Corp.	43,030	5,092,17
TotalEnergies SE <sup>#</sup>	44,074	2,817,65
······································		13,920,37
INTEGRATED TELECOMMUNICATION SERVICES-1.2%		
AT&T. Inc.	54,783	968,0 <sup>2</sup>
Verizon Communications, Inc.	73,603	2,858,00
	10,000	3,826,02
INTERACTIVE MEDIA & SERVICES—6.3%		0,020,01
Alphabet, Inc., Cl. A*	85,437	9,170,80
Alphabet, Inc., Cl. C*	65,999	7,142,4
Meta Platforms, Inc., Cl. A*	13,239	3,181,59
	10,200	19,494,8
INVESTMENT BANKING & BROKERAGE-2.4%		13,737,0
Morgan Stanley	82,888	7,457,43
LEISURE FACILITIES—0.5%	02,000	1,101,1
Vail Resorts, Inc.	6,054	1,456,10
MANAGED HEALTHCARE—2.8%	0,004	1,430,10
UnitedHealth Group, Inc.	17,982	8,848,7
MULTI-LINE INSURANCE—0.5%	17,502	0,040,7
The Hartford Financial Services Group, Inc.	21,232	1,507,20
MULTI-UTILITIES-0.7%	21,232	1,307,2
Sempra Energy	14,099	2,192,2
OIL & GAS EXPLORATION & PRODUCTION-0.5%	14,033	2,132,2
Pioneer Natural Resources Co.	7 502	4 654 0
OIL & GAS STORAGE & TRANSPORTATION-0.5%	7,593	1,651,8
	01 700	4 440 20
	21,700	1,419,3
PHARMACEUTICALS—6.6%	10 175	2 000 0
AstraZeneca PLC#	42,175	3,088,0
Bristol-Myers Squibb Co.	25,520	1,703,9
Eli Lilly & Co.	8,460	3,348,9
GSK PLC <sup>#</sup>	25,088	903,9
Johnson & Johnson	32,186	5,268,8
Merck & Co., Inc.	20,845	2,406,9
Novartis AG <sup>#</sup>	14,930	1,531,3
Pfizer, Inc.	59,637	2,319,28
		20,571,3

COMMON STOCKS—90.9% (CONT.)	SHARES	VALUE
RAIL TRANSPORTATION-0.6%		
Union Pacific Corp.	9,944	\$ 1,946,041
RESTAURANTS—1.7%		
McDonald's Corp.	9,160	2,709,070
Starbucks Corp.	22,945	2,622,384
		5,331,454
SEMICONDUCTOR MATERIALS & EQUIPMENT—2.4%		
KLA Corp.	19,343	7,476,843
SEMICONDUCTORS—4.6%		
Broadcom, Inc.	13,081	8,195,246
QUALCOMM, Inc.	34,891	4,075,269
Taiwan Semiconductor Manufacturing Co., Ltd.#	23,422	1,974,475
		14,244,990
SOFT DRINKS & NON-ALCOHOLIC BEVERAGES—2.9%		
PepsiCo, Inc.	26,841	5,123,678
The Coca-Cola Co.	62,552	4,012,711
		9,136,389
SYSTEMS SOFTWARE—9.9%		
Microsoft Corp.	93,864	28,840,653
Oracle Corp.	20,566	1,948,011
		30,788,664
TECHNOLOGY HARDWARE STORAGE & PERIPHERALS—8.3%		
Apple, Inc.	153,088	25,975,972
TOBACCO—1.3%	47.000	0 000 400
Altria Group, Inc.	47,999	2,280,433
Philip Morris International, Inc.	17,327	1,732,180 4,012,613
TRANSACTION & PAYMENT PROCESSING SERVICES-1.5%		4,012,013
Visa, Inc., Cl. A	19,475	4,532,417
TOTAL COMMON STOCKS	13,475	4,332,417
(Cost \$191,772,295)		283,226,514
MASTER LIMITED PARTNERSHIP—0.5%	SHARES	VALUE
OIL & GAS STORAGE & TRANSPORTATION-0.5%	SHAKES	VALUE
Cheniere Energy Partners LP	35,211	1,605,974
(Cost \$1,508,792)	35,211	1,605,974
	0114.050	
REAL ESTATE INVESTMENT TRUST—3.8% HEALTHCARE—0.6%	SHARES	VALUE
	04.040	4 000 070
Welltower, Inc. INDUSTRIAL-0.5%	24,010	1,902,072
	11,480	4 427 070
Prologis, Inc. MORTGAGE—0.4%	11,400	1,437,870
Blackstone Mortgage Trust, Inc., CI. A	67,406	1,229,485
RETAIL—0.7%	01,400	1,223,403
Simon Property Group, Inc.	18,684	2,117,271
SPECIALIZED—0.6%	10,004	2,117,271
Lamar Advertising Co., Cl. A	18,096	1,912,385
Lamai Auventising OU., OI. A	10,030	1,912,303

REAL ESTATE INVESTMENT TRUST—3.8% (CONT.)	SHARES	VALUE
TELECOM TOWER—1.0%		
Crown Castle, Inc.	25,786	\$ 3,173,999
TOTAL REAL ESTATE INVESTMENT TRUST		
(Cost \$12,063,404)		11,773,082
SHORT—TERM INVESTMENTS—2.9%	SHARES	VALUE
U.S. GOVERNMENT-2.9%		
U.S. Treasury Bill, 0.00%, 5/2/23	9,000,000	8,999,158
(Cost \$8,999,158)		8,999,158
Total Investments		
(Cost \$214,343,649)	98.1%	\$ 305,604,728
Unaffiliated Securities (Cost \$214,343,649)		305,604,728
Other Assets in Excess of Liabilities	1.9%	5,978,533
NET ASSETS	100.0%	\$ 311,583,261

# American Depositary Receipts.

\* Non-income producing security.

COMMON STOCKS—97.8%	SHARES	VALUE
ADVERTISING—2.1%		
The Trade Desk, Inc., Cl. A*	62,233	\$ 4,004,071
AEROSPACE & DEFENSE—4.8%		
HEICO Corp.	25,359	4,276,542
TransDigm Group, Inc.	6,399	4,895,235
		9,171,777
APPAREL ACCESSORIES & LUXURY GOODS—1.4%		
Lululemon Athletica, Inc.*	7,141	2,713,080
APPAREL RETAIL—0.5%		
Burlington Stores, Inc.*	5,008	965,592
APPLICATION SOFTWARE—13.3%		
Cadence Design Systems, Inc.*	23,067	4,831,383
Constellation Software, Inc.	2,959	5,792,017
Datadog, Inc., Cl. A*	31,602	2,129,342
Guidewire Software, Inc.*	43,602	3,322,037
Manhattan Associates, Inc.*	19,227	3,185,529
Paycom Software, Inc.*	9,239	2,682,729
The Descartes Systems Group, Inc.*	40,289	3,192,786
		25,135,823
AUTOMOTIVE PARTS & EQUIPMENT—0.6%		
Mobileye Global, Inc., Cl. A*	28,058	1,056,103
AUTOMOTIVE RETAIL—3.0%		
AutoZone, Inc.*	2,127	5,664,860
BIOTECHNOLOGY—4.5%		
Apellis Pharmaceuticals, Inc.*	14,858	1,239,603
Celldex Therapeutics, Inc.*	33,918	1,066,382
Natera, Inc.*	64,058	3,249,022
Prometheus Biosciences, Inc.*	12,676	2,458,510
Vaxcyte, Inc.*	10,944	468,731
		8,482,248
BUILDING PRODUCTS—0.5%		
Trex Co., Inc.*	18,515	1,012,030
CARGO GROUND TRANSPORTATION—1.8%		
Old Dominion Freight Line, Inc.	10,899	3,491,931
CONSTRUCTION & ENGINEERING—1.5%		
WillScot Mobile Mini Holdings Corp.*	63,070	2,863,378
<b>CONSTRUCTION MACHINERY &amp; HEAVY TRANSPORTATION EQ</b>		
Wabtec Corp.	28,635	2,796,780
CONSTRUCTION MATERIALS—2.0%		
Martin Marietta Materials, Inc.	10,499	3,813,237
CONSUMER STAPLES MERCHANDISE RETAIL—1.0%		
BJ's Wholesale Club Holdings, Inc.*	25,661	1,959,731
DIVERSIFIED METALS & MINING-0.4%		
MP Materials Corp.*	33,485	725,620
ELECTRONIC COMPONENTS—1.7%		
Amphenol Corp., Cl. A	43,884	3,311,926
ELECTRONIC EQUIPMENT & INSTRUMENTS—1.7%		
Novanta, Inc.*	20,584	3,146,059

COMMON STOCKS—97.8% (CONT.)	SHARES	VALUE
ENVIRONMENTAL & FACILITIES SERVICES—3.6%		
GFL Environmental, Inc.	189,273	\$ 6,870,61
FINANCIAL EXCHANGES & DATA—2.6%		
MSCI, Inc., CI. A	10,292	4,965,37
HEALTHCARE EQUIPMENT—3.5%		
IDEXX Laboratories, Inc.*	6,835	3,363,91
Insulet Corp.*	10,072	3,203,29
		6,567,21
HEALTHCARE FACILITIES—1.9%		
Acadia Healthcare Co., Inc.*	48,942	3,538,01
HEALTHCARE TECHNOLOGY—1.7%		
Veeva Systems, Inc., Cl. A*	18,072	3,236,33
HOME IMPROVEMENT RETAIL—2.3%		
Floor & Decor Holdings, Inc., Cl. A*	43,756	4,346,72
HOMEBUILDING-1.1%		
NVR, Inc.*	347	2,026,48
HOTELS RESORTS & CRUISE LINES—2.0%		
Hilton Worldwide Holdings, Inc.	26,152	3,766,41
INSURANCE BROKERS—0.5%		
Ryan Specialty Holdings, Inc., Cl. A*	23,227	949,05
INTERNET SERVICES & INFRASTRUCTURE—1.2%		
MongoDB, Inc., CI. A*	9,656	2,317,05
IT CONSULTING & OTHER SERVICES—0.5%		
EPAM Systems, Inc.*	3,136	885,73
LIFE SCIENCES TOOLS & SERVICES—6.9%		
Mettler-Toledo International, Inc.*	2,112	3,150,04
Repligen Corp.*	21,539	3,265,95
West Pharmaceutical Services, Inc.	18,349	6,628,39
		13,044,39
METAL, GLASS & PLASTIC CONTAINERS—1.0%		
Ball Corp.	36,749	1,954,31
MOVIES & ENTERTAINMENT—2.2%		
Liberty Media Corp. Series C Liberty Formula One*	46,727	3,373,22
Live Nation Entertainment, Inc.*	12,920	875,71
		4,248,94
OIL & GAS EQUIPMENT & SERVICES—1.0%		
Baker Hughes Co., Cl. A	64,552	1,887,50
OIL & GAS EXPLORATION & PRODUCTION—2.8%		
Diamondback Energy, Inc.	37,191	5,288,56
PROPERTY & CASUALTY INSURANCE—1.6%		
Intact Financial Corp.	19,953	3,018,39
REAL ESTATE SERVICES—3.6%		
FirstService Corp.	45,230	6,817,97
RESEARCH & CONSULTING SERVICES—4.0%		
CoStar Group, Inc.*	45,994	3,539,23
Verisk Analytics, Inc., CI. A	21,278	4,130,27
		7,669,51

COMMON STOCKS—97.8% (CONT.)	SHARES	VALUE
RESTAURANTS—3.5%		
Chipotle Mexican Grill, Inc., CI. A*	2,320	\$ 4,796,87
Domino's Pizza, Inc.	5,612	1,781,64
		6,578,52
SEMICONDUCTOR MATERIALS & EQUIPMENT—2.4%		
KLA Corp.	6,704	2,591,36
SolarEdge Technologies, Inc.*	6,700	1,913,72
		4,505,08
SEMICONDUCTORS—3.9%		
Marvell Technology, Inc.	52,448	2,070,64
Microchip Technology, Inc.	39,820	2,906,46
ON Semiconductor Corp.*	33,540	2,413,53
		7,390,64
SYSTEMS SOFTWARE—1.7%		
Palo Alto Networks, Inc.*	17,341	3,164,03
TOTAL COMMON STOCKS		
(Cost \$166,711,582)		185,351,12
PREFERRED STOCKS—0.0%	SHARES	VALUE
BIOTECHNOLOGY-0.0%		
Prosetta Biosciences, Inc., Series D*.@.(a).(b)	219,610	
(Cost \$988,245)		
RIGHTS—0.2%	SHARES	VALUE
BIOTECHNOLOGY-0.2%		
Tolero CDR*,@,(a),(c)	590,059	395,34
(Cost \$315,501)		395,34
SPECIAL PURPOSE VEHICLE—0.9%		VALUE
DATA PROCESSING & OUTSOURCED SERVICES-0.9%		
Crosslink Ventures Capital C, LLC, CI. A*.@.(a).(b)		1,252,70
Crosslink Ventures Capital C, LLC, Cl. B*.@.(a).(b)		498,88
		1,751,58
TOTAL SPECIAL PURPOSE VEHICLE		, ,-
(Cost \$1,675,000)		1,751,58
Total Investments		, ,-
(Cost \$169,690,328)	98.9%	\$ 187,498,05
Affiliated Securities (Cost \$2,663,245)		1,751,58
Unaffiliated Securities (Cost \$167,027,083)		185,746,46
Other Assets in Excess of Liabilities	1.1%	1,991,66
NET ASSETS	100.0%	\$ 189,489,71

(9) Security is valued in good faith at fair value determined using significant unobservable inputs pursuant to procedures established by the Valuation Designee (as defined in Note 2).

(b) Deemed an affiliate of the Fund in accordance with Section 2(a)(3) of the Investment Company Act of 1940. See Note 11 - Affiliated Securities.

<sup>(e)</sup> Contingent Deferred Rights.

\* Non-income producing security.

<sup>®</sup> Restricted security - Investment in security not registered under the Securities Act of 1933. Sales or transfers of the investment may be restricted only to qualified buyers.

			<u>% of net assets</u>		<u>% of net assets</u>
	<u>Acquisition</u>	<u>Acquisition</u>	<u>(Acquisition</u>	<u>Market</u>	<u>as of</u>
<u>Security</u>	<u>Date(s)</u>	<u>Cost</u>	<u>Date</u> )	<u>Value</u>	<u>4/30/2023</u>
Crosslink Ventures Capital C, LLC, Cl.	4 10/2/20	\$1,200,000	0.50%	\$1,252,704	0.66%
Crosslink Ventures Capital C, LLC, Cl. 1	3 12/16/20	475,000	0.19%	498,883	0.26%
Prosetta Biosciences, Inc., Series D	2/6/15	988,245	0.50%	0	0.00%
Tolero CDR	2/6/17	315,501	0.19%	395,340	0.21%
Tota	l			\$2,146,927	1.13%

## THE ALGER FUNDS | ALGER MID CAP FOCUS FUND Schedule of Investments April 30, 2023 (Unaudited)

COMMON STOCKS—98.0%	SHARES	VALUE
ADVERTISING—0.5%		
The Trade Desk, Inc., Cl. A*	26,555	\$ 1,708,549
AEROSPACE & DEFENSE—5.9%		
Axon Enterprise, Inc.*	31,061	6,544,863
HEICO Corp.	45,840	7,730,458
Mercury Systems, Inc.*	129,063	6,152,433
		20,427,754
APPLICATION SOFTWARE—26.5%	200,440	40.004.000
ACI Worldwide, Inc.*	398,418	10,091,928
Agilysys, Inc.*	132,627	10,350,211
Alteryx, Inc., CI. A*	77,958	3,206,413
ANSYS, Inc.*	17,696	5,555,128
AppFolio, Inc., Cl. A*	41,452	5,787,528
Bentley Systems, Inc., Cl. B	317,825	13,526,632
Bill.com Holdings, Inc.*	50,466	3,876,293
Cadence Design Systems, Inc.*	33,663	7,050,715
Datadog, Inc., Cl. A*	72,011	4,852,101
Everbridge, Inc.*	346,599	9,108,622
Manhattan Associates, Inc.*	23,022	3,814,285
Splunk, Inc.*	77,427	6,677,305
Tyler Technologies, Inc.*	21,329	8,084,331
		91,981,492
AUTOMOTIVE RETAIL—2.4%		
O'Reilly Automotive, Inc.*	8,971	8,229,188
BIOTECHNOLOGY-7.8%		
Madrigal Pharmaceuticals, Inc.*	16,641	5,191,992
Natera, Inc.*	294,020	14,912,694
Viridian Therapeutics, Inc.*	249,134	6,983,226
		27,087,912
CARGO GROUND TRANSPORTATION-1.7%	40.000	F 000 000
Old Dominion Freight Line, Inc.	18,622	5,966,303
CASINOS & GAMING-4.0%	20.054	7 000 450
Flutter Entertainment PLC*	36,951	7,383,459
Las Vegas Sands Corp.*	102,692	6,556,884
		13,940,343
CONSTRUCTION MATERIALS—1.2%	11 200	4 400 000
Martin Marietta Materials, Inc.	11,306	4,106,339
ELECTRONIC EQUIPMENT & INSTRUMENTS-1.8%	11 110	6 220 404
Novanta, Inc.*	41,410	6,329,104
ENVIRONMENTAL & FACILITIES SERVICES—3.3%		44 070 040
Waste Connections, Inc.	81,715	11,370,642
FINANCIAL EXCHANGES & DATA-0.9%	10 707	0 000 455
Tradeweb Markets, Inc., Cl. A	45,767	3,222,455
FOOTWEAR-0.7%	70.101	
On Holding AG, Cl. A*	78,491	2,547,033

COMMON STOCKS—98.0% (CONT.)	SHARES	VALUE
HEALTHCARE EQUIPMENT—9.5%		
Dexcom, Inc.*	52,180	\$ 6,331,52
IDEXX Laboratories, Inc.*	15,300	7,530,04
Insulet Corp.*	48,944	15,566,15
Shockwave Medical, Inc.*	12,623	3,662,69
		33,090,40
HEALTHCARE FACILITIES—1.2%		
Acadia Healthcare Co., Inc.*	59,967	4,335,01
HEALTHCARE TECHNOLOGY—1.7%		
Veeva Systems, Inc., Cl. A*	32,551	5,829,23
INTERNET SERVICES & INFRASTRUCTURE—2.2%		
Shopify, Inc., Cl. A*	155,054	7,512,36
LIFE SCIENCES TOOLS & SERVICES—6.2%		
Agilent Technologies, Inc.	31,949	4,326,85
Illumina, Inc.*	29,601	6,084,78
Repligen Corp.*	31,589	4,789,84
West Pharmaceutical Services, Inc.	17,224	6,221,99
· · · · · · · · · · · · · · · · · · ·	,	21,423,47
MOVIES & ENTERTAINMENT-4.8%		
Liberty Media Corp. Series C Liberty Formula One*	127,034	9,170,58
World Wrestling Entertainment, Inc., Cl. A	69,186	7,414,66
	00,100	16,585,24
OIL & GAS EXPLORATION & PRODUCTION—3.6%		-,,
Diamondback Energy, Inc.	86,873	12,353,34
OTHER SPECIALTY RETAIL—4.2%		
Five Below, Inc.*	26,650	5,259,64
Ulta Beauty, Inc.*	17,183	9,475,22
· · · · · · · · · · · · · · · · · · ·	,	14,734,86
RESTAURANTS-0.9%		
Chipotle Mexican Grill, Inc., Cl. A*	1,582	3,270,97
SEMICONDUCTOR MATERIALS & EQUIPMENT-1.6%		
SolarEdge Technologies, Inc.*	19,053	5,442,10
SEMICONDUCTORS-3.5%		
Advanced Micro Devices, Inc.*	82,730	7,393,58
ON Semiconductor Corp.*	68,515	4,930,34
p	,	12,323,92
SYSTEMS SOFTWARE—1.9%		
Palo Alto Networks, Inc.*	36,465	6,653,40
TOTAL COMMON STOCKS		
(Cost \$329,777,451)		340,471,47
Total Investments		
(Cost \$329,777,451)	98.0%	\$ 340,471,47
Unaffiliated Securities (Cost \$329,777,451)		340,471,47
Other Assets in Excess of Liabilities	2.0%	6,972,84
NET ASSETS	100.0%	\$ 347,444,31

\* Non-income producing security.

# THE ALGER FUNDS | ALGER WEATHERBIE SPECIALIZED GROWTH FUND Schedule of Investments April 30, 2023 (Unaudited)

COMMON STOCKS—95.5%	SHARES		VALUE
ADVERTISING-0.3%	01111120		
TechTarget, Inc.*	49,604	\$	1,691,000
AEROSPACE & DEFENSE-0.7%	,		.,,
Kratos Defense & Security Solutions, Inc.*	362,041		4,670,329
APPAREL ACCESSORIES & LUXURY GOODS-0.1%			,
Canada Goose Holdings, Inc.*	37,027		726,470
APPAREL RETAIL-0.2%			
MYT Netherlands Parent BV <sup>#,*</sup>	289,506		1,421,474
APPLICATION SOFTWARE—9.6%			
nCino, Inc.*	55,801		1,379,959
SPS Commerce, Inc.*	255,393		37,619,389
Vertex, Inc., Cl. A*	1,143,425		23,611,726
			62,611,074
ASSET MANAGEMENT & CUSTODY BANKS—5.4%			
Hamilton Lane, Inc., CI. A	253,803		18,700,205
StepStone Group, Inc., CI. A	749,244		16,505,845
			35,206,050
BIOTECHNOLOGY—4.2%			
ACADIA Pharmaceuticals, Inc.*	582,916		12,433,598
Natera, Inc.*	142,602		7,232,773
Ultragenyx Pharmaceutical, Inc.*	183,807		8,026,852
			27,693,223
BROADLINE RETAIL—1.7%			
Ollie's Bargain Outlet Holdings, Inc.*	168,774		11,012,504
CARGO GROUND TRANSPORTATION—1.0%			
RXO, Inc.*	353,255		6,390,383
CONSUMER FINANCE—0.0%			
Upstart Holdings, Inc.*	22,251		309,289
EDUCATION SERVICES—2.8%			
Chegg, Inc.*	996,631		17,919,425
ELECTRONIC EQUIPMENT & INSTRUMENTS—3.4%			
Novanta, Inc.*	145,218		22,195,119
ENVIRONMENTAL & FACILITIES SERVICES—9.5%			
Casella Waste Systems, Inc., CI. A*	441,330		39,278,370
Montrose Environmental Group, Inc.*	745,960		22,721,942
			62,000,312
HEALTHCARE EQUIPMENT—9.1%			
Glaukos Corp.*	472,383		22,442,916
Impulse Dynamics PLC, Class E <sup>*,@,(a)</sup>	904,912		2,986,210
Inmode Ltd.*	146,002		5,440,035
Inogen, Inc.*	361,130		4,806,640
Inspire Medical Systems, Inc.*	42,161		11,283,548
Nevro Corp.*	387,602		11,345,111
Tandem Diabetes Care, Inc.*	27,999		1,108,200
			59,412,660
HEALTHCARE FACILITIES—1.5%			
US Physical Therapy, Inc.	91,208		9,710,004

# THE ALGER FUNDS | ALGER WEATHERBIE SPECIALIZED GROWTH FUND Schedule of Investments April 30, 2023 (Unaudited) (Continued)

COMMON STOCKS—95.5% (CONT.)	SHARES	VALUE
HEALTHCARE SERVICES—2.6%		
Agiliti, Inc.*	915,370	\$ 15,304,98
NeoGenomics, Inc.*	120,400	1,760,24
		17,065,23
HEALTHCARE TECHNOLOGY—1.3%		
Definitive Healthcare Corp., Cl. A*	815,903	8,730,16
IT CONSULTING & OTHER SERVICES—2.6%		
CI&T, Inc., CI. A*	943,688	3,718,13
Globant SA*	67,877	10,647,86
Grid Dynamics Holdings, Inc.*	263,154	2,860,48
		17,226,48
LEISURE FACILITIES—5.3%		
Planet Fitness, Inc., Cl. A*	405,408	33,705,62
Xponential Fitness, Inc., Cl. A*	15,092	499,24
		34,204,86
LEISURE PRODUCTS-0.2%	F20 407	4 070 40
Latham Group, Inc.* MANAGED HEALTHCARE—5.5%	530,497	1,278,49
	1 074 244	25 744 40
Progyny, Inc.* OIL & GAS EQUIPMENT & SERVICES—5.8%	1,074,344	35,711,19
Core Laboratories NV	1 004 957	04 645 00
	1,094,857	24,645,23
Dril-Quip, Inc.*	486,126	13,261,51 37,906,74
REAL ESTATE SERVICES—6.0%		31,900,14
FirstService Corp.	261,036	39,348,56
REGIONAL BANKS-0.5%	201,000	
Axos Financial. Inc.*	46,561	1,893,63
Seacoast Banking Corp. of Florida	58.250	1,292,56
	,	3,186,20
RESTAURANTS-0.9%		
Wingstop, Inc.	27,744	5,551,85
SEMICONDUCTORS-1.6%		
Impinj, Inc.*	93,071	8,228,40
SiTime Corp.*	18,685	2,026,76
		10,255,16
SYSTEMS SOFTWARE—0.9%		
Rapid7, Inc.*	122,208	5,940,53
TRADING COMPANIES & DISTRIBUTORS—7.9%		
SiteOne Landscape Supply, Inc.*	204,065	30,148,56
Transcat, Inc.*	245,470	18,726,90
Xometry, Inc., Cl. A*	189,530	2,632,57
		51,508,04
TRANSACTION & PAYMENT PROCESSING SERVICES—4.9%	4 000 000	
Flywire Corp.*	1,096,603	31,987,91
TOTAL COMMON STOCKS		
(Cost \$637,402,193)		622,870,77

#### THE ALGER FUNDS | ALGER WEATHERBIE SPECIALIZED GROWTH FUND Schedule of Investments April 30, 2023 (Unaudited) (Continued)

	0114 0 50	
PREFERRED STOCKS—0.0%	SHARES	VALUE
BIOTECHNOLOGY-0.0%		
Prosetta Biosciences, Inc., Series D*,@,(a),(b)	231,474	\$ -
(Cost \$1,041,633)		-
SHORT—TERM INVESTMENTS—3.4%	SHARES	VALUE
U.S. GOVERNMENT—3.4%		
U.S. Treasury Bill, 0.0%, 5/2/23	22,000,000	21,997,942
(Cost \$21,997,942)		21,997,942
Total Investments		
(Cost \$660,441,768)	98.9%	\$ 644,868,712
Affiliated Securities (Cost \$1,041,633)		-
Unaffiliated Securities (Cost \$659,400,135)		644,868,712
Other Assets in Excess of Liabilities	1.1%	7,026,458
NET ASSETS	100.0%	\$ 651,895,170

# American Depositary Receipts.

(9) Security is valued in good faith at fair value determined using significant unobservable inputs pursuant to procedures established by the Valuation Designee (as defined in Note 2).

<sup>(b)</sup> Deemed an affiliate of the Fund in accordance with Section 2(a)(3) of the Investment Company Act of 1940. See Note 11 - Affiliated Securities.

\* Non-income producing security.

<sup>®</sup> Restricted security - Investment in security not registered under the Securities Act of 1933. Sales or transfers of the investment may be restricted only to qualified buyers.

			<u>% of net assets</u>		<u>% of net assets</u>
	<u>Acquisition</u>	<u>Acquisition</u>	<u>(Acquisition</u>	<u>Market</u>	<u>as of</u>
<u>Security</u>	<u>Date(s)</u>	<u>Cost</u>	<u>Date)</u>	<u>Value</u>	4/30/2023
Impulse Dynamics PLC, Class E	2/11/22	\$2,986,210	0.24%	\$2,986,210	0.46%
Prosetta Biosciences, Inc., Series D	2/6/15	1,041,633	0.10%	0	0.00%
Total				\$2,986,210	0.46%

COMMON STOCKS—96.9%	SHARES		VALUE
ADVERTISING-0.4%	1.10 700	•	4 407 00
Magnite, Inc.*	149,769	\$	1,407,82
AEROSPACE & DEFENSE—6.2%	00 704		45 404 05
HEICO Corp.	89,724		15,131,05
Hexcel Corp.	34,820		2,509,82
Mercury Systems, Inc.*	71,176		3,392,96 21,033,84
APPAREL ACCESSORIES & LUXURY GOODS-1.6%			21,033,04
Capri Holdings Ltd.*	131,164		5,443,30
APPAREL RETAIL-0.7%	- , -		-, -,
Aritzia. Inc.*	26,284		835,42
Victoria's Secret & Co.*	53,575		1,661,36
			2,496,78
APPLICATION SOFTWARE—23.1%			
ACI Worldwide, Inc.*	257,174		6,514,21
AppFolio, Inc., Cl. A*	26,631		3,718,22
Bill.com Holdings, Inc.*	51,956		3,990,74
Blackbaud, Inc.*	79,209		5,493,54
Blackline, Inc.*	55,731		3,104,7
Everbridge, Inc.*	93,302		2,451,9
Guidewire Software, Inc.*	36,894		2,810,9
HubSpot, Inc.*	16,330		6,874,1 <sup>-</sup>
Manhattan Associates, Inc.*	70,581		11,693,80
Paycom Software, Inc.*	21,276		6,177,9 <sup>-</sup>
Q2 Holdings, Inc.*	108,919		2,681,58
SEMrush Holdings, Inc., CI. A*	94,341		911,33
Smartsheet, Inc., Cl. A*	71,669		2,929,1 <sup>-</sup>
Sprout Social, Inc., CI. A*	73,507		3,620,95
SPS Commerce, Inc.*	64,213		9,458,5
Vertex, Inc., CI. A*	260,255		5,374,26
			77,806,13
ASSET MANAGEMENT & CUSTODY BANKS—0.3% Affiliated Managers Group, Inc.	7,756		1,119,8 <sup>,</sup>
BIOTECHNOLOGY—4.7%	7,750		1,119,0
ADMA Biologics, Inc.*	506,775		1,697,69
Alkermes PLC*	40,937		1,168,7
Arcus Biosciences. Inc.*	40,904		730,13
Avidity Biosciences, Inc.*	70,040		868,49
Cabaletta Bio, Inc.*	200,093		2,076,96
Celldex Therapeutics, Inc.*	53,039		1,667,54
Karuna Therapeutics, Inc.*	12,763		2,532,69
MoonLake Immunotherapeutics, CI. A*	44,970		957,86
Morphic Holding, Inc.*	35,366		1,671,39
RAPT Therapeutics, Inc.*	72,460		1,318,77
Vaxcyte, Inc.*	24,964		1,069,20
10,07,0, iio.	24,004		15,759,51
CONSUMER STAPLES MERCHANDISE RETAIL—3.2%			· ,· · · ,•
BJ's Wholesale Club Holdings, Inc.*	140,639		10,740,60

COMMON STOCKS—96.9% (CONT.)	SHARES		VALUE
DIVERSIFIED SUPPORT SERVICES—0.4%			
Ritchie Bros. Auctioneers, Inc.	22,371	\$	1,279,397
ELECTRICAL COMPONENTS & EQUIPMENT-0.4%			
Sunrun, Inc.*	66,735		1,404,104
ELECTRONIC EQUIPMENT & INSTRUMENTS-0.9%			
908 Devices, Inc.*	456,169		3,083,702
FOOD DISTRIBUTORS—2.9%			
The Chefs' Warehouse, Inc.*	94,528		3,144,001
US Foods Holding Corp.*	170,857		6,560,909
			9,704,910
FOOTWEAR-0.5%			
On Holding AG, Cl. A*	53,861		1,747,789
HEALTHCARE DISTRIBUTORS—0.2%			
PetIQ, Inc., Cl. A*	62,035		731,393
HEALTHCARE EQUIPMENT—10.3%			
Impulse Dynamics PLC, Class E <sup>*,@,(a)</sup>	1,105,151		3,646,998
Inmode Ltd.*	103,438		3,854,100
Insulet Corp.*	29,158		9,273,410
Mesa Laboratories, Inc.	27,736		4,618,322
Paragon 28, Inc.*	75,516		1,391,005
QuidelOrtho Corp.*	79,576		7,157,861
Shockwave Medical, Inc.*	6,006		1,742,702
Tandem Diabetes Care, Inc.*	79,550		3,148,589
			34,832,986
HEALTHCARE SERVICES—0.6%			
Guardant Health, Inc.*	30,906		697,239
Privia Health Group, Inc.*	48,330		1,335,358
			2,032,597
HEALTHCARE SUPPLIES—2.3%			
Neogen Corp.*	443,260		7,632,937
HEALTHCARE TECHNOLOGY—2.5%			
Doximity, Inc., Cl. A*	18,271		671,459
Veeva Systems, Inc., CI. A*	43,687		7,823,468
			8,494,927
HOMEBUILDING-0.5%			
Skyline Champion Corp.*	23,895		1,772,292
INDUSTRIAL MACHINERY & SUPPLIES & COMPONENTS-0.6%			
Gates Industrial Corp., PLC*	161,017		2,168,899
INTERACTIVE HOME ENTERTAINMENT—1.3%			
Take-Two Interactive Software, Inc.*	35,288		4,385,946
INTERACTIVE MEDIA & SERVICES—0.8%			
Bumble, Inc., Cl. A*	66,183		1,205,193
Tripadvisor, Inc.*	80,266		1,423,116
			2,628,309
LEISURE FACILITIES—1.0%			
Planet Fitness, Inc., Cl. A*	40,235		3,345,138

COMMON STOCKS—96.9% (CONT.)	SHARES	VALUE
LIFE SCIENCES TOOLS & SERVICES—7.0%		
Akoya Biosciences, Inc.*	139,659	\$ 972,02
Bio-Techne Corp.	135,569	10,829,25
CryoPort, Inc.*	115,779	2,435,99
ICON PLC*	9,581	1,846,16
MaxCyte, Inc.*	193,490	967,45
NanoString Technologies, Inc.*	153,836	1,507,59
Personalis, Inc.*	314,078	716,09
Repligen Corp.*	28,185	4,273,69
		23,548,26
MANAGED HEALTHCARE—1.5%		
HealthEquity, Inc.*	96,344	5,149,58
MOVIES & ENTERTAINMENT-1.4%		
Live Nation Entertainment, Inc.*	69,490	4,710,03
OIL & GAS EQUIPMENT & SERVICES-1.0%		
ChampionX Corp.	79,644	2,156,76
ProPetro Holding Corp.*	166,265	1,153,87
······································	,	3,310,63
OIL & GAS EXPLORATION & PRODUCTION-4.9%		-,,
Coterra Energy, Inc.	85,796	2,196,37
Magnolia Oil & Gas Corp., Cl. A	683,486	14,435,22
	000,100	16,631,60
PHARMACEUTICALS—1.2%		10,001,00
Pliant Therapeutics, Inc.*	54,049	1,526,88
Reata Pharmaceuticals, Inc., Cl. A*	17,099	1,690,40
Ventyx Biosciences, Inc.*	24,827	933,49
	24,027	4,150,78
REGIONAL BANKS-0.9%		1,100,10
Webster Financial Corp.	79,755	2,974,86
RESEARCH & CONSULTING SERVICES—0.4%		_,,
LegalZoom.com, Inc.*	144,125	1,351,89
RESTAURANTS-6.9%	144,120	1,001,00
Kura Sushi USA, Inc., Cl. A*	48,845	3,366,39
Shake Shack, Inc., Cl. A*	151,624	8,310,51
The Cheesecake Factory, Inc.	80,375	2,707,83
Wingstop, Inc.	43,860	8,776,82
wingstop, inc.	43,000	
SEMICONDUCTOR MATERIALS & EQUIPMENT-0.9%		23,161,56
SolarEdge Technologies, Inc.*	10,807	2 006 00
SEMICONDUCTORS-0.9%	10,007	3,086,80
	00.400	2 000 04
Universal Display Corp.	22,496	3,002,31
SPECIALTY CHEMICALS—2.7%	~~~~~	
Balchem Corp.	68,033	8,939,53
SYSTEMS SOFTWARE-0.4%	00.071	4 400
Rapid7, Inc.*	28,874	1,403,56
TRADING COMPANIES & DISTRIBUTORS-0.3%		
Xometry, Inc., CI. A*	62,192	863,84

COMMON STOCKS—96.9% (CONT.)	SHARES		VALUE
TRANSACTION & PAYMENT PROCESSING SERVICES-1.1%	SHARES		VALUE
DLocal Ltd., Cl. A*	173,167	\$	2,424,338
Margeta, Inc., Cl. A*	288,721	Ψ	1,169,320
	200,721		3,593,658
TOTAL COMMON STOCKS			0,000,000
(Cost \$327,651,324)			326,932,110
PREFERRED STOCKS—0.0%	SHARES		VALUE
BIOTECHNOLOGY-0.0%	UTAILEO		TALUL
Prosetta Biosciences, Inc., Series D <sup>*.@.(a).(b)</sup>	50.688		_
(Cost \$228,096)	00,000		_
RIGHTS-0.0%	SHARES		VALUE
BIOTECHNOLOGY-0.0%	UTAILE		VALUE
Tolero CDR*.@.(a).(c)	174,782		117,104
(Cost \$94,483)	114,102		117,104
REAL ESTATE INVESTMENT TRUST—1.5%	SHARES		VALUE
RETAIL-1.5%	UTAILEO		TALUL
Tanger Factory Outlet Centers, Inc.	258,634		5,071,813
(Cost \$4,259,450)	200,001		5,071,813
SPECIAL PURPOSE VEHICLE—0.7% DATA PROCESSING & OUTSOURCED SERVICES—0.7%			VALUE
Crosslink Ventures Capital C, LLC, Cl. A*.@.(a).(b)			1 970 056
Crosslink Ventures Capital C, LLC, Cl. A (8(4)(4))			1,879,056
			498,883 2,377,939
TOTAL SPECIAL PURPOSE VEHICLE			2,311,939
(Cost \$2,275,000)			2,377,939
	SHARES		
SHORT—TERM INVESTMENTS—1.5% U.S.GOVERNMENT—1.5%	SHARES		VALUE
U.S. Treasury Bill, 0.0%, 5/2/23	5.000.000		4,999,532
(Cost \$4,999.532)	5,000,000		4,999,532
Total Investments			4,333,332
(Cost \$339,507,885)	100.6%	\$	339,498,498
Affiliated Securities (Cost \$2,503,096)	100.070	Ψ	2,377,939
Unaffiliated Securities (Cost \$337,004,789)			337,120,559
Liabilities in Excess of Other Assets	(0.6)%		(2,126,534)
NET ASSETS	100.0%	\$	337,371,964
		<b>T</b>	

(9) Security is valued in good faith at fair value determined using significant unobservable inputs pursuant to procedures established by the Valuation Designee (as defined in Note 2).

<sup>(b)</sup> Deemed an affiliate of the Fund in accordance with Section 2(a)(3) of the Investment Company Act of 1940. See Note 11 - Affiliated Securities.

<sup>(e)</sup> Contingent Deferred Rights.

\* Non-income producing security.

<sup>®</sup> Restricted security - Investment in security not registered under the Securities Act of 1933. Sales or transfers of the investment may be restricted only to qualified buyers.

			<u>% of net assets</u>		<u>% of net assets</u>
	<u>Acquisition</u>	<u>Acquisition</u>	<u>(Acquisition</u>	<u>Market</u>	<u>as of</u>
<u>Security</u>	<u>Date(s)</u>	<u>Cost</u>	<u>Date)</u>	<u>Value</u>	<u>4/30/2023</u>
Crosslink Ventures Capital C, LLC, Cl. A	1 10/2/20	\$1,800,000	0.49%	\$1,879,056	0.56%
Crosslink Ventures Capital C, LLC, Cl. B	12/16/20	475,000	0.10%	498,883	0.15%
Impulse Dynamics PLC, Class E	2/11/22	3,646,998	0.69%	3,646,998	1.08%
Prosetta Biosciences, Inc., Series D	2/6/15	228,096	0.10%	0	0.00%
Tolero CDR	2/6/17	94,483	0.08%	117,104	0.03%
Tota	l			\$6,142,041	1.82%

# THE ALGER FUNDS | ALGER SMALL CAP FOCUS FUND Schedule of Investments April 30, 2023 (Unaudited)

COMMON STOCKS—97.8%	SHARES	VALUE
AEROSPACE & DEFENSE—3.4%		
Axon Enterprise, Inc.*	- / -	\$ 31,863,14
Mercury Systems, Inc.*	919,513	43,833,18
APPLICATION SOFTWARE-24.7%		75,696,32
ACI Worldwide, Inc.*	1,077,549	27,294,3
Agilysys, Inc.*	676,507	52,794,6
Altair Engineering, Inc., Cl. A*	338,264	23,357,1
AppFolio, Inc., Cl. A*	347,061	48,456,6
Blackline, Inc.*	829,468	46,209,6
Clearwater Analytics Holdings, Inc., Cl. A*	3,771,754	58,122,7
Everbridge, Inc.*	1,403,607	36,886,7
Guidewire Software. Inc.*	856,913	65,288,2
Model N. Inc.*	657,343	20,246,1
PagerDuty, Inc.*	847,654	25,480,4
PROS Holdings, Inc. <sup>*,(a)</sup>	2,881,995	81,762,1
Q2 Holdings, Inc.*	746,982	18,390,6
Smartsheet, Inc., Cl. A*	658,540	26,914,5
Sprout Social, Inc., Cl. A*	275,448	, ,
	275,440	13,568,5 544,772,7
BIOTECHNOLOGY—7.9%		011,112,1
Cabaletta Bio, Inc.*.(a)	3,058,993	31,752,3
Natera, Inc.*	1,705,418	86,498,8
Prometheus Biosciences, Inc.*	295,777	57,365,9
		175,617,0
HEALTHCARE EQUIPMENT—23.0%		
AtriCure, Inc.*	1,318,646	58,007,2
Axonics, Inc.*	731,897	42,054,8
Heska Corp.*. <sup>(a)</sup>	713,593	83,604,5
Inari Medical, Inc.*	209,358	13,905,5
Inspire Medical Systems, Inc.*	291,886	78,117,4
Insulet Corp.*	181,525	57,732,2
QuidelOrtho Corp.*	625,713	56,282,8
Shockwave Medical, Inc.*	271,212	78,694,8
TransMedics Group, Inc.*	499,532	39,512,9
		507,912,5
HEALTHCARE SUPPLIES—2.1%	4 0 4 7 7 7 7	10 100 0
Silk Road Medical, Inc.*	1,047,757	46,122,2
HEALTHCARE TECHNOLOGY—3.8%	4 405 040	40 450 5
Evolent Health, Inc., Cl. A*	1,185,349	43,158,5
Veeva Systems, Inc., Cl. A*	226,645	40,587,5
INDUSTRIAL MACHINERY & SUPPLIES & COMPONENTS-4.3%		83,746,14
RBC Bearings, Inc.*	420,178	95,384,6
	120,110	00,00-1,0

COMMON STOCKS—97.8% (CONT.)	SHARES		VALUE
LIFE SCIENCES TOOLS & SERVICES—11.6%			
BioLife Solutions, Inc.*	1,674,562	\$	29,405,309
Bio-Techne Corp.	765,923	765,923	
Bruker Corp.	789,640		62,484,213
CryoPort, Inc.*	1,911,090		40,209,334
Repligen Corp.*	411,668		62,421,219
			255,702,004
OIL & GAS EQUIPMENT & SERVICES—2.5% ChampionX Corp.	2,082,466		56,393,179
OIL & GAS EXPLORATION & PRODUCTION—4.4%	2,002,400		50,595,175
PDC Energy, Inc.	712,141		46,324,772
Viper Energy Partners LP	1,698,261		40,324,772
viper Energy Faithers LF	1,090,201		96,321,57
PACKAGED FOODS & MEATS-0.9%			50,521,51
Freshpet, Inc.*	306,471		21,137,30
PHARMACEUTICALS—1.0%			,,00
Pliant Therapeutics, Inc.*	825,578		23,322,579
RESEARCH & CONSULTING SERVICES—0.6%	0_0,0.0		,•,•1
Exponent, Inc.	145,591		13,401,65
RESTAURANTS-3.6%			, - ,
Kura Sushi USA, Inc., CI. A*	85,335		5,881,288
Wingstop, Inc.	363,371		72,714,17
0 17			78,595,459
SYSTEMS SOFTWARE—3.1%			
Gitlab, Inc., Cl. A*	444,594		13,497,874
Rapid7, Inc.*	461,783		22,447,27
Tenable Holdings, Inc.*	868,113		32,111,500
			68,056,64
TRADING COMPANIES & DISTRIBUTORS-0.9%			
Herc Holdings, Inc.	80,097		8,011,302
Xometry, Inc., Cl. A*	899,547		12,494,708
			20,506,010
TOTAL COMMON STOCKS			
(Cost \$1,903,163,290)			2,162,688,134
RIGHTS—0.0%	SHARES		VALUE
BIOTECHNOLOGY-0.0%			
Tolero CDR*.@.(b).(c)	11,905		7,97
(Cost \$6,436)			7,97
SHORT—TERM INVESTMENTS—0.5%	SHARES		VALUE
U.S. GOVERNMENT-0.5%			
U.S. Treasury Bill, 0.0%, 5/2/23	10,000,000		9,999,064
(Cost \$9.999.064)	,		9,999,064
Total Investments			· ,,••
(Cost \$1,913,168,790)	98.3%	\$	2,172,695,174
Affiliated Securities (Cost \$202,483,189)		•	197,119,10
Unaffiliated Securities (Cost \$1,710,685,601)			1,975,576,073
···· / / ·/·· /	1 70/		
Other Assets in Excess of Liabilities	1.7%		36,554,794

- <sup>(9)</sup> Deemed an affiliate of the Fund in accordance with Section 2(a)(3) of the Investment Company Act of 1940. See Note 11 Affiliated Securities.
- <sup>(b)</sup> Security is valued in good faith at fair value determined using significant unobservable inputs pursuant to procedures established by the Valuation Designee (as defined in Note 2).
- <sup>(c)</sup> Contingent Deferred Rights.
- \* Non-income producing security.
- <sup>®</sup> Restricted security Investment in security not registered under the Securities Act of 1933. Sales or transfers of the investment may be restricted only to qualified buyers.

				<u>% of net assets</u>		<u>% of net assets</u>
		<u>Acquisition</u>	<u>Acquisition</u>	(Acquisition	<u>Market</u>	<u>as of</u>
<u>Security</u>		<u>Date(s)</u>	<u>Cost</u>	<u>Date)</u>	<u>Value</u>	4/30/2023
Tolero CDR		2/6/17	\$6,436	0.00%	\$7,976	0.00%
	Total				\$7,976	0.00%

# THE ALGER FUNDS | ALGER INTERNATIONAL FOCUS FUND Schedule of Investments April 30, 2023 (Unaudited)

COMMON STOCKS—96.1%	SHARES	VALUE
ARGENTINA-2.8%		
BROADLINE RETAIL—2.8%		
MercadoLibre, Inc.*	3,100	\$ 3,960,219
(Cost \$4,207,483)		
AUSTRALIA—3.7%		
HEALTHCARE SUPPLIES—1.9%	604.060	0 644 204
Nanosonics Ltd.*	694,062	2,644,324
HEALTHCARE TECHNOLOGY—1.8% Pro Medicus Ltd.	62,000	2 5/5 101
TOTAL AUSTRALIA	62,000	2,545,101
(Cost \$4,793,451)		5,189,425
BRAZIL—5.8%		•,.••,.=
DIVERSIFIED BANKS-2.7%		
NU Holdings Ltd., Cl. A*	723,000	3,730,680
DIVERSIFIED CAPITAL MARKETS-1.6%		
Banco BTG Pactual SA	491,000	2,305,492
FOOTWEAR—1.5%		
Arezzo Industria e Comercio SA	158,000	2,102,760
TOTAL BRAZIL		
(Cost \$8,158,006)		8,138,932
CHINA—11.2%		
AUTOMOBILE MANUFACTURERS—3.1%		
BYD Co., Ltd., Cl. H	144,484	4,381,658
BREWERS—2.4%		
Budweiser Brewing Co. APAC Ltd.	1,153,000	3,331,260
BROADLINE RETAIL—1.5%		
Alibaba Group Holding Ltd. <sup>#,*</sup>	24,800	2,100,312
HOTELS RESORTS & CRUISE LINES-2.0%		
Trip.com Group Ltd.#.*	78,000	2,769,780
RESTAURANTS-2.2%	404.000	0 454 000
Meituan, Cl. B* TOTAL CHINA	184,600	3,154,898
(Cost \$16,720,256)		15,737,908
DENMARK—2.5%		10,101,000
PHARMACEUTICALS—2.5%		
Novo Nordisk AS, Cl. B	20,800	3,459,84
(Cost \$2,859,218)		-,,-
FRANCE—14.0%		
APPAREL ACCESSORIES & LUXURY GOODS-2.6%		
LVMH Moet Hennessy Louis Vuitton SE	3,850	3,703,243
DATA PROCESSING & OUTSOURCED SERVICES-2.4%		
Teleperformance	16,857	3,368,965
ELECTRICAL COMPONENTS & EQUIPMENT-2.4%		
Schneider Electric SE	19,300	3,365,764
HEALTHCARE SUPPLIES-2.2%		
EssilorLuxottica SA	15,900	3,147,882
		- 67 -

- 67 -

## THE ALGER FUNDS | ALGER INTERNATIONAL FOCUS FUND Schedule of Investments April 30, 2023 (Unaudited) (Continued)

COMMON STOCKS—96.1% (CONT.)	SHARES	VALUE
FRANCE—14.0% (CONT.)		
LIFE SCIENCES TOOLS & SERVICES—2.5%		
Eurofins Scientific SE	50,500	\$ 3,527,417
OIL & GAS STORAGE & TRANSPORTATION-1.9%		
Gaztransport Et Technigaz SA	24,324	2,601,238
TOTAL FRANCE		
(Cost \$16,443,701)		19,714,509
GERMANY—6.2%		
AEROSPACE & DEFENSE—2.6%		
Hensoldt AG	98,800	3,705,501
LIFE SCIENCES TOOLS & SERVICES—2.1%		
Gerresheimer AG	27,700	3,018,397
OIL & GAS REFINING & MARKETING-1.5%		
VERBIO Vereinigte BioEnergie AG	55,054	2,050,427
TOTAL GERMANY		
(Cost \$8,172,674)		8,774,32
HONG KONG—4.0%		
APPAREL ACCESSORIES & LUXURY GOODS-2.0%		
Samsonite International SA*	900,000	2,851,96
FINANCIAL EXCHANGES & DATA-2.0%		
Hong Kong Exchanges & Clearing Ltd.	67,000	2,781,63
TOTAL HONG KONG		
(Cost \$5,297,206)		5,633,59
INDIA—5.3%		
APPAREL ACCESSORIES & LUXURY GOODS—1.2%		
Kalyan Jewellers India Ltd.*	1,309,074	1,652,07
DIVERSIFIED BANKS—2.6%		
HDFC Bank Ltd.#	52,900	3,692,42
HOTELS RESORTS & CRUISE LINES—1.5%		
MakeMyTrip Ltd.*	91,778	2,151,27
TOTAL INDIA		
(Cost \$6,757,542)		7,495,77
IRELAND—3.0%		
PACKAGED FOODS & MEATS—3.0%		
Kerry Group PLC, Cl. A	40,441	4,259,43
(Cost \$4,489,017)		
ITALY—6.8%		
APPAREL ACCESSORIES & LUXURY GOODS—2.5%		
Moncler SpA	47,386	3,515,14
AUTOMOBILE MANUFACTURERS—4.3%		
Ferrari NV	21,462	5,980,172
TOTAL ITALY		
(Cost \$4,763,745)		9,495,32
JAPAN—3.3%		
ELECTRONIC EQUIPMENT & INSTRUMENTS—2.5%		
Keyence Corp.	7,900	3,563,07
<u></u>		

## THE ALGER FUNDS | ALGER INTERNATIONAL FOCUS FUND Schedule of Investments April 30, 2023 (Unaudited) (Continued)

COMMON STOCKS—96.1% (CONT.)	SHARES	VALUE
JAPAN-3.3% (CONT.)		
SEMICONDUCTOR MATERIALS & EQUIPMENT—0.8%		
Lasertec Corp.	8,200	\$ 1,115,74
TOTAL JAPAN		
(Cost \$3,657,229)		4,678,81
MEXICO-2.5%		
AIRPORT SERVICES—2.5%		
Grupo Aeroportuario del Centro Norte SAB de CV	323,000	3,543,79
(Cost \$3,031,019)		
NETHERLANDS—8.6%		
HEAVY ELECTRICAL EQUIPMENT—2.1%		
Alfen Beheer BV*	36,800	2,977,46
SEMICONDUCTOR MATERIALS & EQUIPMENT—4.1%		
ASML Holding NV	9,100	5,774,9
TRANSACTION & PAYMENT PROCESSING SERVICES—2.4%		
Adyen NV*	2,075	3,334,2
TOTAL NETHERLANDS		
(Cost \$4,618,115)		12,086,6
NORWAY—1.1%		
ENVIRONMENTAL & FACILITIES SERVICES—1.1%		
Aker Carbon Capture ASA*	1,560,510	1,601,2
(Cost \$3,626,911)		
SPAIN—1.9%		
BIOTECHNOLOGY—1.9%		
Grifols SA#*	350,741	2,616,52
(Cost \$5,818,963)		
SWEDEN—1.7%		
ASSET MANAGEMENT & CUSTODY BANKS—1.7%		
EQTAB	112,298	2,418,7
(Cost \$1,658,438)		
SWITZERLAND—3.6%		
ASSET MANAGEMENT & CUSTODY BANKS—1.6%		
Partners Group Holding AG	2,284	2,217,1
SPECIALTY CHEMICALS—2.0%		
Sika AG	10,150	2,803,66
TOTAL SWITZERLAND		
(Cost \$3,032,454)		5,020,81
UNITED KINGDOM—5.4%		
FINANCIAL EXCHANGES & DATA—2.9%		
London Stock Exchange Group PLC	39,200	4,115,40
PHARMACEUTICALS—2.5%		
AstraZeneca PLC	23,500	3,458,05
TOTAL UNITED KINGDOM		
(Cost \$6,013,748)		7,573,46

## THE ALGER FUNDS | ALGER INTERNATIONAL FOCUS FUND Schedule of Investments April 30, 2023 (Unaudited) (Continued)

COMMON STOCKS—96.1% (CONT.)	SHARES	VALUE
UNITED STATES—2.7%		
OIL & GAS EQUIPMENT & SERVICES—2.7%		
Schlumberger Ltd.	75,400	\$ 3,720,990
(Cost \$2,359,583)		
TOTAL COMMON STOCKS		
(Cost \$116,478,759)		135,120,366
Total Investments		
(Cost \$116,478,759)	96.1%	\$ 135,120,366
Unaffiliated Securities (Cost \$116,478,759)		135,120,366
Other Assets in Excess of Liabilities	3.9%	5,531,803
NET ASSETS	100.0%	\$ 140,652,169

# American Depositary Receipts.

\* Non-income producing security.

## THE ALGER FUNDS | ALGER HEALTH SCIENCES FUND Schedule of Investments April 30, 2023 (Unaudited)

ADMA Biologics, Inc.* Aerovate Therapeutics, Inc.* 65.527 7.1374,10 Aerovate Therapeutics, Inc.* 65.527 7.1374,10 Aerovate Therapeutics, Inc.* 7.74,06 Aerovate Therapeutics, Inc.* 7.759 7.73 80 1.74,13 8 1.74,14 8 1.74,14 8 1.74 8 1.74,14 8 1.74,14 8 1.74,14 8 1.74,14 1 1.75 8	COMMON STOCKS—97.4%	SHARES	VALUE
ADMA Biologics, Inc.* 65,527 1,374,106 Aerovate Therapeutics, Inc.* 65,527 1,374,10 Aerovate Therapeutics, Inc.* 65,527 1,374,10 Aerovate Therapeutics, Inc.* 104,438 1,366,04 BioMarin Pharmaceutical, Inc.* 20,773 3,080,29 Celldex Therapeutics, Inc.* 13,573 426,73 Compass Therapeutics, Inc.* 146,63 52,43 Exact Sciences Corp.* 11,584 742,18 HilleVax, Inc.* 17,406 Regeneron Pharmaceuticals, Inc.* 42,648 2,163,10 Prothena Corp., PLC* 23,491 1,286,00 Regeneron Pharmaceuticals, Inc.* 4,863 3,899,10 Vaxyte, Inc.* 24,793 1,061,88 Vertex Pharmaceuticals, Inc.* 36,830,45 HEALTHCARE DISTRIBUTORS—1.7% Cardinal Health, Inc. 32,057 2,631,88 HEALTHCARE EQUIPMENT—24.4% Bexcon, Inc.* 78,871 64,23,50 Impulse Dynamics PLC, Class E <sup>*,g,(n)</sup> Insulet Corp.* 58,271 42,144,53 Compass	BIOTECHNOLOGY—24.1%		
Aerovate Therapeutics, Inc.*       66,527       1,374,10         Apellis Pharmaceuticals, Inc.*       41,640       3,474,02         Biogen, Inc.*       5,789       1,761,18         Biohaven Ltd.*       104,438       1,366,04         BioMain Pharmaceutical, Inc.*       32,073       3080,29         Celldex Therapeutics, Inc.*       13,673       426,73         Compass Therapeutics, Inc.*       174,563       525,43         Exact Sciences Corp.*       11,584       742,18         HilleVax, Inc.*       87,043       1,218,60         Natera, Inc.*       42,648       2,163,10         Prothena Corp., PLC*       23,491       1,208,09         Regeneron Pharmaceuticals, Inc.*       42,643       3,899,10         Vaxcyte, Inc.*       24,793       1,061,88         Vertex Pharmaceuticals, Inc.*       24,793       1,061,88         HEALTHCARE DISTRIBUTORS—1.7%       32,057       2,631,88         HEALTHCARE For Technologies, Inc.*       146,197       7,619,78         Dexcom, Inc.*       20,176       2,448,15         Edwards Lifesciences Corp.*       38,504       33,758         GE HealthCare Technologies, Inc.*       78,971       6,423,501         Insulse Dynamics PLC, Class E*@i///	AbbVie, Inc.	37,676 \$	5,693,597
Apellis Pharmaceuticals, Inc.*       41,640       3,474,02         Biogen, Inc.*       5,789       1,761,18         Biohaven Ltd.*       104,438       1,360,44         Biohaven Ltd.*       32,073       3,080,29         Celldex Therapeutics, Inc.*       32,073       3,080,29         Celldex Therapeutics, Inc.*       174,563       525,43         Exact Sciences Corp.*       11,584       742,18         HilleVax, Inc.*       87,043       1,218,60         Natera, Inc.*       42,648       2,163,10         Prothena Corp., PLC*       23,491       1,236,09         Regeneron Pharmaceuticals, Inc.*       4,863       3,899,10         Vaxyte, Inc.*       24,793       1,061,88         Vertex Pharmaceuticals, Inc.*       24,863       3,899,10         Vaxyte, Inc.*       24,793       1,061,88         Vertex Pharmaceuticals, Inc.*       24,648       3,809,10         Vaxyte, Inc.*       24,619       7,619,78         Cardinal Health, Inc.       32,057       2,631,88         HEALTHCARE EOUPINENT-24.4%       550       3,875.85         GE HealthCare Technologies, Inc.*       78,971       6,423,50         Inpulse Dynamics PLC, Class E*&#in*       1,515,152       5,00</td><td>ADMA Biologics, Inc.*</td><td>828,080</td><td>2,774,068</td></tr><tr><td>Biogen, Inc.*         5,789         1,761,18           Biohaven Ltd.*         104,438         1,366,04           BioMarin Pharmaceutical, Inc.*         32,073         3,080,29           Celldex Therapeutics, Inc.*         13,573         426,73           Compass Therapeutics, Inc.*         174,563         525,43           Exact Sciences Corp.*         11,584         742,18           Natera, Inc.*         87,043         1,218,60           Natera, Inc.*         42,648         2,183,10           Prothena Corp., PLC*         23,491         1,236,09           Naxcyte, Inc.*         4,863         3,899,10           Vaxcyte, Inc.*         24,793         1,061,88           Vertex Pharmaceuticals, Inc.*         24,793         1,061,88           Vertex Pharmaceuticals, Inc.*         146,197         7,619,78           Easton Scientific Corp.*         146,197         7,619,78           Dexcon, Inc.*         20,176         2,448,15           Edwards Lifesciences Corp.*         38,504         3,387,58           Ed HealthCare Technologies, Inc.*         78,971         6,423,50           Ingulse Dynamics PLC, Class E*®™         1,515,152         5,000,00           Insulet Corp.*         6,177         1,964,53</</td><td>Aerovate Therapeutics, Inc.*</td><td>65,527</td><td>1,374,101</td></tr><tr><td>Bionaven Ltd.*         104,438         1,366,04           BioMarin Pharmaceutical, Inc.*         32,073         3,080,29           Celldex Therapeutics, Inc.*         13,573         426,73           Compass Therapeutics, Inc.*         174,563         525,43           Exact Sciences Corp.*         11,584         742,18           HilleVax, Inc.*         87,043         1,218,60           Natera, Inc.*         42,648         2,163,10           Prothena Corp., PLC*         23,491         1,236,09           Regeneron Pharmaceuticals, Inc.*         48,663         3,899,10           Vaxcyte, Inc.*         24,793         1,061,88           Vertex Pharmaceuticals, Inc.*         24,793         1,061,88           Vertex Pharmaceuticals, Inc.*         24,793         1,061,88           Vertex Pharmaceuticals, Inc.*         20,07         2,631,88           HEALTHCARE EQUIPMENT—24.4%         20,176         2,448,15           Dexcom, Inc.*         20,176         2,448,15           Edwards Lifesciences Corp.*         38,504         3,387,58           GE HealthCare Technologies, Inc.*         78,971         6,423,00           Insule Corp.*         1,513         3,144,33           TransMedics Group, Inc.*         7,886</td</td><td>Apellis Pharmaceuticals, Inc.*</td><td>41,640</td><td>3,474,025</td></tr><tr><td>BioMarin Pharmaceutical, Inc.*         32,073         3,080,29           Celldex Therapeutics, Inc.*         13,573         426,73           Compass Therapeutics, Inc.*         174,563         525,43           Exact Sciences Corp.*         11,584         742,18           HilleVax, Inc.*         87,043         1,218,60           Natera, Inc.*         42,648         2,163,10           Prothena Corp., PLC*         23,491         1,236,00           Regeneron Pharmaceuticals, Inc.*         4,863         3,899,10           Vaxcyte, Inc.*         24,793         1,061,88           Vertex Pharmaceuticals, Inc.*         146,197         7,619,78           Dexcom, Inc.*         20,176         2,484,15           Edwards Lifesciences Corp.*         38,504         3,387,58           Get Health Corp.         146,197         7,619,78           Dexcom, Inc.*         78,971         6,423,50           Impulse Dynamics PLC, Class E*®™         <t</td><td>Biogen, Inc.*</td><td>5,789</td><td>1,761,187</td></tr><tr><td>Celldex Therapeutics, Inc.*       13,573       426,73         Compass Therapeutics, Inc.*       174,563       525,43         Exact Sciences Corp.*       11,584       774,218         Natera, Inc.*       87,043       1,218,60         Natera, Inc.*       42,648       2,163,10         Prothena Corp., PLC*       23,491       1,236,00         Regeneron Pharmaceuticals, Inc.*       4,863       3,899,10         Vaxcyte, Inc.*       24,793       1,061,88         Vertex Pharmaceuticals, Inc.*       4,863       3,899,10         Vaxcyte, Inc.*       24,793       1,061,88         Vertex Pharmaceuticals, Inc.*       4,863       3,899,10         Vaxcyte, Inc.*       20,176       2,481,58         Cardinal Health, Inc.       32,057       2,631,88         HEALTHCARE EQUIPMENT—24.4%       52,514       3,87,58         Dexcom, Inc.*       20,176       2,448,15         Edwards Lifesciences Corp.*       146,197       7,619,78         Dexcom, Inc.*       20,176       2,448,15         Edwards Lifesciences Corp.*       38,504       3,387,58         GE HealthCare Technologies, Inc.*       78,971       6,423,50         Inpulse Dynamics PLC, Class E*@init       1,515,152</td><td>Biohaven Ltd.*</td><td>104,438</td><td>1,366,049</td></tr><tr><td>Compass Therapeutics, Inc.*         174,563         525,43           Exact Sciences Corp.*         11,584         742,18           HilleVax, Inc.*         87,043         1,218,60           Natera, Inc.*         42,648         2,163,10           Prothena Corp., PLC*         23,491         1,236,09           Regeneron Pharmaceuticals, Inc.*         4,863         3,899,10           Vaxcyte, Inc.*         24,793         1,061,88           Vertex Pharmaceuticals, Inc.*         17,709         6,033,98           Cardinal Health, Inc.         32,057         <b>2,631,88</b>           HEALTHCARE EQUIPMENT—24.4%         E         E           Boston Scientific Corp.*         146,197         7,619,78           Dexcom, Inc.*         20,176         2,448,15           Edwards Lifesciences Corp.*         38,504         3,387,58           GE HealthCare Technologies, Inc.*         78,971         6,423,50           Ingulse Dynamics PLC, Class E*.®.(e)         1,515,152         5,000,00           Insulet Corp.*         6,177         1,964,53           Masimo Corp.*         7,886         2,240,57           Teleflex, Inc.         11,538         3,144,33           TransMedics Group, Inc.*         78,866         2,240,57</t</td><td>BioMarin Pharmaceutical, Inc.*</td><td>32,073</td><td>3,080,291</td></tr><tr><td>Compass Therapeutics, Inc.*         174,563         525,43           Exact Sciences Corp.*         11,584         742,18           HilleVax, Inc.*         87,043         1,218,60           Natera, Inc.*         42,648         2,163,10           Prothena Corp., PLC*         23,491         1,236,09           Regeneron Pharmaceuticals, Inc.*         4,863         3,899,10           Vaxcyte, Inc.*         24,793         1,061,88           Vertex Pharmaceuticals, Inc.*         17,709         6,033,98           Cardinal Health, Inc.         32,057         <b>2,631,88</b>           HEALTHCARE EQUIPMENT—24.4%         E         E           Boston Scientific Corp.*         146,197         7,619,78           Dexcom, Inc.*         20,176         2,448,15           Edwards Lifesciences Corp.*         38,504         3,387,58           GE HealthCare Technologies, Inc.*         78,971         6,423,50           Ingulse Dynamics PLC, Class E*.®.(e)         1,515,152         5,000,00           Insulet Corp.*         6,177         1,964,53           Masimo Corp.*         7,886         2,240,57           Teleflex, Inc.         11,538         3,144,33           TransMedics Group, Inc.*         78,866         2,240,57</t</td><td>Celldex Therapeutics, Inc.*</td><td>13,573</td><td>426,735</td></tr><tr><td>Exact Sciences Corp.*         11,584         742,18           HilleVax, Inc.*         87,043         1,218,60           Natera, Inc.*         42,648         2,163,10           Prothena Corp., PLC*         23,491         1,236,09           Regeneron Pharmaceuticals, Inc.*         4,863         3,899,10           Vertex Pharmaceuticals, Inc.*         4,863         3,899,10           Vertex Pharmaceuticals, Inc.*         17,709         6,033,98           HEALTHCARE EDUSTRIBUTORS—1.7%         36,804,57         2,631,88           HEALTHCARE EQUIPMENT—24.4%         Boston Scientific Corp.*         146,197         7,619,78           Boston Scientific Corp.*         146,197         7,619,78         2,438,564         3,387,58           Edwards Lifesciences Corp.*         38,504         3,387,58         26,500,00         Insule Corp.*         7,897,1         6,423,50           Impulse Dynamics PLC, Class E*®.60         1,515,152         5,000,00         Insule Corp.*         7,886         2,240,57           Teleflex, Inc.         7,886         2,240,57         1,515,152         5,000,00           Insule Corp.*         7,886         2,240,57         1,538         3,144,33           TransMedics Group, Inc.*         58,271         4,212,41         <td</td><td></td><td></td><td>525,435</td></tr><tr><td>HilleVax, Inc.*         87,043         1,218,60           Natera, Inc.*         42,648         2,163,10           Prothena Corp., PLC*         23,491         1,236,09           Regeneron Pharmaceuticals, Inc.*         4,863         3,899,10           Vaxcyte, Inc.*         24,793         1,061,88           Vertex Pharmaceuticals, Inc.*         17,709         6,033,98           Boston Scientific Corp.*         32,057         2,631,88           HEALTHCARE EQUIPMENT—24.4%         Beadon Scientific Corp.*         146,197         7,619,78           Dexcom, Inc.*         20,176         2,448,15         1,600,00           Insulet Corp.*         146,197         7,619,78         3,8504         3,887,58           Dexom, Inc.*         20,176         2,448,15         5,000,00         Insulet Corp.*         6,177         1,946,35           Insulet Corp.*         6,177</td><td></td><td>,</td><td>742,187</td></tr><tr><td>Natera, Inc.*         42,648         2,163,10           Prothena Corp., PLC*         23,491         1,236,09           Regeneron Pharmaceuticals, Inc.*         4,863         3,899,10           Vaxcyte, Inc.*         24,793         1,061,86           Vertex Pharmaceuticals, Inc.*         17,709         6,033,98           Gardinal Health, Inc.         32,057         2,631,88           HEALTHCARE EDUPMENT—24.4%           Boston Scientific Corp.*         146,197         7,619,78           Dexcom, Inc.*         20,176         2,448,15           Edwards Lifesciences Corp.*         38,504         3,387,58           GE HealthCare Technologies, Inc.*         78,971         6,423,50           Impulse Dynamics PLC, Class E*@.0         1,515,152         5,000,00           Insulet Corp.*         6,177         1,964,53           Masimo Corp.*         8,320         1,573,64           Penumbra, Inc.*         7,886         2,240,57           TransMedics Group, Inc.*         45,101         3,567,48           Tenet Healthcare Co., Inc.*         45,101         3,567,48           HEALTHCARE FACILITIES—8.0%         20,2108         2,734,52           Accolade, Inc.*         9,120         2,620,45</td><td>1</td><td>,</td><td>,</td></tr><tr><td>Prothena Corp., PLC*         23,491         1,236,09           Regeneron Pharmaceuticals, Inc.*         4,863         3,899,10           Vaxcyte, Inc.*         24,793         1,061,88           Vertex Pharmaceuticals, Inc.*         17,709         6,033,95           HEALTHCARE DISTRIBUTORS—1.7%           Cardinal Health, Inc.         32,057         2,631,88           HEALTHCARE DISTRIBUTORS—1.7%           Cardinal Health, Inc.         32,057         2,631,88           HEALTHCARE DISTRIBUTORS—1.7%           Cardinal Health, Inc.         32,057         2,631,88           HEALTHCARE EQUIPMENT—24.4%         Beston Scientific Corp.*         146,197         7,619,78           Dexcom, Inc.*         20,176         2,448,15         2,448,15           Edwards Lifesciences Corp.*         38,504         3,387,58         GE           GE HealthCare Technologies, Inc.*         78,971         6,423,50         Inpulse Dynamics PLC, Class E*@.01         1,515,152         5,000,00           Insulet Corp.*         6,177         1,964,53         3,144,33         3,144,33           TransMedics Group, Inc.*         7,886         2,240,57         7,886         2,240,57           Teleflex, Inc.         11,538         3,144,33</td><td></td><td>,</td><td></td></tr><tr><td>Regeneron Pharmaceuticals, Inc.*         4,863         3,899,10           Vaxcyte, Inc.*         24,793         1,061,88           Vertex Pharmaceuticals, Inc.*         17,709         6,033,98           HEALTHCARE DISTRIBUTORS—1.7%         36,830,455           Cardinal Health, Inc.         32,057         2,631,88           HEALTHCARE EQUIPMENT—24.4%         Boston Scientific Corp.*         146,197         7,619,78           Dexcom, In.*         20,176         2,448,15         24,481,15           Edwards Lifesciences Corp.*         38,504         3,387,58         38,504         3,387,58           GE HealthCare Technologies, Inc.*         78,971         6,423,50         1mpulse Dynamics PLC, Class E*®!**         1,515,152         5,000,00           Insulet Corp.*         6,177         1,964,53         3,373,443         3,374,433         3,144,33           YransMedics Group, Inc.*         7,886         2,240,57         11,538         3,144,33         3,144,33           TransMedics Group, Inc.*         7,886         2,240,57         3,669,00         3,67,48           HEALTHCARE FACILITIES—8.0%         3,144,33         3,144,33         3,144,33         3,144,33           TransMedics Group, Inc.*         58,271         4,212,41         HCA Healthcare, Inc.</td><td></td><td>,</td><td></td></tr><tr><td>Vaxcyte, Inc.*         24,793         1,061,88           Vertex Pharmaceuticals, Inc.*         17,709         6,033,98           36,830,45           HEALTHCARE DISTRIBUTORS—1.7%           Cardinal Health, Inc.         32,057         2,631,88           HEALTHCARE EQUIPMENT—24.4%           Boston Scientific Corp.*         146,197         7,619,78           Dexcom, Inc.*         20,176         2,448,15           Edwards Lifesciences Corp.*         38,504         3,387,53           GE HealthCare Technologies, Inc.*         78,871         6,423,50           Impulse Dynamics PLC, Class E*®.(*)         1,515,152         5,000,00           Insulet Corp.*         6,177         1,964,53           Masimo Corp.*         8,320         1,573,64           Penumbra, Inc.*         7,886         2,240,57           TransMedics Group, Inc.*         45,101         3,567,48           TransMedics Group, Inc.*         58,271         4,212,41           HCALTHCARE FACILITIES—8.0%         4,262,41         4,262,41           HEALTHCARE SERVICES—2.5%         4,263,45         1,106,2           HEALTHCARE SERVICES—2.5%         202,108         2,734,52           Accolade, Inc.*         3,464,35</t</td><td>• •</td><td></td><td></td></tr><tr><td>Vertex Pharmaceuticals, Inc.*         17,709         6,033,98           36,830,45           HEALTHCARE DISTRIBUTORS—1.7%           Cardinal Health, Inc.         32,057         2,631,88           HEALTHCARE EQUIPMENT—24.4%         Boston Scientific Corp.*         146,197         7,619,78           Dexcom, Inc.*         20,176         2,448,15         Edwards Lifesciences Corp.*         38,504         3,387,58           GE HealthCare Technologies, Inc.*         78,971         6,423,500         Inpulse Dynamics PLC, Class E*®.(*)         1,515,152         5,000,00           Insulet Corp.*         6,177         1,964,53         Masimo Corp.*         8,320         1,573,64           Penumbra, Inc.*         7,886         2,240,57         Teleflex, Inc.         11,538         3,144,33           TransMedics Group, Inc.*         45,101         3,667,48         3,464,33         3,643,49           HEALTHCARE FACILITIES—8.0%         TarasMedics Group, Inc.*         58,271         4,212,41           HCA Healthcare Co., Inc.*         9,120         2,620,455         1,10,62           Tenet Healthcare Corp.*         74,768         5,481,99           Cordial Healthcare, Inc.*         34,545         1,110,62           Tenet Healthcare Corp.*         202,1</td><td>•</td><td>,</td><td>, ,</td></tr><tr><td>36,830,45           HEALTHCARE DISTRIBUTORS—1.7%           Cardinal Health, Inc.           32,057           HEALTHCARE EQUIPMENT—24.4%           Boston Scientific Corp.*         146,197         7,619,78           Dexcom, Inc.*         20,176         2,448,15           Edwards Lifesciences Corp.*         38,504         3,387,58           GE HealthCare Technologies, Inc.*         78,971         6,423,50           Impulse Dynamics PLC, Class E*<sup>(@,(e)</sup>         1,515,152         5,000,00           Insulet Corp.*         6,177         1,964,53           Masimo Corp.*         8,320         1,573,64           Penumbra, Inc.*         7,886         2,240,57           Teleflex, Inc.         11,538         3,144,33           TransMedics Group, Inc.*         45,101         3,567,48           Acadia Healthcare Co., Inc.*         45,2101         3,567,48           Acadia Healthcare Co., Inc.*         58,271         4,212,41           HEALTHCARE FACILITIES—8.0%           Acadia Healthcare Corp.*         74,768         5,481,99           Contor are Health, Inc.*         202,108         2,734,52</td><td></td><td>,</td><td></td></tr><tr><td>HEALTHCARE DISTRIBUTORS—1.7%           Cardinal Health, Inc.         32,057         2,631,88           HEALTHCARE EQUIPMENT—24.4%         Boston Scientific Corp.*         146,197         7,619,78           Boston Scientific Corp.*         20,176         2,448,15         24,48,15           Edwards Lifesciences Corp.*         38,504         3,387,58         GE HealthCare Technologies, Inc.*         78,971         6,423,50           Impulse Dynamics PLC, Class E*@.(*)         1,515,152         5,000,00         Insulet Corp.*         6,177         1,964,53           Masimo Corp.*         6,177         1,964,53         1,536         2,240,57           Teleflex, Inc.         11,538         3,144,33         1,573,64           Penumbra, Inc.*         7,886         2,240,57           Teleflex, Inc.         11,538         3,144,33           TransMedics Group, Inc.*         45,101         3,567,48           Acadia Healthcare Co., Inc.*         58,271         4,212,41           HCA Healthcare Corp.*         74,768         5,481,99           Tenet Healthcare Corp.*         74,768         5,481,99           LCA Healthcare, Inc.         34,545         1,110,62           Uption Care Health, Inc.*         34,545         1,110,62</td><td></td><td>11,105</td><td>36,830,45</td></tr><tr><td>HEALTHCARE EQUIPMENT—24.4%           Boston Scientific Corp.*         146,197         7,619,78           Dexcom, Inc.*         20,176         2,448,15           Edwards Lifesciences Corp.*         38,504         3,387,58           GE HealthCare Technologies, Inc.*         78,971         6,423,50           Impulse Dynamics PLC, Class E*®(ie)         1,515,152         5,000,00           Insulet Corp.*         6,177         1,964,53           Masimo Corp.*         8,320         1,573,64           Penumbra, Inc.*         7,886         2,240,57           Teleflex, Inc.         11,538         3,144,33           TransMedics Group, Inc.*         45,101         3,567,48           Acadia Healthcare Co., Inc.*         58,271         4,212,41           HCA Healthcare, Inc.         9,120         2,620,45           Tenet Healthcare Corp.*         74,768         5,481,99           Iz,314,85           HEALTHCARE SERVICES—2.5%         202,108         2,734,52           Accolade, Inc.*         202,108         2,734,52           Option Care Health, Inc.*         34,545         1,110,62            22,691         3,269,02           Merit Medical Systems, Inc.*         <td</td><td>HEALTHCARE DISTRIBUTORS—1.7%</td><td></td><td></td></tr><tr><td>Boston Scientific Corp.*         146,197         7,619,78           Dexcom, Inc.*         20,176         2,448,15           Edwards Lifesciences Corp.*         38,504         3,387,58           GE HealthCare Technologies, Inc.*         78,971         6,423,50           Impulse Dynamics PLC, Class E*®.         1,515,152         5,000,00           Insulet Corp.*         6,177         1,964,53           Masimo Corp.*         8,320         1,573,64           Penumbra, Inc.*         7,886         2,240,57           Teleflex, Inc.         11,538         3,144,33           TransMedics Group, Inc.*         45,101         3,567,48           Acadia Healthcare Co., Inc.*         58,271         4,212,41           HCAL HCARE FACILITIES—8.0%         34,745         1,433           Acadia Healthcare Corp.*         31,269,40           HEALTHCARE SERVICES—2.5%           Accolade, Inc.*         202,108         2,734,52           Option Care Health, Inc.*         34,545         1,110,62            6,344         2,063,70           Coloplast AS, Cl. B         22,691         3,269,02           Merit Medical Systems, Inc.*         25,914         2,106,54</td><td>,</td><td>32,057</td><td>2,631,880</td></tr><tr><td>Dexcom, Inc.*         20,176         2,448,15           Edwards Lifesciences Corp.*         38,504         3,387,58           GE HealthCare Technologies, Inc.*         78,971         6,423,50           Impulse Dynamics PLC, Class E*®(e)         1,515,152         5,000,00           Insulet Corp.*         6,177         1,964,53           Masimo Corp.*         8,320         1,573,64           Penumbra, Inc.*         7,886         2,240,57           Teleflex, Inc.         11,538         3,144,33           TransMedics Group, Inc.*         45,101         3,567,48           Acadia Healthcare Co., Inc.*         58,271         4,212,41           HCA Healthcare Corp.*         74,768         5,481,99           Iz,314,85           HEALTHCARE SERVICES—2.5%           Accolade, Inc.*         202,108         2,734,52           Option Care Health, Inc.*         3,845,14         110,62            6,344         2,063,70           Alcon, Inc.         71,051         5,173,67           Align Technology, Inc.*         6,344         2,063,70            22,691         3,269,02           Mign Technology, Inc.*         6,344         2,063,70</td</td><td></td><td>440 407</td><td>7 040 70</td></tr><tr><td>Edwards Lifesciences Corp.*         38,504         3,387,58           GE HealthCare Technologies, Inc.*         78,971         6,423,50           Impulse Dynamics PLC, Class E*.@.(#)         1,515,152         5,000,00           Insulet Corp.*         6,177         1,964,53           Masimo Corp.*         8,320         1,573,64           Penumbra, Inc.*         7,886         2,240,57           Teleflex, Inc.         11,538         3,144,33           TransMedics Group, Inc.*         45,101         3,567,48           Acadia Healthcare Co., Inc.*         58,271         4,212,41           HCA Healthcare, Inc.         9,120         2,620,45           Tenet Healthcare Corp.*         74,768         5,481,99           Iz,314,85           HEALTHCARE SERVICES—2.5%           Accolade, Inc.*         202,108         2,734,52           Option Care Health, Inc.*         34,545         1,110,62           IteletIntermeters Supplies—8.2%           Alcon, Inc.         71,051         5,173,67           Alcon, Inc.         71,051         5,173,67           Alcon, Inc.         71,051         5,173,67           Alcon, Inc.         71,051         5,173,67</td><td>•</td><td></td><td></td></tr><tr><td>GE HealthCare Technologies, Inc.*         78,971         6,423,50           Impulse Dynamics PLC, Class E*@.(a)         1,515,152         5,000,00           Insulet Corp.*         6,177         1,964,53           Masimo Corp.*         8,320         1,573,64           Penumbra, Inc.*         7,886         2,240,57           Teleflex, Inc.         11,538         3,144,33           TransMedics Group, Inc.*         45,101         3,567,48           Acadia Healthcare Co., Inc.*         58,271         4,212,41           HCA Healthcare, Inc.         9,120         2,620,45           Tenet Healthcare Corp.*         74,768         5,481,99           Image: Services—2.5%           HEALTHCARE SERVICES—2.5%           HEALTHCARE SUPPLIES—8.2%         202,108         2,734,52           Option Care Health, Inc.*         202,108         2,734,52           Option Care Health, Inc.*         202,108         2,734,52           Alcon, Inc.         71,051         5,173,67           Align Technology, Inc.*         6,344         2,063,70           Coloplast AS, Cl. B         22,691         3,269,02           Merit Medical Systems, Inc.*         25,914         2,106,54           <td colspanst AS, C</td><td></td><td>,</td><td></td></tr><tr><td>Impulse Dynamics PLC, Class E*.@.(a)         1,515,152         5,000,00           Insulet Corp.*         6,177         1,964,53           Masimo Corp.*         8,320         1,573,64           Penumbra, Inc.*         7,886         2,240,57           Teleflex, Inc.         11,538         3,144,33           TransMedics Group, Inc.*         45,101         3,567,48           <b>Acadia Healthcare Co., Inc.*</b>           Acadia Healthcare Co., Inc.*           Acadia Healthcare Co., Inc.*           HEALTHCARE FACILITIES—8.0%           Acadia Healthcare Corp.*           Acadia Healthcare Corp.*           P.120           P.200           D.201           Acadia Healthcare Corp.*           Tarest PACILITIES—8.0%           HEALTHCARE SERVICES—2.5%           HEALTHCARE SUPPLIES—8.2%           Accolade, Inc.*           Alcon, Inc.           T,051           Alcon, Inc.           Alcon, Inc.           Alcon, Inc.           Alcon, Inc.            22,691</td><td>•</td><td></td><td></td></tr><tr><td>Insulet Corp.*         6,177         1,964,53           Masimo Corp.*         8,320         1,573,64           Penumbra, Inc.*         7,886         2,240,57           Teleflex, Inc.         11,538         3,144,33           TransMedics Group, Inc.*         45,101         3,567,48           <b>Acadia Healthcare Co., Inc.*</b>           Acadia Healthcare Co., Inc.*         58,271         4,212,41           HCA Healthcare, Inc.         9,120         2,620,45           Tenet Healthcare Corp.*         74,768         5,481,99           <b>HEALTHCARE SERVICES—2.5%</b>           <b>HEALTHCARE SERVICES—2.5%</b>           Accolade, Inc.*         202,108         2,734,52           Option Care Health, Inc.*         34,545         1,110,62           <b>Accolade, Inc.</b>*         202,108         2,734,52           Alcon, Inc.         71,051         5,173,67           Algin Technology, Inc.*         6,344         2,063,70           Coloplast AS, Cl. B         22,691         3,269,02           Merit Medical Systems, Inc.*         25,914         2,106,54           <b>HEALTHCARE TECHNOLOGY—0.3%</b></td><td><b>U</b></td><td></td><td></td></tr><tr><td>Masimo Corp.*         8,320         1,573,64           Penumbra, Inc.*         7,886         2,240,57           Teleflex, Inc.         11,538         3,144,33           TransMedics Group, Inc.*         45,101         3,567,48           <b>37,369,60</b>           <b>HEALTHCARE FACILITIES—8.0%</b>           Acadia Healthcare Co., Inc.*         58,271         4,212,41           HCA Healthcare Corp.tor.*         58,271         4,212,41           HEALTHCARE SERVICES—2.0%           HEALTHCARE SERVICES—2.5%           Accolade, Inc.*         202,108         2,734,52           Option Care Health, Inc.*         202,108         2,734,52           Alcon, Inc.         71,051         5,173,67           Alcon, Inc.         71,051         5,173,67           Alcon, Inc.         71,051         5,173,67           Alcon, Inc.         71,051         5,173,67</td><td></td><td></td><td></td></tr><tr><td>Penumbra, Inc.*         7,886         2,240,57           Teleflex, Inc.         11,538         3,144,33           TransMedics Group, Inc.*         45,101         3,567,48           37,369,60           HEALTHCARE FACILITIES—8.0%           Acadia Healthcare Co., Inc.*         58,271         4,212,41           HCA Healthcare, Inc.         9,120         2,620,45           Tenet Healthcare Corp.*         74,768         5,481,99           Iterat Health Inc.*         202,108         2,734,52           Option Care Health, Inc.*         202,108         2,734,52           Alcon, Inc.         71,051         5,173,67           Alcon, Inc.</td><td></td><td>,</td><td></td></tr><tr><td>Teleflex, Inc.       11,538       3,144,33         TransMedics Group, Inc.*       45,101       3,567,48         37,369,60         HEALTHCARE FACILITIES—8.0%         Acadia Healthcare Co., Inc.*       58,271       4,212,41         HCA Healthcare, Inc.       9,120       2,620,45         Tenet Healthcare Corp.*       74,768       5,481,99         HEALTHCARE SERVICES—2.5%       12,314,85         Accolade, Inc.*       202,108       2,734,52         Option Care Health, Inc.*       34,545       1,110,62         3,845,14         HEALTHCARE SUPPLIES—8.2%         Alcon, Inc.       71,051       5,173,67         Align Technology, Inc.*       6,344       2,063,70         Coloplast AS, Cl. B       22,691       3,269,02         Merit Medical Systems, Inc.*       25,914       2,106,54         12,612,95         HEALTHCARE TECHNOLOGY—0.3%</td><td></td><td>,</td><td></td></tr><tr><td>TransMedics Group, Inc.*       45,101       3,567,48         37,369,60         HEALTHCARE FACILITIES—8.0%         Acadia Healthcare Co., Inc.*       58,271       4,212,41         HCA Healthcare, Inc.       9,120       2,620,45         Tenet Healthcare Corp.*       74,768       5,481,99         HEALTHCARE SERVICES—2.5%       12,314,85         Accolade, Inc.*       202,108       2,734,52         Option Care Health, Inc.*       34,545       1,110,62         Alcon, Inc.         Alcon, Inc.       71,051       5,173,67         Alcon, Inc.       71,051       5,173,67         Align Technology, Inc.*       6,344       2,063,70         Coloplast AS, Cl. B       22,691       3,269,02         Merit Medical Systems, Inc.*       25,914       2,106,54         HEALTHCARE TECHNOLOGY—0.3%</td><td>· · · · · · · · · · · · · · · · · · ·</td><td>,</td><td></td></tr><tr><td>37,369,60         HEALTHCARE FACILITIES—8.0%         Acadia Healthcare Co., Inc.*       58,271       4,212,41         HCA Healthcare, Inc.       9,120       2,620,45         Tenet Healthcare Corp.*       74,768       5,481,99         IL2,314,85         HEALTHCARE SERVICES—2.5%         Accolade, Inc.*       202,108       2,734,52         Option Care Health, Inc.*       34,545       1,110,62         Alcon, Inc.         Alcon, Inc.       71,051       5,173,67         Align Technology, Inc.*       6,344       2,063,70         Coloplast AS, Cl. B       22,691       3,269,02         Merit Medical Systems, Inc.*       25,914       2,106,54         HEALTHCARE TECHNOLOGY—0.3%</td><td></td><td></td><td>3,144,33</td></tr><tr><td>HEALTHCARE FACILITIES—8.0%         Acadia Healthcare Co., Inc.*       58,271       4,212,41         HCA Healthcare, Inc.       9,120       2,620,45         Tenet Healthcare Corp.*       74,768       5,481,99         12,314,85         HEALTHCARE SERVICES—2.5%       202,108       2,734,52         Accolade, Inc.*       202,108       2,734,52         Option Care Health, Inc.*       34,545       1,110,62         3,845,14         HEALTHCARE SUPPLIES—8.2%       71,051       5,173,67         Alcon, Inc.       71,051       5,173,67         Algin Technology, Inc.*       6,344       2,063,70         Coloplast AS, Cl. B       22,691       3,269,02         Merit Medical Systems, Inc.*       25,914       2,106,54         HEALTHCARE TECHNOLOGY—0.3%</td><td>TransMedics Group, Inc.*</td><td>45,101</td><td>3,567,48</td></tr><tr><td>Acadia Healthcare Co., Inc.*       58,271       4,212,41         HCA Healthcare, Inc.       9,120       2,620,45         Tenet Healthcare Corp.*       74,768       5,481,99         12,314,85         HEALTHCARE SERVICES—2.5%       202,108       2,734,52         Accolade, Inc.*       202,108       2,734,52         Option Care Health, Inc.*       34,545       1,110,62         3,845,14         HEALTHCARE SUPPLIES—8.2%       34,545         Alcon, Inc.       71,051       5,173,67         Align Technology, Inc.*       6,344       2,063,70         Coloplast AS, Cl. B       22,691       3,269,02         Merit Medical Systems, Inc.*       25,914       2,106,54         12,612,95         HEALTHCARE TECHNOLOGY—0.3%       3%</td><td>HEALTHCARE FACILITIES-8.0%</td><td></td><td>37,369,60</td></tr><tr><td>HCA Healthcare, Inc.       9,120       2,620,45         Tenet Healthcare Corp.*       74,768       5,481,99         12,314,85         HEALTHCARE SERVICES—2.5%       202,108       2,734,52         Accolade, Inc.*       202,108       2,734,52         Option Care Health, Inc.*       34,545       1,110,62         3,845,14         HEALTHCARE SUPPLIES—8.2%         Alcon, Inc.       71,051       5,173,67         Align Technology, Inc.*       6,344       2,063,70         Coloplast AS, Cl. B       22,691       3,269,02         Merit Medical Systems, Inc.*       25,914       2,106,54         HEALTHCARE TECHNOLOGY—0.3%</td><td></td><td>58 271</td><td>4 212 41</td></tr><tr><td>Tenet Healthcare Corp.*         74,768         5,481,99           HEALTHCARE SERVICES—2.5%         12,314,85           Accolade, Inc.*         202,108         2,734,52           Option Care Health, Inc.*         34,545         1,110,62           3,845,14         34,545         1,110,62           HEALTHCARE SUPPLIES—8.2%         34,545         1,110,62           Alcon, Inc.         71,051         5,173,67           Align Technology, Inc.*         6,344         2,063,70           Coloplast AS, Cl. B         22,691         3,269,02           Merit Medical Systems, Inc.*         25,914         2,106,54           IteALTHCARE TECHNOLOGY—0.3%</td><td></td><td>,</td><td></td></tr><tr><td>12,314,85           HEALTHCARE SERVICES—2.5%           Accolade, Inc.*         202,108         2,734,52           Option Care Health, Inc.*         34,545         1,110,62           3,845,14         3,845,14           HEALTHCARE SUPPLIES—8.2%         3           Alcon, Inc.         71,051         5,173,67           Align Technology, Inc.*         6,344         2,063,70           Coloplast AS, Cl. B         22,691         3,269,02           Merit Medical Systems, Inc.*         25,914         2,106,54           12,612,95           HEALTHCARE TECHNOLOGY—0.3%         3</td><td></td><td></td><td></td></tr><tr><td>HEALTHCARE SERVICES—2.5%           Accolade, Inc.*         202,108         2,734,52           Option Care Health, Inc.*         34,545         1,110,62           <b>3,845,14</b>           HEALTHCARE SUPPLIES—8.2%           Alcon, Inc.         71,051         5,173,67           Align Technology, Inc.*         6,344         2,063,70           Coloplast AS, Cl. B         22,691         3,269,02           Merit Medical Systems, Inc.*         25,914         2,106,54           <b>HEALTHCARE TECHNOLOGY—0.3%</b></td><td></td><td>74,700</td><td></td></tr><tr><td>Option Care Health, Inc.*         34,545         1,110,62           3,845,14         3,845,14           HEALTHCARE SUPPLIES—8.2%         3           Alcon, Inc.         71,051         5,173,67           Align Technology, Inc.*         6,344         2,063,70           Coloplast AS, Cl. B         22,691         3,269,02           Merit Medical Systems, Inc.*         25,914         2,106,54           IZ,612,95           HEALTHCARE TECHNOLOGY—0.3%</td><td>HEALTHCARE SERVICES-2.5%</td><td></td><td>,•,••</td></tr><tr><td>3,845,14           HEALTHCARE SUPPLIES—8.2%           Alcon, Inc.         71,051         5,173,67           Align Technology, Inc.*         6,344         2,063,70           Coloplast AS, Cl. B         22,691         3,269,02           Merit Medical Systems, Inc.*         25,914         2,106,54           12,612,95           HEALTHCARE TECHNOLOGY—0.3%</td><td>Accolade, Inc.*</td><td>202,108</td><td>2,734,52</td></tr><tr><td>3,845,14           HEALTHCARE SUPPLIES—8.2%           Alcon, Inc.         71,051         5,173,67           Align Technology, Inc.*         6,344         2,063,70           Coloplast AS, Cl. B         22,691         3,269,02           Merit Medical Systems, Inc.*         25,914         2,106,54           12,612,95           HEALTHCARE TECHNOLOGY—0.3%</td><td>Option Care Health, Inc.*</td><td>34,545</td><td>1,110,62</td></tr><tr><td>Alcon, Inc.         71,051         5,173,67           Align Technology, Inc.*         6,344         2,063,70           Coloplast AS, Cl. B         22,691         3,269,02           Merit Medical Systems, Inc.*         25,914         2,106,54           IteALTHCARE TECHNOLOGY—0.3%</td><td></td><td></td><td>3,845,14</td></tr><tr><td>Align Technology, Inc.*         6,344         2,063,70           Coloplast AS, Cl. B         22,691         3,269,02           Merit Medical Systems, Inc.*         25,914         2,106,54           IEALTHCARE TECHNOLOGY—0.3%</td><td></td><td></td><td></td></tr><tr><td>Coloplast AS, ČÍ. B         22,691         3,269,02           Merit Medical Systems, Inc.*         25,914         2,106,54           IteALTHCARE TECHNOLOGY—0.3%</td><td>· · · · · · · · · · · · · · · · · · ·</td><td>,</td><td></td></tr><tr><td>Merit Medical Systems, Inc.*         25,914         2,106,54           HEALTHCARE TECHNOLOGY—0.3%</td><td><b>o</b> <b>o</b>,</td><td></td><td>2,063,704</td></tr><tr><td>12,612,95 HEALTHCARE TECHNOLOGY—0.3%</td><td></td><td>22,691</td><td>3,269,02</td></tr><tr><td>HEALTHCARE TECHNOLOGY-0.3%</td><td>Merit Medical Systems, Inc.*</td><td>25,914</td><td>2,106,54</td></tr><tr><td></td><td></td><td></td><td>12,612,953</td></tr><tr><td></td><td></td><td>14 535</td><td>459,887</td></tr></tbody></table>			

## THE ALGER FUNDS | ALGER HEALTH SCIENCES FUND Schedule of Investments April 30, 2023 (Unaudited) (Continued)

COMMON STOCKS—97.4% (CONT.)	SHARES	VALUE
LIFE SCIENCES TOOLS & SERVICES—11.1%		
Bruker Corp.	67,320	\$ 5,327,032
Charles River Laboratories International, Inc.*	27,489	5,226,209
Lonza Group AG	6,687	4,170,282
Stevanato Group SpA	83,352	2,209,661
		16,933,184
MANAGED HEALTHCARE—3.3%		
Humana, Inc.	9,498	5,038,594
PHARMACEUTICALS—13.8%		
AstraZeneca PLC <sup>#</sup>	64,275	4,706,216
Catalent, Inc.*	22,315	1,118,428
Daiichi Sankyo Co., Ltd.	105,400	3,617,291
Eli Lilly & Co.	7,293	2,887,007
Merck & Co., Inc.	40,557	4,683,117
Reata Pharmaceuticals, Inc., CI. A*	28,443	2,811,875
Ventyx Biosciences, Inc.*	36,075	1,356,420
		21,180,354
TOTAL COMMON STOCKS		
(Cost \$137,217,022)		149,216,903
PREFERRED STOCKS—0.0%	SHARES	VALUE
BIOTECHNOLOGY-0.0%		
Prosetta Biosciences, Inc., Series D*.@.(a).(b)	897,366	-
(Cost \$4,038,147)		-
RIGHTS-0.9%	SHARES	VALUE
BIOTECHNOLOGY-0.9%		
Tolero CDR*.@.(a).(c)	1,956,996	1,311,187
(Cost \$1,044,370)		1,311,187
Total Investments		
(Cost \$142,299,539)	98.3%	\$ 150,528,090
Affiliated Securities (Cost \$4,038,147)		_
Unaffiliated Securities (Cost \$138,261,392)		150,528,090
Other Assets in Excess of Liabilities	1.7%	2,649,599
NET ASSETS	100.0%	\$ 153,177,689

# American Depositary Receipts.

(a) Security is valued in good faith at fair value determined using significant unobservable inputs pursuant to procedures established by the Valuation Designee (as defined in Note 2).

<sup>(b)</sup> Deemed an affiliate of the Fund in accordance with Section 2(a)(3) of the Investment Company Act of 1940. See Note 11 - Affiliated Securities.

(c) Contingent Deferred Rights.

\* Non-income producing security.

## THE ALGER FUNDS | ALGER HEALTH SCIENCES FUND Schedule of Investments April 30, 2023 (Unaudited) (Continued)

<sup>®</sup> Restricted security - Investment in security not registered under the Securities Act of 1933. Sales or transfers of the investment may be restricted only to qualified buyers.

			<u>% of net assets</u>		<u>% of net assets</u>
	<u>Acquisition</u>	<u>Acquisition</u>	<u>(Acquisition</u>	<u>Market</u>	<u>as of</u>
<u>Security</u>	<u>Date(s)</u>	<u>Cost</u>	<u>Date)</u>	<u>Value</u>	4/30/2023
Impulse Dynamics PLC, Class E	2/11/22	\$5,000,002	2.09%	\$5,000,002	3.26%
Prosetta Biosciences, Inc., Series D	2/6/15	4,038,147	2.00%	0	0.00%
Tolero CDR	2/6/17	1,044,370	0.90%	1,311,187	0.86%
Total				\$6,311,189	4.12%

	Alger Capital preciation Fund	Alger 35 Fund
ASSETS:		
Investments in unaffiliated securities, at value (Identified cost		
below)* see accompanying schedules of investments	\$ 1,707,143,517	\$ 25,745,751
Investments in affiliated securities, at value (Identified cost		
below)** see accompanying schedules of investments	2,896,878	_
Cash and cash equivalents	35,107,858	_
Foreign cash †	143,557	_
Receivable for investment securities sold	7,570,469	128,152
Receivable for shares of beneficial interest sold	1,868,867	600,000
Dividends and interest receivable	594,473	11,011
Receivable from Investment Manager	36,836	8,175
Prepaid expenses	283,561	15,095
Total Assets	1,755,646,016	26,508,184
LIABILITIES:		
Payable for investment securities purchased	19,963,783	_
Payable for shares of beneficial interest redeemed	8,001,157	_
Bank overdraft		561,606
Accrued investment advisory fees	1,144,135	9,492
Accrued distribution fees	220.858	
Accrued shareholder administrative fees	18,623	211
Accrued administrative fees	38,844	580
Accrued transfer agent fees	429,252	256
Accrued fund accounting fees	56,403	8,741
Accrued printing fees	54,368	488
Accrued professional fees	37,221	18,320
Accrued custodian fees	14,509	172
Accrued trustee fees	5,384	57
Accrued other expenses	995	823
Total Liabilities	29,985,532	600,746
NET ASSETS	\$ 1,725,660,484	\$ 25,907,438
NET ASSETS CONSIST OF:	4 005 000 054	40 200 474
Paid in capital (par value of \$.001 per share)	1,095,606,351	40,308,171
Distributable earnings (Distributions in excess of earnings)	630,054,133	(14,400,733)
NET ASSETS	\$ 1,725,660,484	\$ 25,907,438
* Identified cost	\$ 1,106,349,242(a)	24,138,498 <sup>(b)</sup>
** Identified cost	\$ 2,775,000 <sup>(a)</sup>	
† Cost of foreign cash	\$ 143,529	\$ _
See Notes to Financial Statements		

		Alger Capital Appreciation Fund		Alger 35 Fund	
NET ASSETS BY CLASS:					
Class A	\$	771,340,961	\$	_	
Class C	\$	77,864,628	\$	_	
Class Z	\$	876,454,895	\$	25,907,438	
SHARES OF BENEFICIAL INTEREST OUTSTANDING - Class A	– NOTE 6:	35,402,930		_	
Class C		6,068,139		_	
Class Z		37,515,448		2,662,714	
NET ASSET VALUE PER SHARE:					
Class A — Net Asset Value Per Share Class A	\$	21.79	\$	_	
Class A — Offering Price Per Share					
(includes a 5.25% sales charge)	\$	22.99	\$	_	
Class C — Net Asset Value Per Share Class C	\$	12.83	\$	_	
Class Z — Net Asset Value Per Share Class Z	\$	23.36	\$	9.73	
See Notes to Financial Statements.					

(a) At April 30, 2023, the net unrealized appreciation on investments, based on cost for federal income tax purposes of \$1,140,324,071, amounted to \$569,716,324 which consisted of aggregate gross unrealized appreciation of \$623,648,025 and aggregate gross unrealized depreciation of \$53,931,701.

(b) At April 30, 2023, the net unrealized appreciation on investments, based on cost for federal income tax purposes of \$25,262,257, amounted to \$483,494 which consisted of aggregate gross unrealized appreciation of \$2,457,525 and aggregate gross unrealized depreciation of \$1,974,031.

		Alger Growth & Income Fund		Alger Mid Cap Growth Fund		
				Stowart and		
ASSETS:						
Investments in unaffiliated securities, at value (Identified cost						
below)* see accompanying schedules of investments	\$	305,604,728	\$	185,746,464		
Investments in affiliated securities, at value (Identified cost						
below)** see accompanying schedules of investments		_		1,751,587		
Cash and cash equivalents		5,334,761		3,933,966		
Foreign cash †		_		5		
Receivable for investment securities sold		_		1,051,467		
Receivable for shares of beneficial interest sold		447,701		85,239		
Dividends and interest receivable		412,958		8,607		
Receivable from Investment Manager		_		5,717		
Prepaid expenses		87,713		95,278		
Total Assets		311,887,861		192,678,330		
LIABILITIES:						
Payable for investment securities purchased		_		2,812,236		
Payable for shares of beneficial interest redeemed		40,222		95,518		
Accrued investment advisory fees		126,402		117,780		
Accrued distribution fees		45,077		41,977		
Accrued shareholder administrative fees		3,309		2,409		
Accrued administrative fees		6,952		4,262		
Accrued transfer agent fees		39,146		45,561		
Accrued professional fees		18,900		29,114		
Accrued fund accounting fees		14,230		13,393		
Accrued printing fees		7,234		15,388		
Accrued custodian fees		2,133		5,245		
Accrued trustee fees		353		456		
Accrued other expenses		642		5,273		
Total Liabilities		304,600		3,188,612		
NET ASSETS	\$	311,583,261	\$	189,489,718		
NET ASSETS CONSIST OF: Daid in control (convolute of \$ 001 per chare)		210 076 740		241 004 942		
Paid in capital (par value of \$.001 per share)		218,076,710		241,994,813		
Distributable earnings (Distributions in excess of earnings)	•	93,506,551	•	(52,505,095)		
NET ASSETS	\$	311,583,261	\$	189,489,718		
* Identified cost	\$	214,343,649 <sup>(a</sup>		167,027,083 <sup>(t</sup>		
** Identified cost	\$		\$	2,663,245 <sup>(t</sup>		
† Cost of foreign cash See Notes to Financial Statements	\$	_	\$	5		

		Alger Growth & Income Fund		Alger Mid Cap Growth Fund
NET ASSETS BY CLASS:				
Class A	\$	123,374,070	\$	146,971,144
Class B	\$		\$	10,547,097
Class C	\$	24,613,583	\$	4,010,847
Class Z	\$	163,595,608	\$	27,960,630
SHARES OF BENEFICIAL INTEREST OUTSTANDING - Class A Class B	- NOTE 6:	2,173,715		12,877,151 1,475,361
Class B Class C		441,209		602,441
Class Z		2,878,502		2,371,491
NET ASSET VALUE PER SHARE:				
Class A — Net Asset Value Per Share Class A	\$	56.76	\$	11.41
Class A — Offering Price Per Share (includes a 5.25% sales charge)	\$	59.90	\$	12.05
Class B — Net Asset Value Per Share Class B	\$	_	\$	7.15
Class C — Net Asset Value Per Share Class C	\$	55.79	\$	6.66
Class Z — Net Asset Value Per Share Class Z	\$	56.83	\$	11.79
See Notes to Financial Statements.				

At April 30, 2023, the net unrealized appreciation on investments, based on cost for federal income tax purposes of \$213,554,607, amounted to \$92,050,121 which consisted of aggregate gross unrealized appreciation of \$94,266,972 and aggregate gross unrealized depreciation of \$2,216,851.

(b) At April 30, 2023, the net unrealized appreciation on investments, based on cost for federal income tax purposes of \$172,002,917, amounted to \$15,495,134 which consisted of aggregate gross unrealized appreciation of \$23,498,226 and aggregate gross unrealized depreciation of \$8,003,092.

	Alge	Alger Mid Cap Focus Fund		ger Weatherbie ecialized Growth Fund
ASSETS:				
Investments in unaffiliated securities, at value (Identified cost				
below)* see accompanying schedules of investments	\$	340,471,471	\$	644,868,712
Investments in unaffiliated securities, at value (Identified cost				
below)** see accompanying schedules of investments		_		_
Cash and cash equivalents		442,596		7,108,472
Receivable for investment securities sold		11,073,287		4,811,174
Receivable for shares of beneficial interest sold		174,694		277,800
Dividends and interest receivable		2,856		18,090
Receivable from Investment Manager		_		1,831
Prepaid expenses		104,241		140,386
Total Assets		352,269,145		657,226,465
LIABILITIES:				
Payable for investment securities purchased		4,137,798		3,080,411
Payable for shares of beneficial interest redeemed		362,608		1,488,347
Due to investment adviser		24		
Accrued investment advisory fees		185.678		437,666
Accrued distribution fees		7,521		58,647
Accrued shareholder administrative fees		2,935		6,177
Accrued administrative fees		7,952		14,859
Accrued printing fees		52,468		68,135
Accrued professional fees		21,482		28,072
Accrued fund accounting fees		20,472		30,874
Accrued transfer agent fees		18,682		107,564
Accrued custodian fees		2,570		6.037
Accrued trustee fees		1,279		2,311
Accrued other expenses		3,359		2,195
Total Liabilities		4,824,828		5,331,295
NET ASSETS	\$	347,444,317	\$	651,895,170
NET ASSETS CONSIST OF: Daid in partial (partyclus of \$ 001 partycles)		E11 7/2 00E		071 000 500
Paid in capital (par value of \$.001 per share)		511,743,225		971,220,502
Distributions in excess of earnings	¢	(164,298,908)	¢	(319,325,332)
NET ASSETS	\$	347,444,317	\$	651,895,170
* Identified cost	\$	329,777,451 <sup>(a)</sup>		659,400,135 <sup>(b)</sup>
** Identified cost	\$		\$	1,041,633
See Notes to Financial Statements.				

	Alge	Alger Mid Cap Focus Fund		ger Weatherbie cialized Growth Fund
NET ASSETS BY CLASS:				
Class A	\$	5,387,535	\$	105,467,753
Class C	\$	2,638,265	\$	37,581,316
Class I	\$	19,838,064	\$	26,066,567
Class Y	\$	207,723	\$	44,657,728
Class Z	\$	319,372,730	\$	438,121,806
SHARES OF BENEFICIAL INTEREST OUTSTANDING – Class A Class C Class I Class I		452,568 224,801 1,665,153 17,243		9,414,364 6,197,544 2,245,943 3,744,960
Class Z  NET ASSET VALUE PER SHARE:  Class A — Net Asset Value Per Share Class A	\$	26,511,593	\$	35,495,986
Class A — Offering Price Per Share	Ψ	11.00	Ψ	11.20
(includes a 5.25% sales charge)	\$	12.56	\$	11.82
Class C — Net Asset Value Per Share Class C	\$	11.74	\$	6.06
Class I — Net Asset Value Per Share Class I	\$	11.91	\$	11.61
Class Y — Net Asset Value Per Share Class Y	\$	12.05	\$	11.92
Class Z — Net Asset Value Per Share Class Z	\$	12.05	\$	12.34
See Notes to Financial Statements.				

(a) At April 30, 2023, the net unrealized appreciation on investments, based on cost for federal income tax purposes of \$335,039,965, amounted to \$5,431,506 which consisted of aggregate gross unrealized appreciation of \$29,864,148 and aggregate gross unrealized depreciation of \$24,462,642.

(b) At April 30, 2023, the net unrealized depreciation on investments, based on cost for federal income tax purposes of \$687,235,959, amounted to \$42,367,247 which consisted of aggregate gross unrealized appreciation of \$73,910,914 and aggregate gross unrealized depreciation of \$116,278,161.

	Alger Small Cap Growth Fund		Alger Small Cap Focus Fund		
ASSETS:					
Investments in unaffiliated securities, at value (Identified cost					
below)* see accompanying schedules of investments	\$ 337,120,559	\$	1,975,576,073		
Investments in affiliated securities, at value (Identified cost	, .,		,,,		
below)** see accompanying schedules of investments	2,377,939		197,119,101		
Cash and cash equivalents	2,077,699		23,903,731		
Receivable for investment securities sold	4,942,704		19,837,415		
Receivable for shares of beneficial interest sold	232,059		1,069,929		
Dividends and interest receivable	83,902		_		
Receivable from Investment Manager	2,090		18,179		
Prepaid expenses	127,315		323,712		
Total Assets	346,964,267		2,217,848,140		
LIABILITIES:	0 704 000		0 4 40 005		
Payable for investment securities purchased	8,764,222		2,149,065		
Payable for shares of beneficial interest redeemed	392,897		3,989,710		
Accrued investment advisory fees	227,232		1,378,668		
Accrued distribution fees	43,878		132,171		
Accrued shareholder administrative fees	3,616		19,885		
Accrued administrative fees	7,715		50,551		
Accrued transfer agent fees	62,784		531,411		
Accrued professional fees	35,046		27,932		
Accrued printing fees	22,436		225,790		
Accrued fund accounting fees	15,641		63,244		
Accrued custodian fees	11,751		15,687		
Accrued trustee fees	1,136		10,588		
Accrued other expenses	3,949		3,470		
Total Liabilities	9,592,303		8,598,172		
NET ASSETS	\$ 337,371,964	\$	2,209,249,968		
NET ASSETS CONSIST OF:					
Paid in capital (par value of \$.001 per share)	415,386,006		2,814,234,051		
Distributions in excess of earnings	(78,014,042)		(604,984,083)		
NET ASSETS	\$ 337,371,964	\$	2,209,249,968		
* Identified cost	\$ 337,004,789 <sup>(a)</sup>		1,710,685,601		
** Identified cost	\$ 2,503,096 <sup>(a)</sup>		202,483,189%		
See Notes to Financial Statements.			. ,		

		Alger Small Cap Growth Fund	Alger Small Cap Focus Fund	
NET ASSETS BY CLASS:				
Class A	\$	130,103,734	\$	189,342,087
Class B	\$	2,538,719	\$	
Class C	\$	17,983,702	\$	89,079,170
Class I	\$	_	\$	91,595,198
Class Y	\$	8,790,130	\$	205,291,747
Class Z	\$	177,955,679	\$	1,633,941,766
SHARES OF BENEFICIAL INTEREST OUTSTANDING - Class A	– NOTE 6	15,067,229		11,607,736
Class B		437,539		_
Class C		3,354,285		6,277,929
Class I		—		5,439,471
Class Y		964,117		11,866,433
Class Z		19,565,219		94,461,648
NET ASSET VALUE PER SHARE:				
Class A — Net Asset Value Per Share Class A	\$	8.63	\$	16.31
Class A — Offering Price Per Share				
(includes a 5.25% sales charge)	\$	9.11	\$	17.22
Class B — Net Asset Value Per Share Class B	\$	5.80	\$	_
Class C — Net Asset Value Per Share Class C	\$	5.36	\$	14.19
Class I — Net Asset Value Per Share Class I	\$		\$	16.84
Class Y — Net Asset Value Per Share Class Y	\$	9.12	\$	17.30
Class Z — Net Asset Value Per Share Class Z	\$	9.10	\$	17.30
See Notes to Financial Statements.				

(a) At April 30, 2023, the net unrealized depreciation on investments, based on cost for federal income tax purposes of \$339,798,207, amounted to \$299,709 which consisted of aggregate gross unrealized appreciation of \$75,777,290 and aggregate gross unrealized depreciation of \$76,076,999.

(b) At April 30, 2023, the net unrealized appreciation on investments, based on cost for federal income tax purposes of \$1,941,898,662, amounted to \$230,796,512 which consisted of aggregate gross unrealized appreciation of \$509,455,136 and aggregate gross unrealized depreciation of \$278,658,624.

		ger International Focus Fund		Alger Health Sciences Fund	
ASSETS:					
Investments in unaffiliated securities, at value (Identified cost	\$	125 100 266	¢	150 500 000	
below)* see accompanying schedules of investments	φ	135,120,366	\$	150,528,090	
Investments in unaffiliated securities, at value (Identified cost below)** see accompanying schedules of investments					
Cash and cash equivalents		5,339,208		1,943,022	
Foreign cash †		25,305		1,943,022	
Receivable for investment securities sold		23,303		1,704,074	
Receivable for shares of beneficial interest sold		9,288		12,841	
Dividends and interest receivable		9,288 308,764		170,107	
Receivable from Investment Manager		9,080		170,107	
Prepaid expenses		81.076		76,640	
Total Assets		140,893,156		154,434,774	
10101733013		140,000,100		107,707,777	
LIABILITIES:					
Payable for investment securities purchased		_		757,281	
Payable for shares of beneficial interest redeemed		4,520		276,545	
Accrued investment advisory fees		82,220		68,941	
Accrued distribution fees		34,880		22,927	
Accrued shareholder administrative fees		1,816		1,736	
Accrued administrative fees		3,184		3,447	
Accrued transfer agent fees		37,464		53,718	
Accrued professional fees		32,894		27,877	
Accrued fund accounting fees		11,718		11,559	
Accrued printing fees		11,311		24,924	
Accrued custodian fees		8,891		2,558	
Accrued trustee fees		222		532	
Accrued other expenses		11,867		5,040	
Total Liabilities		240,987		1,257,085	
NET ASSETS	\$	140,652,169	\$	153,177,689	
NET ASSETS CONSIST OF:		100 010 000			
Paid in capital (par value of \$.001 per share)		132,643,632		176,218,714	
Distributable earnings (Distributions in excess of earnings)		8,008,537		(23,041,025)	
NET ASSETS	\$	140,652,169	\$	153,177,689	
* Identified cost	\$	116,478,759 <sup>(a)</sup>		138,261,392 <sup>(b</sup>	
** Identified cost	\$		\$	4,038,147 <sup>(t</sup>	
† Cost of foreign cash	\$	25,300	\$		
See Notes to Financial Statements					

	•	Alger International Focus Fund		Alger Health Sciences Fund
NET ASSETS BY CLASS:				
Class A	\$	107,811,859	\$	83,832,495
Class B	\$	13,840,840	\$	_
Class C	\$	1,304,048	\$	7,153,983
Class I	\$	1,173,096	\$	_
Class Z	\$	16,522,326	\$	62,191,211
Class A Class B Class C		6,385,615 957,137 95,498		4,015,169 — 548,525
Class C		69.238		546,525
Class Z		956,016		2,919,494
NET ASSET VALUE PER SHARE:				
Class A — Net Asset Value Per Share Class A	\$	16.88	\$	20.88
Class A — Offering Price Per Share				
Class A — Offering Price Per Share (includes a 5.25% sales charge)	\$	17.82	\$	22.04
•	\$ \$	17.82 14.46	\$ \$	22.04
(includes a 5.25% sales charge)			-	22.04 — 13.04
(includes a 5.25% sales charge) Class B — Net Asset Value Per Share Class B	\$	14.46	\$	

(a) At April 30, 2023, the net unrealized appreciation on investments, based on cost for federal income tax purposes of \$118,865,079, amounted to \$16,255,287 which consisted of aggregate gross unrealized appreciation of \$30,495,184 and aggregate gross unrealized depreciation of \$14,239,897.

(b) At April 30, 2023, the net unrealized appreciation on investments, based on cost for federal income tax purposes of \$143,081,719, amounted to \$7,446,371 which consisted of aggregate gross unrealized appreciation of \$15,716,295 and aggregate gross unrealized depreciation of \$8,269,924.

		Alger Capital		
	Арр	preciation Fund		Alger 35 Fund
INCOME:				
Dividends (net of foreign withholding taxes*)	\$	6,186,134	\$	51,870
Interest		562,627		13,052
Total Income		6,748,761		64,922
EXPENSES:				
Investment advisory fees — Note 3(a)		6,836,241		56,529
Distribution fees — Note 3(c)		-,,		,
Class A		925,702		_
Class C		403,131		_
Shareholder administrative fees — Note 3(f)		111,087		1,256
Administration fees — Note 3(b)		232,095		3,455
Transfer agent fees — Note 3(f)		478,121		1,357
Fund accounting fees		136,977		27,002
Professional fees		71,533		18,908
Printing fees		53,704		478
Registration fees		50,008		2,286
Trustee fees — Note 3(g)		43,671		633
Custodian fees		38,414		1,549
Interest expenses		235		1,498
Other expenses		85,023		2,118
Total Expenses		9,465,942		117,069
Less, expense reimbursements/waivers — Note 3(a)		(283,270)		(46,171)
Net Expenses		9,182,672		70,898
NET INVESTMENT LOSS		(2,433,911)		(5,976)
REALIZED AND UNREALIZED GAIN (LOSS) ON INVESTMEN	TS ANI	O FOREIGN CURI	REN	CY:
Net realized gain (loss) on unaffiliated investments		68,480,540		(2,684,391)
Net realized (loss) on foreign currency transactions		(3,216)		(678)
Net change in unrealized appreciation on unaffiliated				
investments		87,216,785		3,164,071
Net change in unrealized (depreciation) on affiliated				
investments		(37,962)		
Net change in unrealized appreciation on foreign currency		20,426		49
Net realized and unrealized gain on investments and foreign		455 070 570		170 054
currency		155,676,573		479,051
NET INCREASE IN NET ASSETS RESULTING FROM	¢	452 343 663	¢	472 075
OPERATIONS * Foreign withholding taxes	\$ \$	<b>153,242,662</b> 66,549	\$ \$	473,075 207
See Notes to Financial Statements.	φ	00,049	φ	207

		Alger Growth & Income Fund		ger Mid Cap rowth Fund
INCOME:				
Dividends (net of foreign withholding taxes*)	\$	3,415,669	\$	621,898
Interest		281,625		87,067
Income from securities lending		25		· —
Total Income		3,697,319		708,965
EXPENSES:				
Investment advisory fees — Note 3(a)		704,827		706,601
Distribution fees — Note 3(c)				
Class A		144,677		179,273
Class B		_		50,971
Class C		118,105		20,855
Shareholder administrative fees — Note 3(f)		18,626		14,425
Administration fees — Note 3(b)		38,765		25,568
Transfer agent fees — Note 3(f)		55,505		58,395
Fund accounting fees		44,432		41,405
Registration fees		25,085		20,448
Professional fees		23,235		28,991
Custodian fees		10,262		9,774
Printing fees		8,666		12,169
Trustee fees — Note 3(g)		6,941		4,675
Interest expenses		4		263
Other expenses		13,764		12,535
Total Expenses		1,212,894		1,186,348
Less, expense reimbursements/waivers — Note 3(a)		_		(34,392)
Net Expenses		1,212,894		1,151,956
NET INVESTMENT INCOME (LOSS)		2,484,425		(442,991)
REALIZED AND UNREALIZED GAIN (LOSS) ON INVESTMEN	TS A	AND FOREIGN CURR	ENCY:	
Net realized gain (loss) on unaffiliated investments		812,287		(11,319,401)
Net realized (loss) on foreign currency transactions		(4)		(3,290
Net change in unrealized appreciation on unaffiliated		( )		
investments		21,459,422		21,783,569
Net change in unrealized (depreciation) on affiliated		, ,		
investments		_		(23,959)
Net change in unrealized appreciation on foreign currency		_		538
Net realized and unrealized gain on investments and foreign				
currency		22,271,705		10,437,457
NET INCREASE IN NET ASSETS RESULTING FROM				
OPERATIONS	\$	24,756,130	\$	9,994,466
* Foreign withholding taxes	\$	29,109	\$	7,734
	Ψ	20,100	Ŧ	1,104

	Alge	r Mid Cap Focus Fund		r Weatherbie alized Growth Fund
INCOME:				
Dividends (net of foreign withholding taxes*)	\$	779,594	\$	976,442
Interest	Ŷ	155,679	÷	435,957
Total Income		935,273		1,412,399
EXPENSES:				
Investment advisory fees — Note 3(a)		1,230,375		2,847,007
Distribution fees — Note 3(c)				
Class A		6,585		140,272
Class C		13,067		202,483
Class I		63,389		34,535
Shareholder administrative fees — Note 3(f)		19,905		40,111
Administration fees — Note 3(b)		54,034		96,658
Registration fees		54,498		47,408
Fund accounting fees		53,843		76,322
Printing fees		36,637		48,933
Transfer agent fees — Note 3(f)		34,825		126,624
Professional fees		31,627		43,660
Custodian fees		11,028		29,676
Trustee fees — Note 3(g)		10,234		18,026
Interest expenses		9,966		_
Other expenses		21,684		42,264
Total Expenses		1,651,697		3,793,979
Less, expense reimbursements/waivers — Note 3(a)		(225)		(16,163
Net Expenses		1,651,472		3,777,816
NET INVESTMENT LOSS		(716,199)		(2,365,417
REALIZED AND UNREALIZED GAIN (LOSS) ON INVESTMEN	rs and	O FOREIGN CURF	RENCY:	
Net realized (loss) on unaffiliated investments		(54,245,607)		(85,131,710
Net realized (loss) on foreign currency transactions		(2,712)		(12
Net change in unrealized appreciation on unaffiliated investments		47,353,778		64,395,834
Net change in unrealized appreciation on foreign currency		59		
Net realized and unrealized (loss) on investments and foreign				
currency		(6,894,482)		(20,735,888
NET DECREASE IN NET ASSETS RESULTING FROM OPERATIONS	\$	(7,610,681)	\$	(23,101,305
* Foreign withholding taxes	\$	6,251	\$	21,761
See Notes to Financial Statements.	Ŧ	-,• ·	,	,. • .

		ger Small Cap Browth Fund	A	Alger Small Cap Focus Fund
INCOME:				
Dividends (net of foreign withholding taxes*)	\$	704,461	\$	4,544,453
Interest		174,671		528,149
Total Income		879,132		5,072,602
EXPENSES:				
Investment advisory fees — Note 3(a)		1,435,641		9,222,721
Distribution fees — Note 3(c)				
Class A		166,348		250,132
Class B		13,518		
Class C		93,724		474,385
Class I		· _		142,919
Shareholder administrative fees — Note 3(f)		22,746		132,556
Administration fees — Note 3(b)		48,741		338,167
Transfer agent fees — Note 3(f)		81,207		554,680
Fund accounting fees		51,938		176,954
Registration fees		47,529		84,719
Professional fees		36,931		88,943
Custodian fees		13,379		42,927
Trustee fees — Note 3(g)		9,333		63,933
Printing fees		6,494		154,516
Interest expenses		954		32,915
Other expenses		20.817		147,975
Total Expenses		2,049,300		11,908,442
Less, expense reimbursements/waivers — Note 3(a)		(13,547)		(30,498
Net Expenses		2,035,753		11,877,944
NET INVESTMENT LOSS		(1,156,621)		(6,805,342
				NV-
REALIZED AND UNREALIZED GAIN (LOSS) ON INVESTMEN Net realized (loss) on unaffiliated investments	I S ANL	(48,684,785)	KEINU	(239,280,805
Net realized (loss) on affiliated investments		(40,004,703)		(28,881,463
Net realized (loss) on foreign currency transactions		(18,758)		(20,001,403
Net change in unrealized appreciation on unaffiliated		(10,700)		(1,004
investments		42,237,730		124,820,378
Net change in unrealized appreciation (depreciation) on		42,201,100		124,020,070
affiliated investments		(32,167)		47,917,221
Net realized and unrealized (loss) on investments and foreign		,		
currency		(6,497,980)		(95,426,173
NET DECREASE IN NET ASSETS RESULTING FROM				
OPERATIONS	\$	(7,654,601)	\$	(102,231,515
* Foreign withholding taxes	\$	3,624	\$	49,005
Notes to Florestal October at				

		er International Focus Fund		Alger Health Sciences Fund
NCOME:				
Dividends (net of foreign withholding taxes*)	\$	634,762	\$	380,081
Interest	Ŧ	46.918	Ŧ	70,795
Total Income		681,680		450,876
EXPENSES:				
Investment advisory fees — Note 3(a)		490,320		448,603
Distribution fees — Note 3(c)		100,020		
Class A		132,819		107,883
Class B		68,599		
Class C		7,292		36,749
Class		1,429		_
Shareholder administrative fees — Note 3(f)		10,852		11,200
Administration fees — Note $3(b)$		18,991		22,430
Transfer agent fees — Note 3(f)		47,433		50,163
Fund accounting fees		40,130		36,377
Professional fees		30,755		25,909
Registration fees		28,341		17,683
Custodian fees		20,812		7,315
Printing fees		8,028		15,128
Trustee fees — Note 3(g)		3,323		4,233
Interest expenses		150		821
Other expenses		8,348		12,809
Total Expenses		917,622		797,303
Less, expense reimbursements/waivers — Note 3(a)		(57,238)		· —
Net Expenses		860,384		797,303
NET INVESTMENT LOSS		(178,704)		(346,427
REALIZED AND UNREALIZED GAIN (LOSS) ON INVESTMEN				·V.
Net realized gain (loss) on unaffiliated investments	I U ANL	(758,110)		13,077,347
Net realized (loss) on foreign currency transactions		(21,125)		(42,744
Net change in unrealized appreciation (depreciation) on		(21,123)		(72,744
unaffiliated investments		15,045,724		(12,682,563
Net change in unrealized appreciation on foreign currency		21,477		4,810
Net realized and unrealized gain on investments and foreign		21,411		-7,010
currency		14,287,966		356,850
NET INCREASE IN NET ASSETS RESULTING FROM		11,207,000		000,000
OPERATIONS	\$	14,109,262	\$	10,423
* Foreign withholding taxes	\$	64,806	\$	3,529
See Notes to Financial Statements.				

		Alger Capital Appreciation Fund			
		For the	For the		
		Six Months Ended	Year Ende		
		April 30, 2023	October 31, 202		
Net investment loss	\$	(2,433,911) \$	(8,588,618)		
Net realized gain on investments and foreign currency		68,477,324	54,838,009		
Net change in unrealized appreciation (depreciation) on		, ,			
investments and foreign currency		87,199,249	(1,140,768,396)		
Net increase (decrease) in net assets resulting from operations		153,242,662	(1,094,519,005)		
Dividends and distributions to shareholders:					
Class A		(30,288,660)	(284,398,857)		
Class C		(5,650,846)	(53,540,254)		
Class Z		(33,055,502)	(297,591,139)		
Total dividends and distributions to shareholders		(68,995,008)	(635,530,250)		
Increase (decrease) from shares of beneficial interest transactio	ns:				
Class A		(39,784,544)	13,515,228		
Class C		(14,933,419)	(4,551,506)		
Class Z		(119,406,673)	113,901,081		
Net increase (decrease) from shares of beneficial interest		( , , , , , , , , , , , , , , , , , , ,			
transactions — Note 6		(174,124,636)	122,864,803		
Total decrease		(89,876,982)	(1,607,184,452)		
Net Assets:					
Beginning of period		1,815,537,466	3,422,721,918		
END OF PERIOD	\$	1,725,660,484 \$	1.815,537,466		

		Alger 35 Fund				
		For the Six Months Endec April 30, 2023	b		For the Year Ended October 31, 2022	
		April 30, 2023	5			
Net investment income (loss)	\$	(5,976)		\$	4,021	
Net realized loss on investments and foreign currency Net change in unrealized appreciation (depreciation) on		(2,685,069)			(4,926,564)	
investments and foreign currency		3,164,120			(12,333,559)	
Net increase (decrease) in net assets resulting from operations		473,075			(17,256,102)	
Dividends and distributions to shareholders:						
Class Z		(5,582)			(10,551,417)	
Total dividends and distributions to shareholders		(5,582)			(10,551,417)	
Increase (decrease) from shares of beneficial interest transactions	:					
Class Z		(536,453)			9,624,945	
Net increase (decrease) from shares of beneficial interest		. ,				
transactions — Note 6		(536,453)			9,624,945	
Total decrease		(68,960)			(18,182,574)	
Net Assets:						
Beginning of period		25,976,398			44,158,972	
END OF PERIOD	\$	25,907,438		\$	25,976,398	
See Notes to Financial Statements.						

		Alger Growth & Income Fund			
		For the	)	For the	
		Six Months Endeo	1	Year Endeo	
		April 30, 2023	}	October 31, 2022	
Net investment income	\$	2,484,425	\$	2,552,839	
Net realized gain (loss) on investments and foreign currency	•	812.283		(246,144)	
Net change in unrealized appreciation (depreciation) on		,		(,	
investments and foreign currency		21,459,422		(27,439,139)	
Net increase (decrease) in net assets resulting from operations		24,756,130		(25,132,444)	
Dividends and distributions to shareholders:					
Class A		(819,760)		(4,709,966)	
Class C		(85,053)		(687,923)	
Class Z		(1,197,850)		(2,219,203)	
Total dividends and distributions to shareholders		(2,102,663)		(7,617,092)	
Increase (decrease) from shares of beneficial interest transactio	ns:				
Class A		5.907.738		19.951.923	
Class C		1,605,164		6,180,541	
Class Z		37.015.410		88,363,764	
Net increase from shares of beneficial interest transactions —		- ,, -		, , -	
Note 6		44,528,312		114,496,228	
Total increase		67,181,779		81,746,692	
Net Assets:					
Beginning of period		244,401,482		162,654,790	
END OF PERIOD	\$	311,583,261	\$	244.401.482	

	Alger Mid Cap Growth Fund			
		For the	For th	
		Six Months Ended	Year Ende	
		April 30, 2023	October 31, 202	
Net investment loss	\$	(442,991)	\$ (1,528,046)	
Net realized loss on investments and foreign currency		(11,322,691)	(55,825,563)	
Net change in unrealized appreciation (depreciation) on		( , , , ,	( , , , ,	
investments and foreign currency		21,760,148	(73,648,453)	
Net increase (decrease) in net assets resulting from operation	s	9,994,466	(131,002,062)	
Dividends and distributions to shareholders:				
Class A		_	(67,153,291)	
Class B		_	(6,406,978)	
Class C		_	(2,944,693)	
Class Z		_	(15,837,405)	
Total dividends and distributions to shareholders		_	(92,342,367)	
Increase (decrease) from shares of beneficial interest transac	ione			
	10115.	(7.470.075)	F0 400 704	
Class A		(7,479,975)	52,482,791	
Class B		(403,064)	5,161,326	
Class C		(751,758)	2,481,849	
Class Z		(3,972,604)	16,160,525	
Net increase (decrease) from shares of beneficial interest transactions — Note 6		(40 007 404)	70 000 404	
		(12,607,401)	76,286,491	
Total decrease		(2,612,935)	(147,057,938)	
Net Assets:				
Beginning of period		192,102,653	339,160,591	
END OF PERIOD	\$	189.489.718	\$ 192.102.653	

		Alger Mid Cap Fo	ocus Fund
		For the	For th
		Six Months Ended	Year Ende
		April 30, 2023	October 31, 202
Net investment loss	\$	(716,199) \$	(2,374,048)
Net realized loss on investments and foreign currency		(54,248,319)	(114,966,878)
Net change in unrealized appreciation (depreciation) on		( , , , ,	( , , , ,
investments and foreign currency		47,353,837	(271,346,889)
Net decrease in net assets resulting from operations		(7,610,681)	(388,687,815)
Dividends and distributions to shareholders:			
Class A		_	(237,662)
Class C		_	(228,199)
Class I		_	(12,826,323)
Class Y		_	(12,097)
Class Z		162	(70,824,262)
Total dividends and distributions to shareholders		162	(84,128,543)
Increase (decrease) from shares of beneficial interest transact	ons:		
Class A		380,433	5,256,417
Class C		256.967	1,924,208
Class I		(41,552,019)	(12,108,519)
Class Y		(228,756)	422,581
Class Z		(40,235,137)	(31,386,124)
Net decrease from shares of beneficial interest transactions —		,	,
Note 6		(81,378,512)	(35,891,437)
Total decrease		(88,989,031)	(508,707,795)
Net Assets:			
Beginning of period		436,433,348	945,141,143
END OF PERIOD	\$	347.444.317 \$	436.433.348

	Alg	ger Weatherbie Specia	lized Growth Fund
		For the	For the
		Six Months Ended	Year Ende
		April 30, 2023	October 31, 202
Net investment loss	\$	(2,365,417) \$	(8,040,908)
Net realized loss on investments and foreign currency	Ŧ	(85,131,722)	(193,750,586)
Net change in unrealized appreciation (depreciation) on		(00):0:,:==)	(100,100,000)
investments and foreign currency		64,395,834	(501,688,673)
Net decrease in net assets resulting from operations		(23,101,305)	(703,480,167)
Dividends and distributions to shareholders:			
Class A		_	(45,296,523)
Class C		_	(27,504,338)
Class I		_	(12,964,988)
Class Y		_	(10,407,118)
Class Z		_	(205,452,142)
Total dividends and distributions to shareholders		_	(301,625,109)
Increase (decrease) from shares of beneficial interest transa	ctions:		
Class A	610113.	(10 651 242)	8.933.676
Class C		(10,651,343) (5,775,676)	9,708,887
Class I		(2,651,353)	(4,904,091)
Class Y		(1,355,660)	26,302,379
Class Z		(81,287,377)	(36,895,543)
Net increase (decrease) from shares of beneficial interest		(01,207,017)	(00,000,040)
transactions — Note 6		(101,721,409)	3,145,308
Total decrease		(124,822,714)	(1,001,959,968)
Net Assets:			
Beginning of period		776,717,884	1,778,677,852
END OF PERIOD	\$	651,895,170 \$	776,717,884

		Alger Small Cap G	Fowth Fund
		For the	For th
		Six Months Ended	Year Ende
		April 30, 2023	October 31, 202
Net investment loss	\$	(1,156,621) \$	(4,114,910)
Net realized loss on investments and foreign currency Net change in unrealized appreciation (depreciation) on		(48,703,543)	(24,248,827)
investments and foreign currency		42,205,563	(242,568,455)
Net decrease in net assets resulting from operations		(7,654,601)	(270,932,192)
Dividends and distributions to shareholders:			
Class A		_	(21,314,734)
Class B		_	(673,335)
Class C		_	(4,854,023)
Class Z		_	(30,391,004)
Total dividends and distributions to shareholders		_	(57,233,096)
Increase (decrease) from shares of beneficial interest transac	ctions:		
Class A		(9,026,266)	1,762,230
		(-,,,	, ,
Class A		(431,283)	32.505
		(431,283) (2.581.876)	- ,
Class B		(431,283) (2,581,876) 895,171	32,505 2,204,699 8,398,532
Class B Class C		(2,581,876)	2,204,699
Class B Class C Class Y Class Z		(2,581,876) 895,171	2,204,699 8,398,532
Class B Class C Class Y Class Z		(2,581,876) 895,171	2,204,699 8,398,532
Class B Class C Class Y Class Z Net increase (decrease) from shares of beneficial interest		(2,581,876) 895,171 (33,085,434)	2,204,699 8,398,532 13,599,272
Class B Class C Class Y Class Z Net increase (decrease) from shares of beneficial interest transactions — Note 6		(2,581,876) 895,171 (33,085,434) (44,229,688)	2,204,699 8,398,532 13,599,272 25,997,238
Class B Class C Class Y Class Z Net increase (decrease) from shares of beneficial interest transactions — Note 6 Total decrease		(2,581,876) 895,171 (33,085,434) (44,229,688)	2,204,699 8,398,532 13,599,272 25,997,238

		Alger Small Cap I	Focus Fund					
		For the	For th					
		Six Months Ended	Year Ende					
		April 30, 2023	October 31, 202					
Net investment loss	\$	(6,805,342) \$	(24,812,632)					
Net realized loss on investments and foreign currency		(268, 163, 772)	(562,947,494)					
Net change in unrealized appreciation (depreciation) on		( , , )	(					
investments and foreign currency		172,737,599	(2,516,845,916)					
Net decrease in net assets resulting from operations		(102,231,515)	(3,104,606,042)					
Dividends and distributions to shareholders:								
Class A		_	(30,754,287)					
Class C		_	(16,779,423)					
Class I		_	(22,355,553)					
Class Y		_	(21,468,256)					
Class Z		_	(324,678,159)					
Total dividends and distributions to shareholders		_	(416,035,678)					
Increase (decrease) from shares of beneficial interest transacti	ons:							
Class A	0110.	(28,998,122)	(79,791,951)					
Class C		(15,567,626)	(33,316,935)					
Class I		(47,048,840)	(96,988,803)					
Class Y		(44,998,029)	58,351,945					
Class 7		(481,348,941)	(1,239,048,797)					
Net decrease from shares of beneficial interest transactions —		(101,010,011)	(1,200,010,101)					
Note 6		(617,961,558)	(1,390,794,541)					
Total decrease		(720,193,073)	(4,911,436,261)					
Net Assets:								
Beginning of period		2,929,443,041	7,840,879,302					
END OF PERIOD	\$	2,209,249,968 \$	2.929.443.041					

		Alger International	Focus Fund
		For the	For the
		Six Months Ended	Year Ende
		April 30, 2023	October 31, 202
Net investment loss	\$	(178,704) \$	(803,647)
Net realized loss on investments and foreign currency	Ŷ	(779,235)	(7,032,633)
Net change in unrealized appreciation (depreciation) on		(110,200)	(1,002,000)
investments and foreign currency		15,067,201	(63,553,455)
Net increase (decrease) in net assets resulting from operatio	ns	14,109,262	(71,389,735)
Dividends and distributions to shareholders:			
Class A			(10 265 251)
Class B		_	(12,365,251) (1,940,439)
Class C		—	(1,940,439) (400,190)
Class L		_	( , ,
Class Z		_	(49,121) (2,237,931)
Total dividends and distributions to shareholders			(16.992.932)
			(10,002,002)
Increase (decrease) from shares of beneficial interest transa	ctions:		
Class A		(3,274,035)	7,386,726
Class B		(776,260)	116,320
Class C		(446,338)	(1,107,606)
Class I		(3,420)	1,119,741
Class Z		397,920	(2,079,971)
Net increase (decrease) from shares of beneficial interest			
transactions — Note 6		(4,102,133)	5,435,210
Total increase (decrease)		10,007,129	(82,947,457)
Net Assets:			
Beginning of period		130,645,040	213,592,497
END OF PERIOD	\$	140,652,169 \$	130,645,040

		Alger Health Sciences Fund							
		For the	For th						
		Six Months Ended	Year Ende						
		April 30, 2023	October 31, 202						
Net investment loss	\$	(346,427) \$	(408,441)						
Net realized gain (loss) on investments and foreign currency	*	13.034,603	(43,429,932)						
Net change in unrealized depreciation on investments and		,	(,)						
foreign currency		(12,677,753)	(47,165,991)						
Net increase (decrease) in net assets resulting from operations		10,423	(91,004,364)						
Dividends and distributions to shareholders:									
Class A		_	(28,166,595)						
Class C		_	(3,704,768)						
Class Z		_	(34,925,658)						
Total dividends and distributions to shareholders		_	(66,797,021)						
Increase (decrease) from shares of beneficial interest transactio	ns:								
Class A		(7,273,438)	7,680,846						
Class C		(642,446)	956,992						
Class Z		(16,731,996)	(23,842,039)						
Net decrease from shares of beneficial interest transactions —			( - / - / /						
Note 6		(24,647,880)	(15,204,201)						
Total decrease		(24,637,457)	(173,005,586)						
Net Assets:									
Beginning of period		177,815,146	350,820,732						
END OF PERIOD	\$	153,177,689 \$	177,815,146						

Alger Capital Appreciation Fund					Cla	ass	A				
	Six months ended //30/2023 <sup>(1)</sup>		/ear ended 0/31/2022		Year ended 10/31/2021		Year ended 10/31/2020		Year ended 10/31/2019		Year ended 10/31/2018
Net asset value, beginning of period INCOME FROM INVESTMENT OPERATIONS:	\$ 20.77	\$	39.48	\$	33.76	\$	27.12	\$	26.20	\$	25.86
Net investment loss <sup>(ii)</sup> Net realized and unrealized gain (loss)	(0.05)		(0.13)		(0.24)		(0.12)		(0.07)		(0.06)
on investments	1.91		(11.17)		11.11		8.96		3.53		2.07
Total from investment operations	1.86		(11.30)		10.87		8.84		3.46		2.01
Distributions from net realized gains	(0.84)		(7.41)		(5.15)		(2.20)		(2.54)		(1.67)
Net asset value, end of period	\$ 21.79	\$	20.77	\$	39.48	\$	33.76	\$	27.12	\$	26.20
Total return(iii)	9.42%	, 0	(34.88)%	6	35.41%	6	34.79%	0	15.29%	6	8.15%
RATIOS/SUPPLEMENTAL DATA: Net assets, end of period (000's omitted)	\$ 771,341	\$	774,249	\$	1,523,572	\$	1,320,073	\$	1,174,346	\$	1,257,811
Ratio of gross expenses to average net assets	1.26%	, 0	1.20%	6	1.15%	6	1.17%	, 0	1.21%	6	1.21%
Ratio of net expenses to average net assets	1.26%	, 0	1.20%	6	1.15%	6	1.17%	, 0	1.21%	6	1.21%
Ratio of net investment loss to average net assets	(0.47)%	, 0	(0.49)%	6	(0.67)%	6	(0.41)%	, 0	(0.27)%	6	(0.23)%
Portfolio turnover rate	56.98%	, 0	108.26%	6	78.77%	6	89.91%	ó	77.04%	6	67.33%
See Notes to Einspeial Statements											

<sup>(i)</sup> Ratios have been annualized; total return and portfolio turnover rate have not been annualized.

(ii) Amount was computed based on average shares outstanding during the period.

(iii) Does not reflect the effect of sales charges, if applicable.

Alger Capital Appreciation Fund	_					Cla	ass	С				
		Six months ended //30/2023 <sup>(1)</sup>		'ear ended 0/31/2022		(ear ended 10/31/2021		rear ended 10/31/2020		(ear ended 10/31/2019		'ear ended 0/31/2018
Net asset value, beginning of period INCOME FROM INVESTMENT OPERATIONS:	\$	12.63	\$	27.13	\$	24.79	\$	20.60	\$	20.69	\$	20.91
Net investment loss <sup>(iii)</sup> Net realized and unrealized gain (loss)		(0.07)		(0.20)		(0.35)		(0.25)		(0.20)		(0.20)
on investments		1.11		(6.89)		7.84		6.64		2.65		1.65
Total from investment operations		1.04		(7.09)		7.49		6.39		2.45		1.45
Distributions from net realized gains		(0.84)		(7.41)		(5.15)		(2.20)		(2.54)		(1.67)
Net asset value, end of period	\$	12.83	\$	12.63	\$	27.13	\$	24.79	\$	20.60	\$	20.69
Total return(iii)		8.98%	6	(35.36)%	6	34.43%	6	33.82%	6	14.44%	6	7.35%
RATIOS/SUPPLEMENTAL DATA: Net assets, end of period (000's omitted)	\$	77,865	\$	91,815	\$	211,972	\$	204,909	\$	219,511	\$	243,523
Ratio of gross expenses to average net assets		2.02%	6	1.95%	6	1.90%	6	1.91%	6	1.95%	6	1.94%
Ratio of net expenses to average net assets		2.02%	6	1.95%	6	1.90%	6	1.91%	6	1.95%	6	1.94%
Ratio of net investment loss to average net assets		(1.22)%	6	(1.24)%	6	(1.42)%	6	(1.13)%	6	(1.01)%	6	(0.96)%
Portfolio turnover rate		56.98%	6	108.26%	6	78.77%	6	89.91%	6	77.04%	6	67.33%
See Notes to Einspeiel Statements												

<sup>0</sup> Ratios have been annualized; total return and portfolio turnover rate have not been annualized.

<sup>(</sup>ii) Amount was computed based on average shares outstanding during the period.

<sup>(</sup>iii) Does not reflect the effect of sales charges, if applicable.

Alger Capital Appreciation Fund						Cla	iss	Z				
		ended /30/2023		(ear ended 10/31/2022		Year ended 10/31/2021		Year ended 10/31/2020		Year ended 10/31/2019		Year ended 10/31/2018
Net asset value, beginning of period	\$	22.16	\$	41.50	\$	35.15	\$	28.06	ç	\$ 26.94	\$	26.46
INCOME FROM INVESTMENT OPERATIONS:												
Net investment income (loss) <sup>(ii)</sup> Net realized and unrealized gain (loss)		(0.01)		(0.04)		(0.13)		(0.03)		0.02		0.03
on investments		2.05		(11.89)		11.63		9.32		3.64		2.12
Total from investment operations		2.04		(11.93)		11.50		9.29		3.66		2.15
Distributions from net realized gains		(0.84)		(7.41)		(5.15)		(2.20)		(2.54)		(1.67)
Net asset value, end of period	\$	23.36	\$	22.16	\$	41.50	\$	35.15	ę	\$ 28.06	\$	26.94
Total return(iii)		9.65%	, 0	(34.67)%	6	35.85%	6	35.26%	6	15.69%	6	8.51%
RATIOS/SUPPLEMENTAL DATA: Net assets, end of period (000's omitted)	\$	876,455	\$	949,473	\$	1,687,179	\$	1,823,041		\$1,409,374	\$	1,240,605
Ratio of gross expenses to average net assets		0.92%	/ 0	0.86%	6	0.83%	6	0.84%	6	0.87%	6	0.87%
Ratio of expense reimbursements to average net assets		(0.07)%	/ 0	(0.01)%	6	-	_	-	_		_	-
Ratio of net expenses to average net assets		0.85%	, 0	0.85%	6	0.83%	6	0.84%	6	0.87%	6	0.87%
Ratio of net investment income (loss) to average net assets	)	(0.05)%	/ 0	(0.14)%	6	(0.34)%	6	(0.09)%	6	0.06%	6	0.10%
Portfolio turnover rate		56.98%	, 0	108.26%	6	78.77%	6	89.91%	6	77.04%	6	67.33%

<sup>&</sup>lt;sup>(i)</sup> Ratios have been annualized; total return and portfolio turnover rate have not been annualized.

<sup>(</sup>ii) Amount was computed based on average shares outstanding during the period.

<sup>(</sup>iii) Does not reflect the effect of sales charges, if applicable.

Alger 35 Fund	Class Z											
	-	ix months ended /30/2023 <sup>(i)</sup>		'ear ended 0/31/2022		Year ended 0/31/2021 <sup>(vii)</sup>		Year ended 10/31/2020		Year ended 10/31/2019	(co of	om 3/29/2018 ommencement operations) to 10/31/2018 <sup>(ii)</sup>
Net asset value, beginning of period	\$	9.55	\$	21.33	\$	17.41	\$	11.61	\$	10.38	\$	10.00
INCOME FROM INVESTMENT OPERATIONS:												
Net investment income (loss)(iii)		_(iv)		_(iv)		(0.01)		(0.05)		0.03		0.01
Net realized and unrealized gain (loss)												
on investments		0.18		(6.68)		6.95		5.87		1.31		0.37
Total from investment operations		0.18		(6.68)		6.94		5.82		1.34		0.38
Dividends from net investment income		_(v)		-		_(v)		(0.02)		(0.04)		-
Distributions from net realized gains		-		(5.10)		(3.02)		-		(0.07)		-
Net asset value, end of period	\$	9.73	\$	9.55	\$	21.33	\$	17.41	\$	11.61	\$	10.38
Total return <sup>(vi)</sup>		1.91%	, 0	(39.09)%	6	44.27%	, 0	50.22%	6	13.19%	6	3.80%
RATIOS/SUPPLEMENTAL DATA:												
Net assets, end of period (000's omitted)	\$	25,907	\$	25,976	\$	44,159	\$	14,128	\$	9,094	\$	7,782
Ratio of gross expenses to average net assets		0.93%	, 0	0.94%	6	0.92%	, 0	2.02%	6	2.37%	6	2.46%
Ratio of expense reimbursements to average net assets		(0.37)%	, 0	(0.39)%	6	(0.52)%	, 0	(1.12)%	6	(1.97)%	6	(2.06)%
Ratio of net expenses to average net												
assets		0.56%	0	0.55%	6	0.40%	ó	0.90%	6	0.40%	6	0.40%
Ratio of net investment income (loss) to	)	(0.05)0	,	0.040	,	(0.07)0/	,	0.000	,	0.000	,	0.020/
average net assets		(0.05)%		0.01%		(0.07)%		0.36%		0.30%		0.23%
Portfolio turnover rate		158.70%	Ó	202.40%	6	136.61%	o	121.74%	6	115.25%	6	31.20%

<sup>10</sup> Ratios have been annualized; total return and portfolio turnover rate have not been annualized.

- <sup>(ii)</sup> Ratios have been annualized; total return has not been annualized; portfolio turnover is for the seven months then ended.
- (iii) Amount was computed based on average shares outstanding during the period.
- (iv) Amount was less than \$0.005 per share.
- (v) Amount was more than (0.001) per share.
- (vi) Does not reflect the effect of sales charges, if applicable.
- (vii) Class P Shares were reclassified as Class Z Shares on May 7, 2021 and after the close of business on October 29, 2021, Class P-2 Shares were converted to Class Z Shares.

Alger Growth & Income Fund	Class A											
		Six months ended 1/30/2023 <sup>(1)</sup>		'ear ended 0/31/2022		(ear ended 10/31/2021		Year ended 10/31/2020		Year ended 10/31/2019		ear ended 0/31/2018
Net asset value, beginning of period	\$	52.35	\$	61.76	\$	43.88	\$	43.55	\$	40.77	\$	39.68
INCOME FROM INVESTMENT OPERATIONS:												
Net investment income <sup>(ii)</sup>		0.45		0.71		0.63		0.69		0.70		0.65
Net realized and unrealized gain (loss) on investments		4.34		(7.49)		18.47		1.88		4.54		1.64
Total from investment operations		4.79		(6.78)		19.10		2.57		5.24		2.29
Dividends from net investment income		(0.38)		(0.56)		(0.55)		(0.66)		(0.61)		(0.57)
Distributions from net realized gains		-		(2.07)		(0.67)		(1.58)		(1.85)		(0.63)
Net asset value, end of period	\$	56.76	\$	52.35	\$	61.76	\$	43.88	\$	43.55	\$	40.77
Total return(iii)		9.20%	, 0	(11.53)%	6	44.12%	6	5.98%	6	13.94%	, 0	5.78%
RATIOS/SUPPLEMENTAL DATA: Net assets, end of period (000's omitted)	\$	123,374	\$	108,039	\$	106,439	\$	74,251	\$	74,924	\$	70,859
Ratio of gross expenses to average net assets		0.96%	, 0	0.97%	6	0.98%	6	1.06%	6	1.07%	/ 0	1.06%
Ratio of net expenses to average net assets		0.96%	, 0	0.97%	6	0.98%	6	1.06%	6	1.07%	/ 0	1.06%
Ratio of net investment income to		4.070	,	4.040	,	4 4 5 0	,	4 000	,	4 700	,	4 500/
average net assets		1.67%	-	1.24%	-	1.15%	-	1.60%	-	1.72%	-	1.59%
Portfolio turnover rate		2.06%	o	1.96%	6	8.40%	6	9.29%	6	7.30%	ō	11.05%

<sup>(i)</sup> Ratios have been annualized; total return and portfolio turnover rate have not been annualized.

(ii) Amount was computed based on average shares outstanding during the period.

(iii) Does not reflect the effect of sales charges, if applicable.

Alger Growth & Income Fund						Cla	ass	С				
	5	Bix months ended	v	ear ended	,	lear ended		Year ended	,	Year ended	V	ear ended
	4	/30/2023(1)		0/31/2022		10/31/2021		10/31/2020		10/31/2019		0/31/2018
Net asset value, beginning of period	\$	51.46	\$	60.77	\$	43.22	\$	42.93	\$	40.20	\$	39.14
INCOME FROM INVESTMENT OPERATIONS:												
Net investment income <sup>(ii)</sup>		0.24		0.28		0.21		0.36		0.39		0.34
Net realized and unrealized gain (loss) on investments		4.28		(7.38)		18.18		1.85		4,49		1.60
Total from investment operations		4.52		(7.10)		18.39		2.21		4.88		1.94
Dividends from net investment income		(0.19)		(0.14)		(0.17)		(0.34)		(0.30)		(0.25)
Distributions from net realized gains		-		(2.07)		(0.67)		(1.58)		(1.85)		(0.63)
Net asset value, end of period	\$	55.79	\$	51.46	\$	60.77	\$	43.22	\$	42.93	\$	40.20
Total return <sup>(iii)</sup>		8.79%	, 0	(12.18)%	6	43.01%	6	5.19%	6	13.12%	, D	4.96%
RATIOS/SUPPLEMENTAL DATA: Net assets, end of period (000's omitted)	\$	24,614	\$	21,111	\$	18,194	\$	13,127	\$	14,946	\$	16,074
Ratio of gross expenses to average												
net assets		1.71%	0	1.73%	6	1.73%	6	1.81%	6	1.82%	, D	1.82%
Ratio of net expenses to average net assets		1.71%	, 0	1.73%	6	1.73%	6	1.81%	6	1.82%	, D	1.82%
Ratio of net investment income to												
average net assets		0.92%		0.49%	-	0.40%	-	0.86%	-	0.97%		0.84%
Portfolio turnover rate		2.06%	0	1.96%	6	8.40%	6	9.29%	6	7.30%	Ď	11.05%

<sup>0</sup> Ratios have been annualized; total return and portfolio turnover rate have not been annualized.

<sup>(</sup>ii) Amount was computed based on average shares outstanding during the period.

<sup>(</sup>iii) Does not reflect the effect of sales charges, if applicable.

Alger Growth & Income Fund	Class Z											
		Six months ended 1/30/2023 <sup>(i)</sup>		/ear ended 0/31/2022		Year ended 10/31/2021		Year ended 10/31/2020		Year ended 10/31/2019		'ear ended 0/31/2018
Net asset value, beginning of period	\$	52.42	\$	61.84	\$	43.94	\$	43.60	\$	40.81	\$	39.71
INCOME FROM INVESTMENT OPERATIONS:												
Net investment income <sup>(ii)</sup>		0.54		0.90		0.80		0.86		0.85		0.80
Net realized and unrealized gain (loss) on investments		4.34		(7.51)		18.49		1.88		4.56		1.64
Total from investment operations		4.88		(6.61)		19.29		2.74		5.41		2.44
Dividends from net investment income		(0.47)		(0.74)		(0.72)		(0.82)		(0.77)		(0.71)
Distributions from net realized gains		_		(2.07)		(0.67)		(1.58)		(1.85)		(0.63)
Net asset value, end of period	\$	56.83	\$	52.42	\$	61.84	\$	43.94	\$	43.60	\$	40.81
Total return <sup>(iii)</sup>		9.37%	6	(11.25)%	6	44.54%	6	6.39%	6	14.39%	, 0	6.16%
RATIOS/SUPPLEMENTAL DATA: Net assets, end of period (000's												
omitted)	\$	163,596	\$	115,251	\$	38,021	\$	21,672	\$	26,979	\$	24,604
Ratio of gross expenses to average net assets		0.64%	6	0.65%	6	0.66%	6	0.73%	6	0.76%	, 0	0.76%
Ratio of expense reimbursements to average net assets		-	_		_	_(i	v)	(0.04)%	6	(0.07)%	, 0	(0.05)%
Ratio of net expenses to average net assets		0.64%	6	0.65%	6	0.66%	6	0.69%	6	0.69%	, 0	0.71%
Ratio of net investment income to average net assets		1.98%	6	1.62%	6	1.45%	6	2.00%	6	2.10%	/ 0	1.96%
Portfolio turnover rate		2.06%	6	1.96%	6	8.40%	6	9.29%	6	7.30%	6	11.05%

<sup>(i)</sup> Ratios have been annualized; total return and portfolio turnover rate have not been annualized.

<sup>(ii)</sup> Amount was computed based on average shares outstanding during the period.

(iii) Does not reflect the effect of sales charges, if applicable.

(iv) Amount was less than 0.005%.

Alger Mid Cap Growth Fund	Class A											
		Six months ended /30/2023 <sup>(i)</sup>		/ear ended 0/31/2022		Year ended 10/31/2021		Year ended 10/31/2020		Year ended 10/31/2019		'ear ended 0/31/2018
Net asset value, beginning of period	\$	10.82	\$	25.20	\$	19.29	\$	14.81	\$	14.13	\$	13.47
INCOME FROM INVESTMENT OPERATIONS:												
Net investment income (loss) <sup>(ii)</sup> Net realized and unrealized gain (loss)		(0.03)		(0.09)		0.48		(0.12)		(0.09)		(0.11)
on investments		0.62		(7.71)		7.58		5.80		1.48		0.88
Total from investment operations		0.59		(7.80)		8.06		5.68		1.39		0.77
Dividends from net investment income		-		(0.45)		-		-		-		-
Distributions from net realized gains		-		(6.13)		(2.15)		(1.20)		(0.71)		(0.11)
Net asset value, end of period	\$	11.41	\$	10.82	\$	25.20	\$	19.29	\$	14.81	\$	14.13
Total return <sup>(iii)</sup>		5.45%	6 0	(39.13)%	6	44.05% <sup>(ir</sup>	v)	41.34%	, 0	10.95%	6	5.78%
RATIOS/SUPPLEMENTAL DATA: Net assets, end of period (000's omitted)	\$	146,971	\$	146,648	\$	259,895	\$	187,552	\$	139,110	\$	138,370
Ratio of gross expenses to average net assets		1.27%	/ 0	1.24%	6	1.21%	6	1.30%	, 0	1.30%	6	1.30%
Ratio of net expenses to average net assets		1.27%	, 0	1.24%	6	1.21%	6	1.30%	, 0	1.30%	6	1.30%
Ratio of net investment income (loss) to average net assets		(0.50)%	, 0	(0.68)%	6	2.15%	6	(0.76)%	, 0	(0.65)%	6	(0.77)%
Portfolio turnover rate		48.19%	, 0	204.79%	6	170.96%	6	181.73%	, 0	182.97%	6	125.34%
See Notes to Einancial Statements	_	40.197	0	204.797	0	170.907	0	101.73%	0	102.977	0	120.0

<sup>(6)</sup> Ratios have been annualized; total return and portfolio turnover rate have not been annualized.

(ii) Amount was computed based on average shares outstanding during the period.

<sup>(</sup>iii) Does not reflect the effect of sales charges, if applicable.

<sup>(</sup>ii) Pursuant to the U.S. Securities and Exchange Commission's Rules on Fair Fund and Disgorgement Plans, the Alger Mid Cap Growth Fund received a Fair Fund distribution of \$9,346,397, which contributed approximately 3.89% to its annual return.

Alger Mid Cap Growth Fund						Cla	ass	в				
	-	ix months ended /30/2023 <sup>(i)</sup>		/ear ended 0/31/2022		Year ended 10/31/2021		Year ended 10/31/2020		Year ended 10/31/2019		/ear ended 10/31/2018
Net asset value, beginning of period	\$	6.78	\$	18.60	\$	14.70	\$	11.55	\$	11.22	\$	10.80
INCOME FROM INVESTMENT OPERATIONS:												
Net investment income (loss)(ii)		(0.02)		(0.06)		0.35		(0.08)		(0.10)		(0.17)
Net realized and unrealized gain (loss)												
on investments		0.39		(5.15)		5.70		4.43		1.14		0.70
Total from investment operations		0.37		(5.21)		6.05		4.35		1.04		0.53
Dividends from net investment income		-		(0.48)		-		-		-		-
Distributions from net realized gains		-		(6.13)		(2.15)		(1.20)		(0.71)		(0.11)
Net asset value, end of period	\$	7.15	\$	6.78	\$	18.60	\$	14.70	\$	11.55	\$	11.22
Total return(iii)		5.46%	6	(39.16)%	6	44.24% <sup>(i</sup>	v)	41.41%	6	10.66%	, 0	4.98%
RATIOS/SUPPLEMENTAL DATA:												
Net assets, end of period (000's												
omitted)	\$	10,547	\$	10,404	\$	18,276	\$	15,411	\$	13,772	\$	15,361
Ratio of gross expenses to average net assets		1.97%	6	1.95%	6	1.93%	6	2.03%	6	2.04%	, 0	2.05%
Ratio of expense reimbursements to average net assets		(0.67)%	6	(0.67)%	6	(0.76)%	6	(0.82)%	6	(0.47)%	, 0	_
Ratio of net expenses to average net												
assets		1.30%	6	1.28%	6	1.17%	6	1.21%	6	1.57%	, 0	2.05%
Ratio of net investment income (loss) to average net assets	)	(0.54)%	6	(0.71)%	6	2.08%	6	(0.66)%	6	(0.92)%	, 0	(1.50)%
Portfolio turnover rate		48.19%	6	204.79%	6	170.96%	6	181.73%	6	182.97%	6	125.34%

<sup>(0)</sup> Ratios have been annualized; total return and portfolio turnover rate have not been annualized.

- <sup>(ii)</sup> Amount was computed based on average shares outstanding during the period.
- (iii) Does not reflect the effect of sales charges, if applicable.

Alger Mid Cap Growth Fund					Cla	ass	C				
	ix months ended /30/2023 <sup>(i)</sup>		Year ended 10/31/2022		Year ended 10/31/2021		Year ended 10/31/2020		Year ended 10/31/2019		/ear ended 0/31/2018
Net asset value, beginning of period	\$ 6.34	\$	17.82	\$	14.26	\$	11.33	\$	11.08	\$	10.67
INCOME FROM INVESTMENT OPERATIONS:											
Net investment income (loss)(iii)	(0.04)		(0.12)		0.23		(0.18)		(0.16)		(0.18)
Net realized and unrealized gain (loss) on investments	0.36		(4.88)		5.48		4.31		1.12		0.70
Total from investment operations	 0.32		(5.00)		5.71		4.13		0.96		0.52
Dividends from net investment income	 -		(0.35)		-		-		-		-
Distributions from net realized gains	_		(6.13)		(2.15)		(1.20)		(0.71)		(0.11)
Net asset value, end of period	\$ 6.66	\$	6.34	\$	17.82	\$	. ,	\$	11.33	\$	11.08
Total return <sup>(iii)</sup>	5.05%	/ 0	(39.60)%	6	42.91% <sup>(ir</sup>	v)	40.26%	b	10.03%	, 0	4.94%
RATIOS/SUPPLEMENTAL DATA: Net assets, end of period (000's omitted)	\$ 4,011	\$	4,562	\$	8,244	\$	5,691	\$	6,014	\$	7,647
Ratio of gross expenses to average net assets	2.11%	6	2.05%	6	2.00%	6	2.10%	b	2.14%	, 0	2.11%
Ratio of net expenses to average net assets	2.11%	/ 0	2.05%	6	2.00%	6	2.10%	Ď	2.14%	, 0	2.11%
Ratio of net investment income (loss) to average net assets	(1.35)%	6	(1.49)%	6	1.41%	6	(1.52)%	, D	(1.48)%	, 0	(1.55)%
Portfolio turnover rate	 48.19%		204.79%		170.96%		181.73%		182.97%		125.34%
See Notes to Einancial Statements											

<sup>(i)</sup> Ratios have been annualized; total return and portfolio turnover rate have not been annualized.

(ii) Amount was computed based on average shares outstanding during the period.

<sup>(</sup>iii) Does not reflect the effect of sales charges, if applicable.

<sup>(</sup>ii) Pursuant to the U.S. Securities and Exchange Commission's Rules on Fair Fund and Disgorgement Plans, the Alger Mid Cap Growth Fund received a Fair Fund distribution of \$9,346,397, which contributed approximately 3.89% to its annual return.

Alger Mid Cap Growth Fund	_					Cla	ass	sΖ				
		Six months ended /30/2023 <sup>(i)</sup>		/ear ended 0/31/2022		Year ended 10/31/2021		Year ended 10/31/2020		Year ended 10/31/2019		'ear ended 0/31/2018
Net asset value, beginning of period	\$	11.16	\$	25.78	\$	19.63	\$	15.01	\$	14.27	\$	13.56
INCOME FROM INVESTMENT OPERATIONS:												
Net investment income (loss) <sup>(ii)</sup> Net realized and unrealized gain (loss)		(0.01)		(0.05)		0.63		(0.07)		(0.06)		(0.07)
on investments		0.64		(7.92)		7.67		5.89		1.51		0.89
Total from investment operations		0.63		(7.97)		8.30		5.82		1.45		0.82
Dividends from net investment income		-		(0.52)		-		-		-		-
Distributions from net realized gains		-		(6.13)		(2.15)		(1.20)		(0.71)		(0.11)
Net asset value, end of period	\$	11.79	\$	11.16	\$	25.78	\$	19.63	\$	15.01	\$	14.27
Total return(iii)		5.65%	, 0	(38.95)%	6	44.55% <sup>(ir</sup>	v)	41.75%	6	11.27%	, 0	6.03%
RATIOS/SUPPLEMENTAL DATA: Net assets, end of period (000's omitted)	\$	27,961	\$	30,488	\$	52,746	\$	26,804	\$	17,558	\$	14,230
Ratio of gross expenses to average net assets		0.95%	/ 0	0.93%	6	0.92%	6	0.99%	6	1.03%	, D	1.03%
Ratio of net expenses to average net assets		0.95%	, 0	0.93%	6	0.92%	6	0.99%	6	1.03%	, 0	1.03%
Ratio of net investment income (loss) to average net assets		(0.18)%	, 0	(0.37)%	6	2.75%	6	(0.46)%	6	(0.38)%	, 0	(0.49)%
Portfolio turnover rate		48.19%	6	204.79%	6	170.96%	6	181.73%	6	182.97%	0	125.34%
See Notes to Einancial Statements												

<sup>(i)</sup> Ratios have been annualized; total return and portfolio turnover rate have not been annualized.

- (ii) Amount was computed based on average shares outstanding during the period.
- (iii) Does not reflect the effect of sales charges, if applicable.

Alger Mid Cap Focus Fund				Class A		
		Six months ended 4/30/2023®		Year ended 10/31/2022	(co of	om 7/29/2021 ommencement operations) to 10/31/2021 <sup>(ii)</sup>
Net asset value, beginning of period	\$	12.14	\$	23.43	\$	20.67
INCOME FROM INVESTMENT OPERATIONS:						
Net investment loss(iii)		(0.04)		(0.09)		(0.04)
Net realized and unrealized gain (loss) on investments		(0.20)		(9.14)		2.80
Total from investment operations		(0.24)		(9.23)		2.76
Distributions from net realized gains		-		(2.06)		-
Net asset value, end of period	\$	11.90	\$	12.14	\$	23.43
Total return <sup>(iv)</sup>		(1.98)%	6	(42.27)%	6	13.35%
RATIOS/SUPPLEMENTAL DATA: Net assets, end of period (000's omitted)	\$	5,388	\$	5,083	\$	1,669
Ratio of gross expenses to average net assets		1.10%		1.05%		0.96%
Ratio of net expenses to average net assets		1.10%	6	1.05%	6	0.96%
Ratio of net investment loss to average net assets	)	(0.64)%	6	(0.66)%	6	(0.72)%
Portfolio turnover rate		78.62%	6	267.86%	6	250.31%
See Notes to Einancial Statement						

- (ii) Ratios have been annualized; total return has not been annualized; portfolio turnover is for the twelve months then ended.
- (iii) Amount was computed based on average shares outstanding during the period.
- (iv) Does not reflect the effect of sales charges, if applicable.

Alger Mid Cap Focus Fund				Class C		
		ix months ended 30/2023 <sup>(i)</sup>		ear ended 0/31/2022	(co of o	om 7/29/2021 mmencement operations) to 0/31/2021 <sup>(ii)</sup>
Net asset value, beginning of period	\$	12.01	\$	23.38	\$	20.67
INCOME FROM INVESTMENT OPERATIONS:						
Net investment loss(iii)		(0.08)		(0.21)		(0.09)
Net realized and unrealized gain (loss)		(0.40)		(0.40)		0.00
on investments		(0.19)		(9.10)		2.80
Total from investment operations		(0.27)		(9.31)		2.71
Distributions from net realized gains		-		(2.06)		-
Net asset value, end of period	\$	11.74	\$	12.01	\$	23.38
Total return <sup>(iv)</sup>		(2.25)%	6	(42.78)%	, 0	13.16%
RATIOS/SUPPLEMENTAL DATA: Net assets, end of period (000's omitted)	\$	2,638	\$	2,433	\$	2,317
Ratio of gross expenses to average net assets	÷	1.91%		1.85%		1.76%
Ratio of net expenses to average net assets		1.91%	6	1.85%	/ 0	1.76%
Ratio of net investment loss to average net assets		(1.45)%	6	(1.46)%	6	(1.50)%
Portfolio turnover rate		78.62%		267.86%		250.31%
See Notes to Financial Statements	_					

- Amount was computed based on average shares outstanding during the period.
- (v) Does not reflect the effect of sales charges, if applicable.

<sup>(</sup>i) Ratios have been annualized; total return has not been annualized; portfolio turnover is for the twelve months then ended.

Six months ended 4/30/2023 <sup>(7)</sup> Year ended 10/31/202         Year ended 10/31/202           Net asset value, beginning of period         \$ 12.14         \$ 23.43         \$ 15.14           INCOME FROM INVESTMENT         \$ 21.14         \$ 23.43         \$ 15.14	021 10/31/2	ded of op	n 6/14/2019 mencement perations) to (31/2019 <sup>(ii)</sup> 10.00
	.10 \$ 9	.70 \$	10.00
INCOME FROM INVESTMENT			
OPERATIONS:			
Net investment loss <sup>(iii)</sup> (0.03) (0.10) (0.	17) (0.	14)	(0.04)
Net realized and unrealized gain (loss)			
on investments (0.20) (9.13) 8.	.76 5	.54	(0.26)
Total from investment operations (0.23) (9.23) 8.	.59 5	.40	(0.30)
Distributions from net realized gains – (2.06) (0.2	26)	-	-
Net asset value, end of period \$ 11.91 \$ 12.14 \$ 23.	.43 \$ 15	.10 \$	9.70
Total return <sup>(iv)</sup> (1.89)% (42.28)% 57.	.36% 55	.35%	(3.00)%
RATIOS/SUPPLEMENTAL DATA: Net assets, end of period (000's omitted) \$ 19,838 \$ 62,499 \$ 145,5	539 \$ 67.7	796 \$	2,023
Ratio of gross expenses to average		.14%	1.91%
Ratio of expense reimbursements to average net assets – –	- (0.	03)%	(0.71)%
Ratio of net expenses to average net assets 1.07% 1.01% 0.	.95% 1	.11%	1.20%
Ratio of net investment loss to average net assets (0.54)% (0.63)% (0.6	85)% (1.	04)%	(0.97)%
Portfolio turnover rate 78.62% 267.86% 250.	.31% 123	.43%	65.50%

- <sup>(ii)</sup> Ratios have been annualized; total return has not been annualized; portfolio turnover is for the five months then ended.
- (iii) Amount was computed based on average shares outstanding during the period.
- (iv) Does not reflect the effect of sales charges, if applicable.

Alger Mid Cap Focus Fund				Class Y		
		Six months ended 1/30/2023 <sup>(1)</sup>		/ear ended 10/31/2022	(co of o	om 2/26/2021 mmencement operations) to 0/31/2021 <sup>(ii)</sup>
Net asset value, beginning of period	\$	12.26	\$	23.56	\$	20.65
INCOME FROM INVESTMENT OPERATIONS:						
Net investment loss <sup>(iii)</sup> Net realized and unrealized gain (loss)		(0.01)		(0.06)		(0.08)
on investments		(0.20)		(9.18)		2.99
Total from investment operations		(0.21)		(9.24)		2.91
Distributions from net realized gains		-		(2.06)		-
Net asset value, end of period	\$	12.05	\$	12.26	\$	23.56
Total return <sup>(iv)</sup>		(1.71)%	6	(42.07)%	, 0	14.09%
RATIOS/SUPPLEMENTAL DATA: Net assets, end of period (000's omitted)	\$	208	\$	443	¢	137
Ratio of gross expenses to average	Ψ	200	Ψ		Ψ	107
net assets		0.81%	6	0.74%	, 0	0.72%
Ratio of expense reimbursements to average net assets		(0.11)%	6	(0.05)%	/ 0	(0.02)%
Ratio of net expenses to average net assets		0.70%	6	0.69%	, 0	0.70%
Ratio of net investment loss to average net assets	•	(0.20)%	6	(0.44)%	, 0	(0.57)%
Portfolio turnover rate		78.62%	6	267.86%	, 0	250.31%
See Notes to Financial Statements	s.					

- (i) Ratios have been annualized; total return has not been annualized; portfolio turnover is for the twelve months then ended.
- (iii) Amount was computed based on average shares outstanding during the period.
- (v) Does not reflect the effect of sales charges, if applicable.

Alger Mid Cap Focus Fund						Class Z				
		Six months ended 1/30/2023 <sup>(i)</sup>		/ear ended 10/31/2022		fear ended 10/31/2021		/ear ended 10/31/2020	(cc of	om 6/14/2019 ommencement operations) to 0/31/2019 <sup>(ii)</sup>
Net asset value, beginning of period	\$	12.26	\$	23.57	\$	15.15	\$	9.71	\$	10.00
INCOME FROM INVESTMENT OPERATIONS:										
Net investment loss(iii)		(0.02)		(0.05)		(0.12)		(0.10)		(0.03)
Net realized and unrealized gain (loss)										
on investments		(0.19)		(9.20)		8.80		5.54		(0.26)
Total from investment operations		(0.21)		(9.25)		8.68		5.44		(0.29)
Distributions from net realized gains		-		(2.06)		(0.26)		-		-
Net asset value, end of period	\$	12.05	\$	12.26	\$	23.57	\$	15.15	\$	9.71
Total return <sup>(iv)</sup>		(1.71)%	Ď	(42.10)%	6	57.77%	6	55.70%	6	(2.80)%
RATIOS/SUPPLEMENTAL DATA: Net assets, end of period (000's omitted)	\$	319,373	\$	365,976	\$	795,479	\$	307,532	\$	28,230
Ratio of gross expenses to average net assets		0.79%	, D	0.71%	6	0.68%	6	0.91%	6	1.86%
Ratio of expense reimbursements to average net assets		-	-	-	-	-	_	(0.05)%	6	(0.87)%
Ratio of net expenses to average net assets		0.79%	Ď	0.71%	6	0.68%	6	0.86%	6	0.99%
Ratio of net investment income (loss) to	)									
average net assets		(0.33)%	b	(0.33)%	6	(0.58)%	6	(0.77)%	6	(0.74)%
Portfolio turnover rate		78.62%	b	267.86%	6	250.31%	6	123.43%	6	65.50%

- <sup>(ii)</sup> Ratios have been annualized; total return has not been annualized; portfolio turnover is for the five months then ended.
- (iii) Amount was computed based on average shares outstanding during the period.
- (iv) Does not reflect the effect of sales charges, if applicable.

#### Alger Weatherbie Specialized المستحر بالد

Growth Fund					Cla	ass	A				
	Six months ended 1/30/2023 <sup>(1)</sup>		'ear ended 0/31/2022		/ear ended 10/31/2021		Year ended 10/31/2020		Year ended 10/31/2019		'ear ended 0/31/2018
Net asset value, beginning of period INCOME FROM INVESTMENT OPERATIONS:	\$ 11.57	\$	24.96	\$	17.46	\$	13.30	\$	13.08	\$	12.87
Net investment loss <sup>(ii)</sup> Net realized and unrealized gain (loss)	(0.05)		(0.14)		(0.23)		(0.16)		(0.14)		(0.15)
on investments	(0.32)		(8.91)		8.70		4.88		1.39		1.90
Total from investment operations	(0.37)		(9.05)		8.47		4.72		1.25		1.75
Distributions from net realized gains	-		(4.34)		(0.97)		(0.56)		(1.03)		(1.54)
Net asset value, end of period	\$ 11.20	\$	11.57	\$	24.96	\$	17.46	\$	13.30	\$	13.08
Total return(iii)	(3.20)%	, 0	(42.03)%	6	49.80%	6	36.57%	b	11.57%	, 0	15.02%
RATIOS/SUPPLEMENTAL DATA: Net assets, end of period (000's omitted)	\$ 105,468	\$	119,741	\$	259,394	\$	174,709	\$	140,368	\$	111,456
Ratio of gross expenses to average net assets	1.30%	, 0	1.25%	6	1.20%	6	1.27%	b	1.31%	/ 0	1.33%
Ratio of net expenses to average net assets	1.30%	, 0	1.25%	6	1.20%	6	1.27%	b	1.31%	, 0	1.33%
Ratio of net investment loss to average net assets	(0.90)%	, 0	(0.95)%	6	(1.03)%	6	(1.09)%	b	(1.08)%	/ 0	(1.16)%
Portfolio turnover rate	20.02%	, 0	55.97%	6	61.53%	6	66.84%	b	64.83%	, 0	42.56%
See Notes to Financial Statements											

See Notes to Financial Statements.

(i)Ratios have been annualized; total return and portfolio turnover rate have not been annualized.

(ii)Amount was computed based on average shares outstanding during the period.

(iii) Does not reflect the effect of sales charges, if applicable.

	Six months ended 4/30/2023 <sup>(i)</sup> 6.29	Year e 10/31/ \$1	2022	Year ei 10/31/2			ar ended	Y	ear ended	Y	ear ended
Net asset value beginning of period \$	6.29	\$ 1			2021	10/	31/2020	1	0/31/2019		0/31/2018
INCOME FROM INVESTMENT OPERATIONS:		Ç.	5.93	\$ 1 <sup>′</sup>	1.52	\$	9.01	\$	9.30	\$	9.65
Net investment loss <sup>(ii)</sup> Net realized and unrealized gain (loss)	(0.05)	,	.14)		.25)		(0.19)		(0.17)		(0.18)
on investments	(0.18)	,	.16)		5.63		3.26		0.91		1.37
Total from investment operations	(0.23)	(5	.30)	{	5.38		3.07		0.74		1.19
Distributions from net realized gains	-	(4	.34)	(0	.97)		(0.56)		(1.03)		(1.54)
Net asset value, end of period \$	6.06	\$	6.29	\$ 15	5.93	\$	11.52	\$	9.01	\$	9.30
Total return(iii)	(3.66)%	6 (42	.46)%	48	8.68%	)	35.62	%	10.70%	6	14.11%
RATIOS/SUPPLEMENTAL DATA: Net assets, end of period (000's omitted) \$	37,581	\$ 44	815	\$ 103,	331	\$	64,497	\$	44,908	\$	36,325
Ratio of gross expenses to average net assets Ratio of net expenses to average net	2.05%	0	2.02%		1.95%	)	2.03	%	2.05%	6	2.08%
assets	2.05%	, o	2.02%		1.95%	)	2.03	%	2.05%	6	2.08%
Ratio of net investment loss to average net assets	(1.65)%	6 (1	.72)%	(1	.79)%	)	(1.85)	%	(1.82)%	6	(1.91)%
Portfolio turnover rate	20.02%	6 5	5.97%	6	1.53%	)	66.84	%	64.83%	6	42.56%

See Notes to Financial Statements.

<sup>(i)</sup> Ratios have been annualized; total return and portfolio turnover rate have not been annualized.

(iii) Does not reflect the effect of sales charges, if applicable.

<sup>(</sup>ii) Amount was computed based on average shares outstanding during the period.

Growth Fund					Cla	ass	s I				
	Six months ended //30/2023®		Year ended 10/31/2022		Year ended 10/31/2021		Year ended 10/31/2020		Year ended 10/31/2019		/ear ended 10/31/2018
Net asset value, beginning of period INCOME FROM INVESTMENT OPERATIONS:	\$ 11.99	\$	25.67	\$	17.94	\$	13.64	\$	13.38	\$	13.14
Net investment loss <sup>(ii)</sup> Net realized and unrealized gain (loss)	(0.05)		(0.14)		(0.23)		(0.16)		(0.14)		(0.16)
on investments	(0.33)		(9.20)		8.93		5.02		1.43		1.94
Total from investment operations	(0.38)		(9.34)		8.70		4.86		1.29		1.78
Distributions from net realized gains	-		(4.34)		(0.97)		(0.56)		(1.03)		(1.54)
Net asset value, end of period	\$ 11.61	\$	11.99	\$	25.67	\$	17.94	\$	13.64	\$	13.38
Total return <sup>(iii)</sup>	(3.17)%	6	(42.02)%	6	49.81%	6	36.69%	6	11.61%	6	14.94%
RATIOS/SUPPLEMENTAL DATA: Net assets, end of period (000's omitted)	\$ 26,067	\$	29,612	\$	77,214	\$	66,294	\$	58,615	\$	35,669
Ratio of gross expenses to average net assets Ratio of net expenses to average net	1.27%	6	1.25%	6	1.19%	6	1.24%	6	1.26%	6	1.35%
assets	1.27%	6	1.25%	6	1.19%	6	1.24%	6	1.26%	6	1.35%
Ratio of net investment loss to average net assets	(0.87)%	6	(0.95)%	6	(1.02)%	6	(1.07)%	6	(1.03)%	6	(1.18)%
Portfolio turnover rate	20.02%	6	55.97%	6	61.53%	6	66.84%	6	64.83%	6	42.56%
Can Natao to Financial Statements											

See Notes to Financial Statements.

<sup>0</sup> Ratios have been annualized; total return and portfolio turnover rate have not been annualized.

(ii) Amount was computed based on average shares outstanding during the period.

(iii) Does not reflect the effect of sales charges, if applicable.

Growth Fund						Cla	ass	γ				
	-	ix months ended /30/2023 <sup>(i)</sup>		/ear ended 10/31/2022		Year ended 10/31/2021		Year ended 10/31/2020		Year ended 10/31/2019		Year ended 10/31/2018
Net asset value, beginning of period INCOME FROM INVESTMENT OPERATIONS:	\$	12.29	\$	26.12	\$	18.17	\$	13.77	ç	\$ 13.44	\$	13.14
Net investment loss <sup>(ii)</sup> Net realized and unrealized gain (loss) on investments		(0.03) (0.34)		(0.08) (9.41)		(0.16) 9.08		(0.11) 5.07		(0.09) 1.45		(0.10) 1.94
Total from investment operations		(0.37)		(9.49)		8.92		4.96		1.46		1.84
Distributions from net realized gains		(0.57)		(4.34)		(0.97)		(0.56)		(1.03)		(1.54)
Net asset value, end of period	\$	11.92	\$	12.29	\$	26.12	\$	18.17	ę	\$ 13.77	\$	13.44
Total return <sup>(iii)</sup>		(2.93)%	, 0	(41.81)%	6	50.35%	6	37.08%	6	12.12%	6	15.45%
RATIOS/SUPPLEMENTAL DATA: Net assets, end of period (000's omitted)	\$	44,658	\$	47,379		61,163	\$	32,702		\$ 12,903	\$	3,832
Ratio of gross expenses to average net assets		0.95%		0.91%		0.89%		0.94%		0.97%		1.05%
Ratio of expense reimbursements to average net assets		(0.07)%	, 0	(0.04)%	6	(0.02)%	6	(0.07)%	6	(0.10)%	6	(0.18)%
Ratio of net expenses to average net assets		0.88%	/ 0	0.87%		0.87%	6	0.87%	6	0.87%	6	0.87%
Ratio of net investment loss to average net assets		(0.48)%	, 0	(0.55)%	6	(0.70)%	6	(0.69)%	6	(0.64)%	6	(0.67)%
Portfolio turnover rate		20.02%	, 0	55.97%	6	61.53%	6	66.84%	6	64.83%	6	42.56%

See Notes to Financial Statements.

<sup>(</sup>ii) Amount was computed based on average shares outstanding during the period.

<sup>(</sup>iii) Does not reflect the effect of sales charges, if applicable.

	_						ISS	2				
		Six months ended 1/30/2023 <sup>(i)</sup>		Year ended 10/31/2022		Year ended 10/31/2021		Year ended 10/31/2020		Year ended 10/31/2019		'ear ended 0/31/2018
Net asset value, beginning of period INCOME FROM INVESTMENT OPERATIONS:	\$	12.73	\$	26.87	\$	18.68	\$	14.15	\$	13.80	\$	13.46
Net investment loss <sup>(ii)</sup> Net realized and unrealized gain (loss) on investments		(0.03)		(0.10)		(0.17) 9.33		(0.12) 5.21		(0.10) 1.48		(0.12)
		(0.36)		(9.70)								
Total from investment operations		(0.39)		(9.80)		9.16		5.09		1.38		1.88
Distributions from net realized gains		-		(4.34)		(0.97)		(0.56)		(1.03)		(1.54)
Net asset value, end of period	\$	12.34	\$	12.73	\$	26.87	\$	18.68	\$	14.15	\$	13.80
Total return(iii)		(3.06)%	6	(41.82)%	6	50.32%	6	37.00%	6	11.94%	0	15.379
RATIOS/SUPPLEMENTAL DATA: Net assets, end of period (000's omitted)	\$	438,122	\$	535,172	\$	1,277,576	\$	620,005	\$	284,393	\$	147,665
Ratio of gross expenses to average net assets		0.95%	6	0.91%		0.88%		0.94%		0.97%	6	1.00%
Ratio of expense reimbursements to average net assets		-	-		_		_	-	-	-	-	(0.01)%
Ratio of net expenses to average net assets		0.95%	6	0.91%	6	0.88%	6	0.94%	6	0.97%	6	0.99%
Ratio of net investment loss to average net assets		(0.54)%	6	(0.61)%	6	(0.72)%	6	(0.76)%	6	(0.73)%	6	(0.82)%
Portfolio turnover rate		20.02%	6	55.97%	6	61.53%	6	66.84%	6	64.83%	6	42.56%

See Notes to Financial Statements.

<sup>0</sup> Ratios have been annualized; total return and portfolio turnover rate have not been annualized.

<sup>(ii)</sup> Amount was computed based on average shares outstanding during the period.

(iii) Does not reflect the effect of sales charges, if applicable.

Alger Small Cap Growth Fund					Cla	ass	A				
	Six months ended /30/2023®		'ear ended 0/31/2022		(ear ended 10/31/2021		Year ended 10/31/2020		(ear ended 10/31/2019		'ear ended 0/31/2018
Net asset value, beginning of period INCOME FROM INVESTMENT	\$ 8.83	\$	16.21	\$	12.59	\$	9.34	\$	9.54	\$	8.40
OPERATIONS: Net investment loss <sup>(ii)</sup> Net realized and unrealized gain (loss)	(0.03)		(0.11)		(0.07)		(0.12)		(0.11)		(0.10)
on investments	(0.17)		(5.93)		3.76		3.91		0.85		1.34
Total from investment operations	(0.20)		(6.04)		3.69		3.79		0.74		1.24
Distributions from net realized gains	-		(1.34)		(0.07)		(0.54)		(0.94)		(0.10)
Net asset value, end of period	\$ 8.63	\$	8.83	\$	16.21	\$	12.59	\$	9.34	\$	9.54
Total return(iii)	(2.15)%	6	(39.87)%	6	29.27% <sup>(i</sup>	v)	42.80%	, 0	9.94%	6	14.94%
RATIOS/SUPPLEMENTAL DATA: Net assets, end of period (000's omitted)	\$ 130,104	\$	142,244	\$	262,708	\$	187,489	\$	116,308	\$	111,271
Ratio of gross expenses to average net assets	1.29%	6	1.29%	6	1.23%	6	1.33%	, 0	1.39%	6	1.38%
Ratio of net expenses to average net assets	1.29%	6	1.29%	6	1.23%	6	1.33%	, 0	1.39%	6	1.38%
Ratio of net investment loss to average net assets	(0.80)%	6	(1.01)%	6	(0.46)%	6	(1.11)%	, 0	(1.17)%	6	(1.06)%
Portfolio turnover rate	11.90%	6	15.44%	6	34.85%	6	12.67%	, 0	17.09%	6	28.68%
Son Notos to Einancial Statements											

<sup>(0)</sup> Ratios have been annualized; total return and portfolio turnover rate have not been annualized.

<sup>(ii)</sup> Amount was computed based on average shares outstanding during the period.

<sup>(</sup>iii) Does not reflect the effect of sales charges, if applicable.

					Cla	ass	s B				
-	ended						Year ended 10/31/2020		Year ended 10/31/2019		Year ended 10/31/2018
\$	5.94	\$	11.41	\$	8.88	\$	6.74	ę	\$ 7.20	\$	6.42
	(0.03)		(0.08)		(0.05)		(0.08)		(0.11)		(0.13)
	(0.11)		(4.05)		2.65		2.76		0.59		1.01
	· /		. ,		2.60		2.68		0.48		0.88
	<u> </u>		. ,		(0.07)		(0.54)		(0.94)		(0.10)
\$	5.80	\$	5.94	\$	11.41	\$	, ,	ç	. ,	\$	7.20
	(2.36)%	6	(39.91)%	6	29.38% <sup>(i</sup>	v)	42.68%	6	9.51%	6	13.93%
\$	2,539	\$	3,038	\$	5,821	\$	5.095		\$ 4,523	\$	4,958
	2.02%	6	2.00%	6	1.96%	6	2.07%	%	2.19%	6	2.23%
	(0.63)%	6	(0.64)%	6	(0.74)%	6	(0.73)%	6	(0.41)%	6	-
	1.39%	6	1.36%	6	1.22%	6	1.34%	%	1.78%	6	2.23%
	(0.89)%	6	(1.09)%	6	(0.48)%	6	(1.11)%	6	(1.57)%	6	(1.90)%
	· /		, ,		( )		. ,		, ,		28.68%
	4, \$ \$	4/30/2023® \$5.94 (0.03) (0.11) (0.14) \$5.80 (2.36)? \$2,539 2.02? (0.63)? 1.39? (0.89)? 11.90?	ended 4/30/2023 <sup>(0)</sup> \$ 5.94 \$ (0.03) (0.11) (0.14) - \$ 5.80 \$ (2.36)% \$ 2,539 \$ 2.02% (0.63)% 1.39% (0.89)% 11.90%	ended 4/30/2023 <sup>(0)</sup> Year ended 10/31/2022           \$ 5.94         11.41           (0.03)         (0.08)           (0.11)         (4.05)           (0.14)         (4.13)           -         (1.34)           \$ 5.80         \$ 5.94           (2.36)%         (39.91)?           \$ 2,539         \$ 3,038           2.02%         2.00?           (0.63)%         (0.64)?           1.39%         1.36?           (0.89)%         (1.09)?           11.90%         15.44?	ended 4/30/2023 <sup>(0)</sup> Year ended 10/31/2022           \$ 5.94         11.41           (0.03)         (0.08)           (0.11)         (4.05)           (0.14)         (4.13)           -         (1.34)           \$ 5.80         5.94           (2.36)%         (39.91)%           \$ 2.539         3.038           2.02%         2.00%           (0.63)%         (0.64)%           1.39%         1.36%           (0.89)%         (1.09)%           11.90%         15.44%	ended 4/30/2023 <sup>(0)</sup> Year ended 10/31/2022         Year ended 10/31/2021           \$ 5.94         11.41         8.88           (0.03)         (0.08)         (0.05)           (0.11)         (4.05)         2.65           (0.14)         (4.13)         2.60           -         (1.34)         (0.07)           \$ 5.80         5.94         11.41           (2.36)%         (39.91)%         29.38% <sup>0</sup> \$ 2,539         3,038         5,821           2.02%         2.00%         1.969           (0.63)%         (0.64)%         (0.74)%           1.39%         1.36%         1.229           (0.89)%         (1.09)%         (0.48)%           11.90%         15.44%         34.85%	ended 4/30/2023 <sup>(i)</sup> Year ended 10/31/2022         Year ended 10/31/2021           \$ 5.94         11.41         \$ 8.88         \$           (0.03)         (0.08)         (0.05)           (0.11)         (4.05)         2.65           (0.14)         (4.13)         2.60           -         (1.34)         (0.07)           \$ 5.80         5.94         \$ 11.41           (2.36)%         5.94         \$ 11.41           (2.36)%         (39.91)%         29.38% <sup>(m)</sup> \$ 2,539         \$ 3,038         5,821           2.02%         2.00%         1.96%           (0.63)%         (0.64)%         (0.74)%           1.39%         1.36%         1.22%           (0.89)%         (1.09)%         (0.48)%           11.90%         15.44%         34.85%	ended 4/30/2023 <sup>(i)</sup> Year ended 10/31/2021         Year ended 10/31/2021         Year ended 10/31/2020           \$ 5.94         11.41         8.88         6.74           (0.03)         (0.08)         (0.05)         (0.08)           (0.11)         (4.05)         2.65         2.76           (0.14)         (4.13)         2.60         2.68           -         (1.34)         (0.07)         (0.54)           \$ 5.80         \$ 5.94         \$ 11.41         \$ 8.88           (2.36)%         (39.91)%         29.38% <sup>(m)</sup> 42.689           \$ 2.539         \$ 3.038         \$ 5.821         \$ 5.095           2.02%         2.00%         1.96%         2.079           (0.63)%         (0.64)%         (0.74)%         (0.73)9           1.39%         1.36%         1.22%         1.349           (0.89)%         (1.09)%         (0.48)%         (1.11)9	ended 4/30/2023 <sup>(0)</sup> Year ended 10/31/2021         Year ended 10/31/2021         Year ended 10/31/2021           \$ 5.94         11.41         8.88         6.74           (0.03)         (0.08)         (0.05)         (0.08)           (0.11)         (4.05)         2.65         2.76           (0.14)         (4.13)         2.60         2.68           -         (1.34)         (0.07)         (0.54)           \$ 5.80         5.94         11.41         8.88         9           (2.36)%         (39.91)%         29.38% <sup>(m)</sup> 42.68%           \$ 2.539         3.038         5.821         5.095         9           2.02%         2.00%         1.96%         2.07%           (0.63)%         (0.64)%         (0.74)%         (0.73)%           1.39%         1.36%         1.22%         1.34%           (0.89)%         (1.09)%         (0.48)%         (1.11)%           11.90%         15.44%         34.85%         12.67%	ended 4/30/2023 <sup>(i)</sup> Year ended 10/31/2021         Year ended 10/31/2021         Year ended 10/31/2020         Year ended 10/31/2020	ended 4/30/2023 <sup>(0)</sup> Year ended 10/31/2021         Year ended 10/31/2021         Year ended 10/31/2020         Year ended 10/31/2020         Year ended 10/31/2020         Year ended 10/31/2019         Year ended 10/31/2020         Year ended 10/31/2019         Year ended 10/31/2020         Year ended 10/31/2019         Year ended 10/31/2020         Year ended 10/31/2019         Year ended 10/31/2019

<sup>(i)</sup> Ratios have been annualized; total return and portfolio turnover rate have not been annualized.

(ii) Amount was computed based on average shares outstanding during the period.

<sup>(</sup>iii) Does not reflect the effect of sales charges, if applicable.

<sup>(</sup>ii) Pursuant to the U.S. Securities and Exchange Commission's Rules on Fair Fund and Disgorgement Plans, the Alger Small Cap Growth Fund received a Fair Fund distribution of \$3,738,004, which contributed approximately 0.72% to its annual return.

Alger Small Cap Growth Fund					Cla	ass	С				
	ix months ended /30/2023 <sup>(i)</sup>		'ear ended 0/31/2022		Year ended 10/31/2021		Year ended 10/31/2020		Year ended 10/31/2019		/ear ended 0/31/2018
Net asset value, beginning of period INCOME FROM INVESTMENT OPERATIONS:	\$ 5.51	\$	10.76	\$	8.44	\$	6.47		\$ 6.99	\$	6.22
Net investment loss <sup>(ii)</sup> Net realized and unrealized gain (loss)	(0.04)		(0.12)		(0.13)		(0.14)		(0.13)		(0.12)
on investments	 (0.11)		(3.79)		2.52		2.65		0.55		0.99
Total from investment operations	(0.15)		(3.91)		2.39		2.51		0.42		0.87
Distributions from net realized gains	-		(1.34)		(0.07)		(0.54)		(0.94)		(0.10)
Net asset value, end of period	\$ 5.36	\$	5.51	\$	10.76	\$	8.44	9	\$ 6.47	\$	6.99
Total return(iii)	(2.72)%	6	(40.32)%	6	28.41% <sup>(i</sup>	v)	41.76%	6	8.87%	6	14.22%
RATIOS/SUPPLEMENTAL DATA: Net assets, end of period (000's omitted)	\$ 17,984	\$	21,105	\$	39,148	\$	18,365		\$ 6,257	\$	5,837
Ratio of gross expenses to average net assets	2.09%	6	2.09%	6	2.00%	6	2.09%	6	2.20%	6	2.16%
Ratio of net expenses to average net assets	2.09%	6	2.09%	6	2.00%	6	2.09%	6	2.20%	6	2.16%
Ratio of net investment loss to average net assets	(1.59)%	6	(1.81)%	6	(1.21)%	6	(1.90)%	6	(1.98)%	6	(1.82)%
Portfolio turnover rate	11.90%	6	15.44%	6	34.85%	6	12.67%	6	17.09%	6	28.68%
Son Notos to Einancial Statements											

<sup>(0)</sup> Ratios have been annualized; total return and portfolio turnover rate have not been annualized.

<sup>(ii)</sup> Amount was computed based on average shares outstanding during the period.

<sup>(</sup>iii) Does not reflect the effect of sales charges, if applicable.

Alger Small Cap Growth Fund	Class Y
	Six months ended 4/30/2023 <sup>(i)</sup> From 12/31/2021 (commencement of operations) to 10/31/2022 <sup>(ii)</sup>
Net asset value, beginning of period INCOME FROM INVESTMENT OPERATIONS:	\$ 9.31 \$ 13.84
Net investment loss <sup>(iii)</sup> Net realized and unrealized gain (loss)	
on investments	(0.17) (4.49)
Total from investment operations	(0.19) (4.53)
Net asset value, end of period	\$     9.12  \$     9.31
Total return <sup>(iv)</sup>	(2.04)% (32.73)%
RATIOS/SUPPLEMENTAL DATA: Net assets, end of period (000's omitted)	\$ 8,790 \$ 8,050
Ratio of gross expenses to average net assets	0.96% 0.96%
Ratio of expense reimbursements to average net assets	(0.12)% (0.12)%
Ratio of net expenses to average net assets	0.84% 0.84%
Ratio of net investment loss to average net assets	) (0.36)% (0.44)%
Portfolio turnover rate	11.90% 15.44%
See Notes to Financial Statements	3.

<sup>(</sup>i) Ratios have been annualized; total return has not been annualized; portfolio turnover is for the ten months then ended.

<sup>(</sup>iii) Amount was computed based on average shares outstanding during the period.

<sup>(</sup>iv) Does not reflect the effect of sales charges, if applicable.

Alger Small Cap Growth Fund	_					Cla	ass	Z				
		Six months ended 1/30/2023®		rear ended 10/31/2022		Year ended 10/31/2021		Year ended 10/31/2020		Year ended 10/31/2019		Year ended 10/31/2018
Net asset value, beginning of period	\$	9.29	\$	16.92	\$	13.10	\$	9.66	\$	§ 9.80	\$	8.60
INCOME FROM INVESTMENT OPERATIONS:												
Net investment loss(ii)		(0.02)		(0.08)		(0.02)		(0.10)		(0.07)		(0.06)
Net realized and unrealized gain (loss)		(0.47)		(0.04)		0.04		4.00		0.07		4.00
on investments		(0.17)		(6.21)		3.91		4.08		0.87		1.36
Total from investment operations		(0.19)		(6.29)		3.89		3.98		0.80		1.30
Distributions from net realized gains		-		(1.34)		(0.07)		(0.54)		(0.94)		(0.10)
Net asset value, end of period	\$	9.10	\$	9.29	\$	16.92	\$	13.10	9	9.66	\$	9.80
Total return <sup>(iii)</sup>		(2.05)%	6	(39.66)%	6	29.66% <sup>(ir</sup>	v)	43.38%	6	10.33%	6	15.30%
RATIOS/SUPPLEMENTAL DATA: Net assets, end of period (000's omitted)	\$	177,956	\$	214,819	\$	383,748	\$	179,276	9	5 21,782	\$	13,179
Ratio of gross expenses to average net assets		0.97%	6	0.96%	6	0.93%	6	1.00%	%	1.12%	6	1.12%
Ratio of expense reimbursements to average net assets			_		_		_	(0.03)%	%	(0.13)%	6	(0.13)%
Ratio of net expenses to average net assets		0.97%	6	0.96%	6	0.93%	6	0.97%	%	0.99%	6	0.99%
Ratio of net investment loss to average	)											
net assets		(0.47)%	6	(0.68)%	6	(0.12)%	6	(0.81)%	6	(0.78)%	6	(0.65)%
Portfolio turnover rate		11.90%	6	15.44%	6	34.85%	6	12.67%	6	17.09%	6	28.68%
See Notes to Financial Statements												

<sup>(i)</sup> Ratios have been annualized; total return and portfolio turnover rate have not been annualized.

(ii) Amount was computed based on average shares outstanding during the period.

<sup>(</sup>iii) Does not reflect the effect of sales charges, if applicable.

<sup>(</sup>ii) Pursuant to the U.S. Securities and Exchange Commission's Rules on Fair Fund and Disgorgement Plans, the Alger Small Cap Growth Fund received a Fair Fund distribution of \$3,738,004, which contributed approximately 0.72% to its annual return.

Alger Small Cap Focus Fund	_					Cla	ass	а А				
		Six months ended //30/2023 <sup>(1)</sup>		/ear ended 0/31/2022		rear ended 10/31/2021		Year ended 10/31/2020		Year ended 10/31/2019		'ear ended 0/31/2018
Net asset value, beginning of period	\$	16.91	\$	31.74	\$	26.22	\$	19.93	\$	18.86	\$	14.91
INCOME FROM INVESTMENT OPERATIONS:												
Net investment loss(ii)		(0.08)		(0.19)		(0.31)		(0.25)		(0.19)		(0.17)
Net realized and unrealized gain (loss) on investments		(0 5 2)		(10.04)		5.83		7.03		1.41		4.26
		(0.52)		(12.84)								
Total from investment operations		(0.60)		(13.03)		5.52		6.78		1.22		4.09
Dividends from net investment income		-		-		-		(0.19)		-		-
Distributions from net realized gains		-		(1.80)		-		(0.30)		(0.15)		(0.14)
Net asset value, end of period	\$	16.31	\$	16.91	\$	31.74	\$	26.22	\$	19.93	\$	18.86
Total return(iii)		(3.55)%	, 0	(42.88)%	6	21.05%	6	34.74%	, 0	6.59%	6	27.72%
RATIOS/SUPPLEMENTAL DATA: Net assets, end of period (000's omitted)	\$	189,342	\$	226,738	\$	560,577	\$	566,606	\$	523,291	\$	300,066
Ratio of gross expenses to average				-,		,.		,		, .		,.
net assets		1.42%	0	1.32%	6	1.18%	6	1.22%	ó	1.19%	6	1.18%
Ratio of net expenses to average net assets		1.42%	, 0	1.32%	6	1.18%	6	1.22%	, 0	1.19%	6	1.18%
Ratio of net investment loss to average												
net assets		(1.01)%	0	(0.96)%	6	(0.98)%	6	(1.11)%	0	(0.95)%	6	(0.92)%
Portfolio turnover rate		26.08%	, 0	37.57%	6	56.71%	6	37.49%	ó	48.84%	6	27.04%
See Notes to Einancial Statements		_01007			-	201117					-	

<sup>0</sup> Ratios have been annualized; total return and portfolio turnover rate have not been annualized.

(ii) Amount was computed based on average shares outstanding during the period.

(iii) Does not reflect the effect of sales charges, if applicable.

Class C											
-	ended										'ear ended 0/31/2018
\$	14.75	\$	28.12	\$	23.40	\$	17.85	\$	17.04	\$	13.58
	(0.11)		(0.28)		(0.47)		(0.37)		(0.31)		(0.27)
	(0.45)		(11 29)		5 19		6 30		1 27		3.87
	( /		, ,								3.60
	(		_		-		(0.08)		-		-
	-		(1.80)		-		(0.30)		(0.15)		(0.14)
\$	14.19	\$	14.75	\$	28.12	\$	23.40	\$	17.85	\$	17.04
	(3.80)%	, 0	(43.23)%	6	20.17%	6	33.85%	, 0	5.76%	6	26.82%
\$	89,079	\$	108,988	\$	267,800	\$	248,577	\$	212,737	\$	131,655
	1.98%	6	1.93%	6	1.90%	6	1.94%	/ 0	1.95%	6	1.94%
	1.98%	/ 0	1.93%	6	1.90%	6	1.94%	, 0	1.95%	/ 0	1.94%
	(1.57)%	/ 0	(1.57)%	6	(1.70)%	6	(1.83)%	, 0	(1.71)%	6	(1.66)%
	26.08%	6	37.57%	6	56.71%	6	37.49%	, 0	48.84%	6	27.04%
	<u>4/:</u> \$	(0.11) (0.45) (0.56) – \$ 14.19 (3.80)% \$ 89,079 1.98% 1.98% (1.57)%	ended Y 4/30/2023 <sup>(i)</sup> 1 \$ 14.75 \$ (0.11) (0.45) (0.56) - - \$ 14.19 \$ (3.80)%	ended 4/30/2023 <sup>(0)</sup> Year ended 10/31/2022           14.75         28.12           (0.11)         (0.28)           (0.45)         (11.29)           (0.56)         (11.57)           -         -           (1.80)         14.75           \$ 14.19         14.75           (3.80)%         (43.23)%           \$ 89,079         \$ 108,988           1.98%         1.93%           1.98%         1.93%           (1.57)%         (1.57)%	ended Year ended 4/30/2023 <sup>(0)</sup> 10/31/2022 \$ 14.75 \$ 28.12 \$ (0.11) (0.28) (0.45) (11.29) (0.56) (11.57) (1.80) \$ 14.19 \$ 14.75 \$ (3.80)% (43.23)% \$ 89,079 \$ 108,988 \$ 1.98% 1.93% 1.98% 1.93% (1.57)% (1.57)%	ended 4/30/2023 <sup>(0)</sup> Year ended 10/31/2022         Year ended 10/31/2021           \$ 14.75         \$ 28.12         \$ 23.40           (0.11)         (0.28)         (0.47)           (0.45)         (11.29)         5.19           (0.56)         (11.57)         4.72           -         -         -           -         (1.80)         -           \$ 14.19         \$ 14.75         \$ 28.12           \$ (1.80)         -         -           -         (1.80)         -           \$ 14.19         \$ 14.75         \$ 28.12           \$ 13.80)%         (43.23)%         20.179           \$ 89,079         \$ 108,988         \$ 267,800           1.98%         1.93%         1.909           1.98%         1.93%         1.909           (1.57)%         (1.57)%         (1.70)%	ended 4/30/2023 <sup>(0)</sup> Year ended 10/31/2022         Year ended 10/31/2021           \$ 14.75         \$ 28.12         \$ 23.40           (0.11)         (0.28)         (0.47)           (0.45)         (11.29)         5.19           (0.56)         (11.57)         4.72           -         -         -           -         (1.80)         -           \$ 14.19         \$ 14.75         \$ 28.12           \$ 3.80)%         (43.23)%         20.17%           \$ 89,079         \$ 108,988         \$ 267,800           \$ 1.98%         1.93%         1.90%           (1.57)%         (1.57)%         (1.70)%	ended 4/30/2023 <sup>(0)</sup> Year ended 10/31/2022         Year ended 10/31/2021         Year ended 10/31/2020         Year ended 10/31/2020           \$ 14.75         \$ 28.12         \$ 23.40         \$ 17.85           (0.11)         (0.28)         (0.47)         (0.37)           (0.45)         (11.29)         5.19         6.30           (0.56)         (11.57)         4.72         5.93           -         -         -         (0.08)           -         (1.80)         -         (0.30)           \$ 14.19         \$ 14.75         \$ 28.12         \$ 23.40           (3.80)%         (43.23)%         20.17%         33.85%           \$ 89,079         \$ 108,988         \$ 267,800         \$ 248,577           1.98%         1.93%         1.90%         1.94%           1.98%         1.93%         1.90%         1.94%           (1.57)%         (1.57)%         (1.70)%         (1.83)%	ended 4/30/2023 <sup>(0)</sup> Year ended 10/31/2021         Year ended 10/31/2021         Year ended 10/31/2020         Year ended 10/30         Year ended 10/30         Year ended 10/30         Year ended 10/30         Year ended 10/30         Year ended 10/30	ended 4/30/2023 <sup>(0)</sup> Year ended 10/31/2021         Year ended 10/31/2021         Year ended 10/31/2020         Year ended 10/31/2019         Year ended 10/31/2019	ended 4/30/2023 <sup>(0)</sup> Year ended 10/31/2021         Year ended 10/31/2021         Year ended 10/31/2020         Year ended 10/31/2019         Year ended 10/31/2019

<sup>(</sup>ii) Amount was computed based on average shares outstanding during the period.

<sup>(</sup>iii) Does not reflect the effect of sales charges, if applicable.

Alger Small Cap Focus Fund					Cla	ass	s I				
	Six months ended //30/2023 <sup>(1)</sup>		/ear ended 0/31/2022		Year ended		Year ended 10/31/2020		Year ended 10/31/2019		'ear ended 0/31/2018
Net asset value, beginning of period	\$ 17.44	\$	32.61	\$	26.93	\$	20.44	\$	19.34	\$	15.28
INCOME FROM INVESTMENT OPERATIONS:											
Net investment loss(ii)	(0.06)		(0.18)		(0.31)		(0.24)		(0.19)		(0.17)
Net realized and unrealized gain (loss) on investments	(0.54)		(12.10)		F 00		7.22		1.44		4.37
	(0.54)		(13.19)		5.99						
Total from investment operations	(0.60)		(13.37)		5.68		6.98		1.25		4.20
Dividends from net investment income	-		-		-		(0.19)		-		-
Distributions from net realized gains	-		(1.80)		-		(0.30)		(0.15)		(0.14)
Net asset value, end of period	\$ 16.84	\$	17.44	\$	32.61	\$	26.93	\$	20.44	\$	19.34
Total return <sup>(iii)</sup>	(3.44)%	, 0	(42.77)%	6	21.09%	6	34.86%	b	6.58%	6	27.77%
RATIOS/SUPPLEMENTAL DATA: Net assets, end of period (000's omitted)	\$ 91,595	\$	144,513	\$	421,986	\$	360,756	\$	455,937	\$	340,636
Ratio of gross expenses to average net assets	1.19%	/ 0	1.18%	6	1.14%	6	1.15%	b	1.18%	6	1.17%
Ratio of net expenses to average net assets	1.19%	, 0	1.18%	6	1.14%	6	1.15%	Ď	1.18%	6	1.17%
Ratio of net investment loss to average net assets	(0.76)%	/ 0	(0.83)%	6	(0.95)%	6	(1.04)%	,	(0.93)%	6	(0.90)%
Portfolio turnover rate	26.08%		37.57%		56.71%		37.49%		48.84%		27.04%
See Notes to Einancial Statements									,		

<sup>0</sup> Ratios have been annualized; total return and portfolio turnover rate have not been annualized.

<sup>(ii)</sup> Amount was computed based on average shares outstanding during the period.

(iii) Does not reflect the effect of sales charges, if applicable.

Alger Small Cap Focus Fund						Cla	ass	Y				
	-	Six months ended //30/2023 <sup>(1)</sup>		(ear ended 10/31/2022		Year ended 10/31/2021		Year ended 10/31/2020		Year ended 10/31/2019		'ear ended 0/31/2018
Net asset value, beginning of period	\$	17.89	\$	33.29	\$	27.41	\$	20.79	\$	19.60	\$	15.44
INCOME FROM INVESTMENT OPERATIONS:												
Net investment loss(ii)		(0.04)		(0.09)		(0.21)		(0.18)		(0.14)		(0.12)
Net realized and unrealized gain (loss) on investments		(0.55)		(13.51)		6.09		7.36		1.48		4.42
Total from investment operations		(0.59)		(13.60)		5.88		7.18		1.34		4.30
Dividends from net investment income		-		-		-		(0.26)		-		-
Distributions from net realized gains		-		(1.80)		-		(0.30)		(0.15)		(0.14)
Net asset value, end of period	\$	17.30	\$	17.89	\$	33.29	\$	27.41	\$	20.79	\$	19.60
Total return <sup>(iii)</sup>		(3.30)%	, 0	(42.58)%	6	21.45%	6	35.32%	6	6.96%	6	28.13%
RATIOS/SUPPLEMENTAL DATA: Net assets, end of period (000's omitted)	\$	205,292	\$	257,064	\$	394,801	\$	266,570	\$	94,694	\$	25,691
Ratio of gross expenses to average net assets		0.88%	, 0	0.85%	6	0.83%	6	0.84%	6	0.87%	6	0.88%
Ratio of expense reimbursements to average net assets		(0.03)%	, 0		-		_	_(iv	v)	(0.02)%	6	_
Ratio of net expenses to average net assets		0.85%	, 0	0.85%	6	0.83%	6	0.84%	6	0.85%	6	0.88%
Ratio of net investment loss to average net assets		(0.45)%	, 0	(0.46)%	6	(0.65)%	6	(0.74)%	6	(0.64)%	6	(0.63)%
Portfolio turnover rate		26.08%	, 0	37.57%	6	56.71%	6	37.49%	6	48.84%	6	27.04%

<sup>(0)</sup> Ratios have been annualized; total return and portfolio turnover rate have not been annualized.

<sup>(ii)</sup> Amount was computed based on average shares outstanding during the period.

(iii) Does not reflect the effect of sales charges, if applicable.

(iv) Amount was more than (0.005)% per share.

- 128 -

Alger Small Cap Focus Fund						Cla	ass	Z				
	e	months ended 0/2023 <sup>(i)</sup>		'ear ended 0/31/2022		Year ended 10/31/2021		Year ended 10/31/2020		Year ended 10/31/2019		ear ended 0/31/2018
Net asset value, beginning of period	\$	17.88	\$	33.29	\$	27.41	\$	20.79	\$	19.60	\$	15.44
INCOME FROM INVESTMENT OPERATIONS:												
Net investment loss(ii)		(0.04)		(0.10)		(0.21)		(0.18)		(0.13)		(0.12)
Net realized and unrealized gain (loss) on investments		(0.54)		(13.51)		6.09		7.36		1.47		4.42
Total from investment operations		(0.58)		(13.61)		5.88		7.18		1.34		4.30
Dividends from net investment income		_		_		-		(0.26)		-		-
Distributions from net realized gains		-		(1.80)		-		(0.30)		(0.15)		(0.14)
Net asset value, end of period	\$	17.30	\$	17.88	\$	33.29	\$	27.41	\$	20.79	\$	19.60
Total return(iii)		(3.24)%	6	(42.61)%	6	21.45%	6	35.30%	6	6.96%	, D	28.13%
RATIOS/SUPPLEMENTAL DATA: Net assets, end of period (000's omitted)	\$ 1,6	33,942	\$2	2,192,139	\$	6,195,714	\$	4,499,832	\$	2,459,793	\$ 1	,329,712
Ratio of gross expenses to average net assets		0.86%	6	0.84%	6	0.83%	6	0.85%	6	0.86%	, D	0.87%
Ratio of net expenses to average net assets		0.86%	6	0.84%	6	0.83%	6	0.85%	6	0.86%	, D	0.87%
Ratio of net investment loss to average		(0.45)	,	(0.40)	,	(0.05)0	,	(0 7 1) 0	,	(0.00)0	,	(0.04)*(
net assets		(0.45)%		(0.49)%		(0.65)%		(0.74)%		(0.62)%		(0.61)%
Portfolio turnover rate		26.08%	6	37.57%	6	56.71%	6	37.49%	6	48.84%	D	27.04%

<sup>0</sup> Ratios have been annualized; total return and portfolio turnover rate have not been annualized.

(ii) Amount was computed based on average shares outstanding during the period.

(iii) Does not reflect the effect of sales charges, if applicable.

Alger International Focus Fund												
		Six months ended /30/2023		'ear ended 0/31/2022		/ear ended 10/31/2021		Year ended 10/31/2020		rear ended 10/31/2019		'ear ended 0/31/2018
Net asset value, beginning of period	\$	15.23	\$	25.12	\$	18.67	\$	15.51	\$	14.30	\$	17.58
INCOME FROM INVESTMENT OPERATIONS:												
Net investment income (loss)(ii)		(0.02)		(0.10)		(0.11)		(0.06)		(0.02)		0.06
Net realized and unrealized gain (loss) on investments		1.67		(7.82)		6.56		3.91		1.66		(2.46)
				( /								(2.46)
Total from investment operations		1.65		(7.92)		6.45		3.85		1.64		(2.40)
Dividends from net investment income		-		-		-		(0.69)		(0.43)		(0.88)
Distributions from net realized gains		-		(1.97)		-		-		-		-
Net asset value, end of period	\$	16.88	\$	15.23	\$	25.12	\$	18.67	\$	15.51	\$	14.30
Total return <sup>(iii)</sup>		10.83%	ó	(34.27)%	6	34.87% <sup>(ir</sup>	v)	25.69%	b	11.99%	6	(14.35)%
RATIOS/SUPPLEMENTAL DATA: Net assets, end of period (000's omitted)	\$	107,812	\$	100,262	\$	158,223	\$	120,832	\$	100,814	\$	98,105
Ratio of gross expenses to average net assets		1.29%	/ 0	1.27%	6	1.22%	6	1.34%	, D	1.37%	6	1.29%
Ratio of net expenses to average net assets		1.29%	, 0	1.27%	6	1.22%	6	1.34%	, D	1.37%	6	1.29%
Ratio of net investment income (loss) to average net assets		(0.30)%	, 0	(0.53)%	6	(0.49)%	6	(0.37)%	, D	(0.11)%	6	0.38%
Portfolio turnover rate		25.89%	6	49.36%	6	75.27%	6	105.22%	Ď	151.99%	6	207.22%
See Notes to Einancial Statements												

<sup>(6)</sup> Ratios have been annualized; total return and portfolio turnover rate have not been annualized.

(ii) Amount was computed based on average shares outstanding during the period.

<sup>(</sup>iii) Does not reflect the effect of sales charges, if applicable.

Alger International Focus Fund		Class B											
	-	ix months ended /30/2023 <sup>(i)</sup>		'ear ended 0/31/2022		Year ended 10/31/2021		Year ended 10/31/2020		Year ended 10/31/2019		/ear ended 10/31/2018	
Net asset value, beginning of period	\$	13.04	\$	21.81	\$	16.19	\$	13.44	\$	12.38	\$	15.35	
INCOME FROM INVESTMENT OPERATIONS:													
Net investment loss(ii)		(0.02)		(0.09)		(0.08)		(0.02)		(0.04)		(0.06)	
Net realized and unrealized gain (loss) on investments		1.44		(6.71)		5.70		3.38		1.44		(2.13)	
Total from investment operations		1.42		(6.80)		5.62		3.36		1.40		(2.19)	
Dividends from net investment income		-		-		-		(0.61)		(0.34)		(0.78)	
Distributions from net realized gains		-		(1.97)		-		-		-		-	
Net asset value, end of period	\$	14.46	\$	13.04	\$	21.81	\$	16.19	\$	13.44	\$	12.38	
Total return(iii)		10.89%	6	(34.30)%	6	35.02% <sup>(i</sup>	v)	25.83%	6	11.82%	6 0	(15.00)%	
RATIOS/SUPPLEMENTAL DATA: Net assets, end of period (000's													
omitted)	\$	13,841	\$	13,200	\$	22,147	\$	18,427	\$	17,646	\$	17,639	
Ratio of gross expenses to average net assets		1.98%	6	1.97%	6	1.94%	6	2.05%	6	2.09%	/ 0	2.01%	
Ratio of expense reimbursements to average net assets		(0.70)%	6	(0.69)%	6	(0.82)%	6	(0.88)%	6	(0.51)%	, 0	_	
Ratio of net expenses to average net assets		1.28%	6	1.28%	6	1.12%	6	1.17%	6	1.58%	, 0	2.01%	
Ratio of net investment loss to average net assets		(0.30)%	6	(0.54)%	6	(0.39)%	6	(0.18)%	6	(0.30)%	, 0	(0.40)%	
Portfolio turnover rate		25.89%	6	49.36%	6	75.27%	6	105.22%	6	151.99%	6	207.22%	

<sup>(0)</sup> Ratios have been annualized; total return and portfolio turnover rate have not been annualized.

- <sup>(ii)</sup> Amount was computed based on average shares outstanding during the period.
- (iii) Does not reflect the effect of sales charges, if applicable.

Alger International Focus Fund	Class C											
	-	ix months ended /30/2023 <sup>(i)</sup>		'ear ended 0/31/2022		/ear ended 10/31/2021		Year ended 10/31/2020		Year ended 10/31/2019		'ear ended 0/31/2018
Net asset value, beginning of period	\$	12.37	\$	20.94	\$	15.68	\$	13.11	\$	12.07	\$	14.98
INCOME FROM INVESTMENT OPERATIONS:												
Net investment loss(ii)		(0.08)		(0.22)		(0.24)		(0.15)		(0.12)		(0.06)
Net realized and unrealized gain (loss)		4 07		(0.20)		5 50		2.00		4 44		(2.00)
on investments		1.37		(6.38)		5.50		3.29		1.41		(2.09)
Total from investment operations		1.29		(6.60)		5.26		3.14		1.29		(2.15)
Dividends from net investment income		-		-		-		(0.57)		(0.25)		(0.76)
Distributions from net realized gains		-		(1.97)		-		-		-		-
Net asset value, end of period	\$	13.66	\$	12.37	\$	20.94	\$	15.68	\$	13.11	\$	12.07
Total return <sup>(iii)</sup>		10.43%	6	(34.82)%	6	33.86% <sup>(i</sup>	v)	24.68%	, 0	11.07%	, 0	(15.08)%
RATIOS/SUPPLEMENTAL DATA: Net assets, end of period (000's omitted)	\$	1,304	\$	1,594	\$	4,368	\$	2,760	\$	3,603	\$	4,712
Ratio of gross expenses to average net assets		2.10%	/ 0	2.09%	6	1.97%	6	2.13%	, 0	2.23%	, 0	2.09%
Ratio of net expenses to average net assets		2.10%	/ 0	2.09%	6	1.97%	6	2.13%	, 0	2.23%	, 0	2.09%
Ratio of net investment loss to average net assets		(1.15)%	/ 0	(1.40)%	6	(1.23)%	6	(1.13)%	, 0	(0.99)%	, 0	(0.41)%
Portfolio turnover rate		25.89%	, 0	49.36%	6	75.27%	6	105.22%	, 0	151.99%		207.22%
See Notes to Einspeial Statements												

<sup>(6)</sup> Ratios have been annualized; total return and portfolio turnover rate have not been annualized.

(ii) Amount was computed based on average shares outstanding during the period.

<sup>(</sup>iii) Does not reflect the effect of sales charges, if applicable.

Alger International Focus Fund		Class I											
		Six months ended 4/30/2023 <sup>(i)</sup>		Year ended 10/31/2022		Year ended 10/31/2021		Year ended 10/31/2020		Year ended 10/31/2019		/ear ended 0/31/2018	
Net asset value, beginning of period	\$	15.28	\$	25.20	\$	18.72	\$	15.54	\$	14.31	\$	17.54	
INCOME FROM INVESTMENT OPERATIONS:													
Net investment income (loss)(ii)		(0.02)		(0.08)		(0.10)		(0.02)		0.01		0.09	
Net realized and unrealized gain (loss)													
on investments		1.68		(7.87)		6.58		3.93		1.67		(2.48)	
Total from investment operations		1.66		(7.95)		6.48		3.91		1.68		(2.39)	
Dividends from net investment income		-		-		-		(0.73)		(0.45)		(0.84)	
Distributions from net realized gains		-		(1.97)		-		-		-		-	
Net asset value, end of period	\$	16.94	\$	15.28	\$	25.20	\$	18.72	\$	15.54	\$	14.31	
Total return <sup>(iii)</sup>		10.86%	6	(34.28)%	6	34.94% <sup>(i</sup>	v)	25.98%	6	12.41%	6	(14.27)%	
RATIOS/SUPPLEMENTAL DATA:													
Net assets, end of period (000's													
omitted)	\$	1,173	\$	1,061	\$	591	\$	642	\$	970	\$	2,156	
Ratio of gross expenses to average net assets		1.29%	6	1.30%	6	1.24%	6	1.34%	6	1.48%	6	1.19%	
Ratio of expense reimbursements to average net assets		(0.04)%	6	(0.05)%	6	(0.05)%	6	(0.27)%	6	(0.36)%	6	(0.04)%	
Ratio of net expenses to average net		(0.01)/	•	(0.00)/	0	(0.00)/	0	(0.21)/	•	(0.00)/	0	(0.01)/0	
assets		1.25%	6	1.25%	6	1.19%	6	1.07%	6	1.12%	6	1.15%	
Ratio of net investment income (loss) to	C												
average net assets		(0.27)%	6	(0.44)%	6	(0.45)%	6	(0.10)%	6	0.06%	6	0.51%	
Portfolio turnover rate		25.89%	6	49.36%	6	75.27%	6	105.22%	6	151.99%	6	207.22%	
See Notes to Einspeial Statements													

<sup>(0)</sup> Ratios have been annualized; total return and portfolio turnover rate have not been annualized.

- <sup>(ii)</sup> Amount was computed based on average shares outstanding during the period.
- (iii) Does not reflect the effect of sales charges, if applicable.

Alger International Focus Fund		Class Z											
	-	k months ended 30/2023 <sup>(i)</sup>		ear ended )/31/2022		Year ended 10/31/2021		Year ended 10/31/2020		'ear ended 0/31/2019		ear ended 0/31/2018	
Net asset value, beginning of period	\$	15.55	\$	25.52	\$	18.90	\$	15.69	\$	14.46	\$	17.77	
INCOME FROM INVESTMENT OPERATIONS:													
Net investment income (loss)(ii)		0.01		(0.02)		(0.03)		_(iii)		0.05		0.12	
Net realized and unrealized gain (loss)													
on investments		1.72		(7.98)		6.65		3.98		1.67		(2.48)	
Total from investment operations		1.73		(8.00)		6.62		3.98		1.72		(2.36)	
Dividends from net investment income		-		-		-		(0.77)		(0.49)		(0.95)	
Distributions from net realized gains		-		(1.97)		-		-		-		-	
Net asset value, end of period	\$	17.28	\$	15.55	\$	25.52	\$	18.90	\$	15.69	\$	14.46	
Total return <sup>(iv)</sup>		11.13%	6	(34.03)%	6	35.34%	V)	26.23%	)	12.64%	, 0	(14.03)%	
RATIOS/SUPPLEMENTAL DATA: Net assets, end of period (000's													
	\$	16,522	\$	14,528	\$	28,264	\$	12,621	\$	13,462	\$	14,597	
Ratio of gross expenses to average net assets		0.96%	6	0.95%	6	0.92%	6	1.02%	)	1.10%	, 0	1.01%	
Ratio of expense reimbursements to average net assets		(0.12)%	6	(0.09)%	6	(0.03)%	6	(0.13)%	5	(0.21)%	/ 0	(0.12)%	
Ratio of net expenses to average net													
assets		0.84%	6	0.86%	6	0.89%	6	0.89%	)	0.89%	0	0.89%	
Ratio of net investment income (loss) to average net assets	)	0.15%	6	(0.13)%	6	(0.13)%	6	0.01%	5	0.36%	/ 0	0.71%	
Portfolio turnover rate		25.89%	6	49.36%	6	75.27%	6	105.22%	)	151.99%	6	207.22%	

<sup>(i)</sup> Ratios have been annualized; total return and portfolio turnover rate have not been annualized.

(ii) Amount was computed based on average shares outstanding during the period.

(iii) Amount was less than \$0.005 per share.

(iv) Does not reflect the effect of sales charges, if applicable.

Alger Health Sciences Fund					Cla	ass	A				
	Six months ended /30/2023 <sup>(1)</sup>		'ear ended 0/31/2022		'ear ended 0/31/2021		rear ended 10/31/2020		rear ended 10/31/2019		'ear ended 0/31/2018
Net asset value, beginning of period INCOME FROM INVESTMENT OPERATIONS:	\$ 20.85	\$	36.66	\$	31.75	\$	26.55	\$	28.04	\$	25.16
Net investment loss <sup>(ii)</sup> Net realized and unrealized gain (loss)	(0.05)		(0.07)		(0.21)		(0.09)		(0.09)		(0.19)
on investments	0.08		(8.74)		8.87		7.20		0.48		3.82
Total from investment operations	0.03		(8.81)		8.66		7.11		0.39		3.63
Distributions from net realized gains	-		(7.00)		(3.75)		(1.91)		(1.88)		(0.75)
Net asset value, end of period	\$ 20.88	\$	20.85	\$	36.66	\$	31.75	\$	26.55	\$	28.04
Total return(iii)	0.14%	, 0	(27.31)%	6	29.12% <sup>(i</sup>	v)	28.09%	ó	1.96%	, 0	14.92%
RATIOS/SUPPLEMENTAL DATA: Net assets, end of period (000's omitted)	\$ 83,832	\$	91,059	\$	151,514	\$	127,925	\$	108,095	\$	131,731
Ratio of gross expenses to average net assets	1.09%	/ 0	1.05%	6	1.00%	6	1.04%	, 0	1.12%	/ 0	1.15%
Ratio of net expenses to average net assets	1.09%	, 0	1.05%	6	1.00%	6	1.04%	, 0	1.12%	, 0	1.15%
Ratio of net investment loss to average net assets	(0.53)%	, 0	(0.30)%	6	(0.63)%	6	(0.30)%	, D	(0.34)%	/ 0	(0.68)%
Portfolio turnover rate	128.72%	, 0	240.89%	6	152.78%	6	131.29%	, 0	148.78%	, 0	89.73%
See Notes to Einspeiel Statements											

<sup>(i)</sup> Ratios have been annualized; total return and portfolio turnover rate have not been annualized.

<sup>(ii)</sup> Amount was computed based on average shares outstanding during the period.

(iii) Does not reflect the effect of sales charges, if applicable.

Alger Health Sciences Fund					Cla	iss	С				
	ix months ended /30/2023 <sup>(i)</sup>		'ear ended 0/31/2022		(ear ended 10/31/2021		Year ended 10/31/2020		Year ended 10/31/2019		ear ended 0/31/2018
Net asset value, beginning of period INCOME FROM INVESTMENT OPERATIONS:	\$ 13.08	\$	26.11	\$	23.74	\$	20.44	\$	22.21	\$	20.23
Net investment loss <sup>(ii)</sup> Net realized and unrealized gain (loss)	(0.09)		(0.16)		(0.34)		(0.23)		(0.23)		(0.31)
on investments	0.05		(5.87)		6.46		5.44		0.34		3.04
Total from investment operations	(0.04)		(6.03)		6.12		5.21		0.11		2.73
Distributions from net realized gains	-		(7.00)		(3.75)		(1.91)		(1.88)		(0.75)
Net asset value, end of period	\$ 13.04	\$	13.08	\$	26.11	\$	23.74	\$	20.44	\$	22.21
Total return <sup>(iii)</sup>	(0.31)%	Ď	(27.85)%	, 0	28.11% <sup>(i</sup>	v)	27.12%	6	1.20%	, 0	14.03%
RATIOS/SUPPLEMENTAL DATA: Net assets, end of period (000's omitted)	\$ 7,154	\$	7,828	\$	14,334	\$	11,862	\$	10,963	\$	15,322
Ratio of gross expenses to average net assets	1.88%	, D	1.84%	, 0	1.76%	6	1.81%	6	1.89%	/ 0	1.93%
Ratio of net expenses to average net assets	1.88%	, D	1.84%	, 0	1.76%	6	1.81%	6	1.89%	/ 0	1.93%
Ratio of net investment loss to average net assets	(1.33)%	, D	(1.10)%	, 0	(1.39)%	6	(1.07)%	6	(1.12)%	/ 0	(1.46)%
Portfolio turnover rate	128.72%	b	240.89%	ó	152.78%	6	131.29%	6	148.78%	, 0	89.73%
See Notes to Einspeiel Statements											

<sup>(i)</sup> Ratios have been annualized; total return and portfolio turnover rate have not been annualized.

<sup>(ii)</sup> Amount was computed based on average shares outstanding during the period.

(iii) Does not reflect the effect of sales charges, if applicable.

<sup>(</sup>ii) Pursuant to the U.S. Securities and Exchange Commission's Rules on Fair Fund and Disgorgement Plans, the Alger Health Sciences Fund received a Fair Fund distribution of \$179,832, which contributed approximately 0.07% to its annual return. - 136 -

Alger Health Sciences Fund		Class Z										
	-	ended /30/2023 <sup>(i)</sup>		'ear ended 0/31/2022		Year ended 10/31/2021		Year ended 10/31/2020		Year ended 10/31/2019		/ear ended 10/31/2018
Net asset value, beginning of period	\$	21.24	\$	37.09	\$	31.99	\$	26.69	\$	28.09	\$	25.11
INCOME FROM INVESTMENT OPERATIONS:												
Net investment income (loss)(ii)		(0.02)		_(iii)		(0.11)		_(iii)		0.01		(0.09)
Net realized and unrealized gain (loss)												
on investments		0.08		(8.85)		8.96		7.25		0.47		3.82
Total from investment operations		0.06		(8.85)		8.85		7.25		0.48		3.73
Dividends from net investment income		-		-		-		(0.04)		-		-
Distributions from net realized gains		-		(7.00)		(3.75)		(1.91)		(1.88)		(0.75)
Net asset value, end of period	\$	21.30	\$	21.24	\$	37.09	\$	31.99	\$	26.69	\$	28.09
Total return <sup>(iv)</sup>		0.28%	6	(27.05)%	6	29.53%(	v)	28.50%	6	2.34%	, 0	15.32%
RATIOS/SUPPLEMENTAL DATA:												
Net assets, end of period (000's												
omitted)	\$	62,191	\$	78,928	\$	184,972	\$	131,109	\$	77,023	\$	57,640
Ratio of gross expenses to average net assets		0.75%	6	0.72%	6	0.68%	6	0.71%	6	0.79%	6	0.84%
Ratio of expense reimbursements to average net assets		-	-		_	-	_	-	_	(0.04)%	/ 0	(0.06)%
Ratio of net expenses to average net assets		0.75%	6	0.72%	6	0.68%	6	0.71%	6	0.75%	/ 0	0.78%
Ratio of net investment income (loss) to average net assets	C	(0.20)%	6	0.01%	6	(0.31)%	6	(0.01)%	6	0.02%	, 0	(0.32)%
Portfolio turnover rate		128.72%		240.89%	6	152.78%		131.29%		148.78%	, 0	89.73%
See Notes to Einspeiel Statements												

<sup>(i)</sup> Ratios have been annualized; total return and portfolio turnover rate have not been annualized.

(ii) Amount was computed based on average shares outstanding during the period.

(iii) Amount was less than \$0.005 per share.

(iv) Does not reflect the effect of sales charges, if applicable.

### THE ALGER FUNDS NOTES TO FINANCIAL STATEMENTS (Unaudited)

# NOTE 1 — General:

The Alger Funds (the "Trust") is an open-end registered investment company organized as a business trust under the laws of the Commonwealth of Massachusetts. The Trust qualifies as an investment company as defined in Financial Accounting Standards Board ("FASB") Accounting Standards Codification 946-Financial Services - Investment Companies. The Trust operates as a series company currently offering an unlimited number of shares of beneficial interest in ten series - Alger Capital Appreciation Fund, Alger 35 Fund, Alger Growth & Income Fund, Alger Mid Cap Growth Fund, Alger Mid Cap Focus Fund, Alger Weatherbie Specialized Growth Fund, Alger Small Cap Growth Fund, Alger Small Cap Focus Fund, Alger International Focus Fund and Alger Health Sciences Fund (collectively, the "Funds" or individually, each a "Fund"). Alger Capital Appreciation Fund, Alger 35 Fund, Alger Mid Cap Growth Fund, Alger Mid Cap Focus Fund, Alger Weatherbie Specialized Growth Fund, Alger Small Cap Growth Fund, Alger Small Cap Focus Fund, Alger International Focus Fund and Alger Health Sciences Fund normally invest primarily in equity securities and each has an investment objective of long-term capital appreciation. Alger Growth & Income Fund also normally invests primarily in equity securities and has an investment objective of both capital appreciation and current income.

Each Fund offers one or more of the following share classes: Class A, B, C, I, Y and Z. Class A shares are generally subject to an initial sales charge while Class B and C shares are generally subject to a deferred sales charge. Class B shares will automatically convert to Class A shares eight years after the end of the calendar month in which the order to purchase was accepted. The conversion is completed without the imposition of any sales charges or other fees. Class C shares will automatically convert to Class A shares on the fifth business day of the month following the eighth anniversary of the purchase date of a shareholder's Class C shares, without the imposition of any sales load, fee or other charge. Class B and C shares held at certain dealers may not convert to Class A shares or may be converted on a different schedule. At conversion, a proportionate amount of shares representing reinvested dividends and distributions will also be converted into Class A shares. Effective August 27, 2019, Class C shares were closed to direct shareholders and are only available for purchase through certain financial intermediaries and group retirement plan recordkeeping platforms. Class I, Y and Z shares are generally sold to institutional investors and are sold without an initial or deferred sales charge. Class Y and Z shares are generally subject to a minimum initial investment of \$500,000. Each class has identical rights to assets and earnings, except that each share class bears the pro rata allocation of the Fund's expenses other than a class expense (not including advisory or custodial fees or other expenses related to the management of the Fund's assets).

Class Y shares of Alger Small Cap Growth Fund launched on December 31, 2021.

# NOTE 2 — Significant Accounting Policies:

(a) Investment Valuation: The Funds value their financial instruments at fair value using independent dealers or pricing services under policies approved by the Board of Trustees of the Trust (the "Board"). Investments held by the Funds are valued on each day the New

York Stock Exchange (the "NYSE") is open, as of the close of the NYSE (normally 4:00 p.m. Eastern Time).

The Board has designated, pursuant to Rule 2a-5 under the Investment Company Act of 1940, as amended (the "1940 Act"), the Funds' investment adviser, Fred Alger Management, LLC ("Alger Management" or the "Investment Manager") as its valuation designee (the "Valuation Designee") to make fair value determinations subject to the Board's review and oversight. The Valuation Designee has established a Valuation Committee ("Committee") comprised of representatives of the Investment Manager and officers of the Funds to assist in performing the duties and responsibilities of the Valuation Designee.

The Valuation Designee has established valuation processes including but not limited to: (i) making fair value determinations when market quotations for financial instruments are not readily available in accordance with valuation policies and procedures adopted by the Board; (ii) assessing and managing material risks associated with fair valuation determinations; (iii) selecting, applying and testing fair valuation methodologies; and (iv) overseeing and evaluating pricing services used by the Funds. The Valuation Designee regularly reports its fair valuation determinations and related valuation information to the Board. The Committee generally meets quarterly and on an as-needed basis to review and evaluate the effectiveness of the valuation policies and procedures in accordance with the requirements of Rule 2a-5.

Investments in money market funds and short-term securities held by the Funds having a remaining maturity of sixty days or less are valued at amortized cost which approximates market value.

Equity securities, including traded rights, warrants and option contracts for which valuation information is readily available, are valued at the last quoted sales price or official closing price on the primary market or exchange on which they are traded as reported by an independent pricing service. In the absence of quoted sales, such securities are generally valued at the bid price or, in the absence of a recent bid price, the equivalent as obtained from one or more of the major market makers for the securities to be valued.

Securities in which the Funds invest may be traded in foreign markets that close before the close of the NYSE. Developments that occur between the close of the foreign markets and the close of the NYSE may result in adjustments to the closing foreign prices to reflect what the Valuation Designee, through its Committee, believes to be the fair value of these securities as of the close of the NYSE. The Funds may also fair value securities in other situations, for example, when a particular foreign market is closed but the Funds are open.

FASB Accounting Standards Codification 820 – Fair Value Measurements and Disclosures ("ASC 820") defines fair value as the price that the Funds would receive upon selling an investment in a timely transaction to an independent buyer in the principal or most advantageous market of the investment. ASC 820 established a three-tier hierarchy to maximize the use of observable market data and minimize the use of unobservable inputs and to establish classification of fair value measurements for disclosure purposes. Inputs refer broadly to the assumptions that market participants would use in pricing the asset or

liability and may be observable or unobservable. Observable inputs are based on market data obtained from sources independent of the Funds. Unobservable inputs are inputs that reflect the Funds' own assumptions based on the best information available in the circumstances. The three-tier hierarchy of inputs is summarized in the three broad Levels listed below.

- Level 1 quoted prices in active markets for identical investments
- Level 2 significant other observable inputs (including quoted prices for similar investments, amortized cost, interest rates, prepayment speeds, credit risk, etc.)
- Level 3 significant unobservable inputs (including the Funds' own assumptions in determining the fair value of investments)

The Funds' valuation techniques are generally consistent with either the market or the income approach to fair value. The market approach considers prices and other relevant information generated by market transactions involving identical or comparable assets to measure fair value. The income approach converts future amounts to a current, or discounted, single amount. These fair value measurements are determined on the basis of the value indicated by current market expectations about such future events. Inputs for Level 1 include exchange-listed prices and broker quotes in an active market. Inputs for Level 2 include the last trade price in the case of a halted security, an exchange-listed price which has been adjusted for fair value factors, and prices of closely related securities. Additional Level 2 inputs include an evaluated price which is based upon a compilation of observable market information such as spreads for fixed income and preferred securities. Inputs for Level 3 include, but are not limited to, revenue multiples, earnings before interest, taxes, depreciation and amortization ("EBITDA") multiples, discount rates, time to exit and the probabilities of success of certain outcomes. Such unobservable market information may be obtained from a company's financial statements and from industry studies, market data, and market indicators such as benchmarks and indexes. Because of the inherent uncertainty and often limited markets for restricted securities, the valuations assigned to such securities by the Funds may significantly differ from the valuations that would have been assigned by the Funds had there been an active market for such securities.

(b) Cash and Cash Equivalents: Cash and cash equivalents include U.S. dollars, foreign cash and overnight time deposits.

(c) Securities Transactions and Investment Income: Securities transactions are recorded on a trade date basis. Realized gains and losses from securities transactions are recorded on the identified cost basis. Dividend income is recognized on the ex-dividend date and interest income is recognized on the accrual basis.

Premiums and discounts on debt securities purchased are amortized or accreted over the lives of the respective securities.

(d) Foreign Currency Transactions: The books and records of the Funds are maintained in U.S. dollars. Foreign currencies, investments and other assets and liabilities are translated into U.S. dollars at the prevailing rates of exchange on the valuation date. Purchases and sales

of investment securities and income and expenses are translated into U.S. dollars at the prevailing exchange rates on the respective dates of such transactions.

Net realized gains and losses on foreign currency transactions represent net gains and losses from the disposition of foreign currencies, currency gains and losses realized between the trade dates and settlement dates of security transactions, and the difference between the amount of net investment income accrued and the U.S. dollar amount actually received. The effects of changes in foreign currency exchange rates on investments in securities are included in realized and unrealized gain or loss on investments in the accompanying Statements of Operations.

(e) Forward Foreign Exchange Contracts: Certain Funds may enter into forward foreign currency contracts to hedge against foreign currency exchange rate risk on their non-U.S. dollar denominated securities or to facilitate settlement of foreign currency denominated portfolio transactions. A forward foreign currency contract is an agreement between two parties to buy and sell a currency at a set price on a future date. The contract is marked-to-market daily and the change in value is recorded by a Fund as an unrealized gain or loss. Realized gains or losses equal to the difference between the value of the contract at the time it was opened and the value at the time it was closed are recorded upon delivery or receipt of the currency.

These contracts may involve market risk in excess of the unrealized gain or loss reflected on the Statements of Assets and Liabilities. In addition, the Funds could be exposed to risk if the counterparties are unable to meet the terms of the contracts or if the value of the currency changes unfavorably to the base currency.

(f) Lending of Fund Securities: The Funds may lend their securities to financial institutions, provided that the market value of the securities loaned will not at any time exceed one third of a Fund's total assets including borrowings, as defined in its prospectuses. The Funds earn fees on the securities loaned, which are included in interest income in the accompanying Statements of Operations. In order to protect against the risk of failure by the borrower to return the securities loaned or any delay in the delivery of such securities, the loan is collateralized by cash or securities that are maintained with Brown Brothers Harriman & Company, the Funds' custodian (the "Custodian"), in an amount equal to at least 102 percent of the current market value of U.S. loaned securities or 105 percent for non-U.S. loaned securities. The market value of the loaned securities is determined at the close of business of the Funds. Any required additional collateral is delivered to the Custodian each day and any excess collateral is returned to the borrower on the next business day. In the event the borrower fails to return the loaned securities when due, the Funds may take the collateral to replace the securities. If the value of the collateral is less than the purchase cost of replacement securities, the Custodian shall be responsible for any shortfall, but only to the extent that the shortfall is not due to any diminution in collateral value, as defined in the securities lending agreement. The Funds are required to maintain the collateral in a segregated account and determine its value each day until the loaned securities are returned. Cash collateral may be invested as determined by the Funds. Collateral is returned to the borrower upon settlement of the loan. There were no securities loaned as of April 30, 2023.

### THE ALGER FUNDS NOTES TO FINANCIAL STATEMENTS (Unaudited) (Continued)

(g) Dividends to Shareholders: Dividends and distributions payable to shareholders are recorded by the Funds on the ex-dividend date. The Funds declare and pay dividends from net investment income, if available, annually except that Alger Growth & Income Fund declares and pays such dividends quarterly. With respect to all Funds, dividends from net realized gains, offset by any loss carryforward, are declared and paid annually after the end of the fiscal year in which earned.

Each share class is treated separately in determining the amount of dividends from net investment income payable to holders of its shares.

The characterization of distributions to shareholders for financial reporting purposes is determined in accordance with federal income tax rules. Therefore, the source of a Fund's distributions may be shown in the accompanying financial statements as either from, or in excess of, net investment income, net realized gain on investment transactions, or return of capital, depending on the type of book/tax differences that may exist. Capital accounts within the financial statements are adjusted for permanent book/tax differences. Reclassifications result primarily from the differences in tax treatment of net operating losses, passive foreign investment companies, and foreign currency transactions. The reclassifications are done annually at year-end and have no impact on the net asset values of the Funds and are designed to present each Fund's capital accounts on a tax basis.

(b) Federal Income Taxes: It is each Fund's policy to comply with the requirements of the Internal Revenue Code Subchapter M applicable to regulated investment companies and to distribute all of its taxable income to its shareholders. Provided that the Funds maintain such compliance, no federal income tax provision is required. Each Fund is treated as a separate entity for the purpose of determining such compliance.

FASB Accounting Standards Codification 740 – Income Taxes ("ASC 740") requires the Funds to measure and recognize in their financial statements the benefit of a tax position taken (or expected to be taken) on an income tax return if such position will more likely than not be sustained upon examination based on the technical merits of the position. No tax years are currently under investigation. The Funds file income tax returns in the U.S. Federal jurisdiction, as well as the New York State and New York City jurisdictions. The statute of limitations on the Funds' tax returns remains open for the tax years 2019-2022. Management does not believe there are any uncertain tax positions that require recognition of a tax liability.

(*i*) *Allocation Methods:* The Trust accounts separately for the assets, liabilities and operations of each Fund. Expenses directly attributable to each Fund are charged to that Fund's operations; expenses which are applicable to all Funds are allocated among them based on net assets. Income, realized and unrealized gains and losses, and expenses of each Fund are allocated among the Fund's classes based on relative net assets, with the exception of distribution fees, transfer agency fees, and shareholder servicing and related fees.

*(j) Estimates:* These financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America, which require using estimates and assumptions that affect the reported amounts therein. These unaudited interim financial

statements reflect all adjustments that are, in the opinion of management, necessary to present a fair statement of results for the interim period. Actual results may differ from those estimates. All such estimates are of a normal recurring nature.

# NOTE 3 — Investment Advisory Fees and Other Transactions with Affiliates:

(a) Investment Advisory Fees: Fees incurred by each Fund, pursuant to the provisions of the Trust's Investment Advisory Agreement with the Investment Manager, are payable monthly and computed based on the following rates. The actual rate paid as a percentage of average daily net assets, for the six months ended April 30, 2023, is set forth below under the heading "Actual Rate":

	Tier 1	Tier 2	Tier 3	Tier 4	Tier 5	Actual Rate
Alger Capital Appreciation						
Fund <sup>(a)</sup>	0.81%	0.65%	0.60%	0.55%	0.45%	0.81%
Alger 35 Fund <sup>(b)</sup>	0.45	_	_		_	0.45
Alger Growth & Income Fund <sup>(b)</sup>	0.50	_	_	_	_	0.50
Alger Mid Cap Growth Fund <sup>(c)</sup>	0.76	0.70	_	_	_	0.76
Alger Mid Cap Focus Fund <sup>(d)</sup>	0.70	0.50	_	_	_	0.63
Alger Weatherbie Specialized Growth Fund <sup>(c)</sup>	0.81	0.75	_	_	_	0.81
Alger Small Cap Growth Fund <sup>(c)</sup>	0.81	0.75	_	_	_	0.81
Alger Small Cap Focus Fund <sup>(b)</sup>	0.75	_	_	_	_	0.75
Alger International Focus Fund <sup>(c)</sup>	0.71	0.60	_	_	_	0.71
Alger Health Sciences Fund <sup>(b)</sup>	0.55	_	_	_	_	0.55

<sup>(9)</sup> Tier 1 rate is paid on assets up to \$2 billion, Tier 2 rate is paid on assets between \$2 billion and \$3 billion, Tier 3 rate is paid on assets between \$3 billion and \$4 billion, Tier 4 rate is paid on assets between \$4 billion and \$5 billion, and Tier 5 rate is paid on assets in excess of \$5 billion.

<sup>(b)</sup> Tier 1 rate is paid on all assets.

<sup>(e)</sup> Tier 1 rate is paid on assets up to \$1 billion and Tier 2 rate is paid on assets in excess of \$1 billion.

<sup>(d)</sup> Tier 1 rate is paid on assets up to \$250 million, and Tier 2 rate is paid on assets in excess of \$250 million.

The sub-adviser to the Alger Weatherbie Specialized Growth Fund, Weatherbie Capital, LLC ("Weatherbie" or the "Sub-Adviser"), an affiliate of Alger Management, is paid a fee from the advisory fee that Alger Management receives at no additional cost to the Alger Weatherbie Specialized Growth Fund. The sub-advisory fee is equal to 70% of the net management fee paid by the Alger Weatherbie Specialized Growth Fund to Alger Management with respect to the sub-advisory fee of \$1,981,560 for the Alger Weatherbie Specialized Growth Fund to Weatherbie.

Alger Management has contractually agreed to waive and/or reimburse Fund expenses (excluding custody fees, acquired fund fees and expenses, dividend expense on short sales, net borrowing costs, interest, taxes, brokerage and extraordinary expenses, to the extent applicable) through February 28, 2025 to the extent necessary to limit other expenses and any other applicable share class-specific expenses to the rates, based on average daily net assets, as listed in the table below.

Prior to April 1, 2023, Alger Management had contractually agreed to waive and/or reimburse Fund expenses (excluding acquired fund fees and expenses, dividend expense on short sales, borrowing costs, interest, taxes, brokerage and extraordinary expenses, if applicable) for certain Funds in order for the total annual fund operating expenses to not exceed certain rates, based on average net assets.

			CLASS			REIME FOR	NAIVED / BURSED THE SIX IS ENDED
	А	С	<u> </u>	Y	Z	APRIL	30, 2023
Alger Capital Appreciation Fund	-	-	-	-	0.04% <sup>(a)</sup>	\$	283,270
Alger Mid Cap Growth Fund	-	-	-	-	0.23 <sup>(b)</sup>		-
Alger Mid Cap Focus Fund	0.53% <sup>(c)</sup>	1.28% <sup>(c)</sup>	0.58% <sup>(c)</sup>	0.07% <sup>(c)</sup>	0.37 <sup>(c)</sup>		225
Alger Weatherbie Specialized Growth							
Fund	-	-	-	0.07 <sup>(d)</sup>	-		16,163
Alger Small Cap Growth Fund	-	-	-	0.03 <sup>(e)</sup>	0.18 <sup>(e)</sup>		5,025
Alger Small Cap Focus Fund	-	-	-	0.10 <sup>(f)</sup>	-		30,498
Alger International Focus Fund	_	_	0.54 <sup>(g)</sup>	-	0.13 <sup>(g)</sup>		9,227
Alger Health Sciences Fund	_	-	-	_	0.20 <sup>(h)</sup>		-

<sup>(a)</sup> Prior to April 1, 2023, total annual fund operating expenses for Alger Capital Appreciation Fund, Class Z shares, could not exceed 0.85%.

<sup>(h)</sup> Prior to April 1, 2023, total annual fund operating expenses for Alger Mid Cap Growth Fund, Class Z shares, could not exceed 0.99%.

<sup>(6)</sup> Prior to April 1, 2023, total annual fund operating expenses for Alger Mid Cap Focus Fund, Class A, C, I, Y and Z shares, could not exceed 1.15%, 1.90%, 1.20%, 0.69% and 0.99%, respectively.

<sup>(9)</sup> Prior to April 1, 2023, total annual fund operating expenses for Alger Weatherbie Specialized Growth Fund, Class Y shares, could not exceed 0.87%.

<sup>(9)</sup> Prior to April 1, 2023, total annual fund operating expenses for Alger Small Cap Growth Fund, Class Y and Z shares, could not exceed 0.84% and 0.99%, respectively.

<sup>(9)</sup> Prior to April 1, 2023, total annual fund operating expenses for Alger Small Cap Focus Fund, Class Y shares, could not exceed 0.85%.

<sup>(e)</sup> Prior to April 1, 2023, total annual fund operating expenses for Alger International Focus Fund, Class I and Z shares, could not exceed 1.25% and 0.84%, respectively.

<sup>(6)</sup> Prior to April 1, 2023, total annual fund operating expenses for Alger Health Sciences Fund, Class Z shares, could not exceed 0.75%.

Alger Management may recoup any fees waived or expenses reimbursed pursuant to the contract; however, a Fund will only make repayments to the Investment Manager if such repayment does not cause a Fund's expense ratio after the repayment is taken into account, to exceed both (i) the expense cap in place at the time such amounts were waived or reimbursed, and (ii) a Fund's current expense cap. Such recoupment is limited to two years from the date the amount is initially waived or reimbursed. For the period ended April 30,

2023, the recoupment made by the Alger Small Cap Focus Fund to the Investment Manager was \$2,468.

Alger Management has also agreed to limit expenses of the Class Z shares of Alger 35 Fund, for the life of the Fund, whereby it reimburses expenses to the extent Fund operating expenses, excluding advisory fees, exceed 0.10%, based on average daily net assets. The expense reimbursement arrangement does not include interest, taxes, brokerage, dividend expense on short sales, borrowing costs and extraordinary expenses. Fees waived for the Alger 35 Fund were \$46,171 for the six months ended April 30, 2023.

In addition, Alger Management voluntarily reduced its 12b-1 fee effective April 1, 2019, for the Class B shares of the Alger Mid Cap Growth Fund, Alger Small Cap Growth Fund and Alger International Focus Fund by \$34,392, \$8,522 and \$48,011, respectively, for the six months ended April 30, 2023.

(b) Administration Fees: Fees incurred by each Fund, pursuant to the provisions of the Trust's Fund Administration Agreement with Alger Management, are payable monthly and computed based on the average daily net assets of each Fund at the annual rate of 0.0275%.

## (c) Distribution Fees:

*Class A Shares:* The Trust has adopted a Plan of Distribution pursuant to which each Fund pays Fred Alger & Company, LLC, each Fund's distributor (the "Distributor" or "Alger LLC") a fee at the annual rate of 0.25% of the respective average daily net assets of the Class A shares of the designated Fund to compensate Alger LLC for its activities and expenses incurred in distributing and/or administering the Class A shares and/or shareholder servicing. The fees paid may be more or less than the expenses incurred by Alger LLC.

*Class B Shares:* The Trust has adopted a Plan of Distribution pursuant to which Class B shares of each Fund issuing such shares reimburse Alger LLC for costs and expenses incurred by Alger LLC in connection with advertising, marketing and selling the Class B shares, and shareholder servicing, not to exceed an annual rate of 1% of the respective average daily net assets of the Class B shares of the designated Fund. If in any month, the costs incurred by Alger LLC relating to the Class B shares are in excess of the distribution fees charged to the Class B shares of the Fund, the excess may be carried forward, with interest, and sought to be reimbursed in future periods. As of April 30, 2023, such excess carried forward was \$12,939,746, \$20,407,519 and \$20,171,619 for Class B shares of Alger Mid Cap Growth Fund, Alger Small Cap Growth Fund and Alger International Focus Fund, respectively. Contingent deferred sales charges imposed on redemptions of Class B shares will reduce the amount of distribution expenses for which reimbursement may be sought. See Note 3(d) below.

*Class C Shares:* The Trust has adopted a Distribution Plan pursuant to which Class C shares of each Fund pays Alger LLC a fee at the annual rate of 1% of the respective average daily net assets of the Class C shares of the designated Fund to compensate Alger LLC for its activities and expenses incurred in distributing the Class C shares and/or shareholder servicing. Fees paid may be more or less than the expenses incurred by Alger LLC.

*Class I Shares:* The Trust has adopted a Distribution Plan pursuant to which Class I shares of each Fund issuing such shares pays Alger LLC a fee at the annual rate of 0.25% of the average daily net assets of the Fund's Class I shares to compensate Alger LLC for its activities and expenses incurred in distributing the Class I shares and/or shareholder servicing. Fees paid may be more or less than the expenses incurred by Alger LLC.

(d) Sales Charges: Sales of shares of the Funds may be subject to contingent deferred sales charges. The contingent deferred sales charges are used by Alger LLC to offset distribution expenses previously incurred. Sales charges do not represent expenses of the Trust. For the six months ended April 30, 2023, contingent deferred sales charges imposed, all of which were retained by Alger LLC, were as follows:

	CONTINGENT DEFERRED SALES CHARGES				
Alger Capital Appreciation Fund	\$ 1,186				
Alger Growth & Income Fund	819				
Alger Mid Cap Growth Fund	281				
Alger Mid Cap Focus Fund	115				
Alger Weatherbie Specialized Growth Fund	3,013				
Alger Small Cap Growth Fund	1,793				
Alger Small Cap Focus Fund	1,789				
Alger International Focus Fund	1,254				
Alger Health Sciences Fund	881				

(e) Brokerage Commissions: During the six months ended April 30, 2023, Alger Capital Appreciation Fund, Alger 35 Fund, Alger Growth & Income Fund, Alger Mid Cap Growth Fund, Alger Mid Cap Focus Fund, Alger Small Cap Growth Fund, Alger Small Cap Focus Fund, Alger International Focus Fund and Alger Health Sciences Fund paid Alger LLC, \$168,493, \$10,016, \$556, \$6,250, \$107,340, \$45,724, \$159,906, \$11,648 and \$39,061, respectively, in connection with securities transactions.

(f) Shareholder Administrative Fees: The Trust has entered into a Shareholder Administrative Services Agreement with Alger Management to compensate Alger Management for liaising with, and providing administrative oversight of, the Trust's transfer agent, and for other related services. The Funds compensate Alger Management at the annual rate of 0.0165% of their respective average daily net assets for the Class A, Class B and Class C shares and 0.01% of their respective average daily net assets for the Class I, Class Y and Class Z shares for these services.

Alger Management makes payments to intermediaries that provide sub-accounting services to omnibus accounts invested in the Funds. A portion of the fees paid by Alger Management to intermediaries that provide sub-accounting services are charged back to the appropriate Fund, subject to certain limitations, as approved by the Board. For the six months ended April 30, 2023, Alger Management charged back to Alger Capital Appreciation Fund, Alger Growth & Income Fund, Alger Mid Cap Growth Fund, Alger Mid Cap Focus Fund, Alger Weatherbie Specialized Growth Fund, Alger Small Cap Growth Fund, Alger Small Cap -146-

Focus Fund, Alger International Focus Fund and Alger Health Sciences Fund \$290,004, \$26,993, \$22,037, \$9,300, \$64,755, \$36,303, \$364,182, \$12,275 and \$26,077, respectively, for these services, which are included in transfer agent fees in the accompanying Statements of Operations.

(g) Trustee Fees: Each trustee who is not an "interested person" of the Trust, as defined in the 1940 Act ("Independent Trustee"), receives a fee of \$156,000 per annum, paid pro rata based on net assets by each fund in the Alger Fund Complex, plus travel expenses incurred for attending board meetings. The term "Alger Fund Complex" refers to the Trust, The Alger Institutional Funds, The Alger Funds II, The Alger Portfolios, Alger Global Focus Fund and The Alger ETF Trust, each of which is a registered investment company managed by Alger Management. The Independent Trustee appointed as Chairman of the Board receives additional compensation of \$22,000 per annum paid pro rata based on net assets by each fund in the Alger Fund Complex. Additionally, each member of the Audit Committee receives a fee of \$13,000 per annum, paid pro rata based on net assets by each fund in the Alger Fund Complex.

The Board has adopted a policy requiring Trustees to receive a minimum of 10% of their annual compensation in shares of one or more of the funds in the Alger Fund Complex.

(b) Interfund Trades: The Funds may engage in purchase and sale transactions with other funds advised by Alger Management or sub-advised by Weatherbie. For the six months ended April 30, 2023, these purchases and sales were as follows:

	PURCHASES	SALES	REALIZED GAIN (LOSS)
Alger Mid Cap Focus Fund	\$ –	\$ 1,806,412	\$ 245,273
Alger Small Cap Growth Fund	2,417,616	-	-
Alger Small Cap Focus Fund	1,806,412	5,079,448	(7,847,525)

(*i*) Interfund Loans: The Funds, along with other funds in the Alger Fund Complex, may borrow money from and lend money to each other for temporary or emergency purposes with the exception of the Alger International Focus Fund, which can only borrow for temporary or emergency purposes. To the extent permitted under its investment restrictions, each Fund may lend uninvested cash in an amount up to 15% of its net assets to other funds in the Alger Fund Complex. If a Fund has borrowed from other funds in the Alger Fund Complex and has aggregate borrowings from all sources that exceed 10% of the Fund's total assets, such Fund will secure all of its loans from other funds in the Alger Fund Complex. The interest rate charged on interfund loans is equal to the average of the overnight time deposit rate and bank loan rate available to the Funds. There were no interfund loans outstanding as of April 30, 2023.

During the six months ended April 30, 2023, Alger Capital Appreciation Fund and Alger Small Cap Focus Fund earned interfund loan interest income of \$1,242 and \$11,977, respectively, and Alger Capital Appreciation Fund, Alger 35 Fund, Alger Mid Cap Growth Fund, Alger Mid Cap Focus Fund, Alger Small Cap Growth Fund, Alger Small Cap Focus Fund and Alger Health Sciences Fund incurred interfund loan interest expenses of \$221,

\$726, \$237, \$9,961, \$948, \$32,851 and \$462, respectively, which are included in interest income and interest expenses, respectively, in the accompanying Statements of Operations.

(j) Other Transactions with Affiliates: Certain officers and one Trustee of the Trust are directors and/or officers of Alger Management, the Distributor (the "Distributor" or "Alger LLC"), or their affiliates. At April 30, 2023, Alger Management and its affiliated entities owned the following shares:

	SHARE CLASS							
	Α	В	С		Y	Z		
Alger Capital Appreciation Fund	77,161	_	—	_	_	39,620		
Alger 35 Fund	—	—	—	—	_ `	1,593,347		
Alger Growth & Income Fund	—	_	_	_	_	32,315		
Alger Mid Cap Growth Fund	_	_	_	_	_	139,187		
Alger Mid Cap Focus Fund	_	_	_	100,035	4,843	927,860		
Alger Weatherbie Specialized Growth Fund	187,751	_	_	_	10,066	185		
Alger Small Cap Growth Fund	71,040	_	_	_	36,127	106,938		
Alger Small Cap Focus Fund	_	_	_	_	787	310,266		
Alger International Focus Fund	_	_	_	_	_	85,519		

## NOTE 4 — Securities Transactions:

The following summarizes the securities transactions by each Fund, other than U.S. Government securities, short-term securities and forward foreign currency contracts, for the six months ended April 30, 2023:

	PURCHASES	SALES
Alger Capital Appreciation Fund	\$ 968,093,103	\$ 1,175,540,404
Alger 35 Fund	39,574,689	40,084,444
Alger Growth & Income Fund	47,595,653	5,551,451
Alger Mid Cap Growth Fund	88,842,503	89,034,610
Alger Mid Cap Focus Fund	305,980,144	389,444,364
Alger Weatherbie Specialized Growth Fund	138,593,328	240,294,731
Alger Small Cap Growth Fund	41,800,030	64,082,470
Alger Small Cap Focus Fund	646,324,803	1,252,611,638
Alger International Focus Fund	35,132,311	42,794,936
Alger Health Sciences Fund	208,673,042	229,571,779

# NOTE 5 — Borrowing:

The Funds may borrow from the Custodian on an uncommitted basis. Each Fund pays the Custodian a market rate of interest, generally based upon a rate of return with respect to each respective currency borrowed, taking into consideration relevant overnight and short-term reference rates and the range of distribution between and among the interest rates paid on deposits to other institutions, less applicable commissions, if any. Borrowings from the Custodian are included in Bank overdrafts in the Statements of Assets and Liabilities. The Funds may also borrow from other funds in the Alger Fund Complex, as discussed in Note 3(i). For the six months ended April 30, 2023, the Funds had the following borrowings from the Custodian and other funds in the Alger Fund Complex:

	 ERAGE DAILY Orrowing	WEIGHTED AVERAGE INTEREST RATE	
Alger Capital Appreciation Fund	\$ 9,711	4.87%	
Alger 35 Fund	50,445	5.99	
Alger Growth & Income Fund	137	5.91	
Alger Mid Cap Growth Fund	9,902	5.36	
Alger Mid Cap Focus Fund	395,574	5.08	
Alger Weatherbie Specialized Growth Fund	\$ 239	5.92%	
Alger Small Cap Growth Fund	37,794	5.09	
Alger Small Cap Focus Fund	1,343,478	4.94	
Alger International Focus Fund	276	5.90	
Alger Health Sciences Fund	28,555	5.80	

The highest amount borrowed from the Custodian and other funds in the Alger Fund Complex during the six months ended April 30, 2023 by each Fund was as follows:

	HIGHEST BORROWING
Alger Capital Appreciation Fund	\$ 1,039,000
Alger 35 Fund	561,067
Alger Growth & Income Fund	8,281
Alger Mid Cap Growth Fund	1,027,000
Alger Mid Cap Focus Fund	27,329,000
Alger Weatherbie Specialized Growth Fund	14,420
Alger Small Cap Growth Fund	1,108,000
Alger Small Cap Focus Fund	22,988,000
Alger International Focus Fund	22,760
Alger Health Sciences Fund	1,855,000

#### NOTE 6 — Share Capital:

The Trust has an unlimited number of authorized shares of beneficial interest of \$.001 par value which are presently divided into ten series. Each series is divided into separate classes. During the six months ended April 30, 2023, and the year ended October 31, 2022, transactions of shares of beneficial interest were as follows:

		FOR THE SIX MONTHS ENDED APRIL 30, 2023				R ENDED 1, 2022
	SHARES		AMOUNT	SHARES		AMOUNT
Alger Capital Appreciation Fund						
Class A:						
Shares sold	2,102,945	\$	42,381,224	6,000,142	\$	160,613,838
Shares converted from Class C	34,716		700,867	78,399		2,165,868
Dividends reinvested	1,253,214		24,437,672	7,597,941		236,675,867
Shares redeemed	(5,273,687)		(107,304,307)	(14,983,247)		(385,940,345)
Net increase (decrease)	(1,882,812)	\$	(39,784,544)	(1,306,765)	\$	13,515,228
Class C:						
Shares sold	303,150	\$	3,594,335	917,381	\$	14,823,256
Shares converted to Class A	(58,665)		(700,867)	(126,672)		(2,165,868)
Dividends reinvested	464,915		5,355,816	2,637,277		50,292,867
Shares redeemed	(1,913,309)		(23,182,703)	(3,969,807)		(67,501,761)
Net decrease	(1,203,909)	\$	(14,933,419)	(541,821)	\$	(4,551,506)
Class Z:						
Shares sold	2,951,007	\$	63,604,108	8.886,657	\$	247,659,419
Dividends reinvested	1,308,238	Ť	27,316,002	7,554,946	Ť	250,370,897
Shares redeemed	(9,589,453)		(210,326,783)	(14,251,217)		(384,129,235)
Net increase (decrease)	(5,330,208)	\$	(119,406,673)	2,190,386	\$	113,901,081
Alger 35 Fund Class Z:	64 211	¢	602 706	40.255	¢	497.004
Shares sold	64,211	\$	623,786	-,	\$	487,994
Dividends reinvested	216		1,955	747,267		10,551,417
Shares redeemed Net increase (decrease)	(122,292) (57,865)	¢	(1,162,194) (536,453)	(136,944) 650,578	\$	(1,414,466) 9.624.945
Net increase (decrease)	(57,005)	φ	(550,455)	050,576	φ	9,024,945
Alger Growth & Income Fund						
Class A:						
Shares sold	300,532	\$	16,304,219	515,271	\$	29,459,291
Shares converted from Class C	1,534		84,965	3,410		186,340
Dividends reinvested	14,299		761,954	71,532		4,322,564
Shares redeemed	(206,501)		(11,243,400)	(249,872)		(14,016,272)
Net increase	109,864	\$	5,907,738	340,341	\$	19,951,923
Class C:						
Shares sold	108,939	\$	5,762,084	180,118	\$	9,975,860
Shares converted to Class A	(1,560)		(84,965)	(3,467)		(186,340)
Dividends reinvested	1,593		83,551	11,180		673,395
Shares redeemed	(77,963)		(4,155,506)	(77,010)		(4,282,374)
Net increase	31,009	\$	1,605,164	110,821	\$	6,180,541
Class Z:						
Shares sold	1,171,467	\$	63,675,319	1,892,410	\$	104,985,589
Dividends reinvested	21,609		1,151,810	34,141		2,015,228
Shares redeemed	(513,127)		(27,811,719)	(342,836)		(18,637,053)
Net increase	679,949	\$	37,015,410	1,583,715	\$	88,363,764

	FOR THE SIX M APRIL 3		FOR THE YEA OCTOBER 3	
	SHARES	AMOUNT	SHARES	AMOUNT
Alger Mid Cap Growth Fund				
Class A:				
Shares sold	172,609	\$ 1,880,253	914,935 \$	12,779,301
Shares converted from Class B	7,851	86,849	39,929	499,789
Shares converted from Class C	9,505	102,725	4,455	62,406
Dividends reinvested	_	_	3,949,371	62,202,597
Shares redeemed	(870,693)	(9,549,802	) (1,662,534)	(23,061,302)
Net increase (decrease)	(680,728)	\$ (7,479,975	3,246,156 \$	52,482,791
Class B:				
Shares sold	30,087	\$ 209,249	306,507 \$	2,429,187
Shares converted to Class A	(12,533)	(86,849	) (63,092)	(499,789)
Dividends reinvested	_		648,341	6,399,126
Shares redeemed	(77,653)	(525,464	) (338,973)	(3,167,198)
Net increase (decrease)	(60,099)	\$ (403,064	) 552,783 \$	5,161,326
Class C:				
Shares sold	16,461	\$ 104,254	129,451 \$	1,156,792
Shares converted to Class A	(16,257)	(102,725	) (7,374)	(62,406)
Dividends reinvested	_		312,841	2,906,295
Shares redeemed	(117,809)	(753,287	) (177,595)	(1,518,832)
Net increase (decrease)	(117,605)	\$ (751,758	) 257,323 \$	2,481,849
Class Z:				
Shares sold	237,215	\$ 2,717,528	1,467,938 \$	24,776,780
Dividends reinvested	_	_	730,556	11,835,012
Shares redeemed	(598,598)	(6,690,132	) (1,511,602)	(20,451,267)
Net increase (decrease)	(361,383)	\$ (3,972,604	686,892 \$	16,160,525

	FOR THE SIX N APRIL		FOR THE YEAR ENDED OCTOBER 31, 2022			
	SHARES	SHARES AMOUNT		SHARES		AMOUNT
Alger Mid Cap Focus Fund						
Class A:						
Shares sold	150,042	\$	1,785,774	437,847	\$	6,471,602
Dividends reinvested	_		_	12,508		226,140
Shares redeemed	(116,324)		(1,405,341)	(102,747)		(1,441,325)
Net increase	33,718	\$	380,433	347,608	\$	5,256,417
Class C:						
Shares sold	76,501	\$	892,828	205,863	\$	3,441,176
Dividends reinvested	_		_	12,103		218,218
Shares redeemed	(54,212)		(635,861)	(114,553)		(1,735,186)
Net increase	22,289	\$	256,967	103,413	\$	1,924,208
Class I:						
Shares sold	193,844	\$	2,313,624	1,024,323	\$	17,245,006
Dividends reinvested	_		_	678,515		12,274,336
Shares redeemed	(3,675,352)		(43,865,643)	(2,767,242)		(41,627,861)
Net decrease	(3,481,508)	\$	(41,552,019)	(1,064,404)	\$	(12,108,519)
Class Y:*						
Shares sold	2,319	\$	27,630	30,243	\$	420,561
Dividends reinvested	_		_	116		2,107
Shares redeemed	(21,248)		(256,386)	(9)		(87)
Net increase (decrease)	(18,929)	\$	(228,756)	30,350	\$	422,581
Class Z:						
Shares sold	3,823,741	\$	45,649,005	13,358,332	\$	215,931,807
Dividends reinvested	_		_	3,770,479		68,698,120
Shares redeemed	(7,160,522)		(85,884,142)	(21,026,998)		(316,016,051)
Net decrease	(3,336,781)	\$	(40,235,137)	(3,898,187)	\$	(31,386,124)

	FOR THE SIX M APRIL			FOR THE YEAR ENDED OCTOBER 31, 2022			
	SHARES		AMOUNT	SHARES	AMOUNT		
Alger Weatherbie Specialized Growth	Fund						
Class A:							
Shares sold	540,727	\$	6,199,204	2,207,109 \$	31,475,922		
Shares converted from Class C	2,343		26,487	10,193	195,953		
Dividends reinvested	_		_	2,355,077	40,837,032		
Shares redeemed	(1,477,175)		(16,877,034)	(4,618,177)	(63,575,231)		
Net increase (decrease)	(934,105)	\$	(10,651,343)	(45,798) \$	8,933,676		
Class C:							
Shares sold	298,157	\$	1,841,777	1,004,246 \$	8,908,341		
Shares converted to Class A	(4,320)		(26,487)	(17,106)	(195,953)		
Dividends reinvested	_		_	2,635,295	24,982,600		
Shares redeemed	(1,225,119)		(7,590,966)	(2,980,283)	(23,986,101)		
Net increase (decrease)	(931,282)	\$	(5,775,676)	642,152 \$	9,708,887		
Class I:							
Shares sold	86,348	\$	1,039,284	430,300 \$	7,169,370		
Dividends reinvested	_		_	505,518	9,079,102		
Shares redeemed	(311,075)		(3,690,637)	(1,472,639)	(21,152,563)		
Net decrease	(224,727)	\$	(2,651,353)	(536,821) \$	(4,904,091)		
Class Y:							
Shares sold	524,622	\$	6,273,472	2,793,770 \$	42,898,361		
Dividends reinvested	· _		· · · —	343,618	6,305,382		
Shares redeemed	(634,555)		(7,629,132)	(1,624,371)	(22,901,364)		
Net increase (decrease)	(109,933)	\$	(1,355,660)	1,513,017 \$	( ; ; )		
Class Z:							
Shares sold	6,013,033	\$	76,530,108	25,026,249 \$	397.063.874		
Dividends reinvested		,		9,047,802	171,998,722		
Shares redeemed	(12,571,000)		(157,817,485)	(39,559,633)	(605,958,139)		
Net decrease	(6,557,967)	\$	(81,287,377)	(5,485,582) \$	( , , , ,		

	FOR THE SIX M	 	FOR THE YEA	
	SHARES	AMOUNT	SHARES	AMOUNT
Alger Small Cap Growth Fund				
Class A:				
Shares sold	579,472	\$ 4,969,154	2,219,196 \$	24,488,782
Shares converted from Class B	12,049	105,791	49,641	549,484
Shares converted from Class C	467	4,070	1,542	15,219
Dividends reinvested	_	_	1,565,131	20,221,493
Shares redeemed	(1,627,693)	(14,105,281)	(3,937,640)	(43,512,748)
Net increase (decrease)	(1,035,705)	\$ (9,026,266)	(102,130) \$	1,762,230
Class B:				
Shares sold	14,794	\$ 83,645	69,274 \$	489,107
Shares converted to Class A	(17,903)	(105,791)	(73,759)	(549,484)
Dividends reinvested	_	_	77,256	672,125
Shares redeemed	(70,664)	(409,137)	(71,673)	(579,243)
Net increase (decrease)	(73,773)	\$ (431,283)	1,098 \$	32,505
Class C:				
Shares sold	276,727	\$ 1,468,136	791,975 \$	5,337,182
Shares converted to Class A	(750)	(4,070)	(2,453)	(15,219)
Dividends reinvested	_	_	590,149	4,786,108
Shares redeemed	(754,579)	(4,045,942)	(1,186,581)	(7,903,372)
Net increase (decrease)	(478,602)	\$ (2,581,876)	193,090 \$	2,204,699
Class Y:**				
Shares sold	142,291	\$ 1,295,054	890,852 \$	8,643,853
Shares redeemed	(43,208)	(399,883)	(25,818)	(245,321)
Net increase	99,083	\$ 895,171	865,034 \$	8,398,532
Class Z:				
Shares sold	3,604,967	\$ 32,762,015	14,423,124 \$	162,619,241
Dividends reinvested	_	_	2,222,719	30,117,848
Shares redeemed	(7,164,047)	(65,847,449)	(16,204,110)	(179,137,817)
Net increase (decrease)	(3,559,080)	\$ (33,085,434)	441,733 \$	13,599,272

	FOR THE SIX M APRIL 3		FOR THE Y OCTOBE		
	SHARES	AMOUNT	SHARES		AMOUNT
Alger Small Cap Focus Fund					
Class A:					
Shares sold	901,394	\$ 14,580,231	2,079,038	\$	42,247,967
Shares converted from Class C	3,176	51,679	3,678		95,518
Dividends reinvested	_	_	1,045,786		26,134,180
Shares redeemed	(2,703,922)	(43,630,032)	(7,382,999)		(148,269,616)
Net decrease	(1,799,352)	\$ (28,998,122)	(4,254,497)	\$	(79,791,951)
Class C:					
Shares sold	195,587	\$ 2,749,455	361,903	\$	6,758,876
Shares converted to Class A	(3,643)	(51,679)	(4,175)		(95,518)
Dividends reinvested		_	669,148		14,661,031
Shares redeemed	(1,301,570)	(18,265,402)	(3,163,891)		(54,641,324)
Net decrease	(1,109,626)	\$ (15,567,626)	(2,137,015)	\$	(33,316,935)
Class I:					
Shares sold	1,491,996	\$ 24,576,037	2,388,085	\$	52,040,663
Dividends reinvested	_	_	817,179		21,017,843
Shares redeemed	(4,339,025)	(71,624,877)	(7,857,664)		(170,047,309)
Net decrease	(2,847,029)	\$ (47,048,840)	(4,652,400)	\$	(96,988,803)
Class Y:					
Shares sold	2,629,879	\$ 44,194,028	5,178,987	\$	111,652,914
Dividends reinvested	_	_	722,905		19,019,637
Shares redeemed	(5,135,787)	(89,192,057)	(3,388,609)		(72,320,606)
Net increase (decrease)	(2,505,908)	\$ (44,998,029)	2,513,283	\$	58,351,945
Class Z:					
Shares sold	10,675,726	\$ 183,174,303	53,012,266	\$	1,149,885,044
Dividends reinvested		· · · –	10,465,710		275,248,186
Shares redeemed	(38,785,403)	(664,523,244)	(127,025,685)	(	2,664,182,027)
Net decrease	(28,109,677)	\$ (481,348,941)	(63,547,709)	\$(	1,239,048,797)

	FOR THE SIX M APRIL	 	FOR THE YEA	
	SHARES	AMOUNT	SHARES	AMOUNT
Alger International Focus Fund				
Class A:				
Shares sold	83,541	\$ 1,382,214	272,542 \$	5,095,123
Shares converted from Class B	4,084	67,442	11,100	214,147
Shares converted from Class C	656	10,816	2,157	41,626
Dividends reinvested	_	_	517,441	11,740,747
Shares redeemed	(286,827)	(4,734,507)	(517,683)	(9,704,917)
Net increase (decrease)	(198,546)	\$ (3,274,035)	285,557 \$	7,386,726
Class B:				
Shares sold	5,456	\$ 77,979	10,257 \$	145,522
Shares converted to Class A	(4,768)	(67,442)	(12,932)	(214,147)
Dividends reinvested	_	_	99,778	1,938,691
Shares redeemed	(55,666)	(786,797)	(100,637)	(1,753,746)
Net increase (decrease)	(54,978)	\$ (776,260)	(3,534) \$	116,320
Class C:				
Shares sold	8,305	\$ 111,555	14,352 \$	245,440
Shares converted to Class A	(810)	(10,816)	(2,638)	(41,626)
Dividends reinvested	_	_	21,218	393,811
Shares redeemed	(40,921)	(547,077)	(112,626)	(1,705,231)
Net decrease	(33,426)	\$ (446,338)	(79,694) \$	(1,107,606)
Class I:				
Shares sold	2,265	\$ 37,740	64,844 \$	1,462,329
Dividends reinvested	_	_	2,147	48,866
Shares redeemed	(2,485)	(41,160)	(20,997)	(391,454)
Net increase (decrease)	(220)	\$ (3,420)	45,994 \$	1,119,741
Class Z:				
Shares sold	145,778	\$ 2,476,118	356,479 \$	6,998,893
Dividends reinvested	_	· · · —	90,502	2,089,682
Shares redeemed	(123,808)	(2,078,198)	(620,623)	(11,168,546)
Net increase (decrease)	21,970	\$ 397,920	(173,642) \$	(2,079,971)

	FOR THE SIX M APRIL 3		FOR THE YEA OCTOBER 3	
	SHARES	AMOUNT	SHARES	AMOUNT
Alger Health Sciences Fund				
Class A:				
Shares sold	116,973	\$ 2,417,120	551,350 \$	12,970,639
Shares converted from Class C	1,217	24,929	7,202	167,019
Dividends reinvested	_	_	974,155	24,529,213
Shares redeemed	(470,336)	(9,715,487)	) (1,298,720)	(29,986,025)
Net increase (decrease)	(352,146)	\$ (7,273,438)	) 233,987 \$	7,680,846
Class C:				
Shares sold	39,886	\$ 524,266	69,406 \$	1,071,149
Shares converted to Class A	(1,943)	(24,929)	) (11,391)	(167,019)
Dividends reinvested	_	_	226,913	3,607,915
Shares redeemed	(88,103)	(1,141,783)	) (235,168)	(3,555,053)
Net increase (decrease)	(50,160)	\$ (642,446)	) 49,760 \$	956,992
Class Z:				
Shares sold	177,172	\$ 3,722,530	1,269,543 \$	31,739,077
Dividends reinvested	_	_	1,302,121	33,295,227
Shares redeemed	(974,218)	(20,454,526)	) (3,842,061)	(88,876,343)
Net decrease	(797,046)	\$ (16,731,996	) (1,270,397) \$	(23,842,039)

\*Inception date December 17, 2021.

\*\* Inception date December 31, 2021.

# NOTE 7 — Income Tax Information:

At October 31, 2022, the Alger 35 Fund, the Alger Growth & Income Fund, the Alger Mid Cap Growth Fund, the Alger Mid Cap Focus Fund, the Alger Weatherbie Specialized Growth Fund, the Alger Small Cap Growth Fund, the Alger Small Cap Focus Fund, the Alger International Focus Fund and the Alger Health Sciences Fund, for federal income tax purposes, had capital loss carryforwards of \$3,821,422, \$175,048, \$55,039,064, \$112,987,257, \$183,450,481, \$24,317,021, \$545,792,970, \$6,464,970 and \$43,177,529, respectively.

Under the Regulated Investment Company Modernization Act of 2010, capital losses incurred by the Funds will not be subject to expiration.

The difference between book-basis and tax-basis unrealized appreciation (depreciation) is determined annually and is attributable primarily to the tax deferral of losses on wash sales, U.S. Internal Revenue Code Section 988 currency transactions, nondeductible expenses on dividends sold short, the tax treatment of partnership investments, the realization of unrealized appreciation of passive foreign investment companies, and the return of capital from real estate investment trust investments.

The Funds accrue tax on unrealized gains in foreign jurisdictions that impose a foreign capital tax.

#### NOTE 8 — Fair Value Measurements:

The following is a summary of the inputs used as of April 30, 2023 in valuing the Funds' investments carried at fair value on a recurring basis. Based upon the nature, characteristics, and risks associated with their investments, the Funds have determined that presenting them by security type and sector is appropriate.

Alger Capital Appreciation Fund	TOTAL	LEVEL 1	LEVEL 2	LEVEL 3
COMMON STOCKS				
Communication Services	\$ 172,224,590	\$ 172,224,590	\$ _	\$ _
Consumer Discretionary	293,379,487	253,968,446	39,411,041	_
Energy	62,643,104	62,643,104		_
Financials	132,394,267	132,394,267	_	_
Healthcare	275,938,163	275,938,163	_	_
Industrials	118,152,140	118,152,140	_	_
Information Technology	616,142,367	616,142,367	_	_
Materials	35,071,958	35,071,958	_	_
TOTAL COMMON STOCKS	\$ 1,705,946,076	\$ 1,666,535,035	\$ 39,411,041	\$ 
PREFERRED STOCKS				
Information Technology	1,197,441	_	_	1,197,441
SPECIAL PURPOSE VEHICLE				
Information Technology	2,896,878	_	_	2,896,878
TOTAL INVESTMENTS IN				
SECURITIES	\$ 1,710,040,395	\$ 1,666,535,035	\$ 39,411,041	\$ 4,094,319

 847,227	-
 847,227	-
847,227	
	-
_	
_	-
_	-
_	-
_	-
_	
847,227	\$.
	\$.
	847,227 847,227

Alger Growth & Income Fund		TOTAL	LEVEL 1	LEVEL 2	LEVEL 3
COMMON STOCKS					
Communication Services	\$	26,741,639	\$ 26,741,639	\$ — \$	_
Consumer Discretionary		21,481,452	21,481,452	_	_
Consumer Staples		22,668,753	22,668,753	_	_
Energy		16,991,626	16,991,626	_	_
Financials		37,387,062	37,387,062	_	_
Healthcare		43,087,555	43,087,555	_	_
Industrials		18,621,595	18,621,595	_	_
Information Technology		84,156,062	84,156,062	_	_
Materials		7,784,449	7,784,449	_	_
Utilities		4,306,321	4,306,321	_	_
TOTAL COMMON STOCKS	\$	283,226,514	\$ 283,226,514	\$ — \$	
MASTER LIMITED PARTNERS	HIP				
Energy		1,605,974	1,605,974	_	_
REAL ESTATE INVESTMENT	FRUST				
Financials		1,229,485	1,229,485	_	_
Real Estate		10,543,597	10,543,597	_	_
TOTAL REAL ESTATE					
INVESTMENT TRUST	\$	11,773,082	\$ 11,773,082	\$ — \$	_
SHORT TERM INVESTMENTS					
U.S. Government		8,999,158	_	8,999,158	_
TOTAL INVESTMENTS IN					
SECURITIES	\$	305,604,728	\$ 296,605,570	\$ 8,999,158 \$	_

Alger Mid Cap Growth Fund	TOTAL	LEVEL 1	LEVEL 2		LEVEL 3
COMMON STOCKS					
Communication Services	8,253,011	8,253,011		_	—
Consumer Discretionary	27,117,767	27,117,767		_	-
Consumer Staples	1,959,731	1,959,731		_	_
Energy	7,176,061	7,176,061		_	—
Financials	8,932,823	8,932,823		_	—
Healthcare	34,868,210	34,868,210		_	—
Industrials	33,876,017	33,876,017		_	—
Information Technology	49,856,365	49,856,365		_	_
Materials	6,493,169	6,493,169		_	_
Real Estate	6,817,970	6,817,970		—	—
TOTAL COMMON STOCKS	\$ 185,351,124	\$ 185,351,124	\$	— \$	_
PREFERRED STOCKS					
Healthcare	_*	-		_	*
RIGHTS					
Healthcare	395,340	-		_	395,340
SPECIAL PURPOSE VEHICLE					
Information Technology	1,751,587	_		—	1,751,587
TOTAL INVESTMENTS IN					
SECURITIES	\$ 187,498,051	\$ 185,351,124	\$	— \$	2,146,927

Alger Mid Cap Focus Fund	TOTAL	LEVEL 1	LEVEL 2	LEVEL 3
COMMON STOCKS				
Communication Services	\$ 18,293,797	\$ 18,293,797	\$ _	\$ -
Consumer Discretionary	42,722,405	35,338,946	7,383,459	_
Energy	12,353,341	12,353,341	_	_
Financials	3,222,455	3,222,455	_	_
Healthcare	91,766,041	91,766,041	_	_
Industrials	37,764,699	37,764,699	_	_
Information Technology	130,242,394	130,242,394	_	_
Materials	4,106,339	4,106,339	_	_
TOTAL COMMON STOCKS	\$ 340,471,471	\$ 333,088,012	\$ 7,383,459	\$ _
TOTAL INVESTMENTS IN				
SECURITIES	\$ 340,471,471	\$ 333,088,012	\$ 7,383,459	\$ _

Alger Weatherbie Specialized				
Growth Fund	TOTAL	LEVEL 1	LEVEL 2	LEVEL 3
COMMON STOCKS				
Communication Services	1,691,000	1,691,000	_	_
Consumer Discretionary	72,115,087	72,115,087	_	_
Energy	37,906,748	37,906,748	_	_
Financials	70,689,452	70,689,452	_	_
Healthcare	158,322,478	155,336,268	_	2,986,210
Industrials	124,569,065	124,569,065	_	_
Information Technology	118,228,373	118,228,373	_	_
Real Estate	39,348,567	39,348,567	_	_
TOTAL COMMON STOCKS	\$ 622,870,770	\$ 619,884,560	\$ — \$	2,986,210
PREFERRED STOCKS				
Healthcare	_*	_	_	*
SHORT TERM INVESTMENTS				
U.S. Government	21,997,942	_	21,997,942	_
TOTAL INVESTMENTS IN				
SECURITIES	\$ 644,868,712	\$ 619,884,560	\$ 21,997,942 \$	2,986,210

Alger Small Cap Growth Fund		TOTAL	LEVEL 1	LEVEL 2	LEVEL 3
COMMON STOCKS					
Communication Services	\$	13,132,116	\$ 13,132,116	\$ — \$	_
Consumer Discretionary		37,966,876	37,966,876	_	_
Consumer Staples		20,445,510	20,445,510	_	_
Energy		19,942,241	19,942,241	_	_
Financials		7,688,331	7,688,331	_	_
Healthcare		102,332,997	98,685,999	_	3,646,998
Industrials		28,101,981	28,101,981	_	
Information Technology		88,382,522	88,382,522	_	_
Materials		8,939,536	8,939,536	_	_
TOTAL COMMON STOCKS	\$	326,932,110	\$ 323,285,112	\$ — \$	3,646,998
PREFERRED STOCKS					
Healthcare		_*	_	_	*
RIGHTS					
Healthcare		117,104	_	_	117,104
REAL ESTATE INVESTMENT T	RUST				
Real Estate		5,071,813	5,071,813	_	_
SPECIAL PURPOSE VEHICLE					
Information Technology		2,377,939	_	_	2,377,939
SHORT TERM INVESTMENTS					
U.S. Government		4,999,532	_	4,999,532	_
TOTAL INVESTMENTS IN					
SECURITIES	\$	339,498,498	\$ 328,356,925	\$ 4,999,532 \$	6,142,041

Alger Small Cap Focus Fund	TOTAL	LEVEL 1	LEVEL 2	LEVEL 3
COMMON STOCKS				
Consumer Discretionary	78,595,459	78,595,459	_	_
Consumer Staples	21,137,305	21,137,305	_	_
Energy	152,714,755	152,714,755	_	_
Healthcare	1,092,422,641	1,092,422,641	_	_
Industrials	204,988,599	204,988,599	_	_
Information Technology	612,829,375	612,829,375	_	_
TOTAL COMMON STOCKS	\$ 2,162,688,134	\$ 2,162,688,134	\$ _	\$ 
RIGHTS Healthcare SHORT TERM INVESTMENTS	7,976	_	_	7,976
U.S. Government	9,999,064	_	9,999,064	_
TOTAL INVESTMENTS IN SECURITIES	\$ 2,172,695,174	\$ 2,162,688,134	\$ 9,999,064	\$ 7,976

Alger International Focus Fund	TOTAL	LEVEL 1	LEVEL 2	LEVEL 3
COMMON STOCKS				
Consumer Discretionary	\$ 38,323,506	\$ 19,064,519	\$ 19,258,987	\$ _
Consumer Staples	7,590,693	_	7,590,693	_
Energy	8,372,655	3,720,990	4,651,665	_
Financials	24,595,758	9,728,592	14,867,166	_
Healthcare	24,417,545	2,616,528	21,801,017	_
Industrials	18,562,750	3,543,792	15,018,958	_
Information Technology	10,453,795	· · · —	10,453,795	_
Materials	2,803,664	_	2,803,664	_
TOTAL COMMON STOCKS	\$ 135,120,366	\$ 38,674,421	\$ 96,445,945	\$ 
TOTAL INVESTMENTS IN				
SECURITIES	\$ 135,120,366	\$ 38,674,421	\$ 96,445,945	\$ _
Alger Health Sciences Fund	TOTAL	LEVEL 1	LEVEL 2	LEVEL 3
COMMON STOCKS				
Healthcare	\$ 149,216,903	\$ 127,986,628	\$ 16,230,273	\$ 5,000,002
PREFERRED STOCKS				
Healthcare	*	_	_	*
RIGHTS				
Healthcare	1,311,187	_	_	1,311,187
TOTAL INVESTMENTS IN				
SECURITIES	\$ 150,528,090	\$ 127,986,628	\$ 16,230,273	\$ 6,311,189

\* Alger Mid Cap Growth Fund's, Alger Weatherbie Specialized Growth Fund's, Alger Small Cap Growth Fund's and Alger Health Sciences Fund's holdings of Prosetta Biosciences, Inc., Series D shares are classified as a Level 3 investment and are fair valued at zero as of April 30, 2023.

	MEAS USING UNOE	R VALUE SUREMENTS SIGNIFICANT SSERVABLE TS (LEVEL 3)
Alger Capital Appreciation Fund	Com	non Stocks
Opening balance at November 1, 2022	\$	444,301 <sup>(a)</sup>
Transfers into Level 3		_
Transfers out of Level 3		_
Total gains or losses		
Included in net realized gain (loss) on investments		(955,344)
Included in net change in unrealized appreciation (depreciation) on investments		1,446,392
Purchases and sales		
Purchases		_
Sales		(935,349)
Closing balance at April 30, 2023		_
Net change in unrealized appreciation (depreciation) attributable to investments		
still held at April 30, 2023**	\$	_

	MEAS USING UNOB INPUT	R VALUE UREMENTS SIGNIFICANT SERVABLE S (LEVEL 3)
Alger Capital Appreciation Fund		rred Stocks
Opening balance at November 1, 2022	\$	1,215,538
Transfers into Level 3		_
Transfers out of Level 3		_
Total gains or losses		
Included in net realized gain (loss) on investments		_
Included in net change in unrealized appreciation (depreciation) on investments		(18,097)
Purchases and sales		( , ,
Purchases		_
Sales		_
Closing balance at April 30, 2023		1,197,441
Net change in unrealized appreciation (depreciation) attributable to investments		1,107,441
still held at April 30, 2023**	\$	(18,097)
	Ŧ	(10,001)
	FAI	R VALUE
	MEAS	UREMENTS
	USING	SIGNIFICANT
	00110	
		SERVABLE
	UNOB	SERVABLE S (LEVEL 3)
	UNOB INPUT Speci	S (LEVEL 3) al Purpose
	UNOB INPUT Speci	S (LEVEL 3) al Purpose /ehicle
Opening balance at November 1, 2022	UNOB INPUT Speci	S (LEVEL 3) al Purpose
Opening balance at November 1, 2022 Transfers into Level 3	UNOB INPUT Speci	S (LEVEL 3) al Purpose /ehicle
Opening balance at November 1, 2022	UNOB INPUT Speci	S (LEVEL 3) al Purpose /ehicle
	UNOB INPUT Speci	S (LEVEL 3) al Purpose /ehicle
Opening balance at November 1, 2022 Transfers into Level 3 Transfers out of Level 3	UNOB INPUT Speci	S (LEVEL 3) al Purpose /ehicle
Opening balance at November 1, 2022 Transfers into Level 3 Transfers out of Level 3 Total gains or losses Included in net realized gain (loss) on investments	UNOB INPUT Speci	S (LEVEL 3) al Purpose /ehicle
Opening balance at November 1, 2022 Transfers into Level 3 Transfers out of Level 3 Total gains or losses	UNOB INPUT Speci	S (LEVEL 3) ial Purpose /ehicle 2,934,840 
Opening balance at November 1, 2022 Transfers into Level 3 Transfers out of Level 3 Total gains or losses Included in net realized gain (loss) on investments Included in net change in unrealized appreciation (depreciation) on investments Purchases and sales	UNOB INPUT Speci	S (LEVEL 3) ial Purpose /ehicle 2,934,840 
Opening balance at November 1, 2022 Transfers into Level 3 Transfers out of Level 3 Total gains or losses Included in net realized gain (loss) on investments Included in net change in unrealized appreciation (depreciation) on investments Purchases and sales Purchases	UNOB INPUT Speci	S (LEVEL 3) ial Purpose /ehicle 2,934,840 — —
Opening balance at November 1, 2022 Transfers into Level 3 Transfers out of Level 3 Total gains or losses Included in net realized gain (loss) on investments Included in net change in unrealized appreciation (depreciation) on investments Purchases and sales Purchases Sales	UNOB INPUT Speci	S (LEVEL 3) al Purpose /ehicle 2,934,840 
Opening balance at November 1, 2022 Transfers into Level 3 Transfers out of Level 3 Total gains or losses Included in net realized gain (loss) on investments Included in net change in unrealized appreciation (depreciation) on investments Purchases and sales Purchases	UNOB INPUT Speci	S (LEVEL 3) ial Purpose /ehicle 2,934,840 

	FAIR	VALUE
	MEASUF	REMENTS
	USING SIG	GNIFICANT
	UNOBSE	RVABLE
		(LEVEL 3)
Alasa Nid Can Ossuth Fund		· · · · ·
Alger Mid Cap Growth Fund		d Stocks
Opening balance at November 1, 2022	\$	*
Transfers into Level 3		_
Transfers out of Level 3		_
Total gains or losses		
Included in net realized gain (loss) on investments		_
Included in net change in unrealized appreciation (depreciation) on investments		—
Purchases and sales		
Purchases		_
Sales		_
Closing balance at April 30, 2023		*
Net change in unrealized appreciation (depreciation) attributable to investments		
still held at April 30, 2023**	\$	_
	Ψ	
	FAIR	VALUE
		REMENTS
		GNIFICANT
		RVABLE
	INPUTS (	(LEVEL 3)

	INPUT	S (LEVEL 3)
Alger Mid Cap Growth Fund	F	Rights
Opening balance at November 1, 2022	\$	354,035
Transfers into Level 3		_
Transfers out of Level 3		_
Total gains or losses		
Included in net realized gain (loss) on investments		_
Included in net change in unrealized appreciation (depreciation) on investments		41,305
Purchases and sales		
Purchases		_
Sales		_
Closing balance at April 30, 2023		395,340
Net change in unrealized appreciation (depreciation) attributable to investments		
still held at April 30, 2023**	\$	41,305

	MEAS USING UNOE INPUT	IR VALUE SUREMENTS SIGNIFICANT SSERVABLE IS (LEVEL 3) ial Purpose
Alger Mid Cap Growth Fund	• •	Vehicle
Opening balance at November 1, 2022	\$	1,775,546
Transfers into Level 3		—
Transfers out of Level 3		_
Total gains or losses		
Included in net realized gain (loss) on investments		—
Included in net change in unrealized appreciation (depreciation) on investments		(23,959)
Purchases and sales		
Purchases		
Sales		—
Closing balance at April 30, 2023		1,751,587
Net change in unrealized appreciation (depreciation) attributable to investments		
still held at April 30, 2023**	\$	(23,959)
	<b>F</b> A	IR VALUE
		SIGNIFICANT
		BSERVABLE
		S (LEVEL 3)
Alger Weatherbie Specialized Growth Fund		mon Stocks
Opening balance at November 1, 2022	\$	2,986,210
Transfers into Level 3	,	
Transfers out of Level 3		_
Total gains or losses		
Included in net realized gain (loss) on investments		_
Included in net change in unrealized appreciation (depreciation) on investments		_
Purchases and sales		
Purchases		_
Sales		_
Closing balance at April 30, 2023		2,986,210
Net change in unrealized appreciation (depreciation) attributable to investments		,,

Net change in unrealized appreciation (depreciation) attributable to investments still held at April 30, 2023\*\* \$ -

	MEAS USING UNOB INPUT	R VALUE UREMENTS SIGNIFICANT SERVABLE S (LEVEL 3)
Alger Weatherbie Specialized Growth Fund		rred Stocks
Opening balance at November 1, 2022	Prefe \$ ments nts \$ FAI	_^
Transfers into Level 3 Transfers out of Level 3		—
		_
Total gains or losses		
Included in net realized gain (loss) on investments		_
Included in net change in unrealized appreciation (depreciation) on investments		_
Purchases and sales		
Purchases		—
Sales		_
Closing balance at April 30, 2023		*
Net change in unrealized appreciation (depreciation) attributable to investments still held at April 30, 2023**	\$	_
	MEAS USING UNOB INPUT	R VALUE UREMENTS SIGNIFICANT SSERVABLE S (LEVEL 3)
Alger Small Cap Growth Fund	MEAS USING UNOB INPUT Comr	UREMENTS SIGNIFICANT SERVABLE S (LEVEL 3) non Stocks
Opening balance at November 1, 2022	MEAS USING UNOB INPUT	UREMENTS SIGNIFICANT SERVABLE S (LEVEL 3)
Opening balance at November 1, 2022 Transfers into Level 3	MEAS USING UNOB INPUT Comr	UREMENTS SIGNIFICANT SERVABLE S (LEVEL 3) non Stocks
Opening balance at November 1, 2022	MEAS USING UNOB INPUT Comr	UREMENTS SIGNIFICANT SERVABLE S (LEVEL 3) non Stocks
Opening balance at November 1, 2022 Transfers into Level 3 Transfers out of Level 3 Total gains or losses	MEAS USING UNOB INPUT Comr	UREMENTS SIGNIFICANT SERVABLE S (LEVEL 3) non Stocks
Opening balance at November 1, 2022 Transfers into Level 3 Transfers out of Level 3 Total gains or losses Included in net realized gain (loss) on investments	MEAS USING UNOB INPUT Comr	UREMENTS SIGNIFICANT SERVABLE S (LEVEL 3) non Stocks
Opening balance at November 1, 2022 Transfers into Level 3 Transfers out of Level 3 Total gains or losses	MEAS USING UNOB INPUT Comr	UREMENTS SIGNIFICANT SERVABLE S (LEVEL 3) non Stocks
Opening balance at November 1, 2022 Transfers into Level 3 Transfers out of Level 3 Total gains or losses Included in net realized gain (loss) on investments	MEAS USING UNOB INPUT Comr	UREMENTS SIGNIFICANT SERVABLE S (LEVEL 3) non Stocks
Opening balance at November 1, 2022 Transfers into Level 3 Transfers out of Level 3 Total gains or losses Included in net realized gain (loss) on investments Included in net change in unrealized appreciation (depreciation) on investments	MEAS USING UNOB INPUT Comr	UREMENTS SIGNIFICANT SERVABLE S (LEVEL 3) non Stocks
Opening balance at November 1, 2022 Transfers into Level 3 Transfers out of Level 3 Total gains or losses Included in net realized gain (loss) on investments Included in net change in unrealized appreciation (depreciation) on investments Purchases and sales	MEAS USING UNOB INPUT Comr	UREMENTS SIGNIFICANT SERVABLE S (LEVEL 3) non Stocks
Opening balance at November 1, 2022 Transfers into Level 3 Transfers out of Level 3 Total gains or losses Included in net realized gain (loss) on investments Included in net change in unrealized appreciation (depreciation) on investments Purchases and sales Purchases	MEAS USING UNOB INPUT Comr	UREMENTS SIGNIFICANT SERVABLE S (LEVEL 3) non Stocks

	FAIR V MEASUR USING SIG UNOBSE	EMENTS SNIFICANT RVABLE
Algor Small Can Crowth Fund	INPUTS (I Preferred	/
Alger Small Cap Growth Fund Opening balance at November 1, 2022	\$	J SLOCKS
Transfers into Level 3	Ψ	_
Transfers out of Level 3		_
Total gains or losses		
Included in net realized gain (loss) on investments		_
Included in net change in unrealized appreciation (depreciation) on investments		_
Purchases and sales		
Purchases		_
Sales		_
Closing balance at April 30, 2023		_*
Net change in unrealized appreciation (depreciation) attributable to investments		
still held at April 30, 2023**	\$	_
	FAIR V MEASUR	

	MEAS	UREMENTS
	USING	SIGNIFICANT
	UNO	BSERVABLE
	INPU	TS (LEVEL 3)
Alger Small Cap Growth Fund		Rights
Opening balance at November 1, 2022	\$	104,869
Transfers into Level 3		_
Transfers out of Level 3		_
Total gains or losses		
Included in net realized gain (loss) on investments		_
Included in net change in unrealized appreciation (depreciation) on investments		12,235
Purchases and sales		
Purchases		_
Sales		—
Closing balance at April 30, 2023		117,104
Net change in unrealized appreciation (depreciation) attributable to investments		
still held at April 30, 2023**	\$	12,235

	MEAS USING UNOE INPUT	R VALUE SUREMENTS SIGNIFICANT SSERVABLE 'S (LEVEL 3) ial Purpose
Alger Small Cap Growth Fund		Vehicle
Opening balance at November 1, 2022 Transfers into Level 3 Transfers out of Level 3	\$	2,410,106 — —
Total gains or losses Included in net realized gain (loss) on investments Included in net change in unrealized appreciation (depreciation) on investments		(32,167)
Purchases and sales Purchases Sales		_
Closing balance at April 30, 2023		2,377,939
Net change in unrealized appreciation (depreciation) attributable to investments still held at April 30, 2023**	\$	(32,167)
	FAI	RVALUE

	FAIF	R VALUE
	MEASL	JREMENTS
	USING S	IGNIFICANT
	UNOB	SERVABLE
	INPUTS	6 (LEVEL 3)
Alger Small Cap Focus Fund	R	ights
Opening balance at November 1, 2022	\$	7,143
Transfers into Level 3		_
Transfers out of Level 3		_
Total gains or losses		
Included in net realized gain (loss) on investments		_
Included in net change in unrealized appreciation (depreciation) on investments		833
Purchases and sales		
Purchases		_
Sales		_
Closing balance at April 30, 2023		7,976
Net change in unrealized appreciation (depreciation) attributable to investments		
still held at April 30, 2023**	\$	833

	Meas Using Unoe Input	R VALUE SUREMENTS SIGNIFICANT SSERVABLE TS (LEVEL 3)
Alger Health Sciences Fund	Com	mon Stocks
Opening balance at November 1, 2022	\$	5,000,002
Transfers into Level 3		—
Transfers out of Level 3		_
Total gains or losses		
Included in net realized gain (loss) on investments		_
Included in net change in unrealized appreciation (depreciation) on investments	6	—
Purchases and sales		
Purchases		_
Sales		_
Closing balance at April 30, 2023		5,000,002
Net change in unrealized appreciation (depreciation) attributable to investments		
Net change in unrealized appreciation (depreciation) attributable to investments still held at April 30, 2023**	\$	
still held at April 30, 2023**	FAI MEAS USING UNOE INPUT	R VALUE SUREMENTS SIGNIFICANT SSERVABLE 'S (LEVEL 3)
still held at April 30, 2023** Alger Health Sciences Fund	FAI MEAS USING UNOE INPUT Prefe	UREMENTS SIGNIFICANT SSERVABLE
still held at April 30, 2023**         Alger Health Sciences Fund         Opening balance at November 1, 2022	FAI MEAS USING UNOE INPUT	UREMENTS SIGNIFICANT SSERVABLE 'S (LEVEL 3)
still held at April 30, 2023**         Alger Health Sciences Fund         Opening balance at November 1, 2022         Transfers into Level 3	FAI MEAS USING UNOE INPUT Prefe	UREMENTS SIGNIFICANT SSERVABLE 'S (LEVEL 3)
still held at April 30, 2023**         Alger Health Sciences Fund         Opening balance at November 1, 2022	FAI MEAS USING UNOE INPUT Prefe	UREMENTS SIGNIFICANT SSERVABLE 'S (LEVEL 3)
still held at April 30, 2023**         Alger Health Sciences Fund         Opening balance at November 1, 2022         Transfers into Level 3	FAI MEAS USING UNOE INPUT Prefe	UREMENTS SIGNIFICANT SSERVABLE 'S (LEVEL 3)
still held at April 30, 2023**         Alger Health Sciences Fund         Opening balance at November 1, 2022         Transfers into Level 3         Transfers out of Level 3	FAI MEAS USING UNOE INPUT Prefe	UREMENTS SIGNIFICANT SSERVABLE 'S (LEVEL 3)
still held at April 30, 2023**         Alger Health Sciences Fund         Opening balance at November 1, 2022         Transfers into Level 3         Transfers out of Level 3         Total gains or losses	FAI MEAS USING UNOE INPUT Prefe \$	UREMENTS SIGNIFICANT SSERVABLE 'S (LEVEL 3)
still held at April 30, 2023**         Alger Health Sciences Fund         Opening balance at November 1, 2022         Transfers into Level 3         Transfers out of Level 3         Total gains or losses         Included in net realized gain (loss) on investments	FAI MEAS USING UNOE INPUT Prefe \$	UREMENTS SIGNIFICANT SSERVABLE 'S (LEVEL 3)
still held at April 30, 2023**         Alger Health Sciences Fund         Opening balance at November 1, 2022         Transfers into Level 3         Transfers out of Level 3         Total gains or losses         Included in net realized gain (loss) on investments         Included in net change in unrealized appreciation (depreciation) on investments	FAI MEAS USING UNOE INPUT Prefe \$	UREMENTS SIGNIFICANT SSERVABLE 'S (LEVEL 3)
still held at April 30, 2023**         Alger Health Sciences Fund         Opening balance at November 1, 2022         Transfers into Level 3         Transfers out of Level 3         Total gains or losses         Included in net realized gain (loss) on investments         Included in net change in unrealized appreciation (depreciation) on investments         Purchases and sales	FAI MEAS USING UNOE INPUT Prefe \$	UREMENTS SIGNIFICANT SSERVABLE 'S (LEVEL 3)
still held at April 30, 2023**         Alger Health Sciences Fund         Opening balance at November 1, 2022         Transfers into Level 3         Transfers out of Level 3         Total gains or losses         Included in net realized gain (loss) on investments         Included in net change in unrealized appreciation (depreciation) on investments         Purchases and sales         Purchases	FAI MEAS USING UNOE INPUT Prefe \$	UREMENTS SIGNIFICANT SSERVABLE 'S (LEVEL 3)
still held at April 30, 2023**         Alger Health Sciences Fund         Opening balance at November 1, 2022         Transfers into Level 3         Transfers out of Level 3         Total gains or losses         Included in net realized gain (loss) on investments         Included in net change in unrealized appreciation (depreciation) on investments         Purchases and sales         Purchases         Sales	FAI MEAS USING UNOE INPUT Prefe \$	UREMENTS SIGNIFICANT SSERVABLE 'S (LEVEL 3)

	MEAS USING UNOE	R VALUE UREMENTS SIGNIFICANT SERVABLE S (LEVEL 3)
Alger Health Sciences Fund		Rights
Opening balance at November 1, 2022	\$	1,174,198
Transfers into Level 3		—
Transfers out of Level 3		_
Total gains or losses Included in net realized gain (loss) on investments		_
Included in net change in unrealized appreciation (depreciation) on investments		136,989
Purchases and sales		
Purchases		_
Sales		_
Closing balance at April 30, 2023		1,311,187
Net change in unrealized appreciation (depreciation) attributable to investments		
still held at April 30, 2023**	\$	136,989

<sup>(a)</sup> Represents the sale of Level 3 common stock, Altaba, Inc., for the period ended April 30, 2023.

\*Includes securities that are fair valued at zero.

\*\* Net change in unrealized appreciation (depreciation) is included in net change in unrealized appreciation (depreciation) on investments in the accompanying statement of operations.

The following table provides quantitative information about each Fund's Level 3 fair value measurements of its investments as of April 30, 2023. The table below is not intended to be all-inclusive, but rather provides information on the Level 3 inputs as they relate to each Fund's fair value measurements.

	Fair Value Valuation Unobservable April 30, 2023 Methodology Input Input		Input/Range	Weighted Average Inputs		
Alger Capital Appreciation I	unc	1				
Preferred Stocks	\$	1,197,441	Market	Transaction Price	N/A	N/A
			Approach	Revenue Multiple	15.0x-17.0x	
Special Purpose Vehicle		2,896,878	Market	Transaction Price	N/A	N/A
			Approach	Revenue Multiple	15.0x-17.0x	
Alger Mid Cap Growth Fund	I					
Preferred Stocks	\$	*	Income	Discount Rate	100.00%	N/A
			Approach			
Rights		395,340	Income	Discount Rate	8.14%-9.44%	N/A
			Approach	Probability of	0.00%-60.00%	
				Success		
Special Purpose Vehicle		1,751,587	Market	Transaction Price	N/A	N/A
			Approach	Revenue Multiple	15.0x-17.0x	
Alger Weatherbie Specialize	ed G	rowth Fund				
Common Stocks	\$	2,986,210	Market	Priced at Cost	N/A	N/A
			Approach			
Preferred Stocks		*	Income	Discount Rate	100.00%	N/A
			Approach			

		Fair Value April 30, 2023	Valuation Methodology	Unobservable	Input/Range	Weighted
		April 30, 2023	wethodology	Input	input/Range	Average Inputs
Alger Small Cap Growth Fu			1			
Common Stocks	\$	3,646,998	Market	Priced at Cost	N/A	N/A
			Approach			
Preferred Stocks		*	Income	Discount Rate	100.00%	N/A
			Approach			
Rights		117,104	Income	Discount Rate	8.14%-9.44%	N/A
-			Approach	Probability of	0.00%-60.00%	
				Success		
Special Purpose Vehicle		2,377,939	Market	Transaction Price	N/A	N/A
			Approach	Revenue Multiple	15.0x-17.0x	
Alger Small Cap Focus Fun	d					1
Rights		\$ 7.976	Income	Discount Rate	8.14%-9.44%	N/A
0		φ 1,010	Approach	Probability of	0.00%-60.00%	
				Success		
Alger Health Sciences Fund	ł					
Common Stocks	\$	5,000,002	Market	Priced at Cost	N/A	N/A
			Approach			
Preferred Stocks		*	Income	Discount Rate	100.00%	N/A
			Approach			
Rights		1,311,187	Income	Discount Rate	8.14%-9.44%	N/A
		.,,	Approach	Probability of	0.00%-60.00%	
			,	Success	0.0070 00.0070	

\* Prosetta Biosciences, Inc., Series D shares are classified as a Level 3 investment and are fair valued at zero as of April 30, 2023.

The significant unobservable inputs used in the fair value measurement of each Fund's securities are revenue and EBITDA multiples, discount rates, and the probability of success of certain outcomes. Significant increases and decreases in these inputs in isolation and interrelationships between these inputs would have resulted in significantly higher or lower fair value measurements than those noted in the table above. Generally, all other things being equal, increases in revenue and EBITDA multiples, decreases in discount rates, and increases in the probability of success result in higher fair value measurements, whereas decreases in revenues and EBITDA multiples, increases in discount rates, and decreases in the probability of success result in higher fair value measurements, whereas the probability of success result in lower fair value measurements.

Certain of the Funds' assets and liabilities are held at carrying amount or face value, which approximates fair value for financial reporting purposes. As of April 30, 2023, such assets were categorized within the ASC 820 disclosure hierarchy as follows:

#### TOTAL LEVEL 1 LEVEL 2 LEVEL 3 Cash, foreign cash and cash equivalents Alger Capital Appreciation Fund \$ 35,251,415 \$ 143,557 \$ 35,107,858 \$ Alger 35 Fund \_ Bank overdraft (561,606) (561, 606)Alger Growth & Income Fund 5,334,761 5.334.761 Alger Mid Cap Growth Fund 3.933.971 5 3.933.966 Alger Mid Cap Focus Fund 442,596 442.596 \_ \_ Alger Weatherbie Specialized Growth Fund 7,108,472 7,108,472 \_ \_ Alger Small Cap Growth Fund 2,077,699 2,077,699 \_ Alger Small Cap Focus Fund 23,903,731 23,903,731 \_ Alger International Focus Fund 5,364,513 25,305 5,339,208 Alger Health Sciences Fund 1,943,022 1,943,022

# THE ALGER FUNDS NOTES TO FINANCIAL STATEMENTS (Unaudited) (Continued)

#### NOTE 9 — Derivatives:

FASB Accounting Standards Codification 815 – Derivatives and Hedging ("ASC 815") requires qualitative disclosures about objectives and strategies for using derivatives, quantitative disclosures about fair value amounts of and gains and losses on derivative instruments, and disclosures about credit-risk-related contingent features in derivative agreements.

There were no derivative instruments held by the Funds throughout the period or as of April 30, 2023.

# NOTE 10 — Principal Risks:

Alger Capital Appreciation Fund — Investing in the stock market involves risks, including the potential loss of principal. The value of these securities, like other investments, may move up or down, sometimes rapidly and unpredictably. Your Fund shares at any point in time may be worth less than what you invested, even after taking into account the reinvestment of Fund dividends and distributions. Local, regional or global events such as environmental or natural disasters, war, terrorism, pandemics, outbreaks of infectious diseases and similar public health threats, recessions, or other events could have a significant impact on investments. Growth stocks may be more volatile than other stocks as their prices tend to be higher in relation to their companies' earnings and may be more sensitive to market, political, and economic developments. A significant portion of assets may be invested in securities of companies in related sectors, and may be similarly affected by economic, political, or market events and conditions and may be more vulnerable to unfavorable sector developments. Foreign securities involve special risks including currency fluctuations, inefficient trading, political and economic instability, and increased volatility. Active trading may increase transaction costs, brokerage commissions, and taxes, which can lower the return on investment. At times, the Fund may hold a large cash or cash equivalent position, which may underperform relative to equity securities.

Alger 35 Fund — Investing in the stock market involves risks, including the potential loss of principal. The value of these securities, like other investments, may move up or down,

sometimes rapidly and unpredictably. Your Fund shares at any point in time may be worth less than what you invested, even after taking into account the reinvestment of Fund dividends and distributions. Local, regional or global events such as environmental or natural disasters, war, terrorism, pandemics, outbreaks of infectious diseases and similar public health threats, recessions, or other events could have a significant impact on investments. Growth stocks may be more volatile than other stocks as their prices tend to be higher in relation to their companies' earnings and may be more sensitive to market, political, and economic developments. A significant portion of assets may be invested in securities of companies in related sectors, and may be similarly affected by economic, political, or market events and conditions and may be more vulnerable to unfavorable sector developments. Investing in companies of small and medium capitalizations involves the risk that such issuers may have limited product lines or financial resources, lack management depth, or have limited liquidity. Foreign securities involve special risks including currency fluctuations, inefficient trading, political and economic instability, and increased volatility. The Fund is classified as a "non-diversified fund" under federal securities laws because it can invest in fewer individual companies than a diversified fund. Assets may be focused in a small number of holdings, making them susceptible to risks associated with a single economic, political or regulatory event than a more diversified portfolio. Active trading may increase transaction costs, brokerage commissions, and taxes, which can lower the return on investment. At times, the Fund may hold a large cash or cash equivalent position, which may underperform relative to equity securities.

Alger Growth & Income Fund — Investing in the stock market involves risks, including the potential loss of principal. The value of these securities, like other investments, may move up or down, sometimes rapidly and unpredictably. Your Fund shares at any point in time may be worth less than what you invested, even after taking into account the reinvestment of Fund dividends and distributions. Local, regional or global events such as environmental or natural disasters, war, terrorism, pandemics, outbreaks of infectious diseases and similar public health threats, recessions, or other events could have a significant impact on investments. Growth stocks may be more volatile than other stocks as their prices tend to be higher in relation to their companies' earnings and may be more sensitive to market, political, and economic developments. A significant portion of assets may be invested in securities of companies in related sectors, and may be similarly affected by economic, political, or market events and conditions and may be more vulnerable to unfavorable sector developments. Income-producing securities may cut or fail to declare dividends due to market downturns or for other reasons. At times, the Fund may hold a large cash or cash equivalent position, which may underperform relative to equity securities.

Alger Mid Cap Growth Fund — Investing in the stock market involves risks, including the potential loss of principal. The value of these securities, like other investments, may move up or down, sometimes rapidly and unpredictably. Your Fund shares at any point in time may be worth less than what you invested, even after taking into account the reinvestment of Fund dividends and distributions. Local, regional or global events such as environmental or natural disasters, war, terrorism, pandemics, outbreaks of infectious diseases and similar public health threats, recessions, or other events could have a significant impact

on investments. Growth stocks may be more volatile than other stocks as their prices tend to be higher in relation to their companies' earnings and may be more sensitive to market, political, and economic developments. A significant portion of assets may be invested in securities of companies in related sectors, and may be similarly affected by economic, political, or market events and conditions and may be more vulnerable to unfavorable sector developments. Investing in companies of medium capitalizations involves the risk that such issuers may have limited product lines or financial resources, lack management depth, or have limited liquidity. Foreign securities involve special risks including currency fluctuations, inefficient trading, political and economic instability, and increased volatility. Active trading may increase transaction costs, brokerage commissions, and taxes, which can lower the return on investment. At times, the Fund may hold a large cash or cash equivalent position, which may underperform relative to equity securities.

Alger Mid Cap Focus Fund - Investing in the stock market involves risks, including the potential loss of principal. The value of these securities, like other investments, may move up or down, sometimes rapidly and unpredictably. Your Fund shares at any point in time may be worth less than what you invested, even after taking into account the reinvestment of Fund dividends and distributions. Local, regional or global events such as environmental or natural disasters, war, terrorism, pandemics, outbreaks of infectious diseases and similar public health threats, recessions, or other events could have a significant impact on investments. Growth stocks may be more volatile than other stocks as their prices tend to be higher in relation to their companies' earnings and may be more sensitive to market, political, and economic developments. Investing in companies of medium capitalizations involves the risk that such issuers may have limited product lines or financial resources, lack management depth, or have limited liquidity. Assets may be focused in a small number of holdings, making them susceptible to risks associated with a single economic, political or regulatory event than a more diversified portfolio. A significant portion of assets may be invested in securities of companies in related sectors or industries, and may be similarly affected by economic, political, or market events and conditions and may be more vulnerable to unfavorable sector or industry developments. Foreign securities involve special risks including currency fluctuations, inefficient trading, political and economic instability, and increased volatility. Active trading may increase transaction costs, brokerage commissions, and taxes, which can lower the return on investment. At times, the Fund may hold a large cash or cash equivalent position, which may underperform relative to equity securities.

Alger Weatherbie Specialized Growth Fund — Investing in the stock market involves risks, including the potential loss of principal. The value of these securities, like other investments, may move up or down, sometimes rapidly and unpredictably. Your Fund shares at any point in time may be worth less than what you invested, even after taking into account the reinvestment of Fund dividends and distributions. Local, regional or global events such as environmental or natural disasters, war, terrorism, pandemics, outbreaks of infectious diseases and similar public health threats, recessions, or other events could have a significant impact on investments. Growth stocks may be more volatile than other stocks as their prices tend to be higher in relation to their companies' earnings and may be more sensitive to market, political, and economic developments. A significant portion of assets may be invested

in securities of companies in related sectors, and may be similarly affected by economic, political, or market events and conditions and may be more vulnerable to unfavorable sector developments. Investing in companies of small and medium capitalizations involves the risk that such issuers may have limited product lines or financial resources, lack management depth, or have limited liquidity. Assets may be focused in a small number of holdings, making them susceptible to risks associated with a single economic, political or regulatory event than a more diversified portfolio. Foreign securities and emerging markets involve special risks including currency fluctuations, inefficient trading, political and economic instability, and increased volatility. At times, the Fund may hold a large cash or cash equivalent position, which may underperform relative to equity securities.

Alger Small Cap Growth Fund — Investing in the stock market involves risks, including the potential loss of principal. The value of these securities, like other investments, may move up or down, sometimes rapidly and unpredictably. Your Fund shares at any point in time may be worth less than what you invested, even after taking into account the reinvestment of Fund dividends and distributions. Local, regional or global events such as environmental or natural disasters, war, terrorism, pandemics, outbreaks of infectious diseases and similar public health threats, recessions, or other events could have a significant impact on investments. Growth stocks may be more volatile than other stocks as their prices tend to be higher in relation to their companies' earnings and may be more sensitive to market, political, and economic developments. A significant portion of assets may be invested in securities of companies in related sectors, and may be similarly affected by economic, political, or market events and conditions and may be more vulnerable to unfavorable sector developments. Investing in companies of small capitalizations involves the risk that such issuers may have limited product lines or financial resources, lack management depth, or have limited liquidity. At times, the Fund may hold a large cash or cash equivalent position, which may underperform relative to equity securities.

Alger Small Cap Focus Fund — Investing in the stock market involves risks, including the potential loss of principal. The value of these securities, like other investments, may move up or down, sometimes rapidly and unpredictably. Your Fund shares at any point in time may be worth less than what you invested, even after taking into account the reinvestment of Fund dividends and distributions. Local, regional or global events such as environmental or natural disasters, war, terrorism, pandemics, outbreaks of infectious diseases and similar public health threats, recessions, or other events could have a significant impact on investments. Growth stocks may be more volatile than other stocks as their prices tend to be higher in relation to their companies' earnings and may be more sensitive to market, political, and economic developments. A significant portion of assets may be invested in securities of companies in related sectors or industries, and may be similarly affected by economic, political, or market events and conditions and may be more vulnerable to unfavorable sector or industry developments. Investing in companies of small capitalizations involves the risk that such issuers may have limited product lines or financial resources, lack management depth, or have limited liquidity. Assets may be focused in a small number of holdings, making them susceptible to risks associated with a single economic, political or regulatory

event than a more diversified portfolio. At times, the Fund may hold a large cash or cash equivalent position, which may underperform relative to equity securities.

Alger International Focus Fund — Investing in the stock market involves risks, including the potential loss of principal. The value of these securities, like other investments, may move up or down, sometimes rapidly and unpredictably. Your Fund shares at any point in time may be worth less than what you invested, even after taking into account the reinvestment of Fund dividends and distributions. Local, regional or global events such as environmental or natural disasters, war, terrorism, pandemics, outbreaks of infectious diseases and similar public health threats, recessions, or other events could have a significant impact on investments. Growth stocks may be more volatile than other stocks as their prices tend to be higher in relation to their companies' earnings and may be more sensitive to market, political, and economic developments. A significant portion of assets may be invested in securities of companies in related sectors, and may be similarly affected by economic, political, or market events and conditions and may be more vulnerable to unfavorable sector developments. Assets may be focused in a small number of holdings, making them susceptible to risks associated with a single economic, political or regulatory event than a more diversified portfolio. Foreign securities and emerging markets involve special risks including currency fluctuations, inefficient trading, political and economic instability, and increased volatility. Investing in companies of small capitalizations involves the risk that such issuers may have limited product lines or financial resources, lack management depth, or have limited liquidity. At times, the Fund may hold a large cash or cash equivalent position, which may underperform relative to equity securities.

Alger Health Sciences Fund — Investing in the stock market involves risks, including the potential loss of principal. The value of these securities, like other investments, may move up or down, sometimes rapidly and unpredictably. Your Fund shares at any point in time may be worth less than what you invested, even after taking into account the reinvestment of Fund dividends and distributions. Local, regional or global events such as environmental or natural disasters, war, terrorism, pandemics, outbreaks of infectious diseases and similar public health threats, recessions, or other events could have a significant impact on investments. Growth stocks may be more volatile than other stocks as their prices tend to be higher in relation to their companies' earnings and may be more sensitive to market, political, and economic developments. A significant portion of assets will be invested in healthcare companies, which may be significantly affected by competition, innovation, regulation, and product obsolescence, and may be more volatile than the securities of other companies. A significant portion of assets may be invested in securities of companies in related industries, and may be similarly affected by economic, political, or market events and conditions and may be more vulnerable to unfavorable industry developments. Assets may be focused in a small number of holdings, making them susceptible to risks associated with a single economic, political or regulatory event than a more diversified portfolio. Investing in companies of small capitalizations involves the risk that such issuers may have limited product lines or financial resources, lack management depth, or have limited liquidity. Private placements are offerings of a company's securities not registered with the SEC and not offered to the public, for which limited information may be available. Such investments are

generally considered to be illiquid. Foreign securities involve special risks including currency fluctuations, inefficient trading, political and economic instability, and increased volatility. Active trading may increase transaction costs, brokerage commissions, and taxes, which can lower the return on investment. At times, the Fund may hold a large cash or cash equivalent position, which may underperform relative to equity securities.

## NOTE 11 — Affiliated Securities:

During the six-month period ended April 30, 2023, as disclosed in the following table, certain Funds held 5% or more of the outstanding voting securities of the issuers listed below. As such, these issuers were "affiliated persons" of the applicable Fund(s) for purposes of the 1940 Act. Transactions during the six-month period ended April 30, 2023 with such affiliated persons are summarized below. During this period, other Funds in the Trust may also have held voting shares of the issuers at levels below 5%.

Total     \$ -\$ -\$     (37,962) \$ 2,896       Shares Held at October 31, Shares     Shares Held at October 31, Shares     Net Change Held at Shares     Net Change Unrealized       Alger Mid Cap Growth Fund     Prosetta     2023     Income     Gain (Loss)     App(Dep)     2023       Alger Mid Cap Growth Fund     Prosetta     Biosciences, Inc., Series     Prosetta     Security     2023     - \$ - \$ - \$       D**     219,610     -     -     219,610 \$ - \$ - \$ - \$     - \$       Special Purpose Vehicle     Crosslink     Ventures     Capital C, LLC,     -	Security	Shares Held at October 31, 2022	Shares Purchased	Shares Sold	Shares Held at April 30, 2023		Dividend Income	Realized Gain (Loss)	Net Chang in Unrealized App(Dep)		Value at April 30, 2023
Crosslink Ventures Capital C, LLC, CL. $A^{***}$ <b>S</b> $-\$$ $-\$$ $(37,962)$ $\$$ 2,896 <b>Total</b> <b>Shares</b> Held at October 31, Shares Held at October 31, Shares <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b> <b>Shares</b>			Fund								
Ventures Capital C, LLC, CL A*** $$ -$ -$ (37,962) $ 2,896$ Total $$ -$ -$ (37,962) $ 2,896$ Total $$ -$ -$ (37,962) $ 2,896$ Total $$ -$ -$ (37,962) $ 2,896$ Mathematical Sciences in Value is a second sec		ose Vehicle									
Capital C, LLC, CL. $A^{***}$ \$ -\$-\$(37,962) \$2,896Total\$ -\$-\$(37,962) \$2,896Total\$ -\$-\$(37,962) \$2,896Shares\$ -\$-\$-\$(37,962) \$2,896Held at\$ -\$-\$-\$(37,962) \$2,896October 31, \$ hares\$ SharesNet ChangeinValue :October 31, \$ hares\$ SharesApril 30, DividendRealizedApril 20Alger Mid Cap Growth FundProsettaBiosciences,Inc., SeriesPosettaProsettaBiosciences,Inc., Series $219,610$ $  219,610$ $   -$ <th< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></th<>											
$\begin{array}{c c c c c c c c c c c c c c c c c c c $											
Total     \$ -\$ -\$     (37,962) \$ 2,896       Shares     Net Change       Held at     in     Value :       October 31, Shares     April 30, Dividend     Realized     Unrealized       Alger Mid Cap Growth Fund     Purchased     Sold     2023     Income       Preferred Stocks     Prosetta     Biosciences,     Inc., Series       D**     219,610     -     -     \$ -\$ -\$       D**     219,610     -     -     \$ -\$ -\$       Crosslink     Ventures     Capital C, LLC,     Capital C, LLC,		·,									
Shares       Shares       Net Change         Held at       in       Value :         October 31, Shares       Shares       April 30, Dividend       Realized       Unrealized       April 3         Security       2022       Purchased       Sold       2023       Income       Gain (Loss)       App(Dep)       2023         Alger Mid Cap Growth Fund       Preferred Stocks       Prosetta       Biosciences,       Inc., Series       D**       219,610       -       -       \$ - \$       -       \$ - \$       \$       Security       Security       2023       Context and the security of the secure secure security of the secure security of the secure	-								- ( )		2,896,878
Held at       In       Value :         October 31,       Shares       Shares       April 30,       Dividend       Realized       Unrealized       April 3         Security       2022       Purchased       Sold       2023       Income       Gain (Loss)       App(Dep)       2023         Alger Mid Cap Growth Fund       Preferred Stocks       Preferred Stocks       Presenta       Biosciences,       Inc., Series       Posetta       Special Purpose Vehicle       Special Purpose Vehicle       Special Purpose Vehicle       Special Purpose Vehicle       Crosslink       Ventures       Capital C, LLC,       Ventures       Special C, LLC,       Ventures       Special Purpose Vehicle       Special C, LLC,       Special	Total					\$	-	\$ -	\$ (37,962	)\$	2,896,878
Preferred Stocks           Prosetta           Biosciences,           Inc., Series           D**         219,610 <b>Special Purpose Vehicle</b> Crosslink           Ventures           Capital C, LLC,		Held at October 31, 2022	Purchased		Held at April 30,				in Unrealized		Value at April 30, 2023
Prosetta Biosciences, Inc., Series D** 219,610 – – 219,610 \$ – \$ – \$ Special Purpose Vehicle Crosslink Ventures Capital C, LLC,			d								
Biosciences, Inc., Series D** 219,610 – – 219,610 \$ – \$ – \$ Special Purpose Vehicle Crosslink Ventures Capital C, LLC,	Preferred Sto	cks									
Special Purpose Vehicle Crosslink Ventures Capital C, LLC,	Biosciences, Inc., Series										
Crosslink Ventures Capital C, LLC,		,	-	-	219,610	Ş	-	\$ -	\$	- \$	-*
Cl. A*** – – (16.416) 1.252	Crosslink Ventures										
							-		(16.416	9	1,252,704
Crosslink Ventures Capital C, LLC,	Ventures									/	<i>y y</i>
1		·>					_		(7.543	9	498,883
						\$	_	\$ -		/	1,751,587*

	Shares			Shares			Net Change	
	Held at			Held at			in	Value at
	October 31,	Shares	Shares	April 30,	Dividend	Realized	Unrealized	April 30,
Security	2022	Purchased	Sold	2023	Income	Gain (Loss)	App(Dep)	2023
Alger Weathe	erbie Specialize	d Growth Fur	nd					
Preferred Sto	ocks							
Prosetta								
Biosciences,								
Inc., Series								
D**	231,474	-	-	231,474	\$ -	- \$	\$ - \$	_*
Total					\$ -	- \$ —	\$ - \$	-×
	Shares			Shares			Net Change	
	Held at			Held at			in	Value at
	October 31,	Shares	Shares	April 30,	Dividend	Realized	Unrealized	April 30,
Security	2022	Purchased	Sold	2023	Income	Gain (Loss)	App(Dep)	2023

Security	2022	Purchased	Sold	2023	Income	Gain (Loss)	App(Dep)	2023
Alger Small Cap	Growth F	und						
Preferred Stock	s							
Prosetta								
Biosciences,								
Inc., Series								
D**	50,688	-	-	50,688	-		-	_*
Special Purpose	e Vehicle							
Crosslink								
Ventures								
Capital C, LLC,								
Cl. A***					-		(24,624)	1,879,056
Crosslink								
Ventures								
Capital C, LLC,								
Cl. B***					-		(7,543)	498,883
Total				\$	\$ -	\$ -	\$ (32,167) \$	2,377,939*

Security	Shares Held at October 31, 2022	Shares Purchased	Shares Sold	Shares Held at April 30, 2023	Dividend Income	Realized Gain (Loss)	Net Change in Unrealized	Value at April 30, 2023
Alger Small C	-		5010	2023	mcome	Gain (Loss)	App(Dep)	2025
Common Stor	1	•						
908 Devices,								
Inc.****	1,991,055	53,198	(2,044,253)	-	-	(26,557,727)	9,318,305	-
Cabaletta Bio,								
Inc.	-	3,058,993	-	3,058,993	-	_	(1,225,144)	31,752,347
Heska Corp.	468,150	245,443	-	713,593	-	-	29,704,367	83,604,556
PROS								
Holdings, Inc.	2,978,898	-	(96,903)	2,881,995	-	(2,323,736)	12,109,715	81,762,198
Total					\$ -	\$ (28,881,463)	\$ 49,907,243 \$	5 197,119,101

Shares				Shares			Net Change	
	Held at			Held at			in	Value at
	October 31,	Shares	Shares	April 30,	Dividend	Realized	Unrealized	April 30,
Security	2022	Purchased	Sold	2023	Income	Gain (Loss)	App(Dep)	2023
Alger Health	Sciences Fund	1						
Preferred Sto	cks							
Prosetta								
Biosciences,								
Inc., Series								
D**	897,366	-	_	897,366	\$ -	- \$	\$ - \$	_*
Total					s -	- \$	S – S	_*

## THE ALGER FUNDS NOTES TO FINANCIAL STATEMENTS (Unaudited) (Continued)

\* Prosetta Biosciences, Inc., Series D shares are classified as a Level 3 investment and are fair valued at zero as of April 30, 2023.

\*\* Prosetta Biosciences, Inc., Series D is deemed to be an affiliate of the Funds because the Funds and Prosetta Biosciences, Inc., Series D are under common control.

\*\*\* The Alger Fund Complex and other entities managed by Alger Management fully own Crosslink Ventures Capital C, LLC, Class A and Crosslink Ventures Capital C, LLC, Class B. There were no capital increases or decreases for the six-month period ended April 30, 2023.

\*\*\*\* Non-affiliated at April 30, 2023.

# NOTE 12 — Subsequent Events:

Management of each Fund has evaluated events that have occurred subsequent to April 30, 2023, through the issuance date of the Financial Statements. No such events have been identified which require recognition and/or disclosure.

#### THE ALGER FUNDS ADDITIONAL INFORMATION (Unaudited)

### Shareholder Expense Example

As a shareholder of a Fund, you incur two types of costs: transaction costs, if applicable, including sales charges (loads) and redemption fees; and ongoing costs, including management fees, distribution (12b-1) fees, if applicable, and other Fund expenses. This example is intended to help you understand your ongoing costs (in dollars) of investing in a Fund and to compare these costs with the ongoing costs of investing in other mutual funds.

The example below is based on an investment of \$1,000 invested at the beginning of the six-month period starting November 1, 2022 and ending April 30, 2023 and held for the entire period.

#### **Actual Expenses**

The first line for each class of shares in the table below provides information about actual account values and actual expenses. You may use the information in this line, together with the amount you invested, to estimate the expenses that you paid over the period. Simply divide your account value by \$1,000 (for example, an \$8,600 account value divided by \$1,000 = 8.6), then multiply the result by the number in the first line under the heading entitled "Expenses Paid During the Six Months Ended April 30, 2023" to estimate the expenses you paid on your account during this period.

## Hypothetical Example for Comparison Purposes

The second line for each class of shares in the table below provides information about hypothetical account values and hypothetical expenses based on the actual expense ratio for each class of the Fund's shares and an assumed rate of return of 5% per year before expenses, which is not the Fund's actual return. The hypothetical account values and expenses may not be used to estimate the actual ending account balance or expenses you paid for the period. You may use this information to compare the ongoing costs of investing in the Fund and other funds. To do so, compare this 5% hypothetical examples that appear in the shareholder reports of other funds.

Please note that the expenses shown in the table are meant to highlight your ongoing costs only and do not reflect any transaction costs, such as sales charges (loads) and redemption fees. Therefore, the second line under each class of shares in the table is useful in comparing ongoing costs only, and will not help you determine the relative total costs of owning different funds. In addition, if these transactional costs were included, your costs would have been higher.

		1	eginning Account Value mber 1, 2022	Aj	Ending Account Value pril 30, 2023	Pa the	xpenses iid During Six Months Ended il 30, 2023 <sup>(a)</sup>	Annualized Expense Ratio For the Six Months Ended April 30, 2023 <sup>(b)</sup>
	tal Appreciation Fund							
Class A	Actual	\$	1,000.00	\$	1,036.80	\$	6.36	1.26%
	Hypothetical <sup>(c)</sup>		1,000.00		1,018.55		6.31	1.26
Class C	Actual		1,000.00		1,079.80		10.42	2.02
	Hypothetical <sup>(c)</sup>		1,000.00		1,014.78		10.09	2.02
Class Z	Actual		1,000.00		1,096.50		4.42	0.85
	Hypothetical <sup>(c)</sup>		1,000.00		1,020.58		4.26	0.85
Alger 35 F	und							
Class Z	Actual	\$	1,000.00	\$	1,019.10	\$	2.80	0.56%
	Hypothetical <sup>(c)</sup>		1,000.00		1,022.02		2.81	0.56
Alger Grov	vth & Income Fund							
Class A	Actual	\$	1,000.00	\$	1,034.70	\$	4.84	0.96%
	Hypothetical <sup>(c)</sup>		1,000.00		1,020.03		4.81	0.96
Class C	Actual		1,000.00		1,077.90		8.81	1.71
	Hypothetical <sup>(c)</sup>		1,000.00		1,016.31		8.55	1.71
Class Z	Actual		1,000.00		1,093.70		3.32	0.64
	Hypothetical <sup>(c)</sup>		1,000.00		1,021.62		3.21	0.64
Alger Mid Class A	Cap Growth Fund Actual	\$	1,000.00	\$	999.10	\$	6.29	1.27%
	Hypothetical <sup>(c)</sup>		1,000.00		1,018.50		6.36	1.27
Class B	Actual		1,000.00		1,004.60		6.46	1.30
	Hypothetical <sup>(c)</sup>		1,000.00		1,018.35		6.51	1.30
Class C	Actual		1,000.00		1,040.50		10.68	2.11
	Hypothetical <sup>(c)</sup>		1.000.00		1,014.33		10.54	2.11
Class Z	Actual		1,000.00		1,056.50		4.84	0.95
	Hypothetical <sup>(c)</sup>		1,000.00		1,020.08		4.76	0.95
Alaer Mid	Cap Focus Fund							
Class A	Actual	\$	1,000.00	\$	929.00	\$	5.26	1.10%
	Hypothetical <sup>(c)</sup>		1,000.00		1,019.34		5.51	1.10
Class C	Actual		1,000.00		967.70		9.32	1.91
	Hypothetical <sup>(c)</sup>		1,000.00		1,015.32		9.54	1.91
Class I	Actual		1,000.00		981.10		5.26	1.07
	Hypothetical <sup>(c)</sup>		1.000.00		1.019.49		5.36	1.07
Class Y	Actual		1,000.00		982.90		3.44	0.70
	Hypothetical <sup>(c)</sup>		1.000.00		1.021.32		3.51	0.70
Class Z	Actual		1,000.00		982.90		3.88	0.79
	Hypothetical <sup>(c)</sup>		1,000.00		1,020.88		3.96	0.79

		Beginnir Accour Value November 1	t Account Value	Expenses Paid During the Six Months Ended April 30, 2023 <sup>(a)</sup>	Annualized Expense Ratio For the Six Months Ended April 30, 2023
	therbie Specialized Grow				
Class A	Actual	\$ 1,000.0	0 \$ 917.30	\$ 6.18	1.30%
	Hypothetical <sup>(c)</sup>	1,000.0		6.51	1.30
Class C	Actual	1,000.0	0 953.80	9.93	2.05
	Hypothetical <sup>(c)</sup>	1,000.0		10.24	2.05
Class I	Actual	1,000.0	0 968.30	6.20	1.27
	Hypothetical <sup>(c)</sup>	1,000.0	0 1,018.50	6.36	1.27
Class Y	Actual	1,000.0	0 970.70	4.30	0.88
	Hypothetical <sup>(c)</sup>	1,000.0	0 1,020.43	4.41	0.88
Class Z	Actual	1,000.0	0 969.40	4.64	0.95
	Hypothetical <sup>(c)</sup>	1,000.0	0 1,020.08	4.76	0.95
	II Cap Growth Fund				
Class A	Actual	\$ 1,000.0		\$ 6.16	1.29%
	Hypothetical <sup>(c)</sup>	1,000.0	·	6.46	1.29
Class B	Actual	1,000.0	0 927.60	6.64	1.39
	Hypothetical <sup>(c)</sup>	1,000.0	·	6.95	1.39
Class C	Actual	1,000.0	0 963.00	10.17	2.09
	Hypothetical <sup>(c)</sup>	1,000.0		10.44	2.09
Class Y	Actual	1,000.0	0 979.60	4.12	0.84
	Hypothetical <sup>(c)</sup>	1,000.0	0 1,020.63	4.21	0.84
Class Z	Actual	1,000.0	0 979.50	4.76	0.97
	Hypothetical <sup>(c)</sup>	1,000.0	0 1,019.98	4.86	0.97
	ll Cap Focus Fund				
Class A	Actual	\$ 1,000.0		\$ 6.74	1.42%
	Hypothetical <sup>(c)</sup>	1,000.0		7.10	1.42
Class C	Actual	1,000.0		9.58	1.98
	Hypothetical <sup>(c)</sup>	1,000.0		9.89	1.98
Class I	Actual	1,000.0		5.80	1.19
	Hypothetical <sup>(c)</sup>	1,000.0		5.96	1.19
Class Y	Actual	1,000.0	0 967.00	4.15	0.85
	Hypothetical <sup>(c)</sup>	1,000.0	0 1,020.58	4.26	0.85
Class Z	Actual	1,000.0	0 967.60	4.20	0.86
	Hypothetical <sup>(c)</sup>	1.000.0	0 1.020.53	4.31	0.86

		Beginning Account Value November 1, 2022	Ending Account Value April 30, 2023	Expenses Paid During the Six Months Ended April 30, 2023 <sup>(a)</sup>	Annualized Expense Ratio For the Six Months Ended April 30, 2023 <sup>(b)</sup>
Alger Inter	national Focus Fund				
Class A	Actual	\$ 1,000.00	\$ 1,050.40	\$ 6.56	1.29%
	Hypothetical <sup>(c)</sup>	1,000.00	1,018.40	6.46	1.29
Class B	Actual	1,000.00	1,058.90	6.53	1.28
	Hypothetical <sup>(c)</sup>	1,000.00	1,018.45	6.41	1.28
Class C	Actual	1,000.00	1,094.30	10.90	2.10
	Hypothetical <sup>(c)</sup>	1,000.00	1,014.38	10.49	2.10
Class I	Actual	1,000.00	1,108.60	6.54	1.25
	Hypothetical <sup>(c)</sup>	1,000.00	1,018.60	6.26	1.25
Class Z	Actual	1,000.00	1,111.30	4.40	0.84
	Hypothetical <sup>(c)</sup>	1,000.00	1,020.63	4.21	0.84
Alger Heal	th Sciences Fund				
Class A	Actual	\$ 1,000.00	\$ 948.70	\$ 5.27	1.09%
	Hypothetical <sup>(c)</sup>	1,000.00	1,019.39	5.46	1.09
Class C	Actual	1,000.00	987.00	9.26	1.88
	Hypothetical <sup>(c)</sup>	1,000.00	1,015.47	9.39	1.88
Class Z	Actual	1,000.00	1,002.80	3.72	0.75
	Hypothetical <sup>(c)</sup>	1,000.00	1,021.08	3.76	0.75

<sup>(a)</sup> Expenses are equal to the annualized expense ratio of the respective share class, multiplied by the average account value over the period, multiplied by 181/365 (to reflect the one-half year period).

<sup>(b)</sup> Annualized.

(c) 5% annual return before expenses.

# **Privacy Policy**

## U.S. Consumer Privacy Notice

Rev. 6/22/21

FACTS	WHAT DOES ALGER DO WITH YOUR PERSONAL INFORMATION?
Why?	Financial companies choose how they share your personal information. Federal law gives consumers the right to limit some but not all sharing. Federal law also requires us to tell you how we collect, share, and protect your personal information. Please read this notice carefully to understand what we do.
What?	The types of personal information we collect and share depend on the product or service you have with us. This information can include: • Social Security number and • Account balances and • Transaction history and • Purchase history and • Assets When you are no longer our customer, we continue to share your information as described in this notice.
How?	All financial companies need to share personal information to run their everyday business. In the section below, we list the reasons financial companies can share personal information; the reasons Alger chooses to share; and whether you can limit this sharing.

Reasons we can share your personal information	Does Alger share?	Can you limit this sharing?
For our everyday business purposes — such as to process your transactions, maintain your account(s), respond to court orders and legal investigations, or report to credit bureaus	Yes	No
For our marketing purposes — to offer our products and services to you	Yes	No
For joint marketing with other financial companies	No	We don't share
For our affiliates' everyday business purposes — information about your transactions and experiences	Yes	No
For our affiliates' everyday business purposes — information about your creditworthiness	No	We don't share
For nonaffiliates to market to you	No	We don't share
Questions? Call 1-800-223-3810		

Who we are	
Who is providing this notice?	Alger includes Fred Alger Management, LLC and Fred Alger & Company, LLC as well as the following funds: The Alger Funds, The Alger Funds II, The Alger Institutional Funds, The Alger Portfolios, Alger Global Focus Fund, and The Alger ETF Trust.

What we do	
How does Alger protect my personal information?	To protect your personal information from unauthorized access and use, we use security measures that comply with federal law. These measures include computer safeguards and secured files and buildings.
How does Alger collect my personal information?	We collect your personal information, for example, when you: • Open an account or • Make deposits or withdrawals from your account or • Give us your contact information or • Provide account information or • Pay us by check.
Why can't I limit all sharing?	Federal law gives you the right to limit some but not all sharing related to: • sharing for affiliates' everyday business purposes — information about your credit worthiness • affiliates from using your information to market to you • sharing for nonaffiliates to market to you State laws and individual companies may give you additional rights to limit sharing.

Definitions	
Affiliates	Companies related by common ownership or control. They can be financial and nonfinancial companies. • Our affiliates include Fred Alger Management, LLC, Weatherbie Capital, LLC and Fred Alger & Company, LLC as well as the following funds: The Alger Funds, The Alger Funds II, The Alger Institutional Funds, The Alger Portfolios, Alger Global Focus Fund, and The Alger ETF Trust.
Nonaffiliates	Companies not related by common ownership or control. They can be financial and nonfinancial companies.
Joint marketing	A formal agreement between nonaffiliated financial companies that together market financial products or services to you.

# **Proxy Voting Policies**

A description of the policies and procedures the Funds use to determine how to vote proxies relating to portfolio securities and the proxy voting record is available, without charge, by calling (800) 992-3863 or online on the Funds' website at http://www.alger.com or on the SEC's website at http://www.sec.gov.

### **Fund Holdings**

The Board has adopted policies and procedures relating to disclosure of the Funds' portfolio securities. These policies and procedures recognize that there may be legitimate business reasons for holdings to be disclosed and seek to balance those interests to protect the proprietary nature of the trading strategies and implementation thereof by the Funds.

Generally, the policies prohibit the release of information concerning portfolio holdings, which have not previously been made public, to individual investors, institutional investors, intermediaries that distribute the Funds' shares and other parties which are not employed by the Investment Manager or its affiliates except when the legitimate business purposes for selective disclosure and other conditions (designed to protect the Funds) are acceptable.

The Funds file their complete schedules of portfolio holdings with the SEC semi-annually in shareholder reports on Form N-CSR and after the first and third fiscal quarters as an exhibit to their reports on Form N-PORT. The Funds' Forms N-CSR and N-PORT are available online on the SEC's website at www.sec.gov.

In addition, the Funds make publicly available their month-end top 10 holdings (top 5 holdings with respect to Alger 35 Fund) with a 10 day lag and their month-end full portfolios with a 60 day lag on their website www.alger.com and through other marketing communications (including printed advertising/sales literature and/or shareholder telephone customer service centers). No compensation or other consideration is directly received for the non-public disclosure of portfolio holdings information.

In accordance with the foregoing, the Funds provide portfolio holdings information to third parties including financial intermediaries and service providers who need access to this information in the performance of their services and are subject to duties of confidentiality (1) imposed by law, including a duty not to trade on non-public information, and/or (2) pursuant to an agreement that confidential information is not to be disclosed or used (including trading on such information) other than as required by law. From time to time, the Funds will communicate with these third parties to confirm that they understand the Funds' policies and procedures regarding such disclosure. These agreements must be approved by the Trust's Chief Compliance Officer.

The Board periodically reviews a report disclosing the third parties to whom each Fund's holdings information has been disclosed and the purpose for such disclosure, and it considers whether or not the release of information to such third parties is in the best interest of the Fund and its shareholders.

In addition to material the Funds routinely provide to shareholders, the Investment Manager may make additional statistical information available regarding the Alger Family of Funds. Such information may include, but not be limited to, relative weightings and characteristics of a Fund versus an index (such as P/E ratio, alpha, beta, capture ratio, maximum drawdown, standard deviation, EPS forecasts, Sharpe ratio, information ratio, R-squared, and market cap analysis), security specific impact on overall portfolio performance, month-end top ten contributors to and detractors from performance, portfolio turnover, and other similar information. Shareholders should visit www.alger.com or may also contact the Funds at (800) 992-3863 to obtain such information.

## Liquidity Risk Management Program

In accordance with Rule 22e-4 under the 1940 Act (the "Liquidity Rule"), the Trust has adopted and implemented a liquidity risk management program (the "LRMP"), which is reasonably designed to assess and manage the Funds' liquidity risk.

The Board met on December 6, 2022 (the "Meeting") to review the LRMP. The Board previously appointed Alger Management as the program administrator for the LRMP and approved an agreement with ICE Data Services ("ICE"), a third party vendor that assists the Funds with liquidity classifications required by the Liquidity Rule. Alger Management also previously delegated oversight of the LRMP to the Liquidity Risk Committee (the "Committee"). At the Meeting, the Committee, on behalf of Alger Management, provided the Board with a report that addressed the operation of the LRMP and assessed its adequacy and effectiveness of implementation, and any material changes to the LRMP (the "Report"). The Report covered the period from December 1, 2021 through November 30, 2022 (the "Review Period").

The Report stated that the Committee assessed the Funds' liquidity risk by considering qualitative factors such as the Funds' investment strategy, holdings, diversification of investments, redemption policies, cash flows, cash levels, shareholder concentration, and access to borrowings, among others, in conjunction with the quantitative classifications generated by ICE. In addition, in connection with the review of the Funds' liquidity risks and the operation of the LRMP and the adequacy and effectiveness of its implementation, the Committee also evaluated the levels at which to set the reasonably anticipated trade size ("RATS") and market price impact. The Report described the process for determining that the Funds primarily holds investments that are highly liquid. The Report noted that the Committee also performed stress tests on the Funds, and concluded that the Funds remained primarily highly liquid. The Report stated that during the Reporting Period, the Committee approved updated liquidity parameters for the Funds based on discussions with ICE, certain other third parties, and internal groups at Alger Management relating to RATS and average daily trading volumes in normal and stressed conditions for the various market capitalizations of holdings in the Funds.

There were no material changes to the LRMP during the Review Period. The Report provided to the Board stated that the Committee concluded that, based on the operation of the functions, as described in the Report, during the Review Period, the Trust's LRMP was operating effectively and adequately with respect to the Funds and has been effectively implemented during the Review Period.

# THE ALGER FUNDS

100 Pearl Street, 27th Floor New York, NY 10004 (800) 992-3863 www.alger.com

#### **Investment Manager**

Fred Alger Management, LLC 100 Pearl Street, 27th Floor New York, NY 10004

#### Sub-Adviser

Weatherbie Capital, LLC 265 Franklin Street, Suite 1603 Boston, MA 02110

#### Distributor

Fred Alger & Company, LLC 100 Pearl Street, 27th Floor New York, NY 10004

## **Transfer Agent and Dividend Disbursing Agent**

UMB Fund Services, Inc. 235 W. Galena Street Milwaukee, WI 53212

#### Custodian

Brown Brothers Harriman & Company 50 Post Office Square Boston, MA 02110

## Independent Registered Public Accounting Firm

Deloitte & Touche LLP 30 Rockefeller Plaza New York, NY 10112

This report is submitted for the general information of the shareholders of the series of The Alger Funds. It is not authorized for distribution to prospective investors unless accompanied by an effective Prospectus for the Fund, which contains information concerning the Fund's investment policies, fees and expenses as well as other pertinent information.



Inspired by Change, Driven by Growth.

